Modified piv5 vaccine vectors: methods of making and uses
Patent Information
- Application Number
- HK62026124649
- Authority / Receiving Office
- HK · HK
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-02-06
- Filing Date
- 2026-06-10
- Publication Date
- 2026-09-11
Smart Images

Figure 00000000_0000_ABST
Abstract
Description
(19) State Intellectual Property Office (12) Invention Patent Application (10) Application Publication Number (43) Application Publication Date (21) Application Number 202480017122.3 (22) Application Date 2024.02.05 (30) Priority Data 63 / 483,377 2023.02.06 US (85) PCT International Application Entering National Phase Date 2025.09.05 (86) PCT International Application Application Data PCT / US2024 / 014505 2024.02.05 (87) PCT International Application Publication Data WO2024 / 167866 EN 2024.08.15 (71) Applicant: Sevika LLC Address: USA (72) Inventors: B. He, Z. Li, H. Jin, M.C. Gingerridge (74) Patent Agency: Beijing Zhucheng Law Firm 11313 Patent Attorneys Chen Yanjuan and Wang Yanbo (51) Int.Cl. A61K 39 / 215 (2006.01) A61K 39 / 12 (2006.01) (54) PIV5 Vaccine Vector with Modified Invention Name: Manufacturing Method and Use (57) Abstract A CVB virus expression vector containing a PIV5W3A virus genome, wherein the PIV5W3A virus genome contains a mutation at amino acid residue S157 or S156 in the P / V gene of the PIV5W3A virus genome and a deletion of the small hydrophobic (SH) gene, wherein the amino acid substitution at amino acid residue S157 or S156 includes a serine (S) substitution for phenylalanine (F) or asparagine (N), and wherein the SH gene is missing the SH open reading frame or the entire SH gene transcription unit is missing. CVB virus expression vector, wherein the vector expresses a heterologous polypeptide comprising SARS-CoV-2 spike (S) and / or nucleocapsid (N) and / or membrane (M) proteins, RSV fusion protein (F) or other antigens. Claims 2 pages, Description 157 pages, Drawings 15 pages. CN 121263205 A 2026.01.02 CN 1 21 26 32 05 A 1. A composition comprising a modified PIV5 CVB virus expression vector having at least 98% sequence identity with SEQ ID NO:1, wherein the CVB virus expression vector comprises a mutation at amino acid residue S157 or S156 of the P / V gene of the PIV5 viral genome, causing removal of phosphorylation sites and higher transcriptional activity, thereby increasing viral titer in cell culture, and wherein the CVB virus expression vector is highly immunogenic and can be used as an effective vaccine platform. 2. The composition of claim 1, wherein the mutation at amino acid residue S157 or S156 comprises serine.(S) The amino acid residues selected from the group consisting of: alanine (A), cysteine (C), aspartic acid (D), glutamic acid (E), phenylalanine (F), glycine (G), histidine (H), isoleucine (I), lysine (K), leucine (L), methionine (M), asparagine (N), proline (P), glutamine (Q), arginine (R), selenocysteine (U), valine (V), tryptophan (W), and tyrosine (Y). 3. The composition of claim 1, wherein the mutation at amino acid residue S157 or S156 comprises replacing serine (S) at amino acid residue S157 with phenylalanine (F) or replacing serine (S) at amino acid residue S156 with asparagine (N). 4. The composition of claim 1, wherein the CVB viral expression vector expresses a heterologous polypeptide comprising a viral antigen selected from the group consisting of SARS-CoV-2, RSV, or viral or bacterial antigens. 5. The composition of claim 1, wherein the PIV5 genome has a heterologous nucleic acid sequence having at least 98% sequence identity with SEQ ID NO: 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or 13, and wherein the viral expression vector expresses a heterologous polypeptide comprising a coronavirus spike (S) and / or nucleocapsid (N) protein or an RSV-F protein. 6. The composition of claim 5, wherein the coronavirus spike (S) and / or nucleocapsid (N) protein is the S or N protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a SARS-CoV-2 strain, or a variant of SARS-CoV-2, wherein the SARS-CoV-2 variant is a SARS-CoV-2β variant, a SARS-CoV-2γ variant, a SARS-CoV-2δ variant, a SARS-CoV-2O variant, a SARS-CoV-2OBA.1, a SARS-CoV-2OBA.5, BQ1, or XBB1, or any future variant. 7. The composition of claim 5, wherein the coronavirus S gene comprises the coronavirus S gene of SARS-CoV-2 and wherein the cytoplasmic tail of the coronavirus S gene has been replaced by the cytoplasmic tail of the fusion (F) gene of the CVB or CPI vector. 8. The composition of claim 5, wherein the PIV5 genome (CVB) having S157F or S156N in the P / V gene of the PIV5 viral genome further comprises an open reading frame deletion mutation of the SH gene, and wherein the N gene of the SARS-CoV-2 strain is inserted to replace the SH gene of PIV5, and the S gene of the SARS-CoV-2 strain or other variant strain is inserted between the PIV5 hemagglutinin (HN) gene and the polymerase (L) gene of the CVB.9. The composition of claim 5, wherein the entire SH gene transcription unit of the PIV5 viral genome is deleted and the S gene of the SARS-CoV-2 strain or other variant strain is placed between the HN gene and the L gene of the CVB. 10. The composition of claim 5, wherein the S gene of the SARS-CoV-2 variant is inserted to replace the S gene of the SARS-CoV-2 strain and the N gene of the SARS-CoV-2 strain is inserted to replace the SH gene of PIV5. 11. The composition of claim 5, wherein the S gene of the SARS-CoV-2 OBA.5 variant is inserted between the HN gene and the L gene of PIV5 to replace the S gene of the SARS-CoV-2 strain. 12. The composition of claim 5, wherein the S gene of the SARS-CoV-2 OBA.5 variant is inserted to replace the S gene of the SARS-CoV-2 strain and the N gene of the SARS-CoV-2 strain is inserted to replace the SH gene of CVB. 13. The composition of claim 5, wherein the PIV5 F and HN genes are deleted and wherein the S gene of the SARS-CoV-2 strain is between the HN and L genes of CVB. 14. The composition of claim 5, wherein the N gene of the SARS-CoV-2 strain is inserted between F and HN, and the S gene of the SARS-CoV-2 strain is inserted between the HN and L genes of CVB. 15. The composition of claim 5, wherein the M gene from the SARS-CoV-2 strain is inserted between F and HN, and the S gene of the SARS-CoV-2 strain is inserted between the HN and L genes of CVB. 16. The composition of claim 5, wherein the M gene from the SARS-CoV-2 strain is inserted after F of PIV5, the E gene from the SARS-CoV-2 strain is inserted between the M gene and HN of SARS-CoV-2, and the S gene from the SARS-CoV-2 strain is inserted between HN and L of CVB. 17. The composition of claim 5, wherein the M gene from the SARS-CoV-2 strain is inserted after F of PIV5, the N gene from the SARS-CoV-2 strain is inserted between the M gene and the E gene of SARS-CoV-2, the E gene from the SARS-CoV-2 strain is inserted between the N gene and HN of SARS-CoV-2, and the S gene from the SARS-CoV-2 strain is inserted between HN and L of CVB.18. The composition of claim 5, wherein the RSV-F protein is inserted in place of the PIV5 SH gene (ΔSH) or inserted between PIV5 SH and NH (SH-NH) or between HN and L (HN-L). 19. A method of inducing an immune response in a subject suffering from or at risk of SARS-CoV-2, RSV, or other viral or bacterial infection, the method comprising administering the composition of claim 1 to the subject in the form of a primary or booster vaccine, wherein the immune response comprises a humoral immune response and / or a cellular immune response. 20. The method of claim 19, wherein the composition is administered intranasally, intramuscularly, topically, or orally. Claims 2 / 2 Page 3 CN 121263205 A Modified PIV5 Vaccine Vector: Manufacturing Method and Use
[0001] Reference to Related Applications
[0002] This application claims priority to U.S. Provisional Application Serial No. 63 / 483,377, filed February 6, 2023, which is incorporated herein by reference in its entirety. Field of the Invention
[0003] The present invention generally relates to the field of vaccination, and more particularly to compositions and methods for modulating an immune response in subjects infected with infectious agents, such as RSV and SARS-CoV-2, or susceptible to infectious agents, using modified PIV5 vaccine vectors, such as PIV5W3AΔSH or PIV5W3AΔSH (CVB) with a P / V gene mutation.
[0004] Background of the Invention
[0005] Parainfluenza virus type 5 (PIV5) belongs to the family Paramyxoviridae and the genus Rubulavirus (which also includes mumps virus). Its genome is a negative single-stranded RNA with a length of 15246 nt. The full-length structure of the PIV5 genome is 3′-leader sequence-NP-V / P-M-F-SH-HN-L-tail sequence-5′, that is, from the 3′ end to the 5′ end, it encodes the nucleocapsid protein (NP), V protein / phosphorylated protein (P), matrix protein (M), fusion protein (F), small hydrophobic protein (SH), hemagglutinin-neuraminidase protein (HN), and polymerase protein (large protein, L). Among them, V protein and SH protein are non-structural proteins.
[0006] PIV5 is an excellent viral vector for vaccine development, and research on PIV5 recombinant vaccines is underway. In recent years, researchers have been exploring the feasibility of using PIV5 as a vaccine vector. A common approach is to insert a protective antigen gene from a virus or bacteria into a PIV5 vector and express the inserted foreign gene through replication and translation of the PIV5 vector.Because PIV5 can infect the respiratory tract without causing any disease, researchers often take advantage of this and focus on controlling certain respiratory viral infections. Therefore, in-depth research into the molecular biological characteristics and replication mechanisms of this virus is beneficial for a comprehensive and thorough understanding of PIV5, so as to lay the foundation for research on PIV5 as a genetically engineered vaccine vector and the study of viral gene function. However, there is still a need for more effective and high-yield PIV5 vaccine vectors.
[0007] Therefore, the disclosure provided herein provides a more effective and high-yield PIV5 CVB backbone containing the S156N or S157F mutation of the P / V gene, and the generation of a novel SARS-CoV-2 CVB vector vaccine for intranasal immunization. The phosphoprotein (P) protein can be phosphorylated at serine residues at positions 36, 126, and 157 and at a threonine residue at position 286. In addition, host cell Polo-like kinase 1 (PLK1) can phosphorylate the serine residue at position 308. Mutating serine residues at positions 157 or 308 to alanine residues prevents phosphorylation of these residues, thereby significantly enhancing vRdRP activity in microgenomic assays and replication of recombinant viruses with these mutations. It is speculated that mutations at residues 156 and 157 upregulate viral transcription and replication, thereby increasing vaccine virus yield. Changes to the amino acid motif 155-159 TSSPI of the PIV5 P protein will alter the viral phenotype and in vitro and in vivo growth characteristics.
[0008] According to the purposes of the invention, as embodied and broadly described herein, in one aspect the invention relates to a modified PIV5 (referred to as CVB) viral expression vector comprising a PIV5 W3A viral genome having a mutation at amino acid residue S157 or S156 of the P / V gene of the P / V gene and a deletion of the small hydrophobic (SH) gene. This modified CVB backbone has been shown to grow better in cell cultures, for example in serum-free Vero cells, and exhibits higher immunogenicity, for example, in a cotton rat animal model. The modified CVB backbone can be used as an effective vaccine platform.
[0009] In some embodiments, the mutation at amino acid residue S157 or S156 comprises a serine (S) replaced by an amino acid residue selected from the group consisting of: alanine (A), cysteine (C), aspartic acid (D), glutamic acid (E), phenylalanine (F), glycine (G), histidine (H), isoleucine (I), lysine (K), leucine (L), methionine (M), asparagine (N), proline (P), glutamine (Q), arginine (R), selenocysteine (U), valine (V), tryptophan (W), and tyrosine.Amino acid (Y). In one embodiment, the amino acid substitution at amino acid residue S157 includes a serine (S) replaced by phenylalanine (F) or the amino acid substitution at amino acid residue S156 includes a serine (S) replaced by asparagine (N).
[0010] In other embodiments, the SH gene is missing the SH open reading frame or the entire SH gene transcription unit is missing.
[0011] In one embodiment, the CVB viral expression vector expresses a heterologous polypeptide containing a viral antigen selected from the group consisting of SARS-CoV-2, RSV, or other viral or bacterial antigens. In another embodiment, the PIV5 genome has a heterologous nucleic acid sequence having at least 98% sequence identity with SEQ ID NO:2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or 13 and wherein the viral expression vector expresses a heterologous polypeptide containing a coronavirus spike (S) and / or nucleocapsid (N) protein, RSV-F protein, or viral or bacterial antigen.
[0012] In one embodiment, the coronavirus S protein is the coronavirus S protein of SARS-CoV-2, a variant of interest or a variant of concern of SARS-CoV-2, and the coronavirus N protein is the coronavirus N protein of SARS-CoV-2, a variant of interest or a variant of concern of SARS-CoV-2. In some embodiments, the coronavirus S protein is the coronavirus S protein of a SARS-CoV-2 strain, SARS-CoV-2β variant, SARS-CoV-2γ variant, SARS-CoV-2δ variant, or SARS-CoV-2O variant, and the coronavirus N protein is the coronavirus N protein of a SARS-CoV-2 strain, SARS-CoV-2β variant, SARS-CoV-2γ variant, SARS-CoV-2δ variant, or SARS-CoV-2O variant. In some embodiments, the SARS-CoV-2O variant is SARS-CoV-2OBA.1 or SARS-CoV-2OBA.5, BQ1 or XBB1, or any future variant.
[0013] In one embodiment, the coronavirus S protein comprises the coronavirus S protein of SARS-CoV-2 and wherein the cytoplasmic tail of the coronavirus S protein has been replaced by the cytoplasmic tail of the fusion (F) protein of CVB.
[0014] In one embodiment, the PIV5 W3A viral genome comprises an open reading frame deletion mutation of the SH gene and the S gene of the SARS-CoV-2 strain is inserted between the PIV5 hemagglutinin (HN) gene and the polymerase (L) gene of CVB.
[0015] In some embodiments, the entire SH gene transcription unit of the PIV5 W3A viral genome is deleted and the S gene of the SARS-CoV-2 strain is placed between the HN gene and the L gene of CVB.
[0016] In some embodiments, the N gene of the SARS-CoV-2 strain is inserted to replace the SH gene of PIV5, and the S gene of the SARS-CoV-2 strain is inserted between the HN gene and the L gene of CVB.
[0017] In some embodiments, the N gene of the SARS-CoV-2 strain is inserted to replace the SH gene of PIV5, and the S gene of the SARS-CoV-2 OBA.1 variant is inserted between the HN gene and the L gene of CVB.
[0018] In some embodiments, the S gene of the SARS-CoV-2 OBA.5 variant is inserted between the HN gene and the L gene of CVB.
[0019] In some embodiments, the S gene of the SARS-CoV-2 OBA.5 variant is inserted between the HN gene and the L gene, and the N gene of the SARS-CoV-2 strain is inserted to replace the SH gene of CVB.
[0020] In some embodiments, the PIV5 F and HN genes are deleted, and the S gene of the SARS-CoV-2 strain is between the M gene and the L gene of CVB.
[0021] In some embodiments, the N gene of the SARS-CoV-2 strain is inserted between F and HN, and the S gene of the SARS-CoV-2 strain (page 2 / 157, CN 121263205 A) is inserted between the HN and L genes of CVB.
[0022] In some embodiments, the M gene from the SARS-CoV-2 strain is inserted between F and HN, and the S gene of the SARS-CoV-2 strain is inserted between HN and L of CVB.
[0023] In some embodiments, after the M gene from the SARS-CoV-2 strain is inserted into F of PIV5, the E gene from the SARS-CoV-2 strain is inserted between the M gene and HN of SARS-CoV-2, and the S gene of the SARS-CoV-2 strain is inserted between HN and L of CVB.
[0024] In some embodiments, after the M gene from the SARS-CoV-2 strain is inserted into the F gene of PIV5, the N gene from the SARS-CoV-2 strain is inserted between the M and E genes of SARS-CoV-2, the E gene from the SARS-CoV-2 strain is inserted between the N and HN genes of SARS-CoV-2, and the S gene from the SARS-CoV-2 strain is inserted between the HN and L genes of CVB.
[0025] In some embodiments, the F gene from respiratory syncytial virus (RSV) is inserted between the SH and HN genes of the CVB backbone.
[0026] In one embodiment, the viral particle comprises a viral expression vector.
[0027] In another aspect, the present invention relates to a composition comprising the same as SEQ ID NO: 2, 3, 4, 5, 6,7, 8, 9, 10, 11, 12, or 13 are CVB viral expression vectors having nucleic acid sequences with at least 98% sequence identity, and wherein said viral expression vector expresses a heterologous polypeptide comprising coronavirus spike (S) and / or nucleocapsid (N) proteins. In one embodiment, the heterologous coronavirus spike (S) and nucleocapsid (N) proteins are expressed in cells by contacting cells with the composition.
[0028] In another aspect, the present invention relates to a method for inducing an immune response in a subject suffering from or at risk of SARS-CoV-2, RSV, or other viral or bacterial infection, said method comprising administering a composition to the subject, wherein the immune response comprises a humoral immune response and / or a cellular immune response.
[0029] Further advantages of the invention will be set forth in part in the description which follows, and in part will be apparent from the description, or may be learned by practice of the invention. The advantages of the invention will be realized and achieved by means of the elements and combinations particularly pointed out in the appended claims. It should be understood that the above overview and the following detailed description are exemplary and illustrative only, and do not limit the claimed invention. In one embodiment, a subject is vaccinated against a vaccine against COVID-19, RSV, or other viral or bacterial infections, the method comprising administering a composition to the subject, wherein the composition is administered intranasally, intramuscularly, topically, or orally. The method further comprises administering a PIV5 booster vaccine composition comprising a viral expression vector or viral particle having a PIV5 genome comprising a heterologous nucleic acid sequence having at least 98% sequence identity with SEQ ID NO: 27, 28, 29, 30, 31, 32, or 33, wherein the subject has previously received an initial vaccination against SARS-CoV-2, RSV, or other viral or bacterial infections. Brief Description of the Drawings
[0030] The accompanying drawings, which are incorporated in and constitute a part of this specification, illustrate several embodiments of the invention and, together with the description, serve to explain the principles of the invention.
[0031] Figure 1 is a genomic structure diagram of W3A△SH, CPI, and CVB.
[0032] Figures 2A-2B show the RSV F-specific cellular immune response in AGM immunized with W3A△SH-RSV-F versus CPI-RSV-F. RSV F-specific cellular immune response in immunized African green monkeys (AGM). PBMCs were isolated from immunized AGM one day before vaccination and 14 and 28 days after immunization. PBMCs were stimulated with an RSV F peptide pool, and the levels of different cytokines in CD4+ (Figure 2A) and CD8+ (Figure 2B) cells were quantified by ICS and expressed as the sum of all cytokines % . Specification 3 / 157 pages 6 CN 121263205 A
[0033] Figure 3 shows the RSV viral titer in the lungs after RSV challenge following immunization with the indicated control or antigen.
[0034] Figure 4 shows the RSV titer in nasal rinsing fluid after RSV challenge.
[0035] Figure 5 shows the RSV neutralizing antibody response.
[0036] Figure 6 shows the anti-RSV F protein IgG antibody response obtained by ELISA.
[0037] Figure 7 shows a schematic diagram of virus rescue.
[0038] Figure 8 shows a schematic diagram of SARS-CoV-2 vaccine constructs based on PIV5 CVB, indicating the location of SARS-CoV-2 genes and their corresponding source variants.
[0039] Figures 9A-9D show the animal immune responses induced by CVXGA16, CVXGA17, and CVXGA18. IgG antibodies against SARS-CoV-2 S protein (Figure 9A) or S-RBD (Figure 9B) in mice. Mice were immunized intranasally with 50 μL PBS or 10⁵ PFU of CVXGA1, CVXGA16, CVXGA17, and CVXGA18. Blood was collected on day 32. Anti-SWA1 or SWA1 RBD IgG antibodies were measured using ELISA. Figure 9C shows the T-cell response against the S or N peptide in mice. Mice were immunized as described above. Spleens were collected on day 32. IFNγ-secreting cells specific to the S or N protein were identified using ELISPOT. Figure 9D shows IgG antibodies against the S protein in hamsters. Hamsters were immunized intramuscularly with 50 μL PBS or with 2 μg of COVID-19 mRNA vaccine. Following a booster immunization on day 21, hamsters in group 1 received a booster immunization via intranasal administration of 50 μL PBS, and hamsters in group 2 received a second booster immunization on day 42 via intramuscular administration of 2 μg COVID-19 mRNA (group 2A), or via intranasal administration of 2 × 10⁶ PFU CVXGA1 (group 2B) or CVXGA18 (group 2C). Blood was collected 63 days post-immunization. Anti-S IgG antibodies were measured using ELISA.
[0040] Figure 10 shows the growth curves of CVXGA29, CVXGA30, CVXGA31, and CVXGA32 expressing wt% SARS-CoV-2S compared to CVXGA17 expressing SARS-CoV-2S with a PIV5 F tail.
[0041] Figures 11A-11B show the immunogenicity against SARS-CoV-2S (Figure 11A) and the immunogenicity against SARS-CoV-2N (Figure 11B) of CVXGA1, CVXGA18, CVXGA29, CVXGA30, CVXGA31, or CVXGA32.
[0042] Figure 12 shows the RSV in CVB-F-infected cells.Determination of F protein expression percentage. Vero-SF cells were infected with CVB-F pre-MVS virus diluted -3 to -5. After incubation at 37°C for 1 hour, the medium was changed, and the cells were incubated at 37°C for 18 hours. Immunostaining was performed using mouse anti-CVB-HN and human anti-F (Palivizumab) antibodies, followed by anti-mouse Alexa 488 and anti-human Cy3 secondary antibodies, respectively. Three representative images of wells infected with CVB-F pre-MVS show both green and red cells. 100% CVB-infected cells expressed both PIV5 and RSV F proteins. Images were taken at 10X.
[0043] Figures 13A-13E show the replication of CVB-F in serum-free Vero cells at 35°C and 37°C, and on days 2 and 4. Detailed Description
[0044] The invention can be more readily understood by referring to the following detailed description of preferred embodiments of the invention and the examples included therein, as well as the accompanying drawings and their preceding and following description.
[0045] I. Definitions
[0046] Various exemplary embodiments have been explained herein to facilitate understanding of the principles and features of the various embodiments of this disclosure. Although exemplary embodiments of this disclosure have been explained in detail, it should be understood that other embodiments may also be considered. Therefore, it is not intended that the scope of this disclosure be limited to the details of the construction and arrangement of the components set forth in the description or embodiments. This disclosure can have other embodiments and can be implemented or performed in various ways.
[0047] In describing exemplary embodiments, specific terminology will be used for clarity. Unless the context explicitly specifies it as indicated on page 4 / 157 of the specification 7 CN 121263205 A, the singular forms “a,” “an,” and “the” as used in this specification and the appended claims include plural indicators. For example, reference to a component is also intended to include a composition of multiple components. Reference to a composition containing a “one” component is intended to include other components besides the specified one component.
[0048] A range may be expressed herein as starting from and / or ending with "about" or "approximately" or "substantially" one particular value and / or ending with "about" or "approximately" or "substantially" another particular value. When expressing such a range, another exemplary embodiment includes starting from and / or ending with one particular value and / or another particular value.
[0049] Similarly, as used herein, "substantially free" of a substance or "substantially pure" and similar characteristics may include "at least substantially free" of a substance or "at least substantially pure," and "completely free" of a substance or "completely pure."
[0050] The terms "patient," "individual," "subject," and "animal" are used interchangeably herein and refer to mammals, including but not limited to humans and veterinary animals (e.g., cats, dogs, cattle, horses, sheep, pigs, etc.) and laboratory animal models. In a preferred embodiment...In an alternative implementation, the subject is a human.
[0051] As described herein, the term “vaccination” generally refers to the sequential administration of one or more antigens to a subject to produce and / or enhance an immune response against the antigen. Sequential administration includes a primary immunization followed by one or more booster immunizations.
[0052] In the context of this invention, the term “pathogen” refers to any agent that can cause a pathological condition. Examples of “pathogens” include, but are not limited to, cells (e.g., bacterial cells, diseased mammalian cells, cancerous mammalian cells), fungi, parasites, viruses, prions, or toxins. Preferred pathogens are infectious pathogens. In one specific embodiment, an infectious pathogen is a virus, such as a coronavirus.
[0053] As used herein, an antigen refers to any molecule that can elicit a T-cell or B-cell immune response in a subject. Antigens specific to pathogens are typically elements obtained from or derived from the pathogen, containing epitopes, and capable of eliciting an immune response against the pathogen. Depending on the pathogen, antigens can have a variety of properties, such as (poly)peptides, proteins, nucleic acids, lipids, cells, etc. Live attenuated forms of pathogens (e.g., bacteria, viruses) or their killing or inactivated forms, or materials purified therefrom, such as proteins, peptides, lipids, etc., may also be used. Antigens may be naturally occurring or artificially produced. For the mammal receiving treatment, it may be exogenous or endogenous (e.g., tumor antigens). Antigens can be produced using techniques known in the art itself, such as, for example, synthetic or recombinant techniques, or enzymatic methods.
[0054] In one specific embodiment, the antigen is a protein, polypeptide, and / or peptide. The terms “polypeptide,” “peptide,” and “protein” are used interchangeably herein and refer to a polymer of amino acid residues. The term also applies to amino acid polymers, wherein one or more amino acid residues may be modified or non-naturally occurring residues, such as artificial chemical mimics corresponding to naturally occurring amino acids. It should be understood that the term “protein” also includes fragments or variants of different antigens, such as fragments containing epitopes, or proteins obtained from pathogens and subsequently modified enzymatically, chemically, mechanically, or thermally.
[0055] "Therapeutic effective amount" means an amount sufficient to achieve such treatment when a compound (e.g., a CVB-based composition as described herein) is administered to a subject to treat a condition, symptom, or disease. "Therapeutic effective amount" will vary depending on the compound or bacteria administered, the disease and its severity, and the age, weight, physical condition, and responsiveness of the mammal being treated.
[0056] The phrase "pharmaceutically acceptable" as used in connection with the compositions of this disclosure means that the molecular entity and other components of such compositions are physiologically tolerable and generally do not produce adverse effects when administered to mammals (e.g., humans). Preferably, the term "pharmaceutically acceptable" as used herein means that it is administered by a federal or state regulatory agency.Approved or listed in the United States Pharmacopeia or other generally recognized pharmacopoeias for use in mammals and more specifically for use in humans. Instructions for Use 5 / 157 pages 8 CN 121263205 A
[0057] As used herein, the term "pharmaceuticalally acceptable composition" means a composition comprising at least one compound disclosed herein, formulated together with one or more pharmaceutically acceptable carriers.
[0058] The term "administration" means the introduction of a predetermined amount of a substance into a patient by a suitable method. The compositions disclosed herein may be administered via any common route, provided that it reaches the desired tissue, such as, but not limited to, inhalation, intraperitoneal, intravenous, intramuscular, subcutaneous, intradermal, oral, topical, intranasal, intrapulmonary, or rectal administration. However, because peptides are digested upon oral administration, the active ingredient of orally administered compositions should be coated or formulated to prevent degradation in the stomach.
[0059] The term “dosage” means a single amount of a compound or agent administered; and / or “scheme” means multiple predetermined doses, which may differ or be similar in amount, administered at different time intervals, which may differ or be similar in duration. In some embodiments, the scheme also encompasses the duration of a delivery period (e.g., an administration period or a treatment period). Alternatively, a scheme may be multiple predetermined amounts of evaporation administered at predetermined time intervals.
[0060] The term “carrier” refers to a diluent, adjuvant, excipient, or medium administered with a compound. Such drug carriers may be sterile liquids such as water and oils, including petroleum, animal, plant, or synthetic oils, such as peanut oil, soybean oil, mineral oil, sesame oil, etc. Water or aqueous saline solutions, as well as aqueous solutions of dextran and glycerol solutions, are preferred as carriers, particularly for injectable solutions. Alternatively, the carrier may be a solid dosage form carrier, including, but not limited to, one or more of binders (for tablet compression), gliding agents, encapsulating agents, flavoring agents, and coloring agents. Suitable drug delivery systems are described by E.W. Martin in Remington's Pharmaceutical Sciences.
[0061] The term "treat / treatment" includes: (1) preventing or delaying the onset of at least one clinical or subclinical symptom of the condition, symptom, or disease in a subject who may have or is susceptible to the condition, symptom, or disease but has not yet experienced or exhibited clinical or subclinical symptoms of the condition, symptom, or disease; or (2) suppressing the condition, symptom, or disease, i.e., preventing, alleviating, or delaying the development of the disease or its recurrence (in the case of maintenance therapy) or at least one clinical or subclinical symptom of the disease; or (3) alleviating the disease, i.e. causing the resolution of at least one of the condition, symptom, or disease or its clinical or subclinical symptoms. The benefit is either statistically significant or at least statistically significant for the subject receiving the treatment.The amount is perceptible to the patient or physician.
[0062] "Comprising," "containing," or "including" means that the specified compound, element, particle, or method step is present in the composition, article, or method, but does not exclude the presence of other compounds, materials, particles, or method steps, even if such other compounds, materials, particles, or method steps have the same function as the specified compound, material, particle, or method step.
[0063] As used herein, the term "parainfluenza virus 5" (PIV5) includes, for example, but not limited to, strains KNU-11, CC-14, D277, 1168-1, and 08-1990. Non-limiting examples of the PIV5 genome are listed in GenBank accessions NC_006430.1, AF052755.1, KC852177.1, KP893891.1, KC237065.1, KC237064.1, and KC237063.1, which are incorporated herein by reference.
[0064] As used herein, the term “expression” refers to the process of polynucleotide transcription into mRNA and translation into peptides, polypeptides, or proteins. If the polynucleotide is derived from genomic DNA and a suitable eukaryotic host cell or organism is selected, expression may include splicing of mRNA. In the context of this invention, the term also covers the generation of F gene mRNA and the F protein obtained after its expression.
[0065] As used herein, the terms “F protein” or “fusion protein” or “F protein polypeptide” or “fusion protein polypeptide” refer to a polypeptide or protein having all or part of the amino acid sequence of an RSV fusion protein polypeptide. Various RSV fusions and adhesion proteins have been described and are known to those skilled in the art. WO / 2008 / 114149 (which is incorporated herein by reference in its entirety) illustrates exemplary F protein variants and G protein variants (e.g., naturally occurring variants). Specification 6 / 157 pages 9 CN 121263205 A
[0066] As used herein, the term “combination” of a CVB-based composition as described herein with at least a second pharmaceutically active ingredient means at least two, but any desired combination of compounds may be delivered simultaneously or sequentially (e.g., within 24 hours). It is envisioned that the compositions and methods of this disclosure can be used in conjunction with other treatments / agents applicable to the same or similar diseases when used to treat various diseases. Such other treatments / agents may be administered simultaneously (simultaneously or sequentially, in any order) to produce an additive or synergistic effect. Due to additive or synergistic effects, the appropriate therapeutically effective dose of each agent may be reduced. Furthermore, two or more embodiments of this disclosure may also be administered together to produce an additive or synergistic effect.
[0067] The term "coronavirus" refers to a group of related RNA viruses that cause diseases in mammals and birds. In humans, this...These viruses can cause respiratory infections ranging from mild to fatal. Mild symptoms include some common cold cases (which can also be caused by certain other viruses, primarily rhinoviruses), while more deadly types can cause SARS, MERS, and COVID-19. There are currently no vaccines or antiviral drugs to prevent or treat human coronavirus infections.
[0068] “SARS” or “Severe Acute Respiratory Syndrome” refers to a zoonotic viral respiratory disease that emerged in the early 21st century, caused by the severe acute respiratory syndrome coronavirus (SARS-CoV or SARS-CoV-1), the first identified strain of the SARS coronavirus species, severe acute respiratory syndrome-associated coronavirus (SARS-CoV). This syndrome led to the SARS outbreak from 2002 to 2004. In 2019, a subsequent strain—the associated strain severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)—was discovered. The term “Covid-19” or “COVID-19” refers to severe acute respiratory syndrome (SARS) caused by a virus called SARS-CoV-2 (SARS-CoV-2).
[0069] Reference to one or more method steps does not exclude the presence of additional method steps or intermediate method steps between those expressly specified steps. Similarly, it should be understood that reference to one or more components in a composition does not exclude the presence of additional components besides those expressly specified.
[0070] The materials described as constituting various elements of this disclosure are intended to be illustrative and not limiting. It is intended that the scope of this disclosure encompasses many suitable materials that perform the same or similar functions as the materials described herein. Such other materials not described herein may include, but are not limited to, materials developed after the time of development of this disclosure, for example.
[0071] II. Compositions of CPI-RSV-F, W3AΔ SH, and CVB-RSV-F
[0072] Respiratory syncytial virus (RSV) is a member of the genus Pneumoviridae. Human RSV (HRSV) is a major cause of severe lower respiratory tract disease in young children and causes a large number of morbidities and deaths in humans. RSV is also considered an important pathogenic disease in immunocompromised adults and the elderly. Due to the incomplete development of resistance to RSV in the infected host after natural infection, RSV may cause multiple infections in childhood and adulthood.
[0073] The genome of this virus consists of single-stranded antisense RNA, which is tightly associated with viral proteins to form a nucleocapsid. The viral envelope consists of a plasma membrane-derived lipid bilayer containing viral-encoded structural proteins. Viral polymerase is packaged with the virion and transcribes the genomic RNA into mRNA. The RSV genome encodes three transmembrane structural proteins.F, G, and SH, two matrix proteins M and M2, three nucleocapsid proteins N, P, and L, and two non-structural proteins NS1 and NS2.
[0074] The fusion of HRSV with the cell membrane is thought to occur on the cell surface and is a necessary step for the transfer of viral ribonucleoproteins to the cytoplasm in the early stages of infection. This process is mediated by the fusion (F) protein, which also promotes the fusion of the membrane of the infected cell with that of neighboring cells to form the characteristic syncytium, which is both a significant cytopathic effect and another mechanism for viral transmission. Therefore, neutralizing fusion activity is important for host immunity. In fact, monoclonal antibodies developed against the F protein have been shown to neutralize viral infectivity and inhibit membrane fusion (Calder et al., 2000, Virology 271: 122-131).
[0075] The F protein of RSV has the same structural features and limited but significant amino acid sequence identity as the F glycoproteins of other paramyxoviruses. It is synthesized as an inactive precursor of 574 amino acids (F0) and co-translationally glycosylated on asparagine in the endoplasmic reticulum, where it assembles into homooligomers. Before reaching the cell surface, the F0 precursor is cleaved by a protease from the N-terminus to F2 and from the C-terminus to F1. The F2 and F1 chains remain covalently linked by one or more disulfide bonds.
[0076] CPI-RSV-F is a parainfluenza virus (PIV5)-based RSV vaccine that expresses the RSV F protein and is provided herein as a prophylactic intranasal vaccine to prevent RSV infection and serious complications associated with RSV infection. CPI-RSV-F is designed to induce an immune response to the RSV F protein, which is a major antigenic protein that is highly conserved between RSV subtypes A and B. Anti-F antibodies can inhibit viral entry into host cells, and based on efficacy data from the commercial product palizumab (RSV F monoclonal antibody), RSV F is a validated vaccine target. W3AΔSH-RSV-F and CVB-RSV are modified RSV vaccines, and their backbone differences from CPI-RSV-F are summarized in Figure 1.
[0077] This disclosure provides CPI-RSV-F, W3AΔSH-RSV-F, and CVB-RSV compositions, systems, and methods for a variety of applications, including functional genomics, drug discovery, target validation, protein production (e.g., therapeutic proteins, vaccines, monoclonal antibodies), gene therapy, and therapeutic treatments (e.g., cancer therapy).
[0078] A. Pharmacological summary of RSV studies
[0079] This disclosure provides CPI-RSV-F, W3AΔSH-RSV-F, and CVB-RSV compositions, systems, and methods for a variety of applications, including functional genomics, drug discovery, target validation, protein production (e.g., therapeutic proteins, vaccines, monoclonal antibodies), gene therapy, and therapeutic treatments (e.g., cancer therapy).Applications include functional genomics, drug discovery, target validation, protein production (e.g., therapeutic proteins, vaccines, monoclonal antibodies), gene therapy, and therapeutic treatments (e.g., cancer therapy).
[0080] Previously published studies on the W3A strain based on the PIV5 construct (engineered to express the RSV-F protein) include immunogenicity and challenge studies in mice, hamsters, and African green monkeys (1,2,3). As part of these studies, permission for PIV5 replication was confirmed in hamsters and African monkeys (1,2). In addition, the following studies were conducted: 1) comparing CPI-based vector constructs with W3A PIV5 strain-based vector constructs; 2) comparing the expression of the pre-fusion F protein of RSV with wt F protein replacing the PIV5 SH gene (ΔSH) or inserted between PIV5 SH and NH (SH-NH) or inserted between HN and L (HN-L) in vaccine constructs. These studies selected CPI-RSV-F (CPI-RSV-F), which contains the full-length RSV F protein inserted between the SH and HN genes, for preliminary human studies.
[0081] Furthermore, the protective efficacy of the CPI-RSV-F vaccine has been evaluated in RSV challenge studies in mice and hamsters. Compared to controls, significantly reduced RSV viral titers were observed in the lung and nasal lavage fluids of immunized animals, and immunization with a single intranasal dose protected animals from RSV infection.
[0082] Recent preclinical proof-of-concept studies using the vaccine vector construct CPI-RSV-F include immunogenicity and challenge studies in mice and African green monkeys conducted by Blue Lake Biotechnology. In addition, this paper summarizes preclinical data from the CPI-RSV-F construct studies in NIH-sponsored hamster challenge studies. The CPI-RSV-F vaccines used in these recent nonclinical studies used a previous vaccine vector construct (rescued from BHK cells) that was identical to the vector construct used for clinical batch materials (rescued from 293 / Vero cells) and was similarly produced using serum-free Vero cells as a substrate and formulated with sucrose phosphate glutamate (SPG) buffer. These nonclinical studies included a control (a PIV5 W3A strain engineered to express the RSV F protein with a deleted SH gene, W3AΔSH-RSV-F) as an activity comparison.
[0083] In summary, nonclinical studies in various animal models have demonstrated the ability of CPI-RSV-F, W3AΔSH-RSV-F, and CVB-RSV to induce RSV F-specific immune responses, as observed after a single intranasal dose via F-specific antibodies and cell-mediated immune responses. All of these candidate vaccines were well tolerated in these animal models.Sexuality, and no signs of sensitization were observed after vaccination.
[0084] Table 1: Overview of previous vaccine construct studies and recent non-clinical studies using the CPI-RSV-F construct. Specification 8 / 157 pages 11 CN 121263205 A
[0085]
[0086] i. Studies of W3A PIV5 vectors expressing RSV F protein in mice, cotton rats and monkeys
[0087] Studies of PIV5(W3A)-RSV-F and RSV-G proteins in Balb / c mice: In this study, Balb / c mice received a single intranasal dose of W3A-RSV-F (106 PFU dose in 50 μl) and were then challenged with RSV. The PIV5 W3A vaccine vector construct used in this study consisted of wild-type RSV F protein inserted into the region between the PIV5 HN and L genes. The IgG2a / IgG1 RSV response generated by a single intranasal dose was similar to the response observed after wild-type RSV A2 infection on day 21 post-immunization.
[0088] PIV5 (W3A) challenge studies expressing wild-type or pre-fusion RSV F protein in mice and hamsters: This study evaluated PIV5 vector vaccines modified by altering the F protein insertion site (insertion at the SH-HN junction of PIV5 or replacement of SH with the RSV F protein gene). Furthermore, this study evaluated both wild-type (wt) F protein and pre-fusion conformation F protein (pF).
[0089] Mice were immunized with a single intranasal dose of the following at 1×10⁶ PFU: W3AΔSH-RSV-F (RSV F protein gene inserted into the SH region of PIV5) expressing wild-type F protein or a pre-fusion stable RSV F mutant (W3AΔSH-RSV-pF), or modified vectors W3AΔSH-RSV-F or W3A-RSV-pF SH-HN (F protein gene inserted at the SH-HN junction). The study group is as follows (Table 2).
[0090] Table 2: Study Group Specification for Mouse Attack Study 9 / 157 pages 12 CN 121263205 A
[0091]
[0092] Following immunization, humoral and cellular immune responses were observed. The highest neutralizing antibody response was detected with the vaccine construct using the wtF protein. Furthermore, the vaccine construct containing the wtF inserted before HN binding to ΔSH appeared to have the strongest immunogenicity. Cell-mediated immune response levels (based on IFN-γ using ELISPOT) were similar across various vaccine constructs.
[0093] Mice were challenged with RSV A2 28 days post-immunization to determine protective efficacy. On day 4 post-challenge, the challenge virus was detected in only one of five mice in the W3A Δ SH-RSV-F group, while it was not detected in mice in the other vaccination groups.No virus was found in any of the mice. In the PBS control group, all mice recovered from the challenge virus.
[0094] Similar studies were also conducted in cotton rats, which are more susceptible to RSV infection. Rats were immunized with modified vectors containing wild-type or perfusion-stable F protein (pF) at low doses of 103 PFU (W3A-RSV-F(SH-HN), W3A-RSV-pF, W3AΔSH-RSV-F) or 102 PFU of W3AΔSH-RSV-pF.
[0095] Immune responses were observed in all groups, including neutralizing antibody responses against the RSV A Tracy strain (97% identical to the RSV A / A2 strain). Similar to the mouse studies, the groups immunized with the vaccine construct containing wt F protein had higher antibody levels compared to the pF group, with the highest value (titer approximately 128) for F inserted before HN gene binding to ΔSH. Neutralizing antibody titers against RSV / B / 18537 were significantly lower than those against RSV / A Tracy strains, with significant antibody levels (titers of approximately 8) detected only in the W3A(SH-HN)-RSV-F and W3AΔSH-RSV-F groups. Following RSV challenge with 1.21 × 10⁵ PFU of RSV / A / Tracy on day 28, all vaccine dose groups showed reduced RSV viral load in nasal lavage fluid (reduction of 1.4–1.66 Log¹⁰) and reduced RSV viral load in bronchoalveolar lavage fluid (reduction of 2–3 Log¹⁰). All mice in the PBS control group recovered RSV challenge virus (approximately 10⁵ PFU / nasal lavage fluid or 10⁵ PFU / g bronchoalveolar lavage fluid).
[0096] Overall, these preliminary studies in mouse and cotton rat models did not show evidence that the pre-fusion F protein was more immunogenic and protective than the wild-type F protein. Furthermore, no difference in vector performance was observed between the ΔSH and SH-HN insert vector constructs via the intranasal route.
[0097] Sigmovir Protocol #XV-131 Study Report in Cotton Rats Using Intranasal and Subcutaneous Routes (Phan et al. 2017) Challenge Study: In a follow-up study (1, Phan et al. 2017), the efficacy, immunogenicity, and safety of higher doses of 10⁵ and 10⁶ PFU of W3A(SH-NH)-RSV-F and W3AΔSH-RSV-F were tested in cotton rat challenge studies, which evaluated two different routes—intranasal (in) and subcutaneous (sc). This study also included a disease-enhancing positive control (animals immunized with FI-RSV and then challenged with RSV, and a positive control group consisting of animals pre-infected with RSV and then challenged with RSV). Animals in this study were challenged with RSV A2 on day 49 and underwent necropsy and group testing 5 days later (day 54). (Instructions for Use 10 / 157 pages 13 CN)121263205 A Tissue Science. The study groups for this study are as follows (Table 3).
[0098] Table 3: Study groups in protocol #XV-131.
[0099]
[0100] Immunogenicity: W3A(SH-HN)-RSV-F produced similar neutralizing antibody titers between the in and sc groups at doses of 105 and 106. Compared to the sc group, the in group showed slightly higher neutralizing antibody titers induced by W3AΔSH-RSV-F vaccination, with a slightly higher titer at the 106 dose, although this was not statistically significant.
[0101] Efficacy: W3A(SH-HN)-RSV-F provides complete protection of the lower respiratory tract by administration via in or sc. The viral load in the upper respiratory tract of the animals was also significantly lower.
[0102] Compared with control animals sham-immunized with PBS (mean titer 10⁵ PFU), the W3A(SH-HN)-RSV-F vaccine provided complete protection of the lower respiratory tract by sc administration and near-complete protection by in administration, based on the reduced titers observed in lung and nasal lavage fluids (mean titer 10³ PFU).
[0103] Safety: Lung sections from different groups were examined for the characteristics of lung inflammation: peribronchial inflammation, perivasculitis, interstitial pneumonia, and alveolitis, and scored to determine severity. The largest lesions were observed in the group that received FI-RSV immunization and RSV challenge (positive control group). In the groups immunized with W3A-RSV-F (SH-HN) or W3AΔ SH-RSV-F (intranasal or subcutaneous), lung changes were moderate, with levels lower than those observed in the positive control group immunized with RSV and challenged with RSV, and similar to those observed in the PBS sham-immunized group challenged with RSV.
[0104] Measurement of cytokine levels in lung tissue 5 days post-challenge by quantitative real-time PCR (qPCR) did not indicate the possibility of enhanced infection. IL-4 mRNA levels were significantly elevated only in the FI-RSV vaccination group, consistent with histopathological findings and enhanced disease phenotype. IFNγ-mRNA levels were highest in the sham-immunized and FI-RSV vaccination groups. IFN-mRNA levels were similarly low in the groups immunized with the PIV5-based candidate, as in the RSV vaccination group. IL-2 mRNA levels were similar across all groups, but the mean IL-2 level in the FI-RSV vaccination group was significantly higher than in the other groups.
[0105] On day 28 post-immunization, mice were challenged intranasally with RSV A2 (10⁶ PFU in 50 μl). Lung sections obtained on day 4 post-challenge showed no exacerbation of lung lesions compared to RSV-A2 immunized mice. Protective immunity was observed, as assessed by viral load in lung tissue (n = 5 mice per group).
[0106] PIV5 (W3A) challenge studies expressing RSV F or G proteins in mice and African green monkeys: This study evaluated the replication, immunogenicity, and protective efficacy against RSV challenge of the PIV5 vector RSV F protein in mice and African green monkeys. In this study, the F protein was inserted into the intergenic region between the PIV5 HN and L genes.
[0107] PIV5 replication permission in mice and African green monkeys: Mice (n=4 per group) were intranasally inoculated with 1×10⁵ PFU of PIV5 in volumes of 10 μl or 100 μl. Viral titers (up to 1×10⁴ PFU) were observed in the nasal homogenate on day 4, and almost disappeared by day 6. The larger inoculation volume (100 μl) resulted in the observation of vaccine virus in the lungs of all animals on day 6, while the virus was observed only in one animal inoculated with a smaller volume of 10 μl.
[0108] To assess the licensing of PIV5 in African green monkeys, 60 animals were screened for anti-PIV5 antibodies, and all were found to be negative. Animals (n=3 per group) were intranasally infected with 1×10² to 1×10⁸ PFU of PIV5 in a dose volume of 0.25 mL. Viral shedding was assessed in nasal lavage fluid and bronchoalveolar lavage fluid on days 3, 5, 7, 10, and 14. Virus shedding from the nose and lungs persisted for up to 10 days, and viral replication peaked on day 5 at doses as low as 1×10² PFU. This data indicate the licensing of PIV5 in African green monkeys.
[0109] Immunogenicity in mice and African green monkeys after a single dose of W3A-RSV-F: Mice were intranasally immunized with W3A-RSV-F at doses of 1×10³, 1×10⁴, 1×10⁵, and 1×10⁶ PFU. At all dose levels, IgG antibody responses were observed on day 28, and responses were comparable across dose groups. Neutralizing antibodies were observed in all dose groups, with titers ranging from 64 to 256. Furthermore, IgA responses were observed in lung homogenates from all dose groups on day 21 post-vaccination.
[0110] African green monkeys (PIV5 and RSV seronegative) received a single intranasal immunization of 1×10⁴ or 1×10⁶ PFU W3A-RSV-F. Serum obtained on day 21 post-vaccination showed high titers of F-specific antibody responses. Additionally, low levels of neutralizing antibody responses were observed on day 21 (52 in the 1×10⁶ PFU dose group). Nasal swabs obtained on day 21 post-immunization showed significant levels of F protein IgA responses. Cell-mediated responses assessed by interferon gamma showed lower response levels in the 1×10⁶ PFU dose group.
[0111] Protective effect in cotton rats and African green monkeys subjected to RSV attack (Study #131): with 1×10³ to 1×10⁶ PFUSingle-dose intranasal immunization of cotton rats within the W3A-RSV-F range was followed by RSV A2 challenge on day 28 post-immunization. Protective effect was assessed by measuring viral load in nasal and lung tissues. A dose-dependent decrease in viral load was observed, except in the 1×10⁶ PFU group, which showed a higher level relative to the 1×10³ PFU group, but still decreased compared to the control group. In the 1×10⁵ dose group, no virus was detected in the lungs, and a decrease in titer (3 log¹⁰ level) was observed in the nose.
[0112] African green monkeys immunized with 1×10⁴ or 1×10⁶ PFU W3A-RSV-F were followed by RSV A2 challenge on day 28 post-immunization. RSV viral load was assessed in nasal and BAL samples on days 3–14 post-challenge. Immunization with W3A-RSV-F did not shorten the viral shedding time; however, the peak viral RSV load was reduced by 10 to 100-fold in both dose groups, with the highest reduction observed in the 1 × 10⁶ PFU dose group.
[0113] Response to W3A-RSV-F in African green monkeys exposed to RSV: Prior exposure to RSV did not affect the ability of African green monkeys (which undergo seroconversion via intranasal infection with RSV A2) to increase RSV neutralizing antibody titers (by 50-fold).
[0114] Lung pathology in W3A-RSV-F-immunized rats after RSV challenge: In animals immunized with 1 × 10⁶ PFU PIV5-RSV-F on day 0 and challenged with RSV A2 on day 49, lungs obtained five days post-challenge were subjected to blind histopathological examination to examine for alveolitis, interstitial pneumonia, perivasculitis, and peribronchitis, and compared with lungs obtained from control animals inoculated with formalin-inactivated RSV. Positive control animals inoculated with formalin-inactivated RSV scored significantly higher than PBS control animals, but not higher than W3A-RSV-F animals (ANOVA paired t-test).
[0115] B. Parainfluenza virus 5 (PIV5)
[0116] Parainfluenza virus 5 (PIV5) is a negative-strand RNA virus and a member of the genus Rubulavirus in the family Paramyxoviridae. This family includes many important human and animal pathogens, such as mumps virus, human parainfluenza virus types 2 and 4, Newcastle disease virus, Sendai virus, HPIV3, measles virus, canine distemper virus, rinderpest virus, and respiratory syncytial virus. PIV5 was previously known as simian virus-5 (SV5). Although PIV5 is a virus that infects many animals and humans, no known symptoms or diseases associated with PIV5 have been found in humans.Unlike myxoviruses, PIV5 has almost no cytopathic effect when infecting normal cells. As a negative-strand RNA virus, the PIV5 genome is very stable. Because PIV5 has no DNA phase in its life cycle and replicates only in the cytoplasm, it cannot integrate into the host genome. Therefore, using PIV5 as a vector avoids the unintended consequences that may result from genetic modification of the host cell DNA. PIV5 can be grown to high titers in cells, including Vero cells, which have been approved by the WHO and FDA for vaccine production. Therefore, PIV5 presents many advantages as a vaccine vector.
[0117] The PIV5-based vaccine vector of the present invention can be based on any of a variety of wild-type, mutant, or recombinant (rPIV5) strains. Wild-type strains include, but are not limited to, PIV5 strain W3A, WR (code VR-288TM), canine parainfluenza virus strain 78-238 (ATCC code VR-1573) (Evermann et al., 1980, J Am Vet Med Assoc; 177: 1132-1134; and Evermann et al., 1981, Arch Virol; 68:165-172), canine parainfluenza virus strain D008 (ATCC code VR-399) (Binn et al., 1967, Proc Soc Exp Biol Med; 126:140-145), MIL, DEN, LN, MEL, cryptovirus, CPI+, CPI-, H221, 78524, T1, and SER. See, for example, Chatziandreou et al., 2004, J Gen Virol; 85(Pt 10):3007-16; Choppin, 1964, Virology:23:224-233; and Baumgartner et al., 1987, Intervirology; 27:218-223. Alternatively, the PIV5 strain used in commercial kennel cough vaccines, such as BI, FD, Merck, and Merial vaccines, can be used.
[0118] C. PIV5 CPI strain vector backbone
[0119] The differences between the PIV5 CPI strain vector backbone and the PIV5 W3A strain vector backbone are as follows (Figure 1). The most significant difference is in the PIV5 F protein of the CPI strain, which consists of an additional 22 amino acid extension that is part of its cytoplasmic tail. The extension of the F protein is thought to inhibit the fusion properties of the virus (5,6). Compared to W3A-based viruses, which lack an extended PIV5 F protein tail and exhibit additional amino acid differences compared to CPI, CPI-based viruses show stronger solubility and are more effective in infecting viruses.More progeny viruses can be produced in infected cells (4). The CVB backbone with S156N or S157F in PIV5W3A can increase virus production in cell culture and has stronger immunogenicity in vivo than the CPI backbone.
[0120] Previously, recombinant PIV5 viruses expressing exogenous genes from various pathogens, including influenza, rabies, respiratory syncytial virus, tuberculosis, Burkholderia, MERS-CoV, and SARS-CoV-2, have been generated and tested as candidate vaccines (Li, Z. et al., J Virol, 87(1): 354 (2013); Chen, Z. et al., J Virol, 87(6): 2986 (2013); Wang, D. et al., J Virol, 91(11) (2017); Chen, Z. et al., Vaccine, 33(51): 7217 (2015); Lafontaine, ER et al., Vaccine X., 1:100002 (2018); Li, K. et al., mBio, 11(2) (2020); An et al., Sci Adv, July 2; 7, 2021). Since PIV5 vector vaccines actively replicate in the respiratory tract after intranasal immunization, they can generate mucosal immunity, including antigen-specific IgA antibodies and long-lived IgA plasma cells (Wang, D. et al., J Virol, 91(11)(2017). Xiao, P. et al., Front Immunol, 12:623996(2021)).
[0121] D. PIV5 CVB backbone
[0122] This article provides a modified PIV5 vector, CVB. The CVB backbone vector is immunogenic and can be used as an effective vaccine platform. The CVB backbone contains a mutation at amino acid residue S157 or S156 of the P / V gene, in which the phosphorylation site is removed, resulting in higher transcriptional activity, thereby increasing the viral titer in cell culture.
[0123] In some embodiments, the mutation at amino acid residue S157 or S156 comprises the substitution of serine (S) with an amino acid residue selected from the group consisting of: alanine (A), cysteine (C), aspartic acid (D), glutamic acid (E), phenylalanine (F), glycine (G), histidine (H), isoleucine (I), lysine (K), leucine (L), methionine (M), asparagine (N), proline (P), glutamine (Q), arginine (R), selenocysteine (U), valine (V), tryptophan (W), and tyrosine.Amino acid (Y). In one embodiment, the amino acid substitution at amino acid residue S157 includes replacing serine (S) with phenylalanine (F) or the amino acid substitution at amino acid residue S156 includes replacing serine (S) with asparagine (N). i. CVB Backbone
[0125] Provided herein are CVB backbone nucleic acid sequences:
[0126] ACCAAGGGGAAAATGAAGTGGTGACTCAAATCATCGAAGACCCTCGAGATTACATAGGTCCGGAACCT ATGGCCTTCGTGACCGACCTCGAGTCAGAGTAGTTCAATAAGGACCTATCAAGTTTGGGCAATTTTTCGTCCCCGA CACAAAAATGTCATCCGTGCTTAAAGCATATGAGCGATTCACGCTCACTCAAGAACTGCAAGATCAGAGTGAGGAA GGTACAATCCCACCTACAACACTAAAACCGGTAATCAGGGTATTTATACTAACCTCTAATAACCCAGAGCTAAGAT CCCGGCTTCTTCTATTCTGCCTACGGATTGTTCTCAGTAATGGTGCAAGGGATTCCCATCGCTTTGGAGCATTACT CACAATGTTTTCGCTACCATCAGCCACAATGCTCAATCATGTCAAATTAGCTGACCAGTCACCAGAAGCTGATATC GAAAGGGTAGAGATCGATGGCTTTGAGGAGGGATCATTCCGCTTAATCCCCAATGCTCGTTCAGGTATGAGCCGTG GAGAGATCAATGCCTATGCTGCACTTGCAGAAGATCTACCTGACACACTAAACCATGCAACACCTTTCGTTGATTC CGAAGTCGAGGGAACTGCATGGGATGAGATTGAGACTTTCTTAGATATGTGTTACAGTGTCCTAATGCAGGCATGG ATAGTGACTTGCAAGTGCATGACTGCGCCAGACCAACCTGCTGCTTCTATTGAGAAACGCCTGCAAAAATATCGTC AGCAAGGCAGGATCAACCCGAGATATCTCCTGCAACCGGAGGCTCGACGAATAATCCAGAATGTAATCCGGAAGGGAATGGTGGTCAGACATTTCTCACCTTTGAACTGCAGCTTGCCCGAGCACAAAGCCTTGTATCAAATAGGTATTAT GCTATGGTAGGGGATGTTGGAAAGTATATAGAGAATTGTGGAATGGGAGGCTTCTTTTGACACTAAATATGCAT TAGGAACTAGAGTCCCACACTTGCTTTAGCTGCATTTTTCAGGAGAGCTAACAAAGCTAAAGTCCTCATGGCATT ATACCAGACCCTTGGTGAGCAGCCCGATATTTGCCCTATTGGAGTCACCACATTTGGATTTTGCTGCAGCA AACTACCCCACTGCTATATAGCTATGCTATGGGAATAGGCCTTGATGTGTCAACATGAGGAACTACGCTTTCT CCAGATCATACATGAACAAGACATATTTCCAATTGGGAATGGAAACTGCAAGAAAACAACAGGGTGCAGTTGACAT GAGGATGGCAGAAGATTCTCGGTCTAACTCAAGCCGAACGCACGAGATGGCAAATACACTTGCCAAATTGACCA GCAAATCGAGGGGCACACACCAGGGGAGTCAACCCGTTCTCATCTGTCACTGGGACAACTCAGGTGCCCGCTG CAGCAACAGGTGACACACTCGAGAGTTACATGGCAGCGGATCGACTGAGGCAGAGATATGCTGATGCAGGCACCCA TGATGATGAGATGCCACCATTGGAAGAGGAGAAGGACGACACATCTGCAGGTCCACGCACTGGACCAACTCTT GAACAAGTGGCCTTGGACATCCAGAACGCAGCAGTTGGAGCTCCCATCCATACAGATGACCTGAATGCCGCACTGG GTGATCTTGACATCTAGACATTCAGATCCCAATCTAAAATTGACATACCAATTGATTAGTTAGATGGAACTACA GTGGATTCCATAAGGTTCCTGCCTACCATCGGCTTTAAAGAAAAAAATAGGCCCGGACGGGTTAGCAACAAGCGACTGCCGGTGCCAACAGCGCAATCCACAATCTACAATGGATCCCACTGATCTGAGCTTCTCCCCAGATGAGATCAATA AGCTCATAGAGACAGGCCTGAATACTGTAGAGTATTTTACTTCCCAACAAGTCACAGGAACATCCTCTCTTGGAAA GAATACAATACCACCAGGGGTCACAGGACTACTAACCAATGCTGCAGAGGCAAAGATCCAAGAGTCAACTAACCAT CAGAAGGGCTCAGTTGGTGGGGGTGCAAAACCAAAGAAACCGCGACCAAAAATTGCCATTGTGCCAGCAGATGACA AAACAGTGCCCGGAAAGCCGATCCCAAACCCTCTATTAGGTCTGGACTCCACCCCGAGCACCCAAACTGTGCTTGA TCTAAGTGGGAAAACATTACCATCAGGATCCTATAAGGGGGTTAAGCTTGCGAAATTTGGAAAAGAAAATCTGATG ACACGGTTCATCGAGGAACCCAGAGAGAATCCTATCGCAACCAGTTtCCCCATCGATTTTAAGAGGGGCAGGGATA CCGGCGGGTTCCATAGAAGGGAGTACTCAATCGGATGGGTGGGAGATGAAGTCAAGGTCACTGAGTGGTGCAATCC ATCCTGTTCTCCAATCACCGCTGCAGCAAGGCGATTTGAATGCACTTGTCACCAGTGTCCAGTCACTTGCTCTGAA TGTGAACGAGATACTTAATACAGTGAGAAATTTGGACTCTCGGATGAATCAACTGGAGACAAAAGTAGATCGCATT DESCRIPTION Page 14 of 157 17 CN 121263205 A CTCTCATCTCAGTCTCTAATCCAGACCATCAAGAATGACATAGTTGGACTTAAAGCAGGGATGGCTACTTTAGAAG GAATGATTACAACTGTGAAAATCATGGACCCGGGAGTTCCCAGTAATGTTACTGTGGAAGATGTACGCAAGACACTAAGTAACCATGCTGTTGTTGTGGCCAGAATCATTCAATGATAGTTTCTTGACTCAATCTGAAGATGTAATTTCACTT GATGAGTTGGCTCGACCAACTGCAACAAGTGTTAAGAAGATTGTCAGGAAGGTTCCTCCTCAGAAGGATCTGACTG GATTGAAGATTACACTAGAGCAATTGGCAAAGGATTGCATCAGCAAACCGAAGATGAGGGAAGATTCTCCTCAA AATCAACCAGGCTTCCAGTGAGGCTCCAGCTAATTGACCTCCAAGAAAGCAATCATCCGCAGTGCAATTTGATCAAGAAAAGCAATCATCCGCAGTGCAATTTGATCAAAAAAAGATTACACTACACTGGTATGACACTGTACTAACCCTGAGGGTTTTAGAAAAAGATTAAAGATTACCTACGTCA ATCAATAAAAGCGTTCCCAATTGGTGATCAACAGTGATGGGGTGAGAAAAGCCGCCTTGGTTAAACAACTACGCACA ACCTACTTGAATGACCTAGATACTCATGAGCCACTGGTGACATTCATCATAAATATCCTATGGATTCATCTACGAAAAGGAGG ATCGGGGGAATACCATTGTCGGAGAGGATCAACTTGGGAAGAAAAGAGAGGCTGTGACCGCTGCAATGGTTACCCT TGGATGTGGGCCTAATCTACCATTAGGGAATGTCCTGGGACAACTGAGGGAATTCCAGGTCACTGTTAGGAAG ACATCCAGCAAAGCGGAAGAGATGGTCTTTGAAATTGTTAAGTATCGAGAATATTTCGGGGTCATACATTAATCC AGAAAGGACTAGTCTGTGTCTCCGCAGAAAAAATTGTTAAGTCACCAGGAAATACAATCTGGAATGGACTATCT CTTCATTCCGACATTTTCTGTCAGTGACTTACTGTCCAGCTGCAATCAAATTTCAGGTACCTGGCCCCATGTTGAAAATGAGATCAAGATACACTCAGAGCTTACAACTTGAACTAATGATAAGAATCCTGTGTAAGCCCGATTCGCCACTTA TGAAGGTCCATACCCCTGACAAGGAGGGAAGAGGATGTCTTGTATCAGTATGGCTGCATGTATGCAACATCTTCAA ATCAGGAAACAAGAATGGCAGTGAGTGGCAGGAATACTGGATGAGAAAGTGTGCTAACATGCAACTTGAAGTGTCG ATTGCAGATATGTGGGGACCAACTATCATAATTCATGCCAGAGGTCACATTCCCAAAAGTGCTAAGTTGTTTTTTG GAAAGGGTGGATGGAGCTGCCATCCACTTCACGAAGTTGTTCCAAGTGTCACTAAAACACTATGGTCCGTGGGCTG TGAGATTACAAAGGCGAAGGCAATAATACAAGAGAGTAGCATCTCTCTTCTCGTGGAGACTACTGACATCATAAGT CCAAAAGTCAAAATTTCATCTAAGCATCGCCGCTTTGGGAAATCAAATTGGGGTCTGTTCAAGAAAACTAAATCAC TGCCTAACCTGACGGAGCTGGAATGACTGACCTCTAATCGAGACTACACCGCCGCAAACTATAGGTGGGTGGTACC TCAGTGATTAATCTTGTAAGCACTGATCGTAGGCTACAACACACTAATATTATCCAGATTAGAGAGCTTAATTAGC TCTGTATTAATAATAACACTACTATTCCAATAACTGGAATCACCAGCTTGATTTATCTCCAAAATGATTCAAAGAA AACAAATCATATTAAGACTATCCTAAGCACGAACCCATATCGTCCTTCAAATCATGGGTACTATAATTCAATTTCT GGTGGTCTCCTGTCTATTGGCAGGAGCAGGCAGCCTTGATCCAGCAGCCCTCATGCAAATCGGTGTCATTCCAACA AATGTCCGGCAACTTATGTATTATACTGAAGCTTCATCAGCATTCATTGTTGTGAAGTTAATGCCTACAATTGACTCGCCGATTAGTGGATGTAATATAACATCAATTTCAAGCTATAATGCAACAGTGACAAAACTCCTACAGCCGATCGG TGAGAATTTGGAGACGATTAGGAACCAGTTGATTCCAACTCGGAGGAGACGCCGGTTTGCAGGGGTGGTGATTGGA TTAGCTGCATTAGGAGTAGCTACTGCCGCACAGGTCACTGCCGCAGTGGCACTAGTAAAGGCAAATGAAAATGCTG CGGCTATACTCAATCTCAAAAATGCAATCCAAAAAACAAATGCAGCAGTTGCAGATGTGGTCCAGGCCACACAATC ACTAGGAACGGCAGTTCAAGCAGTTCAAGATCACATAAACAGTGTGGTAAGTCCAGCAATTACAGCAGCCAATTGT AAGGCCCAAGATGCTATCATTGGCTCAATCCTCAATCTCTATTTGACCGAGTTGACAACCATCTTCCACAATCAAA TTACAAACCCTGCATTGAGTCCCATTACAATTCAAGCTTTAAGGATCCTACTGGGGAGTACCTTGCCGACTGTGGT CGAAAAATCTTTCAATACCCAGATAAGTGCAGCTGAGCTTCTCTCATCAGGGTTATTGACAGGCCAGATTGTGGGA TTAGATTTGACCTATATGCAGATGGTCATAAAAATTGAGCTGCCAACTTTAACTGTACAACCTGCAACCCAGATCA TAGATCTGGCCACCATTTCTGCATTCATTAACAATCAAGAAGTCATGGCCCAATTACCAACACGTGTTATGGTGAC TGGCAGCTTGATCCAAGCCTATCCCGCATCGCAATGCACCATTACACCCAACACTGTGTACTGTAGGTATAATGAT DESCRIPTION Page 15 of 157 18 CN 121263205 A GCCCAAGTACTCTCAGATGATACTATGGCTTGCCTCCAAGGTAACTTGACAAGATGCACCTTCTCTCCAGTGGTTGGGAGCTTTCTCACTCGATTCGTGCTGTTCGATGGAATAGTTTATGCAAATTGCAGGTCGATGTTGTGCAAGTGCAT GCAACCTGCTGCTGTGATCCTACAGCCGAGTTCATCCCCTGTAACTGTCATTGACATGTACAAATGTGTGAGTCTG CAGCTTGACAATCTCAGATTCACCATCACTCAATTGGCCAATGTAACCTACAATAGCACCATCAAGCTTGAATCAT CCCAGATCTTGTCTATTGATCCGTTGGATATATCCCAGAATCTAGCTGCGGTGAATAAGAGTCTAAGTGATGCACT ACAACACTTAGCACAAAGTGACACATATCTTTCTGCAATCACATCAGCTACGACTACAAGTGTATTATCCATAATA GCAATCTGTCTTGGATCGTTAGGTTTAATATTAATAATCTTTGCTCAGTGTAGTTGTGTGGAAGTTATTGACCATTG TCGTTGCTAATCGAAATAGAATGGAGAATTTTGTTTATCATAAATAAGCATTCCACCACTCACGATCTGATCTCAG TGAGAAAAATCAACCTGCAACTCTTGGAACAAGATAAGACAGTCATCCATTAGTAATTTTTAAGAAAAAAACGATA GGACCGAACCTAGTATTGAAAGAACCGTCTCGGTCAATCTAGGTAATCGAGCTGATACCGTCTCGGAAAGCTCAAA TCCTGCTATAGGCTATCCACTGCATCATCTCTCCTGCCATACTTCCTACTCACATCATATCTATTTTAAAGAAAAA ATAGGCCCGAACACTAATCGTGCCGGCAGTGCCACTGCACACACAACACTACACATACAATACACTACAATGGTTG CAGAAGATGCCCCTGTTAGGGCCACTTGCCGAGTATTATTTCGAACAACAACTTTAATCTTTCTATGCACACTACT AGCATTAAGCATCTCTATCCTTTATGAGAGTTTAATAACCCAAGCAAATCATGAGCCAAGCAGGCTCAACTGGATCTAATTCTGGATTAGGAAGTATCACTGATCTTCTTAATAATATTCTCTCTGTCGCAAATCAGATTATATATAACT CTGCAGTCGCTCTACCTCTACAATTGGACACTCTTGAATCAACACTCCTTACAGCCATTAAGTCTCTTCAAACCAG TGACAAGCTAGAACAGAACTGCTCGTGGAGTGCTGCACTGATTAATGATAATAGATACATTAATGGCATCAATCAG TTCTATTTTTCAATTGCTGAGGGTCGCAATCTGACACTTGGCCCACTTCTTAATATGCCTAGTTTCATTCCAACTG CCACGACACCAGAGGGCTGCACCAGGATCCCATCATTCTCGCTCACTAAGACACACTGGTGTTATACACACAATGT TATCCTGAATGGATGCCAGGATCATGTATCCTCAAATCAATTTGTTTCTATGGGAATCATTGAACCCACTTCTGCC GGGTTTCCATTCTTTCGAACCCTAAAGACTCTATATCTCAGCGATGGGGTCAATCGTAAGAGCTGCTCTATCAGTA CAGTTCCGGGGGGTTGTATGATGTACTGTTTTGTTTCTACTCAACCAGAGAGGGATGACTACTTTTCTGCCGCTCC TCCAGAACAACGAATTATTATAATGTACTATAATGATACAATCGTGGAGCGCATAATTAATCCACCCGGGGTACTA GATGTATGGGCAACATTGAACCCAGGAACAGGAAGCGGGGTATATTATTTAGGTTGGGTGCTCTTTCCAATATATG GCGGCGTGATTAAAGGTACGAGTTTATGGAATAATCAAGCAAATAAATACTTTATCCCCCAGATGGTTGCTGCTCT CTGCTCACAAAACCAGGCAACTCAAGTCCAAAATGCTAAGTCATCATACTATAGCAGCTGGTTTGGCAATCGAATG ATTCAGTCTGGGATCCTGGCATGTCCTCTTCGACAGGATCTAACCAATGAGTGTTTAGTTCTGCCCTTTTCTAATGATCAGGTGCTTATGGGTGCTGAAGGGAGATTATACATGTATGGTGACTCGGTGTATTACTATCAAAGAAGCAATAG TTGGTGGCCTATGACCATGCTGTATAAGGTAACCATAACATTCACTAATGGTCAGCCATCTGCTATATCAGCTCAG AATGTGCCCACACAGCAGGTCCCTAGACCTGGGACAGGAGACTGCTCTGCAACCAATAGATGTCCCGGTTTTTGCT TGACAGGAGTGTATGCCGATGCCTGGTTACTGACCAACCCTTCGTCTACCAGTACATTTGGATCAGAAGCAACCTT CACTGGTTCTTATCTCAACACAGCAACTCAGCGTATCAATCCGACGATGTATATCGCGAACAACACACAGATCATA AGCTCACAGCAATTTGGATCAAGCGGTCAAGAAGCAGCATATGGCCACACAACTTGTTTTAGGGACACAGGCTCTG TTATGGTATACTGTATCTATATTATTGAATTGTCCTCATCTCTCTTAGGACAATTTCAGATTGTCCCATTTATCCG TCAGGTGACACTATCCTAAAGGCAGAAGCCTTCAGGTCTGACCCAGCCAATCAAAGCATTATACCAGACCATGGAA TGCATACCAAACATTATTGACACTAATGACACACAAAATTGGTTTTAAGAAAAACCAAGAGAACAATAGGCCAGAA TGGCTGGGTCTCGGGAGATATTACTCCCTGAAGTCCATCTCAATTCACCAATTGTAAAGCATAAGCTATACTATTA CATTCTACTTGGAAACCTCCCAAATGAGATCGACCTTGacGATTTAGgtccattacataatcaaaattggaatcag atagcacatgaagagtctaacttagctcaacgcttggtaaatgtaagaaattttctaattacccacatccctgatc Description Page 16 / 157 19 CN 121263205 ATTAGAAAGGGCCATTGGCAAGAGTATGTCAATGTAATACTGTGGCCGCGAATTCTTCCCTTGATCCCGGATTTTAA AATCAATGACCAATTGCCTCTGCTCAAAAATTGGGACAAGTTAGTTAAAGAATCATGTTCAGTAATCAATGCAGGT ACTTCCCAGTGCATTCAGAATCTCAGCTATGGACTGACAGGTCGTGGGAACCTCTTTACACGATCACGTGAACTCT CTGGTGACCGCAGGGATATTGATCTTAAGACAGTTGTGGCAGCATGGCATGACTCAGACTGGAAAAGAATAAGTGA TTTTTGGATTATGATCAAATTCCAGATGAGACAATTAATTGTTAGGCAAACAGATCATAATGATTCTGATTTAATC ACGTATATCGAAAATAGAGAAGGCATAATCATCATAACCCCTGAACTGGTAGCATTATTTAACACTGAGAATCATA CACTAACATACATGACCTTTGAAATTGTACTGATGGTTTCAGATATGTACGAAGGTCGTCACAACATTTTATCACT ATGCACAGTTAGCACTTACCTGAATCCTCTGAAGAAAAGAATAACATATTTATTGAGCCTTGTAGATAACTTAGCT TTTCAGATAGGTGATGCTGTATATAACATAATTGCTTTGCTAGAATCCTTTGTATATGCACAGTTGCAAATGTCAG ATCCCATCCCAGAACTCAGAGGACAATTCCATGCATTCGTATGTTCTGAGATTCTTGATGCACTAAGAGGAACTAA TAGTTTCACCCAGGATGAATTAAGAACTGTGACAACTAATTTGATATCCCCATTCCAAGATCTGACCCCAGATCTT ACGGCTGAATTGCTCTGTATAATGAGGCTTTGGGGACACCCCATGCTCACTGCCAGTCAAGCTGCAGGAAAGGTAC GCGAGTCTATGTGTGCTGGAAAAGTATTAGACTTTCCCACCATTATGAAAACACTAGCCTTTTTCCATACTATTCTGATCAATGGATACAGGAGGAAGCATCATGGAGTATGGCCACCCTTAAACTTACCGGGTAATGCTTCAAAGGGTCTC ACGGAACTTATGAATGACAATACTGAAATAAGCTATGAATTCACACTTAAGCATTGGAAGGAAGTCTCTCTTATAA AATTCAAGAAATGTTTTGATGCAGACGCAGGTGAGGAACTCAGTATATTTATGAAAGATAAGGCAATTAGTGCCCC AAAACAAGACTGGATGAGTGTGTTTAGAAGAAGCCTAATCAAACAGCGCCATCAGCATCATCAGGTCCCCCTACCA AATCCATTCAATCGACGGCTGTTGCTAAACTTTCTCGGAGATGACAAATTCGACCCGAATGTGGAGCTACAGTATG TAACATCAGGTGAGTATCTACATGATGACACGTTTTGTGCATCATATTCACTAAAAGAGAAGGAAATTAAACCTGA TGGTCGAATTTTTGCAAAGTTGACTAAGAGAATGAGATCATGTCAAGTTATAGCAGAATCTCTTTTAGCGAACCAT GCTGGGAAGTTAATGAAAGAGAATGGTGTTGTGATGAATCAGCTATCATTAACAAAATCACTATTAACAATGAGTC AGATTGGAATAATATCCGAGAAAGCTAGAAAGTCAACTCGAGATAACATAAATCAACCTGGTTTCCAGAATATCCA GAGAAATAAATCACATCACTCCAAGCAAGTCAATCAGCGAGATCCAAGTGATGACTTTGAATTGGCAGCATCTTTT TTAACTACTGATCTCAAAAAATATTGTTTACAATGGAGGTACCAGACAATTATCCCATTTGCTCAATCATTAAACA GAATGTATGGTTATCCTCATCTCTTTGAGTGGATTCACTTACGGCTAATGCGTAGTACACTTTACGGGGGGATCC CTTCACCCACCAGCAGATACCAGTCAATTTGATCTAGATAAAGTAATTAATGGAGATATCTTCATTGTATCACCCAGAGGTGGAATTGAAGGGCTGTGTCAAAAGGCTTGGACAATGATATCTATCGCTGTGATAATTCTATCTGCCACAG AGTCTGGCACACGAGTAATGAGTATGGTGCAGGGAGATAATCAAGCAATTGCTGTCACCACACGAGTACCAAGGAG CCTGCCGACTCTTGAGAAAAAGACTATTGCTTTTAGATCTTGTAATCTATTCTTTGAGAGGTTAAAATGTAATAAT TTTGGATTAGGTCACCATTTGAAAGAACAAGAGACTATCATTAGTTCTCACTTCTTTGTTTATAGCAAGAGAATAT TCTATCAGGGGAGGATTCTAACGCAAGCCTTAAAAAATGCTAGTAAGCTCTGCTTGACAGCTGATGTCCTAGGAGA ATGCACCCAATCATCATGTTCTAATCTTGCAACTACTGTCATGAGGTTAACTGAGAATGGTGTTGAAAAAGATATC TGTTTCTACTTGAATATCTATATGACCATCAAACAGCTCTCCTATGATATCATCTTCCCTCAAGTGTCAATTCCTG GAGATCAGATCACATTAGAATACATAAATAATCCACACCTGGTATCACGATTGGCTCTTTTGCCATCCCAGTTAGG AGGTCTAAACTACCTGTCATGCAGTAGGCTGTTCAATCGAAACATAGGCGACCCGGTGGTTTCCGCAGTTGCAGAT CTTAAGAGATTAATTAAATCAGGATGTATGGATTACTGGATCCCTTTATAACTTATTAGGGAGAAAACCGGGAAACG GCTCATGGGCTACTTTAGCAGCTGACCCGTACTCAATCAATATAGAGTATCAATACCCTCCAACTACAGCTCTTAA GAGGCACACCCAACAAGCTCTGATGGAACTCAGTACGAATCCAATGTTACGTGGCATATTCTCTGACAATGCACAG GCAGAAGAAAATAACCTTGCTAGGTTTCTCCTGGATAGGGAGGTGATCTTTCCGCGTGTAGCTCACATCATCATTGDescription Page 17 / 157 20 CN 121263205 A AGCAAACCAGTGTCGGGAGGAGAAAACAGATTCAAGGATATTTGGATTCAACTAGATCGATAATGAGGAAATCACT AGAAATTAAGCCCTTATCCAATAGGAAGCTTAATGAAATACTGGATTACAACATCAATTACCTAGCTTACAATTTG GCATTACTCAAGAATGCTATTGAACCTCCGACTTATTTGAAGGCAATGACACTTGAAACATGTAGCATCGACATTG CAAGGAACCTCCGGAAGCTCTCCTGGGCCCCACTCTTGGGTGGGAGAAATCTTGAAGGATTAGAGACGCCAGATCC CATTGAAATTACTGCAGGAGCATTAATTGTTGGATCGGGCTACTGTGAACAGTGTGCTGCAGGAGACAATCGATTC ACATGGTTTTTCTTGCCATCTGGTATCGAGATAGGAGGGGATCCCCGTGATAATCCTCCTATCCGTGTACCGTACA TTGGCTCCAGGACTGATGAGAGGAGGGTAGCCTCAATGGCATACATCAGGGGTGCCTCGAGTAGCTTAAAAGCAGT TCTTAGACTGGCGGGAGTGTACATCTGGGCATTCGGAGATACTCTGGAGAATTGGATAGATGCACTGGATTTGTCT CACACTAGAGTTAACATCACACTTGAACAGCTGCAATCCCTCACCCCACTTCCAACCTCTGCCAATCTAACCCATC GGTTGGATGATGGCACAACTACCCTAAAGTTTACTCCTGCGAGCTCTTACACCTTTTCAAGTTTCACTCATATATC AAATGATGAGCAATACCTGACAATTAATGACAAAACTGCAGATTCAAATATAATCTACCAACAGTTAATGATCACT GGACTCGGAATCTTAGAAACATGGAATAATCCCCCAATCAATAGAACATTCGAAGAATCTACCCTACATTTGCACACTGGTGCATCATGTTGTGTCCGACCTGTGGACTCCTGCATTCTCTCAGAAGCATTAACAGTCAAGCCACATATTAC AGTACCGTACAGCAATAAATTTGTATTTGATGAGGACCCGCTATCTGAATATGAAACTGCAAAACTGGAATCGTTA TCATTCCAAGCCCAATTAGGCAACATTGATGCTGTAGATATGACAGGTAAATTAACATTATTGTCCCAATTCACTG CAAGGCAGATTATCAATGCAATCACTGGACTCGATGAGTCTGTCTCTCTTACTAATGATGCCATTGTTGCATCAGA CTATGTCTCCAATTGGATTAGTGAATGCATGTATACCAAATTAGATGAATTATTTATGTATTGTGGGTGGGAACTA CTATTGGAACTATCCTATCAAATGTATTATCTGAGGGTAGTTGGGTGGAGTAATATAGTGGATTATTCTTACATGA TCTTGAGAAGAATCCCGGGTGCAGCATTAAACAATCTGGCATCTACATTAAGTCATCCAAAACTTTTCCGACGAGC TATCAACCTAGATATAGTTGCCCCCTTAAATGCTCCTCATTTTGCATCTCTGGACTACATCAAGATGAGTGTGGAT GCAATACTCTGGGGCTGTAAAAGAGTCATCAATGTGCTCTCCAATGGAGGGGACTTAGAATTAGTTGTGACATCTG AAGATAGCCTTATTCTCAGTGACCGATCCATGAATCTCATTGCAAGGAAATTAACTTTATTATCACTGATTCACCA TAATGGTTTGGAACTACCAAAGATTAAGGGGTTCTCTCCTGATGAGAAGTGTTTCGCTTTGACAGAATTTTTGAGG AAAGTGGTGAACTCAGGGTTGAGTTCAATAGAGAACCTATCAAATTTTATGTACAATGTGGAGAACCCACGGCTTG CAGCATTCGCCAGCAACAATTACTACCTGACCAGAAAATTATTGAATTCAATACGAGATACTGAGTCGGGTCAAGTAGCAGTCACCTCATATTATGAATCATTAGAATATATTGATAGTCTTAAGCTAACCCCACATGTGCCTGGCACCTCA TGCATTGAGGATGATAGTCTATGTACAAATGATTACATAATCTGGATCATAGAGTCTAATGCAAACTTGGAGAAGT ATCCAATTCCAAATAGCCCTGAGGATGATTCCAATTTCCATAACTTTAAGTTGAATGCTCCATCGCACCATACCTT ACGCCCATTAGGGTTGTCATCAACTGCTTGGTATAAGGGTATAAGCTGCTGCAGGTACCTTGAGCGATTAAAGCTA CCACAAGGTGATCATTTATATATTGCAGAAGGTAGTGGTGCCAGTATGACAATCATAGAATACCTATTCCCAGGAA GAAAGATATATTACAATTCTTTATTTAGTAGTGGTGACAATCCCCCACAAAGAAATTATGCACCAATGCCTACTCA GTTCATTGAGAGTGTCCCATACAAGCTCTGGCAAGCACACACAGATCAATATCCCGAGATTTTTGAGGACTTCATC CCTCTATGGAACGGAAACGCCGCCATGACTGACATAGGAATGACAGCTTGTGTAGAATTCATCATCAATCGAGTCG GCCCAAGGACTTGCAGTTTAGTACATGTAGATTTGGAATCAAGTGCAAGCTTAAATCAACAATGCCTGTCAAAGCC GATAATTAATGCTATCATCACTGCTACAACTGTTTTGTGCCCTCATGGGGTGCTTATTCTGAAATATAGTTGGTTG CCATTTACTAGATTTAGTACTTTGATCACTTTCTTATGGTGCTACTTTGAGAGAATCACTGTTCTTAGGAGCACAT ATTCTGATCCAGCTAATCATGAGGTTTATTTAATTTGTATCCTTGCCAACAACTTTGCATTCCAGACTGTCTCGCA GGCAACAGGAATGGCGATGACTTTAACTGATCAAGGGTTTACTTTGATATCACCTGAAAGAATAAATCAGTATTGGGATGGTCACTTGAAGCAAGAACGTATCGTAGCAGAAGCAATTGATAAGGTGGTTCTAGGAGAAAATGCTCTATTTA DESCRIPTION 18 / 157 Page 21 CN 121263205 A ATTCGAGTGATAATGAATTAATTCTCAAATGTGGAGGGACACCAAATGCACGGAATCTCATCGATATCGAGCCAGT CGCAACTTTCATAGAATTTGAACAATTGATCTGCACAATGTTGACAACCCACTTGAAGGAAATAATTGATATAACA AGGTCTGGAACCCAGGATTATGAAAGTTTATTACTCACTCCTTACAATTTAGGTCTTCTTGGTAAAATCAGTACGA TAGTGAGATTATTAACAGAAAGGATTCTAAATCATACTATCAGGAATTGGTTGATCCTCCCACCTTCGCTCCGGAT GATCGTGAAGCAGGACTTGGAATTCGGCATATTCAGGATTACTTCCATCCTCAATTCTGATCGGTTCCTGAAGCTT TCTCCAAATAGGAAATACTTGATTGCACAATTAACTGCAGGCTACATTAGGAAATTGATTGAGGGGGATTGCAATA TCGATCTAACCAGACCTATCCAAAAGCAAATCTGGAAAGCATTAGGTTGTGTAGTCTATTGTCACGATCCAATGGA TCAAAGGGAGTCAACAGAGTTTATTGATATAAATATTAATGAAGAAATAGACCGCGGGATCGATGGCGAGGAAATC TAAACATATCAAGAATCAGAATTAGTTTAAGAAAAAAGAAGAGGATTAATCTTGGTTTTCCCCTTGGT(SEQ ID NO: 1).
[0127] III. CVB-Based RSV Compositions
[0128] Provided herein is a CVB-RSV-F genomic sequence.
[0129] A. CVB-RSV-F Sequence
[0130] Provided herein is a CVB-RSV-F nucleic acid sequence:
[0131] ACCAAGGGGAAAATGAAGTGGTGACTCAAATCATCGAAGACCCTCGAGATTACATAGGTCCGGAACCTATGGCCTTCGTGACCGACCTCGAGTCAGAGTAGTTCAATAAGGACCTATCAAGTTTGGGCAATTTTTCGTCCCCGA CACAAAAATGTCATCCGTGCTTAAAGCATATGAGCGATTCACGCTCACTCAAGAACTGCAAGATCAGAGTGAGGAA GGTACAATCCCCACCTACAACACTAAACCGGTAATCAGGGTATTTATACTAACCTCTAATAACCCAGAGCTAAGAT CCCGGCTTCTTCTATTCTGCCTACGGATTGTTCTCAGTAATGGTGCAAGGGATTCCCATCGCTTGGAGCATTACT CACAATGTTTTCGCTACCATCAGCCACAATGCTCAATCATGTCAAATTAGCTGACCAGTCACCAGAAGCTGATATC GAAAGGGTAGAGATCGATGGCTTTGAGGAGGGATCATTCCGCTTAATCCCCAATGCTCGTTCAGGTATGAGCCGTG GAGAGATCAATGCCTATGCTGCACTTGCAGAAGATCTACCTGACACACTAAACCATGCAACACCTTTCGTTGATTC CGAAGTCGAGGGAACTGCATGGGATGAGATTGAGACTTTCTTAGATATGGTTTACAGTGTCCTAATGCAGGCATGG ATAGTGACTTGCAAGTGCATGACTGCGCAGACCAACCTGCTGCTTCTATTGAGAAACGCCTGCAAAATATCGTC AGCAAGGCAGGATCAACCCGAGATATCTCCTGCAACCGGAGGCTCGACGAATAATCCCAGAATGTAATCCGGAAGGG AATGGTGTGAGACATTTCCTACCTTTGAACTGCAGCTTGCCCGAGCACAAAGCCTTGTATCAAATAGGTATTAT GCTATGGTAGGGGATGTTGGAAGTATATAGAGAATTGTGGAATGGGAGGCTTCTTTTTGACACTAAAATATGCAT TAGGAACTAGATGGCCCACACTTGCTTTAGCTGCATTTTTCAGGAGAGCTAACAAAGCTAAAGTCCTCATGGCATTATACCAGACCCTTGGTGAGCAGGCCCGATATTTGGCCCTATTGGAGTCACCACATTTGATGGATTTTGCTGCAGCA AACTACCCACTGCTATATAGCTATGCTATGGGAATAGGCTATGTGTTAGATGTCAACATGAGGAACTACGCTTTCT CCAGATCATACATGAACAAGACATATTTCCAATTGGGAATGGAAACTGCAAGAAAACAACAGGGTGCAGTTGACAT GAGGATGGCAGAAGATCTCGGTCTAACTCAAGCCGAACGCACCGAGATGGCAAATACACTTGCCAAATTGACCACA GCAAATCGAGGGGCAGACACCAGGGGAGGAGTCAACCCGTTCTCATCTGTCACTGGGACAACTCAGGTGCCCGCTG CAGCAACAGGTGACACACTCGAGAGTTACATGGCAGCGGATCGACTGAGGCAGAGATATGCTGATGCAGGCACCCA TGATGATGAGATGCCACCATTGGAAGAGGAGGAAGAGGACGACACATCTGCAGGTCCACGCACTGGACCAACTCTT GAACAAGTGGCCTTGGACATCCAGAACGCAGCAGTTGGAGCTCCCATCCATACAGATGACCTGAATGCCGCACTGG GTGATCTTGACATCTAGACAATTCAGATCCCAATCTAAAATTGACATACCTAATTGATTAGTTAGATGGAACTACA GTGGATTCCATAAGGTTCCTGCCTACCATCGGCTTTAAAGAAAAAAATAGGCCCGGACGGGTTAGCAACAAGCGAC TGCCGGTGCCAACAGCGCAATCCACAATCTACAATGGATCCCACTGATCTGAGCTTCTCCCCAGATGAGATCAATA DESCRIPTION Page 19 / 157 22 CN 121263205 A AGCTCATAGAGACAGGCCTGAATACTGTAGAGTATTTTACTTCCCAACAAGTCACAGGAACATCCTCTCTTGGAAAGAATACAATACCACCAGGTCACAGGACTACTAACCAATGCTGCAGAGGCAAAGATCCAAGAGTCAACTAACCAT CAGAAGGGCTCAGTTGTGGGGGTGCAAAACCAAAGAAACCGCCAAAAAATTGCCATTGTGCCAGCAGATGACA AAACAGTGCCCGGAAAGCCGATCCAAACCCTCTATTAGGTCTGGACTCCACCCCGAGCACCAAACTGTGCTTGA TCTAAGTGGGAAACATTACCATCAGGATCCTATAAGGGGGTTAAGCTTGCGAAAATTTGGAAAAAATCTGATG ACACGGTTCATCGAGGAACCCAGAGAGAATCCTATCGCAACCAGTTTCCCCATCGATTTTAAGAGGGGCAGGGATA CCGGCGGGTTCCATAGAAGGGAGTACTCAATCGGATGGGTGGAGATGAAGTCAAGGTCACTGAGTGGTGCAATC ATCCTGTTTCTCCAATCACCGCTGCAGCAAGGCGATTTGAATGCACTTGTCACCAGTCTCCAGTCACTTGCTCTGAA TGTGAACGAGATACTTAATACAGTGAGAAAATTGGACTCTCGGAATGAATCAACTGAGAGAAAAAAGTAGATCGCAT CTCTCATCTCAGTCTCTAATCCAGACCATCAAGAATGACATAGTTGGACTTAAAGCAGGGATGGCTACTTTAGAAG GAATGATTACAACTGTGAAAATCATGGACCCGGGAGTTCCCAGTAATGTTACTGTGGGAAGATGTACGCAAGACACT AAGTAACCATGCTGTTGTTGTGGCCAGAATCATTCAATGATagtTTCTTGACTCAATCTGAAGATGTAATTTCACTT GATGAGTTGGCTCGACCAACTGCAACAAGTGTTAAGAAGATTGTCAGGAAGGTTCTCCTCAGAAGGATCTGACTG GATTGAAGATTACACTAGAGCAATTGGCAAAGGATTGCATCAGCAAACCGAAGATGAGGGAAGATTATCTCCTCAAAATCAACCAGGCTTCCAGTGAGGCTCAGCTAATTGACCTCAAGAAAGCAATCATCCGCAGTGCAATTTGATCAAGA AACACCCAATTACACTACACTGGTATGACACTGTACTAACCCTGAGGGTTTTAGAAAAAACGATTAACGATAAATA AGCCCGAACACTACACACTACCTGAGGCAGCCATGCCATCCATCAGCATTCCCGCAGACCCCACCAATCCACGTCA ATCAATAAAAGCGTTCCCAATTGTGATCAACAGTGATGGGGGTGAGAAAGGCCGCTTGGTTAAACAACTACGCACA ACCTACTTGAATGACCTAGATACTCATGAGCCACTGGTGACATTCATAAATACCTATGGATTCATCTACGAACAGG ATCGGGGGAATACCATTGTCGGAGAGGATCAACTTGGGAAGAAAAGAGAGGCTGTGACCGCTGCAATGGTTACCCT TGGATGTGGGCCTAATCTACCATCATTAGGGAATGTCCTGGGACAACTGAGGGAATTCCAGGTCACTGTTAGGAAG ACATCCAGCAAAGCGGAAGAGATGGTCTTTGAAATTGTTAAGTATCCGAGAATATTTCGGGGTCATACATTAATCC AGAAAGGACTAGTCTGTGTCTCCGCAGAAAAATTTGTTAAGTCACCAGGGAAAATACAATCTGGAATGGACTATCT CTTCATTCCGACATTTCTGTCAGTGACTTACTGTCCAGCTGCAATCAAATTTCAGGTACCTGGCCCCATGTTGAAA ATGAGATCAAGATACACTCAGAGCTTACAACTTGAACTAATGATAAGAATCCTGTGTAAGCCCGATTCGCCACTTA TGAAGGTCCATACCCCTGACAAGGAGGGAAGAGGATGTCTTGTATCAGTATGGCTGCATGTATGCAACATCTTCAA ATCAGGAAACAAGAATGGCAGTGAGTGGCAGGAATACTGGATGAGAAAGTGTGCTAACATGCAACTTGAAGTGTCGATTGCAGATATGTGGGGACCAACTATCATAATTCATGCCAGAGGTCACATTCCCAAAAGTGCTAAGTTGTTTTTTG GAAAGGGTGGATGGAGCTGCCATCCACTTCACGAAGTTGTTCCAAGTGTCACTAAAACACTATGGTCCGTGGGCTG TGAGATTACAAAGGCGAAGGCAATAATACAAGAGAGTAGCATCTCTCTTCTCGTGGAGACTACTGACATCATAAGT CCAAAAGTCAAAATTTCATCTAAGCATCGCCGCTTTGGGAAATCAAATTGGGGTCTGTTCAAGAAAACTAAATCAC TGCCTAACCTGACGGAGCTGGAATGACTGACCTCTAATCGAGACTACACCGCCGCAAACTATAGGTGGGTGGTACC TCAGTGATTAATCTTGTAAGCACTGATCGTAGGCTACAACACACTAATATTATCCAGATTAGAGAGCTTAATTAGC TCTGTATTAATAATAACACTACTATTCCAATAACTGGAATCACCAGCTTGATTTATCTCCAAAATGATTCAAAGAA AACAAATCATATTAAGACTATCCTAAGCACGAACCCATATCGTCCTTCAAATCATGGGTACTATAATTCAATTTCT GGTGGTCTCCTGTCTATTGGCAGGAGCAGGCAGCCTTGATCCAGCAGCCCTCATGCAAATCGGTGTCATTCCAACA AATGTCCGGCAACTTATGTATTATACTGAAGCTTCATCAGCATTCATTGTTGTGAAGTTAATGCCTACAATTGACT CGCCGATTAGTGGATGTAATATAACATCAATTTCAAGCTATAATGCAACAGTGACAAAACTCCTACAGCCGATCGG TGAGAATTTGGAGACGATTAGGAACCAGTTGATTCCAACTCGGAGGAGACGCCGGTTTGCAGGGGTGGTGATTGGA Description Page 20 of 157 23 CN 121263205 ATTAGCTGCATTAGGAGTAGCTACTGCCGCACAGGTCACTGCCGCAGTGGCACTAGTAAAGGCAAATGAAAATGCTG CGGCTATACTCAATCTCAAAAATGCAATCCAAAAAACAAATGCAGCAGTTGCAGATGTGGTCCAGGCCACACAATC ACTAGGAACGGCAGTTCAAGCAGTTCAAGATCACATAAACAGTGTGGTAAGTCCAGCAATTACAGCAGCCAATTGT AAGGCCCAAGATGCTATCATTGGCTCAATCCTCAATCTCTATTTGACCGAGTTGACAACCATCTTCCACAATCAAA TTACAAACCCTGCATTGAGTCCCATTACAATTCAAGCTTTAAGGATCCTACTGGGGAGTACCTTGCCGACTGTGGT CGAAAAATCTTTCAATACCCAGATAAGTGCAGCTGAGCTTCTCTCATCAGGGTTATTGACAGGCCAGATTGTGGGA TTAGATTTGACCTATATGCAGATGGTCATAAAAATTGAGCTGCCAACTTTAACTGTACAACCTGCAACCCAGATCA TAGATCTGGCCACCATTTCTGCATTCATTAACAATCAAGAAGTCATGGCCCAATTACCAACACGTGTTATGGTGAC TGGCAGCTTGATCCAAGCCTATCCCGCATCGCAATGCACCATTACACCCAACACTGTGTACTGTAGGTATAATGAT GCCCAAGTACTCTCAGATGATACTATGGCTTGCCTCCAAGGTAACTTGACAAGATGCACCTTCTCTCCAGTGGTTG GGAGCTTTCTCACTCGATTCGTGCTGTTCGATGGAATAGTTTATGCAAATTGCAGGTCGATGTTGTGCAAGTGCAT GCAACCTGCTGCTGTGATCCTACAGCCGAGTTCATCCCCTGTAACTGTCATTGACATGTACAAATGTGTGAGTCTG CAGCTTGACAATCTCAGATTCACCATCACTCAATTGGCCAATGTAACCTACAATAGCACCATCAAGCTTGAATCATCCCAGATCTTGTCTATTGATCCGTTGGATATATCCCAGAATCTAGCTGCGGTGAATAAGAGTCTAAGTGATGCACT ACAACACTTAGCACAAAGTGACACATATCTTTCTGCAATCACATCAGCTACGACTACAAGTGTATTATCCATAATA GCAATCTGTCTTGGATCGTTAGGTTTAATATTAATAATCTTGCTCAGTGTAGTTGTGTGGAAGTTATTGACCATTG TCGTTGCTAATCGAAATAGAATGGAGAATTTTGTTTATCATAAATAAGCATTCCACCACTCACGATCTGATCTCAG TGAGAAAAATCAACCTGCAACTCTTGGAACAAGATAAGACAGTCATCCATTAGTAATTTTTAAGAAAAAAACGATA GGACCGAACCTAGTATTGAAAGAACCGTCTCGGTCAATCTAGGTAATCGAGCTGATACCGTCTCGGAAAGCTCAAA TCGCCGCCACCatggagctgctgatcctgaaagccaacgctattaccacaatcctgaccgccgtgacattctgctt tgcttccggacagaatatcaccgaggagttctaccagtcaacatgtagcgccgtgagcaaggggtacctgagtgca ctgcgaaccggatggtatacatccgtgattactatcgagctgtctaacatcaagaaaaacaaatgcaatggcactg acgccaagatcaagctgatcaagcaggagctggataagtacaaaaatgctgtgaccgaactgcagctgctgatgca gagcactccagctaccaacaatcgcgcacggagagaactgccccggttcatgaactataccctgaacaatgcaaag aaaacaaatgtgactctgtccaagaaacgcaagaggcgcttcctgggatttctgctgggcgtggggtctgcaatcg ccagtggagtggccgtctctaaagtcctgcacctggagggcgaagtgaacaagatcaaatcagcactgctgagcacaaacaaggccgtggtcagtctgtcaaatggcgtgtccgtcctgacttctaaggtgctggacctgaaaaattatatt gataagcagctgctgcctatcgtcaacaaacagagctgttccatttctaatatcgagaccgtgatcgagttccagc agaagaacaatagacttctagagattacaagggaattttctgtgaacgctggcgtcactacccccgtgagtaccta catgctgacaaatagtgagctgctgtcactgattaacgacatgcctatcaccaatgatcagaagaaactgatgagt aacaatgtgcagatcgtcagacagcagagttactcaatcatgtcaatcattaaggaggaagtcctggcctacgtgg tccagctgccactgtatggcgtgatcgacactccctgctggaaactgcatacctcacctctgtgcacaactaacac caaggaggggagcaatatctgcctgacacgaactgaccggggatggtactgtgataacgccggcagcgtgtccttc tttccccaggctgagacctgcaaggtccagtccaacagggtgttctgtgacactatgaatagcctgaccctgcctt ccgaagtcaacctgtgcaatgtggacatctttaatccaaagtacgattgtaagatcatgaccagcaagacagatgt cagctcgagtgtgattacatcactgggggctatcgtgagctgctacggaaagactaaatgtaccgcaagcaacaaa aatcgcggcatcattaagaccttcagtaacgggtgcgactatgtctcaaacaagggcgtggatacagtgagcgtcg ggaacactctgtactatgtcaataagcaggagggaaaatccctgtacgtgaagggcgaaccaatcattaacttcta tgaccccctggtgttcccttccgacgagtttgatgcctctattagtcaggtgaacgaaaaaatcaatcagagcctgDescription Page 21 / 157 24 CN 121263205 A gcttttattcggaagtccgatgagctgctgcacaacgtgaatgcagtcaagtctaccacaaacattatgatcacta ccatcattatcgtgattatcgtcattctgctgtccctgatcgcagtggggctgctgctgtactgtaaagccagatc tacacccgtgactctgtctaaggatcagctgagtggaattaacaatatcgcctttagcaactgaTAGGTCGACCAC CTGCTATAGGCTATCCACTGCATCATCTCTCCTGCCATACTTCCTACTCACATCATATCTATTTTAAAGAAAAAAT AGGCCCGAACACTAATCGTGCCGGCAGTGCCACTGCACACACAACACTACACATACAATACACTACAATGGTTGCA GAAGATGCCCCTGTTAGGGCCACTTGCCGAGTATTATTTCGAACAACAACTTTAATCTTTCTATGCACACTACTAG CATTAAGCATCTCTATCCTTTATGAGAGTTTAATAACCCAAAAGCAAATCATGAGCCAAGCAGGCTCAACTGGATC TAATTCTGGATTAGGAAGTATcACTGATCTTCTTAATAATATTCTCTCTGTCGCAAATCAGATTATATATAACTCT GCAGTCGCTCTACCTCTACAATTGGACACTCTTGAATCAACACTCCTTACAGCCATTAAGTCTCTTCAAACCAGTG ACAAGCTAGAACAGAACTGCTCGTGGAGTGCTGCACTGATTAATGATAATAGATACATTAATGGCATCAATCAGTT CTATTTTTCAATTGCTGAGGGTCGCAATCTGACACTTGGCCCACTTCTTAATATGCCTAGTTTCATTCCAACTGCC ACGACACCAGAGGGCTGCACCAGGATCCCATCATTCTCGCTCACTAAGACACACTGGTGTTATACACACAATGTTATCCTGAATGGATGCCAGGATCATGTATCCTCAAATCAATTTGTTTCTATGGGAATCATTGAACCCACTTCTGCCGG GTTTCCATTCTTTCGAACCCTAAAGACTCTATATCTCAGCGATGGGGTCAATCGTAAGAGCTGCTCTATCAGTACA GTTCCGGGGGGTTGTATGATGTACTGTTTTGTTTCTACTCAACCAGAGAGGGATGACTACTTTTCTGCCGCTCCTC CAGAACAACGAATTATTATAATGTACTATAATGATACAATCGTGGAGCGCATAATTAATCCACCCGGGGTACTAGA TGTATGGGCAACATTGAACCCAGGAACAGGAAGCGGGGTATATTATTTAGGTTGGGTGCTCTTTCCAATATATGGC GGCGTGATTAAAGGTACGAGTTTATGGAATAATCAAGCAAATAAATACTTTATCCCCCAGATGGTTGCTGCTCTCT GCTCACAAAACCAGGCAACTCAAGTCCAAAATGCTAAGTCATCATACTATAGCAGCTGGTTTGGCAATCGAATGAT TCAGTCTGGGATCCTGGCATGTCCTCTTCGACAGGATCTAACCAATGAGTGTTTAGTTCTGCCCTTTTCTAATGAT CAGGTGCTTATGGGTGCTGAAGGGAGATTATACATGTATGGTGACTCGGTGTATTACTATCAAAGAAGCAATAGTT GGTGGCCTATGACCATGCTGTATAAGGTAACCATAACATTCACTAATGGTCAGCCATCTGCTATATCAGCTCAGAA TGTGCCCACACAGCAGGTCCCTAGACCTGGGACAGGAGACTGCTCTGCAACCAATAGATGTCCCGGTTTTTGCTTG ACAGGAGTGTATGCCGATGCCTGGTTACTGACCAACCCTTCGTCTACCAGTACATTTGGATCAGAAGCAACCTTCA CTGGTTCTTATCTCAACACAGCAACTCAGCGTATCAATCCGACGATGTATATCGCGAACAACACACAGATCATAAGCTCACAGCAATTTGGATCAAGCGGTCCAAGAAGCAGCATATGGCCACACAACTTGTTTTTAGGGACACAGGCTCTGTT ATGGTATACTGTATCTATATTATTGAATTGTCCTCATCTCTCTTAGGACAATTTCAGATTGTCCCATTATCCGTC AGGTGACACTATCCTAAAGGCAGAAGCCTTCAGGTCTGACCCAGCCAAAGCATTATACCAGACCATGGAATG CATACCAAACATTATTGACACTAATGCACACAAAATTGGTTTTAAGAAAAAACCAAGAGAACAATAGGCCAGAATG GCTGGGTCTCGGGAGATATTACTCCCTGAAGTCCATCTCAATTCACCAATTGTAAAGCATAAGCTATACTATTACA TTCTACTTGGAAACCTCCCAAATGAGATCGACCTTGACGATTTAGGTCCATTACATAATCAAAATTGGAATCAGAT AGCACATGAAGAGTCTAACTTAGCTCAAGCCTTGGTAAATGTAAAGAAATTTCTAATTACCACACATCCCTGATCTT AGAAAGGGCCATTGGCAAGAGTATGTCAATGTAATACTGTGGCGAATTCTTCCCTTGAATCCGGATTTTAAAA TCAATGACCAATTGCCTCTGCTCAAAAATTGGGACAAGTTAGTTAAAAGAATCATGTTCAGTAATCAATGCAGGTAC TTCCCAGTGCATTCAGAATCTCAGCTATGGACTGACAGGTCGTGGGAACCTCTTTACACGATCACGTGAACTCTCT GGTGACCGCAGGGATATTGATCTTAAGACAGTTGTGGCAGCATGGCATGACTCAGACTGGAAAAGAATAAGTGATT TTTGGATTATCAAATTCCAGATGAGACAATTAATTGTTAGGCAAACAGATCATAATGATTCTGATTTAATCAC GTATATCGAAAATAGAGAAGGCATAATCATCATAACCCCTGAACTGGTAGCATTATTTAACACTGAGAATCATACACTAACATACATGACCTTTGAAATTGTACTGATGGTTTCAGATATGTACGAAGGTCGTCACAACATTTTATCACTAT DESCRIPTION Page 22 of 157 25 CN 121263205 A GCACAGTTAGCACTTACCTGAATCCTCTGAAGAAAAGAATAACATATTTATTGAGCCTTGTAGATAACTTAGCTTT TCAGATAGGTGATGCTGTATATAACATAATTGCTTTGCTAGAATCCTTTGTATATGCACAGTTGCAAATGTCAGAT CCCATCCCAGAACTCAGAGGACAATTCCATGCATTCGTATGTTCTGAGATTCTTGATGCACTAAGAGGAACTAATA GTTTCACCCAGGATGAATTAAGAACTGTGACAACTAATTTGATATCCCCATTCCAAGATCTGACCCCAGATCTTAC GGCTGAATTGCTCTGTATAATGAGGCTTTGGGGACACCCCATGCTCACTGCCAGTCAAGCTGCAGGAAAGGTACGC GAGTCTATGTGTGCTGGAAAAGTATTAGACTTTCCCACCATTATGAAAACACTAGCCTTTTTCCATACTATTCTGA TCAATGGATACAGGAGGAAGCATCATGGAGTATGGCCACCCTTAAACTTACCGGGTAATGCTTCAAAGGGTCTCAC GGAACTTATGAATGACAATACTGAAATAAGCTATGAATTCACACTTAAGCATTGGAAGGAAGTCTCTCTTATAAAA TTCAAGAAATGTTTTGATGCAGACGCAGGTGAGGAACTCAGTATATTTATGAAAGATAAGGCAATTAGTGCCCCAA AACAAGACTGGATGAGTGTGTTTAGAAGAAGCCTAATCAAACAGCGCCATCAGCATCATCAGGTCCCCCTACCAAA TCCATTCAATCGACGGCTGTTGCTAAACTTTCTCGGAGATGACAAATTCGACCCGAATGTGGAGCTACAGTATGTAACATCAGGTGAGTATCTACATGATGACACGTTTTGTGCATCATATTCACTAAAAGAGAAGGAAATTAAACCTGATG GTCGAATTTTTGCAAAGTTGACTAAGAGAATGAGATCATGTCAAGTTATAGCAGAATCTCTTTTAGCGAACCATGC TGGGAAGTTAATGAAAGAGAATGGTGTTGTGATGAATCAGCTATCATTAACAAAATCACTATTAACAATGAGTCAG ATTGGAATAATATCCGAGAAAGCTAGAAAGTCAACTCGAGATAACATAAATCAACCTGGTTTCCAGAATATCCAGA GAAATAAATCACATCACTCCAAGCAAGTCAATCAGCGAGATCCAAGTGATGACTTTGAATTGGCAGCATCTTTTTT AACTACTGATCTCAAAAAATATTGTTTACAATGGGAGGTACCAGACAATTATCCCATTTGCTCAATCATTAAACAGA ATGTATGGTTATCCTCATCTCTTTGAGTGGATTCACTTACGGCTAATGCGTAGTACACTTTACGTGGGGGATCCCT TCAACCCACCAGCAGATACCAGTCAATTTGATCTAGATAAAGTAATTAATGGAGATATCTTCATTGTATCACCCAG AGGTGGAATTGAAGGGCTGTGTCAAAAGGCTTGGACAATGATATCTATCGCTGTGATAATTCTATCTGCCACAGAG TCTGGCACACGAGTAATGAGTATGGTGCAGGGAGATAATCAAGCAATTGCTGTCACCACACGAGTACCAAGGAGCC TGCCGACTCTTGAGAAAAAGACTATTGCTTTTAGATCTTGTAATCTATTCTTTGAGAGGTTAAAATGTAATAATTT TGGATTAGGTCACCATTTGAAAGAACAAGAGACTATCATTAGTTCTCACTTCTTTGTTTATAGCAAGAGAATATTC TATCAGGGGAGGATTCTAACGCAAGCCTTAAAAAATGCTAGTAAGCTCTGCTTGACAGCTGATGTCCTAGGAGAATGCACCCAATCATCATGTTCTAATCTTGCAACTACTGTCATGAGGTTAACTGAGAATGGTGTTGAAAAAGATATCTG TTTCTACTTGAATATCTATATGACCATCAAACAGCTCTCCTATGATATCATCTTCCCTCAAGTGTCAATTCCTGGA GATCAGATCACATTAGAATACATAAATAATCCACACCTGGTATCACGATTGGCTCTTTTGCCATCCCAGTTAGGAG GTCTAAACTACCTGTCATGCAGTAGGCTGTTCAATCGAAACATAGGCGACCCGGTGGTTTCCGCAGTTGCAGATCT TAAGAGATTAATTAAATCAGGATGTATGGATTACTGGATCCTTTATAACTTATTAGGGAGAAAACCGGGAAACGGC TCATGGGCTACTTTAGCAGCTGACCCGTACTCAATCAATATAGAGTATCAATACCCTCCAACTACAGCTCTTAAGA GGCACACCCAACAAGCTCTGATGGAACTCAGTACGAATCCAATGTTACGTGGCATATTCTCTGACAATGCACAGGC AGAAGAAAATAACCTTGCTAGGTTTCTCCTGGATAGGGAGGTGATCTTTCCGCGTGTAGCTCACATCATCATTGAG CAAACCAGTGTCGGGAGGAGAAAACAGATTCAAGGATATTTGGATTCAACTAGATCGATAATGAGGAAATCACTAG AAATTAAGCCCTTATCCAATAGGAAGCTTAATGAAATACTGGATTACAACATCAATTACCTAGCTTACAATTTGGC ATTACTCAAGAATGCTATTGAACCTCCGACTTATTTGAAGGCAATGACACTTGAAACATGTAGCATCGACATTGCA AGGAACCTCCGGAAGCTCTCCTGGGCCCCACTCTTGGGTGGGAGAAATCTTGAAGGATTAGAGACGCCAGATCCCA TTGAAATTACTGCAGGAGCATTAATTGTTGGATCGGGCTACTGTGAACAGTGTGCTGCAGGAGACAATCGATTCACATGGTTTTTCTTGCCATCTGGTATCGAGATAGGAGGGGATCCCCGTGATAATCCTCCTATCCGTGTACCGTACATT GGCTCCAGGACTGATGAGAGGAGGGTAGCCTCAATGGCATACATCAGGGGTGCCTCGAGTAGCTTAAAAGCAGTTC Description Page 23 / 157 26 CN 121263205 A TTAGACTGGCGGGAGTGTACATCTGGGCATTCGGAGATACTCTGGAGAATTGGATAGATGCACTGGATTTGTCTCA CACTAGAGTTAACATCACACTTGAACAGCTGCAATCCCTCACCCCACTTCCAACCTCTGCCAATCTAACCCATCGG TTGGATGATGGCACAACTACCCTAAAGTTTACTCCTGCGAGCTCTTACACCTTTTCAAGTTTCACTCATATATCAA ATGATGAGCAATACCTGACAATTAATGACAAAACTGCAGATTCAAATATAATCTACCAACAGTTAATGATCACTGG ACTCGGAATCTTAGAAACATGGAATAATCCCCCAATCAATAGAACATTCGAAGAATCTACCCTACATTTGCACACT GGTGCATCATGTTGTGTCCGACCTGTGGACTCCTGCATTCTCTCAGAAGCATTAACAGTCAAGCCACATATTACAG TACCGTACAGCAATAAATTTGTATTTGATGAGGACCCGCTATCTGAATATGAAACTGCAAAACTGGAATCGTTATC ATTCCAAGCCCAATTAGGCAACATTGATGCTGTAGATATGACAGGTAAATTAACATTATTGTCCCAATTCACTGCA AGGCAGATTATCAATGCAATCACTGGACTCGATGAGTCTGTCTCTCTTACTAATGATGCCATTGTTGCATCAGACT ATGTCTCCAATTGGATTAGTGAATGCATGTATACCAAATTAGATGAATTATTTATGTATTGTGGGTGGGAACTACTATTGGAACTATCCTATCAAATGTATTATCTGAGGGTAGTTGGGTGGAGTAATATAGTGGATTATTCTTACATGATC TTGAGAAGAATCCCGGGTGCAGCATTAAACAATCTGGCATCTACATTAAGTCATCCAAAACTTTTCCGACGAGCTA TCAACCTAGATATAGTTGCCCCCTTAAATGCTCCTCATTTTGCATCTCTGGACTACATCAAGATGAGTGTGGATGC AATACTCTGGGGCTGTAAAAGAGTCATCAATGTGCTCTCCAATGGAGGGGACTTAGAATTAGTTGTGACATCTGAA GATAGCCTTATTCTCAGTGACCGATCCATGAATCTCATTGCAAGGAAATTAACTTTATTATCACTGATTCACCATA ATGGTTTGGAACTACCAAAGATTAAGGGGTTCTCTCCTGATGAGAAGTGTTTCGCTTTGACAGAATTTTTGAGGAA AGTGGTGAACTCAGGGTTGAGTTCAATAGAGAACCTATCAAATTTTATGTACAATGTGGAGAACCCACGGCTTGCA GCATTCGCCAGCAACAATTACTACCTGACCAGAAAATTATTGAATTCAATACGAGATACTGAGTCGGGTCAAGTAG CAGTCACCTCATATTATGAATCATTAGAATATATTGATAGTCTTAAGCTAACCCCACATGTGCCTGGCACCTCATG CATTGAGGATGATAGTCTATGTACAAATGATTACATAATCTGGATCATAGAGTCTAATGCAAACTTGGAGAAGTAT CCAATTCCAAATAGCCCTGAGGATGATTCCAATTTCCATAACTTTAAGTTGAATGCTCCATCGCACCATACCTTAC GCCCATTAGGGTTGTCATCAACTGCTTGGTATAAGGGTATAAGCTGCTGCAGGTACCTTGAGCGATTAAAGCTACC ACAAGGTGATCATTTATATATTGCAGAAGGTAGTGGTGCCAGTATGACAATCATAGAATACCTATTCCCAGGAAGAAAGATATATTACAATTCTTTATTAGTAGTGTGTGCAATCCCCACAAAGAAATTATGCACCAATGCCTACTCAGT TCATTGAGAGTGTCCCATACAAGCTCTGGCAAGCACACAGATCAATATCCCGAGATTTTGAGGACTTCATCC TCTATGGAACGGAACGCGCCCATGACTGACATAGGAATGACAGCTTTGTAGAATTCATCATCAATCGAGTCGGC CCAAGGACTTGCAGTTTAGTACATGTAGATTTGGAATCAAGTGCAAGCTTAAATCAACAATGCCCTGTCAAAGCCGA TAATTAATGCTATCATCACTGCTACAACTGTTTTGGCCTCATGGGTGCTTATTCTGAAATATAGTTGGTTGCC ATTTACTAGATTTAGTACTTTGATCACTTTTCTTATGGTGCTACTTTGAGAGAAATCACTGTTCTTAGGAGCACATAT TCTGATCCAGCTAATCATGAGGTTTTATTTAATTTGTATCCTTGCCAACAACTTTGCATTCCAGACTGTCTCTGCCAGG CAACAGGAATGGCGATGACTTTAACTGATCAAGGGTTTACTTTGATATCACCTGAAAGAATAAATCAGTATTGGGA TGGTCACTTGAAGCAAGAACGTATCGTAGCAGAAGCAATTGATAAGGTGGTTCTAGGAGAAAATGCTCTATTTAAT TCGAGTGATAATGAATTAATTCTCAAATGTGGAGGGACACCAAATGCACGGAATCTCATCGATATCGAGCCAGTCG CAACTTTCATAGAATTTGAACAATTGATCTGCACAATGTTGACAACCCACTTGAAGGAAATAATTGATATAACAAG GTCTGGAACCCAGGATTATGAAAGTTTATTACTACTCCTTACAATTTAGGTCTTCTTGGTAAAATCAGGATA GTGAGATTATTAACAGAAAGGATTCTAAATCATACTATCAGGAATTGGTTGATCCTCCCACCTTCGCTCCGGATGATCGTGAAGCAGGACTTGGAATTCGGCATATTCAGGATTACTTCCATCCTCAATTCTGATCGGTTCCTGAAGCTTTC TCCAAATAGGAAATACTTGATTGCACAATTAACTGCAGGCTACATTAGGAAATTGATTGAGGGGGATTGCAATATC GATCTAACCAGACCTATCCAAAAGCAAATCTGGAAAGCATTAGGTTGTGTAGTCTATTGTCACGATCCAATGGATC Instructions 24 / 157 Page 27 CN 121263205 A AAAGGGAGTCAACAGAGTTTATTGATATAAATATTAATGAAGAAATAGACCGCGGGATCGATGGCGAGGAAATCTA AACATATCAAGAATCAGAATTAGTTTAAGAAAAAAGAAGAGGATTAATCTTGGTTTTCCCCTTGGT (SEQ ID NO: 2).
[0132] The inserted RSV-F sequence is lowercase, and the CVB sequence is uppercase.
[0133] IV. CVB-based SARS-CoV-2 compositions
[0134] This disclosure provides CVB-based SARS-CoV-2 compositions, systems, and methods for a variety of applications, including functional genomics, drug discovery, target validation, protein production (e.g., therapeutic proteins, vaccines, monoclonal antibodies), gene therapy, and therapeutic treatments (e.g., cancer therapy).
[0135] A. SARS-CoV-2
[0136] Using the present invention, modified parainfluenza virus type 5 (PIV5) constructs expressing SARS-CoV-2 envelope spike (S) and nucleocapsid (N) proteins have been generated and can be used as vaccines against COVID. These constructs have shown effectiveness as vaccines, with a single intranasal immunization inducing protective immunity in ferrets and cats.
[0137] Coronavirus disease 2019 (COVID-19) is a newly emerging infectious disease currently spreading globally. It is caused by a novel coronavirus, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (Zhu et al., 2020, N Engl J Med; 382:727-733). SARS-CoV-2 was first identified in December 2019, subsequently spreading globally and causing the COVID-19 pandemic. As of September 8, 2021, the virus had infected more than 221 million people worldwide, causing more than 45.74 million deaths.000 people have died, and the virus will continue to spread in the absence of herd immunity. Despite the introduction of vaccines and antibody therapies worldwide, the emergence of multiple viral variants is rapidly replacing the original virus, leading to immune escape in vaccinated populations, thus necessitating improvements in vaccine efficacy.
[0138] SARS-CoV-2 is a single-stranded RNA enveloped virus belonging to the β-coronavirus family (Lu et al., 2020, Lancet; 395:565-74). An RNA-based metagenomic next-generation sequencing method has been used to characterize its entire genome, which is 29,881 nucleotides (nt) long (GenBank accession number MN908947) and encodes 9,860 amino acids (Chen et al., 2020, Emerg Microbes Infect; 9:313-9). Whole-genome sequencing genomes available on GenBank include the SARS-CoV-2 isolates 2019-nCoV WHU01 (GenBank accession number MN988668) and NC_045512, both from the originally identified strains, and at least seven additional sequences (MN938384.1, MN975262.1, MN985325.1, MN988713.1, MN994467.1, MN994468.1, and MN997409.1), which share >99.9% identity and are incorporated herein by reference.
[0139] i. SARS-CoV-2 variants
[0140] Since the first identification of SARS-CoV-2 in 2019, multiple SARS-CoV-2 genetic variants have emerged and spread worldwide. The United States regularly monitors viral mutations and variants through sequence-based surveillance, laboratory studies, and epidemiological surveys. The U.S. government's SARS-CoV-2 interagency task force (SIG) has developed a variant classification scheme that categorizes SARS-CoV-2 variants into three classes: variants of interest, variants of concern, and variants with serious consequences.
[0141] a. Variants of Interest
[0142] A SARS-CoV-2 variant of interest is a variant with specific genetic markers associated with changes in receptor binding, reduced neutralizing effect of antibodies against previous infection or vaccination, reduced treatment efficacy, potential diagnostic impact, or an increase in predicted infectivity or disease severity.
[0143] Variants of interest may require one or more appropriate public health measures, including enhanced sequence surveillance, enhanced laboratory characterization, or epidemiological investigations, to assess the ease with which the virus can be transmitted to others, the severity of the disease, the efficacy of treatments, and whether currently approved or authorized vaccines provide protection. Variants of Interest Under Monitoring and Characterization Specification 25 / 157 pages 28 CN 121263205 AThe list of variants is constantly expanding, including but not limited to η, ι, κ, λ, and μ.
[0144] b. Variants of Concern
[0145] Variants of concern are those with evidence of increased transmissibility, more severe illness (e.g., increased hospitalization or mortality), significantly reduced neutralizing effect of antibodies produced during prior infection or vaccination, reduced effectiveness of treatment or vaccines, or failure of diagnostic tests. Possible characteristics of variants of concern include: evidence of impact on diagnosis, treatment, or vaccines; widespread interference with diagnostic test targets; evidence of significantly reduced sensitivity to one or more therapies; evidence of significantly reduced neutralizing effect of antibodies produced during prior infection or vaccination; evidence of reduced vaccine-induced protection against severe illness; evidence of increased transmissibility; and evidence of increased disease severity.
[0146] Variants of concern may require one or more appropriate public health measures, such as notification to the WHO under the International Health Regulations, reporting to the CDC, implementing local or regional measures to control transmission, and strengthening testing or research to determine the effectiveness of vaccines and treatments against the variant. Depending on the characteristics of the variant, other considerations may include developing new diagnostic methods or modifying vaccines or treatments. The list of variants of concern for close monitoring and characterization is constantly growing, including but not limited to α, β, δ, γ, and ο.
[0147] c. Severe Consequence Variants
[0148] Severe SARS-CoV-2 variants have clear evidence that the effectiveness of preventive measures or medical countermeasures (MCM) has been significantly reduced compared to previously circulating variants. Possible characteristics of severe SARS-CoV-2 variants include: confirmed failure of diagnostic test targets, evidence of significantly reduced vaccine effectiveness, unusually high number of vaccine breakthrough cases or extremely low vaccine-induced protection against severe illness, significantly reduced sensitivity to multiple Emergency Use Authorizations (EUA) or approved therapies, and more severe clinical illness and increased hospitalizations.
[0149] Severe SARS-CoV-2 variants require notification to the WHO, reporting to the CDC, announcement of strategies for prevention or control of transmission, and recommendations for updated treatments and vaccines in accordance with the International Health Regulations. Currently, no SARS-CoV-2 variant has reached the severe consequence level.
[0150] B. PIV5 CVB Vector SARS-CoV-2 Construct
[0151] The PIV5 vaccine vector of the present invention can be constructed using any of a variety of methods, including but not limited to the reverse genetics system described in more detail in He et al. (Virology; 237(2):249-60, 1997). PIV5 encodes eight viral proteins. Nucleocapsid protein (NP), phosphoprotein (P), and large RNA polymerase (L) proteins are responsible for the transcription and replication of the viral RNA genome.The V protein is very important. It plays a crucial role in viral pathogenesis and viral RNA synthesis. The fusion (F) protein is a glycoprotein that mediates cell-to-cell and virus-to-cell fusion in a pH-independent manner, which is essential for viral entry into cells. The structure of the F protein has been determined, and key amino acid residues for efficient fusion have been identified. The hemagglutinin-neuraminidase (HN) glycoprotein is also involved in viral entry into and release from host cells. The matrix (M) protein plays an important role in viral assembly and budding. The hydrophobic (SH) protein is a 44-residue hydrophobic integrated membrane protein located in the membrane with its N-terminus in the cytoplasm. For reviews on the molecular biology of paramyxoviruses, see, for example, Whelan et al., 2004, Curr Top Microbiol Immunol; 283:61-119; and Lamb and Parks, (2006). Paramyxoviridae: the viruses and their replication. Fields Virology, 5th ed., pp.1449-1496. Edited by DMKnipe and PM Howley. Philadelphia, PA: Lippincott Williams & Wilkins.
[0152] Since PIV5 actively replicates in the respiratory tract after intranasal immunization, PIV5 vector vaccines can generate mucosal immunity, including antigen-specific IgA antibodies and long-lived IgA plasma cells (Wang, D. et al., J Virol, 91(11) 26 / 157 pages 29 CN 121263205 A (2017). Xiao, P. et al., Front Immunol, 12:623996 (2021)). Recently, PIV5 vector vaccines expressing the spike protein (WA1; CVXGA1) of the SARS-CoV-2 strain have been shown to be effective in mice and ferrets. A single intranasal dose of CVXGA1 can induce WA1 neutralizing antibodies and protect K18-hACE2 mice from lethal infection with SARS-CoV-2 WA1. Furthermore, a single intranasal dose of CVXGA1 protected ferrets from SARS-CoV-2 WA1 infection and prevented transmission to young ferrets living with them (An, D. et al., Sci Adv, 7(27)(2021)). While these studies have established its efficacy against SARS-CoV-2 WA1, further studies are needed to determine its efficacy against SARS-CoV-2 variants.
[0153] The PIV5 virus vaccine of the present invention may also have one or more of these eight proteins of the PIV5 genome.Mutations, alterations, or deletions. For example, a PIV5 viral expression vector may include one or more mutations, including but not limited to any mutations described herein. In some respects, a combination of two or more (two, three, four, five, six, seven or more) mutations may be advantageous and may exhibit enhanced activity.
[0154] In one embodiment, the PIV5 vector is further modified by introducing a mutation into the PIV5 V / P gene and deleting the PIV5SH gene to further enhance vaccine efficiency. S157F and S308A in the PIV5V / P gene have previously been shown to increase viral polymerase activity and improve viral titer or yield (Timani KA, Sun D, Sun M et al. J Virol., 82(18): 9123-9133 (2008); Sun D, Luthra P, Li Z, He B., PLoS Pathog., 5(7): e1000525 (2009)). An RSV vaccine based on the PIV5 W3A strain with a single S157F mutation induced higher levels of neutralizing antibodies in mice than a PIV5 CPI vector RSV vaccine (see Table 19). The PIV5 W3A strain lacking the SH gene and expressing the influenza virus H5 HA protein induced higher levels of antibodies and provided better protection against influenza virus challenge (Li Z, Gabbard JD, Mooney A et al., J Virol., 87(17):9604-9609 (2013)). In one embodiment, a novel modified PIV5 viral vector backbone, named CVB, was presented by introducing S157F into the V / P gene and deleting the SH gene from the PIV5 W3A viral genome. In another embodiment, a CVB vector SARS-CoV-2 vaccine for intranasal immunization was generated.
[0155] Mutations include, but are not limited to, V / P gene mutations, mutations involving the shared N-terminus of V and P proteins, mutations involving residues 26, 32, 33, 50, 102, 156, and / or 157 at the shared N-terminus of V and P proteins, mutations lacking the C-terminus of V protein, mutations lacking small hydrophobic (SH) protein, fusion (F) protein mutations, phosphoprotein (P) mutations, large RNA polymerase (L) protein mutations, mutations incorporating canine parainfluenza virus residues, and / or mutations enhancing syncytial formation.
[0156] Mutations may include, but are not limited to, rPIV5-V / P-CPI-, rPIV5-CPI-, rPIV5-CPI+, rPIV5V ΔC, rPIV-Rev, rPIV5-RL, rPIV5-P-S156N, rPIV5-P-S157A, rPIV5-P-S308A, rPIV5-L-A1981D, andrPIV5-F-S443P, rPIV5-MDA7, rPIV5ΔSH-CPI-, rPIV5ΔSH-Rev, and combinations thereof.
[0157] PIV5 can effectively infect cells and produces little to no cytopathic effect (CPE) in many cell types. In some cell types, PIV5 infection leads to syncytial formation, i.e., the fusion of many cells together, which leads to cell death. Mutations may include one or more mutations that promote syncytial formation (see, for example, Paterson et al., 2000, Virology; 270:17-30).
[0158] The V protein of PIV5 plays a key role in blocking virus-induced apoptosis. Recombinant PIV5 with a cysteine-rich C-terminus lacking the V protein (rPIV5VΔC) induces apoptosis through various intrinsic apoptotic pathways, possibly initiated by endoplasmic reticulum (ER) stress (Sun et al., 2004, J Virol; 78:5068-5078). Mutant recombinant PIV5 with mutations at the N-terminus of the V / P gene product, such as rPIV5-CPI-, can also induce apoptosis (Wansley and Parks, 2002, J Virol; 76:10109-10121). Mutations include, but are not limited to, rPIV5ΔSH, rPIV5-CPI-, rPIV5VΔC, and combinations thereof.
[0159] i. CVB-based vaccine vector encoding SARS-CoV-2 spike (S) protein specification 27 / 157 pages 30 CN 121263205 A
[0160] Using the CVB-based vaccine vector of the present invention, a heterologous nucleotide sequence encoding coronavirus spike (S) protein (including but not limited to the S protein of SARS-CoV-2) is inserted into the CVB genome. Coronavirus entry into host cells is mediated by transmembrane S glycoprotein (Tortorici and Veesler, 2019, Adv Virus Res; 105:93-116). Because the coronavirus S glycoprotein is exposed on the surface and mediates entry into host cells, it is a major target of post-infection neutralizing antibodies and a focus of therapeutic and vaccine design. The spike S protein of SARS-CoV-2 consists of two subunits, S1 and S2. The S1 subunit contains a receptor-binding domain that recognizes and binds to the host receptor angiotensin-converting enzyme 2, while the S2 subunit forms a hexagonal bundle through two heptapeptide repeat domains, mediating viral cell membrane fusion. (Huang et al., 2020, Acta Pharmacol Sinica; 0:1-9 (available at doi.org / 10.1038 / s41401-020-0485-4).
[0161] The full-length SARS-CoV-2S is 1273 amino acids (aa) and consists of a signal peptide (amino acids 1-13) at the N-terminus, an S1 subunit (residues 14-685), and an S2 subunit (residues 686-1273); the latter two regions are responsible for receptor binding and membrane fusion, respectively. The S1 subunit contains an N-terminal domain (residues 14-305) and a receptor-binding domain (RBD, residues 319-541); the S2 subunit is composed of a fusion peptide (FP) (residues 788-806), a heptapeptide repeat 1 (HR1) (residues 912-984), HR2 (residues 1163-1213), a TM domain (residues 1213-1237), and a cytoplasmic domain (residues 1237-1273) (Xia et al., 2020, Cell Mol Immunol; 17:765-7).
[0162] In some CVB-based vaccine vectors of the present invention, the heteronucleotide sequence encoding the coronavirus spike (S) protein (including but not limited to the S protein of SARS-CoV-2) has been modified such that the cytoplasmic tail of the coronavirus S protein has been replaced by the cytoplasmic tail of the PIV5 fusion (F) protein.
[0163] In some CVB-based vaccine vectors of the present invention, the heteronucleotide sequence encoding the coronavirus S protein (including but not limited to the S protein of SARS-CoV-2) has been modified such that the S protein includes amino acid substitutions at amino acid residues W886 and / or F888. In some aspects, the amino acid substitution at amino acid residue W886 includes the substitution of tryptophan (W) for arginine (R) and / or the amino acid substitution at amino acid residue W888 includes the substitution of phenylalanine (F) for arginine (R).
[0164] In some CVB-based vaccine vectors of the present invention, the heteronucleotide sequence encoding the coronavirus spike (S) protein (including, but not limited to, the S protein of SARS-CoV-2) includes modifications such that the cytoplasmic tail of the coronavirus S protein has been replaced by the cytoplasmic tail of the PIV5 fusion (F) protein, and includes amino acid substitutions at amino acid residues W886 and / or F888. In some aspects, the amino acid substitution at amino acid residue W886 includes a substitution of tryptophan (W) for arginine (R) and / or an amino acid substitution at amino acid residue W888 includes a substitution of phenylalanine (F) for arginine (R).
[0165] The heteronucleotide sequence encoding the coronavirus S protein (including, but not limited to, the S protein of SARS-CoV-2) may be inserted into any of a plurality of locations in the CVB genome.
[0166] CVB vaccine vectors encoding SARS-CoV-2 variants of interest or variants of interest are disclosed herein. CVB-based vaccine vectors may include the insertion of a SARS-CoV-2 spike (S) or nucleocapsid (N) gene from a different variant into a CVB vector.
[0167] The CVB-based vaccine vector of the present invention comprises a CVB viral expression vector containing a mutation at amino acid residue S156 or S157 of the PIV5 W3A viral genome and a deletion of the small hydrophobic (SH) gene.
[0168] In some CVB-based vaccine vectors of the present invention, the mutation at amino acid residue S157 comprises a serine (S) replaced by an amino acid residue selected from the group consisting of: alanine (A), cysteine (C), aspartic acid (D), glutamic acid (E), phenylalanine (F), glycine (G), histidine (H), isoleucine (I), lysine (K), leucine (L), methionine (M), asparagine (N), proline (P), glutamine (Q), arginine (R), selenocysteine (U), valine (V), tryptophan (W), and tyrosine (Y).
[0169] In some CVB-based vaccine vectors of the present invention, the amino acid substitution at amino acid residue S157 includes the substitution of serine (S) for phenylalanine (F) or the amino acid substitution at amino acid residue S156N includes the substitution of serine (S) for asparagine (N).
[0170] In some CVB-based vaccine vectors of the present invention, the SH gene lacks the SH open reading frame or the entire SH gene transcription unit.
[0171] In some CVB-based vaccine vectors of the present invention, the PIV5 genome has a heterologous nucleic acid sequence having at least 98% sequence identity with SEQ ID NO:27, 28, 29, 30, 31, 32 or 33 and wherein the viral expression vector expresses a heterologous polypeptide comprising coronavirus spike (S) and / or nucleocapsid (N) proteins.
[0172] In some CVB-based vaccine vectors of the present invention, the coronavirus S protein is the coronavirus S protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the variant of interest, or a variant of SARS-CoV-2 of interest, and the coronavirus N protein is the coronavirus N protein of SARS-CoV-2, the variant of interest, or a variant of SARS-CoV-2 of interest.
[0173] In another embodiment, the coronavirus S protein is the coronavirus S protein of a SARS-CoV-2 strain, SARS-CoV-2β variant, SARS-CoV-2γ variant, SARS-CoV-2δ variant, or SARS-CoV-2O variant, and the coronavirus N protein is the coronavirus N protein of a SARS-CoV-2 strain, SARS-CoV-2β variant, SARS-CoV-2γ variant, SARS-CoV-2δ variant, or SARS-CoV-2O variant.
[0174] In some CVB-based vaccine vectors of the present invention, the coronavirus S protein comprises the coronavirus S protein of SARS-CoV-2 and wherein the coronavirus S protein has been replaced by the cytoplasmic tail of the fusion (F) protein of CVB.
[0175] In some CVB-based vaccine vectors of the present invention, the PIV5 W3A viral genome comprises an open reading frame deletion mutation of the SH gene and the S gene of the SARS-CoV-2 strain is inserted between the PIV5 hemagglutinin (HN) gene and the polymerase (L) gene of PIV5.
[0176] In some CVB-based vaccine vectors of the present invention, the entire SH gene transcription unit of the PIV5 W3A viral genome is deleted and the S gene of the SARS-CoV-2 strain is placed between the HN gene and the L gene of PIV5.
[0177] In some CVB-based vaccine vectors of the present invention, the N gene of the SARS-CoV-2 strain is inserted to replace the SH gene of PIV5, and the S gene of the SARS-CoV-2 strain is inserted between the HN gene and the L gene of PIV5.
[0178] In some CVB-based vaccine vectors of the present invention, the S gene of the SARS-CoV-2 OBA.1 variant is inserted to replace the S gene of the SARS-CoV-2 strain, and the N gene of the SARS-CoV-2 strain is inserted to replace the SH gene of PIV5.
[0179] In some CVB-based vaccine vectors of the present invention, the S gene of the SARS-CoV-2 OBA.5 variant is inserted between the HN gene and L gene of PIV5 to replace the S gene of the SARS-CoV-2 strain.
[0180] In some CVB-based vaccine vectors of the present invention, the S gene of the SARS-CoV-2 OBA.5 variant is inserted to replace the S gene of the SARS-CoV-2 strain, and the N gene of the SARS-CoV-2 strain is inserted to replace the SH gene of PIV5.
[0181] In some CVB-based vaccine vectors of the present invention, the PIV5 F and HN genes are deleted, and the S gene of the SARS-CoV-2 strain is located between the HN gene and L gene of PIV5.
[0182] The present invention also includes virions and infectious viral particles comprising a PIV5 genome, said PIV5 genome comprising a heterologous nucleotide sequence encoding a coronavirus S protein (including, but not limited to, the S protein of SARS-CoV-2).
[0183] The present invention also includes compositions comprising one or more PIV5 viral constructs or virions as described herein. Such compositions may include pharmaceutically acceptable carriers. As used, a pharmaceutically acceptable carrier refers to one or more compatible solid or liquid fillers, diluents, or encapsulating substances suitable for administration to humans or other vertebrates.These carriers may be pyrogen-free. The invention also includes methods for manufacturing and using the viral vectors and compositions described herein.
[0184] The compositions of this disclosure can be formulated into a variety of pharmaceutical formulations suitable for a chosen route of administration. Those skilled in the art will understand that the compositions will vary depending on the method of administration and dosage unit.
[0185] The agents of the invention can be administered in a variety of ways, including but not limited to intravenous, local, oral, intranasal, subcutaneous, intraperitoneal, intramuscular, and intratumoral delivery. In some aspects, the agents of the invention can be formulated for controlled or sustained release. One advantage of intranasal immunization is the potential to induce a mucosal immune response.
[0186] C. CVB-S backbone vaccine viral sequences
[0187] The CVB vector SARS-CoV-2 vaccine viral sequences of the constructs in Table 1 are listed below. In the SARS-CoV-2 sequence insertion, N is an underlined lowercase letter, M is an italic lowercase letter, E is a bold lowercase letter, and S is a lowercase letter:
[0188] i. CVL104
[0189] The nucleic acid sequence of CVL104 is:
[0190] GCCACCTGACGTCTAAGAAACCATTATTATCATGACATTAACCTATAAAAATAGGCGTATCACGAGGC CCTTTCGTCTCGCGCGTTTCGGTGATGACGGTGAAAACCTCTGACACATGCAGCTCCCGGAGACGGTCACAGCTTG TCTGTAAGCGGATGCCGGGAGCAGACAAGCCCGTCAGGGCGCGTCAGCGGGTGTTGGCGGGTGTCGGGGCTGGCTT AACTATGCGGCATCAGAGCAGATTGTACTGAGAGTGCACCATATATGCGGTGTGAAATACCGCACAGATGCGTAAG GAGAAAATACCGCATCAGGCTAATACGACTCACTATAGGGACCAAGGGGAAAATGAAGTGGTGACTCAAATCATCG AAGACCCTCGAGATTACATAGGTCCGGAACCTATGGCCTTCGTGACCGACCTCGAGTCAGAGTAGTTCAATAAGGA CCTATCAAGTTTGGGCAATTTTTCGTCCCCGACACAAAAATGTCATCCGTGCTTAAAGCATATGAGCGATTCACGCTCACTCAAGAACTGCAAGATCAGAGTGAGGAAGGTACAATCCCACCTACAACACTAAAACCGGTAATCAGGGTATT TATACTAACCTCTAATAACCCAGAGCTAAGATCCCGGCTTCTTCTATTCTGCCTACGGATTGTTCTCAGTAATGGT GCAAGGGATTCCCATCGCTTTGGAGCATTACTCACAATGTTTTCGCTACCATCAGCCACAATGCTCAATCATGTCA AATTAGCTGACCAGTCACCAGAAGCTGATATCGAAAGGGTAGAGATCGATGGCTTTGAGGAGGGATCATTCCGCTT AATCCCCAATGCTCGTTCAGGTATGAGCCGTGGAGAGATCAATGCCTATGCTGCACTTGCAGAAGATCTACCTGAC ACACTAAACCATGCAACACCTTTCGTTGATTCCGAAGTCGAGGGAACTGCATGGGATGAGATTGAGACTTTCTTAG ATATGTGTTACAGTGTCCTAATGCAGGCATGGATAGTGACTTGCAAGTGCATGACTGCGCCAGACCAACCTGCTGC TTCTATTGAGAAACGCCTGCAAAAATATCGTCAGCAAGGCAGGATCAACCCGAGATATCTCCTGCAACCGGAGGCT CGACGAATAATCCAGAATGTAATCCGGAAGGGAATGGTGGTCAGACATTTCCTCACCTTTGAACTGCAGCTTGCCC GAGCACAAAGCCTTGTATCAAATAGGTATTATGCTATGGTAGGGGATGTTGGAAAGTATATAGAGAATTGTGGAAT GGGAGGCTTCTTTTTGACACTAAAATATGCATTAGGAACTAGATGGCCCACACTTGCTTTAGCTGCATTTTCAGGA GAGCTAACAAAGCTAAAGTCCCTCATGGCATTATACCAGACCCTTGGTGAGCAGGCCCGATATTTGGCCCTATTGG AGTCACCACATTTGATGGATTTTGCTGCAGCAAACTACCCACTGCTATATAGCTATGCTATGGGAATAGGCTATGTGTTAGATGTCAACATGAGGAACTACGCTTTCTCCAGATCATACATGAACAAGACATATTTCCAATTGGGAATGGAA ACTGCAAGAAAACAACAGGGTGCAGTTGACATGAGGATGGCAGAAGATCTCGGTCTAACTCAAGCCGAACGCACCG AGATGGCAAATACACTTGCCAAATTGACCACAGCAAATCGAGGGGCAGACACCAGGGGAGGAGTCAACCCGTTCTC ATCTGTCACTGGGACAACTCAGGTGCCCGCTGCAGCAACAGGTGACACACTCGAGAGTTACATGGCAGCGGATCGA CTGAGGCAGAGATATGCTGATGCAGGCACCCATGATGATGAGATGCCACCATTGGAAGAGGAGGAAGAGGACGACA CATCTGCAGGTCCACGCACTGGACCAACTCTTGAACAAGTGGCCTTGGACATCCAGAACGCAGCAGTTGGAGCTCC CATCCATACAGATGACCTGAATGCCGCACTGGGTGATCTTGACATCTAGACAATTCAGATCCCAATCTAAAATTGA CATACCTAATTGATTAGTTAGATGGAACTACAGTGGATTCCATAAGGTTCCTGCCTACCATCGGCTTTAAAGAAAA AAATAGGCCCGGACGGGTTAGCAACAAGCGACTGCCGGTGCCAACAGCGCAATCCACAATCTACAATGGATCCCAC DESCRIPTION Page 30 / 157 33 CN 121263205 A TGATCTGAGCTTCTCCCCAGATGAGATCAATAAGCTCATAGAGACAGGCCTGAATACTGTAGAGTATTTTACTTCC CAACAAGTCACAGGAACATCCTCTCTTGGAAAGAATACAATACCACCAGGGGTCACAGGACTACTAACCAATGCTG CAGAGGCAAAGATCCAAGAGTCAACTAACCATCAGAAGGGCTCAGTTGGTGGGGGTGCAAAACCAAAGAAACCGCGACCAAAAATTGCCATTGTGCCAGCAGATGACAAAACAGTGCCCGGAAAGCCGATCCCAAACCCTCTATTAGGTCTG GACTCCACCCCGAGCACCCAAACTGTGCTTGATCTAAGTGGGAAAACATTACCATCAGGATCCTATAAGGGGGTTA AGCTTGCGAAATTTGGAAAAGAAAATCTGATGACACGGTTCATCGAGGAACCCAGAGAGAATCCTATCGCAACCAG TTtCCCCATCGATTTTAAGAGGGGCAGGGATACCGGCGGGTTCCATAGAAGGGAGTACTCAATCGGATGGGTGGGA GATGAAGTCAAGGTCACTGAGTGGTGCAATCCATCCTGTTCTCCAATCACCGCTGCAGCAAGGCGATTTGAATGCA CTTGTCACCAGTGTCCAGTCACTTGCTCTGAATGTGAACGAGATACTTAATACAGTGAGAAATTTGGACTCTCGGA TGAATCAACTGGAGACAAAAGTAGATCGCATTCTCTCATCTCAGTCTCTAATCCAGACCATCAAGAATGACATAGT TGGACTTAAAGCAGGGATGGCTACTTTAGAAGGAATGATTACAACTGTGAAAATCATGGACCCGGGAGTTCCCAGT AATGTTACTGTGGAAGATGTACGCAAGACACTAAGTAACCATGCTGTTGTTGTGCCAGAATCATTCAATGATAGTT TCTTGACTCAATCTGAAGATGTAATTTCACTTGATGAGTTGGCTCGACCAACTGCAACAAGTGTTAAGAAGATTGT CAGGAAGGTTCCTCCTCAGAAGGATCTGACTGGATTGAAGATTACACTAGAGCAATTGGCAAAGGATTGCATCAGC AAACCGAAGATGAGGGAAGAGTATCTCCTCAAAATCAACCAGGCTTCCAGTGAGGCTCAGCTAATTGACCTCAAGA AAGCAATCATCCGCAGTGCAATTTGATCAAGAAACACCCAATTACACTACACTGGTATGACACTGTACTAACCCTGAGGGTTTTAGAAAAAACGATTAACGATAAATAAGCCCGAACACTACACACTACCTGAGGCAGCCATGCCATCCATC AGCATTCCCCGCAGACCCCACCAATCCACGTCAATCAAAAAGCGTTCCCAATTGTGATCAACAGTGATGGGGGTG AGAAAGGCCGCTTGGTTAAACAACTACGCACAACCTACTTGAATGACCTAGATACTCATGAGCCACTGGTGACATT CATAAATACCTATGGATTCATCTACGAACAGGATCGGGGGAATACCATTGTCGGAGAGGATCAACTTGGGAAAA AGAGAGGCTGTGACCGCTGCAATGGTTACCCTTGGAATTGGGCCTAATCTACCATTAGGGGAATGTCCTGGGAC AACTGAGGGAATTCCAGGTCACTGTTAGGAAGACATCCAGCAAAGCGGAAGAGATGGTCTTTGAAATTGTTAAGTA TCCGAGAATATTTCGGGGTCATACATTAATCCAGAAAGGACTAGTCTGTGTCTCCGCAGAAAAAATTGTTAAGTCCACCAGGAAAATACAATCTGGAATGGACTATCTCTTCATTCCGACATTTCTCTAGTGACTTTACTGTCCAGCTGCAA TCAAATTTCAGGTACCTGGCCCCATGTTGAAAATGAGATCAAGATACACTCAGAGCTTACAACTTGAACTAATGAT AAGAATCCTGTGTAAGCCCGATTCGCCACTTATGAAGGTCCATACCCCTGACAAGGAGGAAGGAGTGTCTTGTA TCAGTATGGCTGCATGTATGCAACATCTTCAAATCAGGAACAAGAAGGGCAGTGAGTGGCAGGAATACTGGATGA GAAAGTGTGCTAACAGTGCAACTTGAAGTGTGCATTGCAGATATGTGGGACCAACTATCATAATTCATGCCAGAGG TCACATTCCCAAAAGTGCTAAGTTGTTTTTGGAAAGGGTGGATGGAGTGCCATCCACTTCACGAAGTTGTTCCAAGTGTCACTAAAACACTATGGTCCGTGGGCTGTGAGATTACAAAGGCGAAGGCAATAATACAAGAGAGTAGCATCT CTCTTCTCGTGGAGACTACTGACATCATAAGTCCAAAAGTCAAAATTTCATCTAAGCATCGCCGCTTTGGGAAATC AAATTGGGGTCTGTTCAAGAAAACTAAATCACTGCCTAACCTGACGGAGCTGGAATGACTGACCTCTAATCGAGAC TACACCGCCGCAAACTATAGGTGGGTGGTACCTCAGTGATTAATCTTGTAAGCACTGATCGTAGGCTACAACACAC TAATATTATCCAGATTAGAGAGCTTAATTAGCTCTGTATTAATAATAACACTACTATTCCAATAACTGGAATCACC AGCTTGATTTATCTCCAAAATGATTCAAAGAAAACAAATCATATTAAGACTATCCTAAGCACGAACCCATATCGTC CTTCAAATCATGGGTACTATAATTCAATTTCTGGTGGTCTCCTGTCTATTGGCAGGAGCAGGCAGCCTTGATCCAG CAGCCCTCATGCAAATCGGTGTCATTCCAACAAATGTCCGGCAACTTATGTATTATACTGAAGCTTCATCAGCATT CATTGTTGTGAAGTTAATGCCTACAATTGACTCGCCGATTAGTGGATGTAATATAACATCAATTTCAAGCTATAAT GCAACAGTGACAAAACTCCTACAGCCGATCGGTGAGAATTTGGAGACGATTAGGAACCAGTTGATTCCAACTCGGA DESCRIPTION Page 31 / 157 34 CN 121263205 A GGAGACGCCGGTTTGCAGGGGTGGTGATTGGATTAGCTGCATTAGGAGTAGCTACTGCCGCACAGGTCACTGCCGC AGTGGCACTAGTAAAGGCAAATGAAAATGCTGCGGCTATACTCAATCTCAAAAATGCAATCCAAAAAACAAATGCAGCAGTTGCAGATGTGGTCCAGGCCACACAATCACTAGGAACGGCAGTTCAAGCAGTTCAAGATCACATAAACAGTG TGGTAAGTCCAGCAATTACAGCAGCCAATTGTAAGGCCCAAGATGCTATCATTGGCTCAATCCTCAATCTCTATTT GACCGAGTTGACAACCATCTTCCACAATCAAATTACAAACCCTGCATTGAGTCCCATTACAATTCAAGCTTTAAGG ATCCTACTGGGGAGTACCTTGCCGACTGTGGTCGAAAAATCTTTCAATACCCAGATAAGTGCAGCTGAGCTTCTCT CATCAGGGTTATTGACAGGCCAGATTGTGGGATTAGATTTGACCTATATGCAGATGGTCATAAAAATTGAGCTGCC AACTTTAACTGTACAACCTGCAACCCAGATCATAGATCTGGCCACCATTTCTGCATTCATTAACAATCAAGAAGTC ATGGCCCAATTACCAACACGTGTTATGGTGACTGGCAGCTTGATCCAAGCCTATCCCGCATCGCAATGCACCATTA CACCCAACACTGTGTACTGTAGGTATAATGATGCCCAAGTACTCTCAGATGATACTATGGCTTGCCTCCAAGGTAA CTTGACAAGATGCACCTTCTCTCCAGTGGTTGGGAGCTTTCTCACTCGATTCGTGCTGTTCGATGGAATAGTTTAT GCAAATTGCAGGTCGATGTTGTGCAAGTGCATGCAACCTGCTGCTGTGATCCTACAGCCGAGTTCATCCCCTGTAA CTGTCATTGACATGTACAAATGTGTGAGTCTGCAGCTTGACAATCTCAGATTCACCATCACTCAATTGGCCAATGT AACCTACAATAGCACCATCAAGCTTGAATCATCCCAGATCTTGTCTATTGATCCGTTGGATATATCCCAGAATCTA GCTGCGGTGAATAAGAGTCTAAGTGATGCACTACAACACTTAGCACAAAGTGACACATATCTTTCTGCAATCACATCAGCTACGACTACAAGTGTATTATCCATAATAGCAATCTGTCTTGGATCGTTAGGTTTAATATTAATAATCTTGCT CAGTGTAGTTGTGTGGAAGTTATTGACCATTGTCGTTGCTAATCGAAATAGAATGGAGAATTTTGTTTATCATAAA TAAGCATTCCACCACTCACGATCTGATCTCAGTGAGAAAAATCAACCTGCAACTCTTGGAACAAGATAAGACAGTC ATCCATTAGTAATTTTTAAGAAAAAAACGATAGGACCGAACCTAGTATTGAAAGAACCGTCTCGGTCAATCTAGGT AATCGAGCTGATACCGTCTCGGAAAGCTCAAATCCTGCTATAGGCTATCCACTGCATCATCTCTCCTGCCATACTT CCTACTCACATCATATCTATTTTAAAGAAAAAATAGGCCCGAACACTAATCGTGCCGGCAGTGCCACTGCACACAC AACACTACACATACAATACACTACAATGGTTGCAGAAGATGCCCCTGTTAGGGCCACTTGCCGAGTATTATTTCGA ACAACAACTTTAATCTTTCTATGCACACTACTAGCATTAAGCATCTCTATCCTTTATGAGAGTTTAATAACCCAAA AGCAAATCATGAGCCAAGCAGGCTCAACTGGATCTAATTCTGGATTAGGAAGTATCACTGATCTTCTTAATAATAT TCTCTCTGTCGCAAATCAGATTATATATAACTCTGCAGTCGCTCTACCTCTACAATTGGACACTCTTGAATCAACA CTCCTTACAGCCATTAAGTCTCTTCAAACCAGTGACAAGCTAGAACAGAACTGCTCGTGGAGTGCTGCACTGATTA ATGATAATAGATACATTAATGGCATCAATCAGTTCTATTTTTCAATTGCTGAGGGTCGCAATCTGACACTTGGCCC ACTTCTTAATATGCCTAGTTTCATTCCAACTGCCACGACACCAGAGGGCTGCACCAGGATCCCATCATTCTCGCTCACTAAGACACACTGGTGTTATACACACAATGTTATCCTGAATGGATGCCAGGATCATGTATCCTCAAATCAATTTG TTTCTATGGGAATCATTGAACCCACTTCTGCCGGGTTTCCATTCTTTCGAACCCTAAAGACTCTATATCTCAGCGA TGGGGTCAATCGTAAGAGCTGCTCTATCAGTACAGTTCCGGGGGGTTGTATGATGTACTGTTTTGTTTCTACTCAA CCAGAGAGGGATGACTACTTTTCTGCCGCTCCTCCAGAACAACGAATTATTATAATGTACTATAATGATACAATCG TGGAGCGCATAATTAATCCACCCGGGGTACTAGATGTATGGGCAACATTGAACCCAGGAACAGGAAGCGGGGTATA TTATTTAGGTTGGGTGCTCTTTCCAATATATGGCGGCGTGATTAAAGGTACGAGTTTATGGAATAATCAAGCAAAT AAATACTTTATCCCCCAGATGGTTGCTGCTCTCTGCTCACAAAACCAGGCAACTCAAGTCCAAAATGCTAAGTCAT CATACTATAGCAGCTGGTTTGGCAATCGAATGATTCAGTCTGGGATCCTGGCATGTCCTCTTCGACAGGATCTAAC CAATGAGTGTTTAGTTCTGCCCTTTTCTAATGATCAGGTGCTTATGGGTGCTGAAGGGAGATTATACATGTATGGT GACTCGGTGTATTACTATCAAAGAAGCAATAGTTGGTGGCCTATGACCATGCTGTATAAGGTAACCATAACATTCA CTAATGGTCAGCCATCTGCTATATCAGCTCAGAATGTGCCCACACAGCAGGTCCCTAGACCTGGGACAGGAGACTG Description Page 32 / 157 35 CN 121263205 A CTCTGCAACCAATAGATGTCCCGGTTTTTGCTTGACAGGAGTGTATGCCGATGCCTGGTTACTGACCAACCCTTCGTCTACCAGTACATTTGGATCAGAAGCAACCTTCACTGGTTCTTATCTCAACACAGCAACTCAGCGTATCAATCCGA CGATGTATATCGCGAACAACACACAGATCATAAGCTCACAGCAATTTGGATCAAGCGGTCAAGAAGCAGCATATGG CCACACAACTTGTTTTAGGGACACAGGCTCTGTTATGGTATACTGTATCTATATTATTGAATTGTCCTCATCTCTC TTAGGACAATTTCAGATTGTCCCATTTATCCGTCAGGTGACACTATCCTAAAGGCAGAAGCCTTCAGGTCTGACCC AGCCAATCAAAGCATTATACCAGACCATGGCCTACCATCGGCTTTAAAGAAAAAAATAGGCCCGGACGGGTTAGCA ACAAGCGGCGGCCGCCatgttcgtcttcctggtcctgctgcctctggtctcctcacagtgcgtcaatctgacaact cggactcagctgccacctgcttatactaatagcttcaccagaggcgtgtactatcctgacaaggtgtttagaagct ccgtgctgcactctacacaggatctgtttctgccattctttagcaacgtgacctggttccacgccatccacgtgag cggcaccaatggcacaaagcggttcgacaatcccgtgctgccttttaacgatggcgtgtacttcgcctctaccgag aagagcaacatcatcagaggctggatctttggcaccacactggactccaagacacagtctctgctgatcgtgaaca atgccaccaacgtggtcatcaaggtgtgcgagttccagttttgtaatgatcccttcctgggcgtgtactatcacaa gaacaataagagctggatggagtccgagtttagagtgtattctagcgccaacaactgcacatttgagtacgtgagc cagcctttcctgatggacctggagggcaagcagggcaatttcaagaacctgagggagttcgtgtttaagaatatcgacggctacttcaaaatctactctaagcacacccccatcaacctggtgcgcgacctgcctcagggcttcagcgccct ggagcccctggtggatctgcctatcggcatcaacatcacccggtttcagacactgctggccctgcacagaagctac ctgacacccggcgactcctctagcggatggaccgccggcgctgccgcctactatgtgggctacctccagccccgga ccttcctgctgaagtacaacgagaatggcaccatcacagacgcagtggattgcgccctggaccccctgagcgagac aaagtgtacactgaagtcctttaccgtggagaagggcatctatcagacatccaatttcagggtgcagccaaccgag tctatcgtgcgctttcctaatatcacaaacctgtgcccatttggcgaggtgttcaacgcaacccgcttcgccagcg tgtacgcctggaataggaagcggatcagcaactgcgtggccgactatagcgtgctgtacaactccgcctctttcag cacctttaagtgctatggcgtgtcccccacaaagctgaatgacctgtgctttaccaacgtctacgccgattctttc gtgatcaggggcgacgaggtgcgccagatcgcccccggccagacaggcaagatcgcagactacaattataagctgc cagacgatttcaccggctgcgtgatcgcctggaacagcaacaatctggattccaaagtgggcggcaactacaatta tctgtaccggctgtttagaaagagcaatctgaagcccttcgagagggacatctctacagaaatctaccaggccggc agcaccccttgcaatggcgtggagggctttaactgttatttcccactccagtcctacggcttccagcccacaaacg gcgtgggctatcagccttaccgcgtggtggtgctgagctttgagctgctgcacgccccagcaacagtgtgcggccccaagaagtccaccaatctggtgaagaacaagtgcgtgaacttcaacttcaacggcctgaccggcacaggcgtgctg accgagtccaacaagaagttcctgccatttcagcagttcggcagggacatcgcagataccacagacgccgtgcgcg acccacagaccctggagatcctggacatcacaccctgctctttcggcggcgtgagcgtgatcacacccggcaccaa tacaagcaaccaggtggccgtgctgtatcaggacgtgaattgtaccgaggtgcccgtggctatccacgccgatcag ctgaccccaacatggcgggtgtacagcaccggctccaacgtcttccagacaagagccggatgcctgatcggagcag agcacgtgaacaattcctatgagtgcgacatcccaatcggcgccggcatctgtgcctcttaccagacccagacaaa ctctcccagaagagcccggagcgtggcctcccagtctatcatcgcctataccatgtccctgggcgccgagaacagc gtggcctactctaacaatagcatcgccatcccaaccaacttcacaatctctgtgaccacagagatcctgcccgtgt ccatgaccaagacatctgtggactgcacaatgtatatctgtggcgattctaccgagtgcagcaacctgctgctcca gtacggcagcttttgtacccagctgaatagagccctgacaggcatcgccgtggagcaggataagaacacacaggag gtgttcgcccaggtgaagcaaatctacaagaccccccctatcaaggactttggcggcttcaatttttcccagatcc tgcctgatccatccaagccttctaagcggagctttatcgaggacctgctgttcaacaaggtgaccctggccgatgc DESCRIPTION Page 33 / 157 36 CN 121263205 Acggcttcatcaagcagtatggcgattgcctgggcgacatcgcagccagggacctgatctgcgcccagaagtttaat ggcctgaccgtgctgccacccctgctgacagatgagatgatcgcacagtacacaagcgccctgctggccggcacca tcacatccggatggaccttcggcgcaggagccgccctccagatcccctttgccatgcagatggcctataggttcaa cggcatcggcgtgacccagaatgtgctgtacgagaaccagaagctgatcgccaatcagtttaactccgccatcggc aagatccaggacagcctgtcctctacagccagcgccctgggcaagctccaggatgtggtgaatcagaacgcccagg ccctgaataccctggtgaagcagctgagcagcaacttcggcgccatctctagcgtgctgaatgacatcctgagccg gctggacaaggtggaggcagaggtgcagatcgaccggctgatcaccggccggctccagagcctccagacctatgtg acacagcagctgatcagggccgccgagatcagggccagcgccaatctggcagcaaccaagatgtccgagtgcgtgc tgggccagtctaagagagtggacttttgtggcaagggctatcacctgatgtccttccctcagtctgccccacacgg cgtggtgtttctgcacgtgacctacgtgcccgcccaggagaagaacttcaccacagcccctgccatctgccacgat ggcaaggcccactttccaagggagggcgtgttcgtgtccaacggcacccactggtttgtgacacagcgcaatttct acgagccccagatcatcaccacagacaacaccttcgtgagcggcaactgtgacgtggtcatcggcatcgtgaacaa taccgtgtatgatccactccagcccgagctggacagctttaaggaggagctggataagtatttcaagaatcacacctcccctgacgtggatctgggcgacatcagcggcatcaatgcctccgtggtgaacatccagaaggagatcgaccgcc tgaacgaggtggctaagaatctgaacgagagcctgatcgacctccaggagctgggcaagtatgagcagtacatcaa gtggccctggtacatctggctgggcttcatcgccggcctgatcgccatcgtgatggtgaccatcatgctgtgctgt atgacatcctgctgttcttgcctgaagggctgctgtagctgtggctcctgctgtaagttattgaccattgtcgttg ctaatcgaaatagaatggagaattttgtttatcataaatgaAGTCGACTCATGGAATGCATACCAAACATTATTGA CACTAATGACACACAAAATTGGTTTTAAGAAAAACCAAGAGAACAATAGGCCAGAATGGCTGGGTCTCGGGAGATA TTACTCCCTGAAGTCCATCTCAATTCACCAATTGTAAAGCATAAGCTATACTATTACATTCTACTTGGAAACCTCC CAAATGAGATCGACCTTGACGATTTAGGTCCATTACATAATCAAAATTGGAATCAGATAGCACATGAAGAGTCTAA CTTAGCTCAACGCTTGGTAAATGTAAGAAATTTTCTAATTACCCACATCCCTGATCTTAGAAAGGGCCATTGGCAA GAGTATGTCAATGTAATACTGTGGCCGCGAATTCTTCCCTTGATCCCGGATTTTAAAATCAATGACCAATTGCCTC TGCTCAAAAATTGGGACAAGTTAGTTAAAGAATCATGTTCAGTAATCAATGCAGGTACTTCCCAGTGCATTCAGAA TCTCAGCTATGGACTGACAGGTCGTGGGAACCTCTTTACACGATCACGTGAACTCTCTGGTGACCGCAGGGATATT GATCTTAAGACAGTTGTGGCAGCATGGCATGACTCAGACTGGAAAAGAATAAGTGATTTTTGGATTATGATCAAATTCCAGATGAGACAATTAATTGTTAGGCAAACAGATCATAATGATTCTGATTTAATCACGTATATCGAAAATAGAGA AGGCATAATCATCATAACCCCTGAACTGGTAGCATTATTTAACACTGAGAATCATACACTAACATACATGACCTTT GAAATTGTACTGATGTTTCAGATATGTACGAAAGGTCGTCGACAACATTTTATCACTATGCACAGTTAGCACTTACC TGAATCCTCTGAAAAAAGAATAACATATTTATTGAGCCTTGTAGATAACTTAGCTTTTCAGATATAGCTGT ATATAACATAATTGCTTTGCTAGAATCCTTTGTATAGCACAGTTGCAAATGTCAGATCTCCATCCCAGAACTCAGA GGACAATTCCATGCATTCGTATGTTCTGAGATTCCTTGAGATTCCTTGATGCACTAAAGGAACTAAGTTTTCACCAGGATGAAT TAAGAACTGTGACAACTAATTTGATATCCCATTCCAAGATCTGACCCCAGATCTTACGGCTGAATTGCTCTGTAT AATGAGGCTTTGGGACACCCATGCTCACTGCCAGTCAAGCTGCAAGGTACGCGATCTATGTGTGTGGA AAAGTATTAGACTTTCCCACCATTATGAAAACACTAGCCTTTTTCCATACTATTCTGATCAATGGATACAGGAGGA AGCATCATGGAGTATGGCCACCTTAAACTTACCGGGTAATGCTTCAAAGGGTCTCACGGAACTTATGAATGACAA TACTGAAATAAGCTATGAATTCACACTTAAGCATTGGAAGGAAGTCTCTCTTATAAAATTCAAGAAATGTTTTGAT GCAGACGCAGGTGAGGAACTCAGTATATTTATGAAAGATAAGGGCAATTGCCCCAAAACAAAGACTGATGAGTG TGTTTAGAAAGCCTAATCAAACAGCGCCATCAGCATCATCAGGTCCCCCTCACCAAATCCATTCAATCGACGGCTDescription Page 34 / 157 37 CN 121263205 A GTTGCTAAACTTTCTCGGAGATGACAAATTCGACCCGAATGTGGAGCTACAGTATGTAACATCAGGTGAGTATCTA CATGATGACACGTTTTGTGCATCATATTCACTAAAAGAGAAGGAAATTAAACCTGATGGTCGAATTTTTGCAAAGT TGACTAAGAGAATGAGATCATGTCAAGTTATAGCAGAATCTCTTTTAGCGAACCATGCTGGGAAGTTAATGAAAGA GAATGGTGTTGTGATGAATCAGCTATCATTAACAAAATCACTATTAACAATGAGTCAGATTGGAATAATATCCGAG AAAGCTAGAAAGTCAACTCGAGATAACATAAATCAACCTGGTTTCCAGAATATCCAGAGAAATAAATCACATCACT CCAAGCAAGTCAATCAGCGAGATCCAAGTGATGACTTTGAATTGGCAGCATCTTTTTTAACTACTGATCTCAAAAA ATATTGTTTACAATGGAGGTACCAGACAATTATCCCATTTGCTCAATCATTAAACAGAATGTATGGTTATCCTCAT CTCTTTGAGTGGATTCACTTACGGCTAATGCGTAGTACACTTTACGTGGGGGATCCCTTCAACCCACCAGCAGATA CCAGTCAATTTGATCTAGATAAAGTAATTAATGGAGATATCTTCATTGTATCACCCAGAGGTGGAATTGAAGGGCT GTGTCAAAAGGCTTGGACAATGATATCTATCGCTGTGATAATTCTATCTGCCACAGAGTCTGGCACACGAGTAATG AGTATGGTGCAGGGAGATAATCAAGCAATTGCTGTCACCACACGAGTACCAAGGAGCCTGCCGACTCTTGAGAAAA AGACTATTGCTTTTAGATCTTGTAATCTATTCTTTGAGAGGTTAAAATGTAATAATTTTGGATTAGGTCACCATTTGAAAGAACAAGAGACTATCATTAGTTCACTTCTTTGTTTATAGCAAGAGAATATTCTTATCAGGGGAGGATTCTA ACGCAAGCCTTAAAAAATGCTAGTAAGCTCTGCTTGACAGCTGATGTCCTAGGAGAATGCACCCAATCATCATGTT CTAATCTTGCAACTACTGTCATGAGGTTAACTGAGAATGGTGTTGAAAAGATATCTGTTTCTCTTGAATATCTA TATGACCATCAAACAGCTCTCTTAGATATCATCTTCCCTCCAAGTGTCAATTCCTGGAGATCAGATCACATTAGAA TACATAAATCACACCACCTGGTATCACGATTGGCTCTTTGCCATCCCAGTTAGGAGGTCTAAACTACCTGTCAT GCAGTAGGCTGTTCAATCGAAACATAGGCGACCCGGTGTTTCCGCAGTTGCAGATCTTTAAGAGATTAATTAATC AGGATGTATGGATTACTGGGATCCTTTATAACTTATTAGGGGAAAACCGGGAAACGGCTCATGGGCTACTTTAGCA GCTGACCGTACTCAATATATAGATCAATACCCTCCAACTACAGCTCTTAAGAGGGCACACCCAACAAGCTC TGATGGAACTCAGTACGAATCCAATGTTACGTGGCATATTCTCTGACAATGCACAGGCAGAAAAATAACCTTGC TAGGTTTCTCCTGGATAGGGAGGTGATCTTTCCGCGTTAGCTCACATCATCATTGAGCAAACCAGTGCGGGAGG AGAAAACAGATTCAAGGATATTGGATTCAACTAGATCGATAATGAGAAATCACTAGAAATTAAGCCCTTATCCA ATAGGAAGCTTAATGAAATACTGGATTACAACATCAATTACCTAGCTTACAATTTGGCATTACTCAAGAATGCTAT TGAACCTCCGACTTATTTGAAGGCAATGACACTTGAAACATGTAGCATCGACATTGCAAGGAACCTCCGGAAGCTCTCCTGGGCCCCACTCTTGGGTGGGAGAAATCTTGAAGGATTAGAGACGCCAGATCCCATTGAAATTACTGCAGGAG CATTAATTGTTGGATCGGGCTACTGTGAACAGTGTGCTGCAGGAGACAATCGATTCACATGGTTTTTCTTGCCATC TGGTATCGAGATAGGAGGGGATCCCCGTGATAATCCTCCTATCCGTGTACCGTACATTGGCTCCAGGACTGATGAG AGGAGGGTAGCCTCAATGGCATACATCAGGGGTGCCTCGAGTAGCTTAAAAGCAGTTCTTAGACTGGCGGGAGTGT ACATCTGGGCATTCGGAGATACTCTGGAGAATTGGATAGATGCACTGGATTTGTCTCACACTAGAGTTAACATCAC ACTTGAACAGCTGCAATCCCTCACCCCACTTCCAACCTCTGCCAATCTAACCCATCGGTTGGATGATGGCACAACT ACCCTAAAGTTTACTCCTGCGAGCTCTTACACCTTTTCAAGTTTCACTCATATATCAAATGATGAGCAATACCTGA CAATTAATGACAAAACTGCAGATTCAAATATAATCTACCAACAGTTAATGATCACTGGACTCGGAATCTTAGAAAC ATGGAATAATCCCCCAATCAATAGAACATTCGAAGAATCTACCCTACATTTGCACACTGGTGCATCATGTTGTGTC CGACCTGTGGACTCCTGCATTCTCTCAGAAGCATTAACAGTCAAGCCACATATTACAGTACCGTACAGCAATAAAT TTGTATTTGATGAGGACCCGCTATCTGAATATGAAACTGCAAAACTGGAATCGTTATCATTCCAAGCCCAATTAGG CAACATTGATGCTGTAGATATGACAGGTAAATTAACATTATTGTCCCAATTCACTGCAAGGCAGATTATCAATGCA ATCACTGGACTCGATGAGTCTGTCTCTCTTACTAATGATGCCATTGTTGCATCAGACTATGTCTCCAATTGGATTAGTGAATGCATGTATACCAAATTAGATGAATTATTTATGTATTGTGGGTGGGAACTACTATTGGAACTATCCTATCA DESCRIPTION Page 35 / 157 38 CN 121263205 A AATGTATTATCTGAGGGTAGTTGGGTGGAGTAATATAGTGGATTATTCTTACATGATCTTGAGAAGAATCCCGGGT GCAGCATTAAACAATCTGGCATCTACATTAAGTCATCCAAAACTTTTCCGACGAGCTATCAACCTAGATATAGTTG CCCCCTTAAATGCTCCTCATTTTGCATCTCTGGACTACATCAAGATGAGTGTGGATGCAATACTCTGGGGCTGTAA AAGAGTCATCAATGTGCTCTCCAATGGAGGGGACTTAGAATTAGTTGTGACATCTGAAGATAGCCTTATTCTCAGT GACCGATCCATGAATCTCATTGCAAGGAAATTAACTTTATTATCACTGATTCACCATAATGGTTTGGAACTACCAA AGATTAAGGGGTTCTCTCCTGATGAGAAGTGTTTCGCTTTGACAGAATTTTTGAGGAAAGTGGTGAACTCAGGGTT GAGTTCAATAGAGAACCTATCAAATTTTATGTACAATGTGGAGAACCCACGGCTTGCAGCATTCGCCAGCAACAAT TACTACCTGACCAGAAAATTATTGAATTCAATACGAGATACTGAGTCGGGTCAAGTAGCAGTCACCTCATATTATG AATCATTAGAATATATTGATAGTCTTAAGCTAACCCCACATGTGCCTGGCACCTCATGCATTGAGGATGATAGTCT ATGTACAAATGATTACATAATCTGGATCATAGAGTCTAATGCAAACTTGGAGAAGTATCCAATTCCAAATAGCCCT GAGGATGATTCCAATTTCCATAACTTTAAGTTGAATGCTCCATCGCACCATACCTTACGCCCATTAGGGTTGTCATCAACTGCTTGGTATAAGGGTATAAGCTGCTGCAGGTACCTTGAGCGATTAAAGCTACCACAAGGTGATCATTTATA TATTGCAGAAGGTAGTGGTGCCAGTATGACAATCATAGAATACCTATTCCCAGGAAGAAAGATATATTACAATTCT TTATTTAGTAGTGGTGACAATCCCCCACAAAGAAATTATGCACCAATGCCTACTCAGTTCATTGAGAGTGTCCCAT ACAAGCTCTGGCAAGCACACACAGATCAATATCCCGAGATTTTTGAGGACTTCATCCCTCTATGGAACGGAAACGC CGCCATGACTGACATAGGAATGACAGCTTGTGTAGAATTCATCATCAATCGAGTCGGCCCAAGGACTTGCAGTTTA GTACATGTAGATTTGGAATCAAGTGCAAGCTTAAATCAACAATGCCTGTCAAAGCCGATAATTAATGCTATCATCA CTGCTACAACTGTTTTGTGCCCTCATGGGGTGCTTATTCTGAAATATAGTTGGTTGCCATTTACTAGATTTAGTAC TTTGATCACTTTCTTATGGTGCTACTTTGAGAGAATCACTGTTCTTAGGAGCACATATTCTGATCCAGCTAATCAT GAGGTTTATTTAATTTGTATCCTTGCCAACAACTTTGCATTCCAGACTGTCTCGCAGGCAACAGGAATGGCGATGA CTTTAACTGATCAAGGGTTTACTTTGATATCACCTGAAAGAATAAATCAGTATTGGGATGGTCACTTGAAGCAAGA ACGTATCGTAGCAGAAGCAATTGATAAGGTGGTTCTAGGAGAAAATGCTCTATTTAATTCGAGTGATAATGAATTA ATTCTCAAATGTGGAGGGACACCAAATGCACGGAATCTCATCGATATCGAGCCAGTCGCAACTTTCATAGAATTTG AACAATTGATCTGCACAATGTTGACAACCCACTTGAAGGAAATAATTGATATAACAAGGTCTGGAACCCAGGATTATGAAAGTTTATTACTCACTCCTTACAATTTAGGTCTTCTTGGTAAAATCAGTACGATAGTGAGATTATTAACAGAA AGGATTCTAAATCATACTATCAGGAATTGGTTGATCCTCCCACCTTCGCTCCGGATGATCGTGAAGCAGGACTTGG AATTCGGCATATTCAGGATTACTTCCATCCTCAATTCTGATCGGTTCCTGAAGCTTTCTCCAAATAGGAAATACTT GATTGCACAATTAACTGCAGGCTACATTAGGAAATTGATTGAGGGGGATTGCAATATCGATCTAACCAGACCTATC CAAAAGCAAATCTGGAAAGCATTAGGTTGTGTAGTCTATTGTCACGATCCAATGGATCAAAGGGAGTCAACAGAGT TTATTGATATAAATATTAATGAAGAAATAGACCGCGGGATCGATGGCGAGGAAATCTAAACATATCAAGAATCAGA ATTAGTTTAAGAAAAAAGAAGAGGATTAATCTTGGTTTTCCCCTTGGTGGGTCGGCATGGCATCTCCACCTCCTCG CGGTCCGACCTGGGCATCCGAAGGAGGACGCACGTCCACTCGGATGGCTAAGGGAGCGGCCGGGGATCCGGCTGCT AACAAAGCCCGAAAGGAAGCTGAGTTGGCTGCTGCCACCGCTGAGCAATAACTAGCATAACCCCTTGGGGCCTCTA AACGGGTCTTGAGGGGTTTTTTGCTGAAAGGAGGAACTATATCCGGATCATGTGAGCAAAAGGCCAGCAAAAGGCC AGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGAC GCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCG CTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTC AGCCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGC DESCRIPTION Page 36 / 157 39 CN 121263205 A AGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAAC TACGGCTACACTAGAAGAACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTA GCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAA AAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGAACGAAAACTCACGTTAAGGG ATTTTGGTCATGAGATTATCAAAAAGGATCTTCACCTAGATCCTTTTAAATTAAAAATGAAGTTTTAAATCAATCT AAAGTATATATGAGTAAACTTGGTCTGACAGTTACCAATGCTTAATCAGTGAGGCACCTATCTCAGCGATCTGTCT ATTTCGTTCATCCATAGTTGCCTGACTCCCCGTCGTGTAGATAACTACGATACGGGAGGGCTTACCATCTGGCCCC AGTGCTGCAATGATACCGCGAGACCCACGCTCACCGGCTCCAGATTTATCAGCAATAAACCAGCCAGCCGGAAGGG CCGAGCGCAGAAGTGGTCCTGCAACTTTATCCGCCTCCATCCAGTCTATTAATTGTTGCCGGGAAGCTAGAGTAAG TAGTTCGCCAGTTAATAGTTTGCGCAACGTTGTTGCCATTGCTACAGGCATCGTGGTGTCACGCTCGTCGTTTGGTATGGCTTCATTCAGCTCCGGTTCCCAACGATCAAGGCGAGTTACATGATCCCCCATGTTGTGCAAAAAAGCGGTTA GCTCCTTCGGTCCTCCGATCGTTGTCAGAAGTAAGTTGGCCGCAGTGTTATCACTCATGGTTATGGCAGCACTGCA TAATTCTCTTACTGTCATGCCATCCGTAAGATGCTTTTCTGTGACTGGTGAGTACTCAACCAAGTCATTCTGAGAA TAGTGTATGCGGCGACCGAGTTGCTCTTGCCCGGCGTCAATACGGGATAATACCGCGCCACATAGCAGAACTTTAA AAGTGCTCATCATTGGAAAACGTTCTTCGGGGCGAAAACTCTCAAGGATCTTACCGCTGTTGAGATCCAGTTCGAT GTAACCCACTCGTGCACCCAACTGATCTTCAGCATCTTTTACTTTCACCAGCGTTTCTGGGTGAGCAAAAACAGGA AGGCAAAATGCCGCAAAAAAGGGAATAAGGGCGACACGGAAATGTTGAATACTCATACTCTTCCTTTTTCAATATT ATTGAAGCATTTATCAGGGTTATTGTCTCATGAGCGGATACATATTTGAATGTATTTAGAAAAATAAACAAATAGG GGTTCCGCGCACATTTCCCCGAAAAGT(SEQ ID NO: 3).
[0191] ii. CVL87
[0192] The nucleic acid sequence of CVL87 is:
[0193] GCCACCTGACGTCTAAGAAACCATTATTATCATGACATTAACCTATAAAAATAGGCGTATCACGAGGC CCTTTCGTCTCGCGCGTTTCGGTGATGACGGTGAAAACCTCTGACACATGCAGCTCCCGGAGACGGTCACAGCTTG TCTGTAAGCGGATGCCGGGAGCAGACAAGCCCGTCAGGGCGCGTCAGCGGGTGTTGGCGGGTGTCGGGGCTGGCTT AACTATGCGGCATCAGAGCAGATTGTACTGAGAGTGCACCATATATGCGGTGTGAAATACCGCACAGATGCGTAAGGAGAAAATACCGCATCAGGCTAATACGACTCACTATAGGGACCAAGGGGAAAATGAAGTGGTGACTCAAATCATCG AAGACCCTCGAGATTACATAGGTCCGGAACCTATGGCCTTCGTGACCGACCTCGAGTCAGAGTAGTTCAATAAGGA CCTATCAAGTTTGGGCAATTTTTCGTCCCCGACACAAAAATGTCATCCGTGCTTAAAGCATATGAGCGATTCACGC TCACTCAAGAACTGCAAGATCAGAGTGAGGAAGGTACAATCCCACCTACAACACTAAAACCGGTAATCAGGGTATT TATACTAACCTCTAATAACCCAGAGCTAAGATCCCGGCTTCTTCTATTCTGCCTACGGATTGTTCTCAGTAATGGT GCAAGGGATTCCCATCGCTTTGGAGCATTACTCACAATGTTTTCGCTACCATCAGCCACAATGCTCAATCATGTCA AATTAGCTGACCAGTCACCAGAAGCTGATATCGAAAGGGTAGAGATCGATGGCTTTGAGGAGGGATCATTCCGCTT AATCCCCAATGCTCGTTCAGGTATGAGCCGTGGAGAGATCAATGCCTATGCTGCACTTGCAGAAGATCTACCTGAC ACACTAAACCATGCAACACCTTTCGTTGATTCCGAAGTCGAGGGAACTGCATGGGATGAGATTGAGACTTTCTTAG ATATGTGTTACAGTGTCCTAATGCAGGCATGGATAGTGACTTGCAAGTGCATGACTGCGCCAGACCAACCTGCTGC TTCTATTGAGAAACGCCTGCAAAAATATCGTCAGCAAGGCAGGATCAACCCGAGATATCTCCTGCAACCGGAGGCT CGACGAATAATCCAGAATGTAATCCGGAAGGGAATGGTGGTCAGACATTTCCTCACCTTTGAACTGCAGCTTGCCC GAGCACAAAGCCTTGTATCAAATAGGTATTATGCTATGGTAGGGGATGTTGGAAAGTATATAGAGAATTGTGGAATGGGAGGCTTCTTTTTGACACTAAAATATGCATTAGGAACTAGATGGCCCACACTTGCTTTAGCTGCATTTTCAGGA DESCRIPTION Page 37 / 157 40 CN 121263205 A GAGCTAACAAAGCTAAAGTCCCTCATGGCATTATACCAGACCCTTGGTGAGCAGGCCCGATATTTGGCCCTATTGG AGTCACCACATTTGATGGATTTTGCTGCAGCAAACTACCCACTGCTATATAGCTATGCTATGGGAATAGGCTATGT GTTAGATGTCAACATGAGGAACTACGCTTTCTCCAGATCATACATGAACAAGACATATTTCCAATTGGGAATGGAA ACTGCAAGAAAACAACAGGGTGCAGTTGACATGAGGATGGCAGAAGATCTCGGTCTAACTCAAGCCGAACGCACCG AGATGGCAAATACACTTGCCAAATTGACCACAGCAAATCGAGGGGCAGACACCAGGGGAGGAGTCAACCCGTTCTC ATCTGTCACTGGGACAACTCAGGTGCCCGCTGCAGCAACAGGTGACACACTCGAGAGTTACATGGCAGCGGATCGA CTGAGGCAGAGATATGCTGATGCAGGCACCCATGATGATGAGATGCCACCATTGGAAGAGGAGGAAGAGGACGACA CATCTGCAGGTCCACGCACTGGACCAACTCTTGAACAAGTGGCCTTGGACATCCAGAACGCAGCAGTTGGAGCTCC CATCCATACAGATGACCTGAATGCCGCACTGGGTGATCTTGACATCTAGACAATTCAGATCCCAATCTAAAATTGA CATACCTAATTGATTAGTTAGATGGAACTACAGTGGATTCCATAAGGTTCCTGCCTACCATCGGCTTTAAAGAAAA AAATAGGCCCGGACGGGTTAGCAACAAGCGACTGCCGGTGCCAACAGCGCAATCCACAATCTACAATGGATCCCACTGATCTGAGCTTCTCCCCAGATGAGATCAATAAGCTCATAGAGACAGGCCTGAATACTGTAGAGTATTTTACTTCC CAACAAGTCACAGGAACATCCTCTCTTGGAAAGAATACAATACCACCAGGGGTCACAGGACTACTAACCAATGCTG CAGAGGCAAAGATCCAAGAGTCAACTAACCATCAGAAGGGCTCAGTTGGTGGGGGTGCAAAACCAAAGAAACCGCG ACCAAAAATTGCCATTGTGCCAGCAGATGACAAAACAGTGCCCGGAAAGCCGATCCCAAACCCTCTATTAGGTCTG GACTCCACCCCGAGCACCCAAACTGTGCTTGATCTAAGTGGGAAAACATTACCATCAGGATCCTATAAGGGGGTTA AGCTTGCGAAATTTGGAAAAGAAAATCTGATGACACGGTTCATCGAGGAACCCAGAGAGAATCCTATCGCAACCAG TTtCCCCATCGATTTTAAGAGGGGCAGGGATACCGGCGGGTTCCATAGAAGGGAGTACTCAATCGGATGGGTGGGA GATGAAGTCAAGGTCACTGAGTGGTGCAATCCATCCTGTTCTCCAATCACCGCTGCAGCAAGGCGATTTGAATGCA CTTGTCACCAGTGTCCAGTCACTTGCTCTGAATGTGAACGAGATACTTAATACAGTGAGAAATTTGGACTCTCGGA TGAATCAACTGGAGACAAAAGTAGATCGCATTCTCTCATCTCAGTCTCTAATCCAGACCATCAAGAATGACATAGT TGGACTTAAAGCAGGGATGGCTACTTTAGAAGGAATGATTACAACTGTGAAAATCATGGACCCGGGAGTTCCCAGT AATGTTACTGTGGAAGATGTACGCAAGACACTAAGTAACCATGCTGTTGTTGTGCCAGAATCATTCAATGATAGTT TCTTGACTCAATCTGAAGATGTAATTTCACTTGATGAGTTGGCTCGACCAACTGCAACAAGTGTTAAGAAGATTGTCAGGAAGGTTCCTCCTCAGAAGGATCTGACTGGATTGAAGATTACACTAGAGCAATTGGCAAAGGATTGCATCAGC AAACCGAAGATGAGGGAAGAGTATCTCCTCAAAATCAACCAGGCTTCCAGTGAGGCTCAGCTAATTGACCTCAAGA AAGCAATCATCCGCAGTGCAATTTGATCAAGAAACACCCAATTACACTACACTGGTATGACACTGTACTAACCCTG AGGGTTTTAGAAAAACGATTAACGATAAATAAGCCCGAACACTACACACTACCTGAGGCAGCCATGCCATCCAT AGCATTCCCGCAGACCCCACCAATCCACGTCAATCAATAAAAGCGTTCCCAATTGTGATCAACAGTGATGGGGGTG AGAAAGGCGCCTTGGTTAAACAACTACGCACAACCTACTTGAATGACCTAGATACTCATGAGCCACTGGTGACATT CATAAATACCTATGGATTCATCTACGAACCAGGATCGGGGGAATACCATTGTCGGAGAGGAATCAACTTGGGAAGAAA AGAGAGGCTTGGACCGCTGCAATGGTTACCCTTGGATGTGGGCCTAATCTACCATCATTAGGAATGTCCTGGGAC AACTGAGGGAATTCCAGGCACTGTTAGGAAGACATCCAGCAAAGCGGAAGAGATGGTCTTTGAAATTGTTAAGTA TCCGAGAATATTTCGGGTCATAATCCAGAAAAGACTAGTCTGTGTCTCCGCAGAAAATTTGTTAAGTCA CCAGGGAAAATACAATCTGGAATGGACTATCTCTTCATTCCGACATTTCTGTCAGTGACTTACTGTTCCAGCTGCAA TCAAATTTCAGGTACCTGGCCCCATGTTGAAAATGAGATCAAGATACACTCAGAGCTTACAACTTGAACTAATGAT AAGAATCCTGTGTAAGCCGATTCGCCACTTATGAAGGTCCATACCCCTGACAAGGAGGGAAGGAGGATGTCTTGTATCAGTATGGCTGCATGTATGCAACATCTTCAAATCAGGAAACAAGAATGGCAGTGAGTGGCAGGAATACTGGATGA GAAAGTGTGCTAACATGCAACTTGAAGTGTCGATTGCAGATATGTGGGGACCAACTATCATAATTCATGCCAGAGG DESCRIPTION Page 38 / 157 41 CN 121263205 A TCACATTCCCAAAAGTGCTAAGTTGTTTTTTGGAAAGGGTGGATGGAGCTGCCATCCACTTCACGAAGTTGTTCCA AGTGTCACTAAAACACTATGGTCCGTGGGCTGTGAGATTACAAAGGCGAAGGCAATAATACAAGAGAGTAGCATCT CTCTTCTCGTGGAGACTACTGACATCATAAGTCCAAAAGTCAAAATTTCATCTAAGCATCGCCGCTTTGGGAAATC AAATTGGGGTCTGTTCAAGAAAACTAAATCACTGCCTAACCTGACGGAGCTGGAATGACTGACCTCTAATCGAGAC TACACCGCCGCAAACTATAGGTGGGTGGTACCTCAGTGATTAATCTTGTAAGCACTGATCGTAGGCTACAACACAC TAATATTATCCAGATTAGAGAGCTTAATTAGCTCTGTATTAATAATAACACTACTATTCCAATAACTGGAATCACC AGCTTGATTTATCTCCAAAATGATTCAAAGAAAACAAATCATATTAAGACTATCCTAAGCACGAACCCATATCGTC CTTCAAATCATGGGTACTATAATTCAATTTCTGGTGGTCTCCTGTCTATTGGCAGGAGCAGGCAGCCTTGATCCAG CAGCCCTCATGCAAATCGGTGTCATTCCAACAAATGTCCGGCAACTTATGTATTATACTGAAGCTTCATCAGCATT CATTGTTGTGAAGTTAATGCCTACAATTGACTCGCCGATTAGTGGATGTAATATAACATCAATTTCAAGCTATAATGCAACAGTGACAAAACTCCTACAGCCGATCGGTGAGAATTTGGAGACGATTAGGAACCAGTTGATTCCAACTCGGA GGAGACGCCGGTTTGCAGGGGTGGTGATTGGATTAGCTGCATTAGGAGTAGCTACTGCCGCACAGGTCACTGCCGC AGTGGCACTAGTAAAGGCAAATGAAAATGCTGCGGCTATACTCAATCTCAAAAATGCAATCCAAAAAACAAATGCA GCAGTTGCAGATGTGGTCCAGGCCACACAATCACTAGGAACGGCAGTTCAAGCAGTTCAAGATCACATAAACAGTG TGGTAAGTCCAGCAATTACAGCAGCCAATTGTAAGGCCCAAGATGCTATCATTGGCTCAATCCTCAATCTCTATTT GACCGAGTTGACAACCATCTTCCACAATCAAATTACAAACCCTGCATTGAGTCCCATTACAATTCAAGCTTTAAGG ATCCTACTGGGGAGTACCTTGCCGACTGTGGTCGAAAAATCTTTCAATACCCAGATAAGTGCAGCTGAGCTTCTCT CATCAGGGTTATTGACAGGCCAGATTGTGGGATTAGATTTGACCTATATGCAGATGGTCATAAAAATTGAGCTGCC AACTTTAACTGTACAACCTGCAACCCAGATCATAGATCTGGCCACCATTTCTGCATTCATTAACAATCAAGAAGTC ATGGCCCAATTACCAACACGTGTTATGGTGACTGGCAGCTTGATCCAAGCCTATCCCGCATCGCAATGCACCATTA CACCCAACACTGTGTACTGTAGGTATAATGATGCCCAAGTACTCTCAGATGATACTATGGCTTGCCTCCAAGGTAA CTTGACAAGATGCACCTTCTCTCCAGTGGTTGGGAGCTTTCTCACTCGATTCGTGCTGTTCGATGGAATAGTTTAT GCAAATTGCAGGTCGATGTTGTGCAAGTGCATGCAACCTGCTGCTGTGATCCTACAGCCGAGTTCATCCCCTGTAACTGTCATTGACATGTACAAATGTGTGAGTCTGCAGCTTGACAATCTCAGATTCACCATCACTCAATTGGCCAATGT AACCTACAATAGCACCATCAAGCTTGAATCATCCCAGATCTTGTCTATTGATCCGTTGGATATATCCCAGAATCTA GCTGCGGTGAATAAGAGTCTAAGTGATGCACTACAACACTTAGCACAAAGTGACACATATCTTTCTGCAATCACAT CAGCTACGACTACAAGTGTATTATCCATAATAGCAATCTGTCTTGGATCGTTAGGTTTAATATTAATAATCTTGCT CAAGTGTAGTTGTGTGGAAGTTATTGACCATTGTCGTTGCTAATCGAAATAGAATGGAGAATTTTGTTTATCATAAA TAAGCATTCCACCACTCACGATCTGATCTCAGTGAGAAAAATCAACCTGCAACTCTTGGAACAAGATAAGACAGTC ATCCATTAGTAATTTTTAAGAAAAAAACGATAGGACCGAACCTAGTATTGAAAGAACCGTCTCGGTCAATCTAGGT AATCGAGCTGATACCGTCTCGGAAAGCTCAAATATGGTTGCAGAAGATGCCCCTGTTAGGGCCACTTGCCGAGTAT TATTTCGAACAACAACTTTAATCTTTCTATGCACACTACTAGCATTAAGCATCTCTATCCTTTATGAGAGTTTAAT AACCCAAAAGCAAATCATGAGCCAAGCAGGCTCAACTGGATCTAATTCTGGATTAGGAAGTATCACTGATCTTCTT AATAATATTCTCTCTGTCGCAAATCAGATTATATATAACTCTGCAGTCGCTCTACCTCTACAATTGGACACTCTTG AATCAACACTCCTTACAGCCATTAAGTCTCTTCAAACCAGTGACAAGCTAGAACAGAACTGCTCGTGGAGTGCTGC ACTGATTAATGATAATAGATACATTAATGGCATCAATCAGTTCTATTTTTCAATTGCTGAGGTCGCAATCTGACACTTGGCCCACTTCTTAATATGCCTAGTTTCATTCCAACTGCCACGACACCAGAGGGCTGCACCAGGATCCCATCAT TCTCGCTCACTAAGACACACTGGTGTTATACACACAATGTTATCCTGAATGGATGCCAGGATCATGTATCCTCAAA TCAATTTGTTTCTATGGGAATCATTGAACCCACTTCTGCCGGGTTTCCATTCTTTCGAACCCTAAAGACTCTATAT Description Page 39 / 157 42 CN 121263205 A CTCAGCGATGGGGTCAATCGTAAGAGCTGCTCTATCAGTACAGTTCCGGGGGGTTGTATGATGTACTGTTTTGTTT CTACTCAACCAGAGAGGGATGACTACTTTTCTGCCGCTCCTCCAGAACAACGAATTATTATAATGTACTATAATGA TACAATCGTGGAGCGCATAATTAATCCACCCGGGGTACTAGATGTATGGGCAACATTGAACCCAGGAACAGGAAGC GGGGTATATTATTTAGGTTGGGTGCTCTTTCCAATATATGGCGGCGTGATTAAAGGTACGAGTTTATGGAATAATC AAGCAAATAAATACTTTATCCCCCAGATGGTTGCTGCTCTCTGCTCACAAAACCAGGCAACTCAAGTCCAAAATGC TAAGTCATCATACTATAGCAGCTGGTTTGGCAATCGAATGATTCAGTCTGGGATCCTGGCATGTCCTCTTCGACAG GATCTAACCAATGAGTGTTTAGTTCTGCCCTTTTCTAATGATCAGGTGCTTATGGGTGCTGAAGGGAGATTATACA TGTATGGTGACTCGGTGTATTACTATCAAAGAAGCAATAGTTGGTGGCCTATGACCATGCTGTATAAGGTAACCAT AACATTCACTAATGGTCAGCCATCTGCTATATCAGCTCAGAATGTGCCCACACAGCAGGTCCCTAGACCTGGGACAGGAGACTGCTCTGCAACCAATAGATGTCCCGGTTTTTGCTTGACAGGAGTGTATGCCGATGCCTGGTTACTGACCA ACCCTTCGTCTACCAGTACATTTGGATCAGAAGCAACCTTCACTGGTTCTTATCCAACACAGCAACTCAGCGTAT CAATCCGACGATGTATATCGCGAACAACACACAGATCATAAGCTCACAGCAATTTGGATCAAGCGGTCAAGAAGCA GCATATGGCCACACAACTTGTTTTTAGGGACACAGGCTCTGTTATGGTATACTGTATCTATATTATTGAATTGTCCT CATCTCTCTTAGGACAATTTCAGATTGTCCCATTTATCCGTCAGGTGACACTATCCTAAAGGCAGAAGCCTTCAGG TCTGACCCAGCCAATCAAAGCATTATACCAGACCATGGCCTACCATCGGCTTTAAAGAAAAAAATAGGCCCGGACG GGTTAGCAACAAGCGGCGGCGCCatgttcgtcttcctggtcctgctgcctctggtctctcacagtgcgtcaatc tgacaactcggactcagctgccacctgcttatactaatagcttcaccagaggcgtgtactatcctgacaaggtgtt tagaagctccgtgctgcactctacagaggatctgtttctgccattctttagcaacgtgacctggttccacgccatc cacgtgagcggcacaatggcacaaagcggttcgacaatcccgtgctgccttttaacgatggcgtgtacttcgcct ctaccgagaagagcaacatcatcagaggctggatctttggcaccacactggactccaagacacagtctctgctgat cgtgaacaatgccaccaacgtggtcatcaaggtgtgcgagttccagttttgtaatgatcccttcctgggcgtgtac tatcacaagaacaataagagctggatggagtccgagtttagagtgtattctagcgccaacaactgcacatttgagtacgtgagccagcctttcctgatggacctggagggcaagcagggcaatttcaagaacctgagggagttcgtgtttaa gaatatcgacggctacttcaaaatctactctaagcacacccccatcaacctggtgcgcgacctgcctcagggcttc agcgccctggagcccctggtggatctgcctatcggcatcaacatcacccggtttcagacactgctggccctgcaca gaagctacctgacacccggcgactcctctagcggatggaccgccggcgctgccgcctactatgtgggctacctcca gccccggaccttcctgctgaagtacaacgagaatggcaccatcacagacgcagtggattgcgccctggaccccctg agcgagacaaagtgtacactgaagtcctttaccgtggagaagggcatctatcagacatccaatttcagggtgcagc caaccgagtctatcgtgcgctttcctaatatcacaaacctgtgcccatttggcgaggtgttcaacgcaacccgctt cgccagcgtgtacgcctggaataggaagcggatcagcaactgcgtggccgactatagcgtgctgtacaactccgcc tctttcagcacctttaagtgctatggcgtgtcccccacaaagctgaatgacctgtgctttaccaacgtctacgccg attctttcgtgatcaggggcgacgaggtgcgccagatcgcccccggccagacaggcaagatcgcagactacaatta taagctgccagacgatttcaccggctgcgtgatcgcctggaacagcaacaatctggattccaaagtgggcggcaac tacaattatctgtaccggctgtttagaaagagcaatctgaagcccttcgagagggacatctctacagaaatctacc aggccggcagcaccccttgcaatggcgtggagggctttaactgttatttcccactccagtcctacggcttccagcccacaaacggcgtgggctatcagccttaccgcgtggtggtgctgagctttgagctgctgcacgccccagcaacagtg tgcggccccaagaagtccaccaatctggtgaagaacaagtgcgtgaacttcaacttcaacggcctgaccggcacag gcgtgctgaccgagtccaacaagaagttcctgccatttcagcagttcggcagggacatcgcagataccacagacgc cgtgcgcgacccacagaccctggagatcctggacatcacaccctgctctttcggcggcgtgagcgtgatcacaccc DESCRIPTION Page 40 / 157 43 CN 121263205 A ggcaccaatacaagcaaccaggtggccgtgctgtatcaggacgtgaattgtaccgaggtgcccgtggctatccacg ccgatcagctgaccccaacatggcgggtgtacagcaccggctccaacgtcttccagacaagagccggatgcctgat cggagcagagcacgtgaacaattcctatgagtgcgacatcccaatcggcgccggcatctgtgcctcttaccagacc cagacaaactctcccagaagagcccggagcgtggcctcccagtctatcatcgcctataccatgtccctgggcgccg agaacagcgtggcctactctaacaatagcatcgccatcccaaccaacttcacaatctctgtgaccacagagatcct gcccgtgtccatgaccaagacatctgtggactgcacaatgtatatctgtggcgattctaccgagtgcagcaacctg ctgctccagtacggcagcttttgtacccagctgaatagagccctgacaggcatcgccgtggagcaggataagaaca cacaggaggtgttcgcccaggtgaagcaaatctacaagaccccccctatcaaggactttggcggcttcaatttttcccagatcctgcctgatccatccaagccttctaagcggagctttatcgaggacctgctgttcaacaaggtgaccctg gccgatgccggcttcatcaagcagtatggcgattgcctgggcgacatcgcagccagggacctgatctgcgcccaga agtttaatggcctgaccgtgctgccacccctgctgacagatgagatgatcgcacagtacacaagcgccctgctggc cggcaccatcacatccggatggaccttcggcgcaggagccgccctccagatcccctttgccatgcagatggcctat aggttcaacggcatcggcgtgacccagaatgtgctgtacgagaaccagaagctgatcgccaatcagtttaactccg ccatcggcaagatccaggacagcctgtcctctacagccagcgccctgggcaagctccaggatgtggtgaatcagaa cgcccaggccctgaataccctggtgaagcagctgagcagcaacttcggcgccatctctagcgtgctgaatgacatc ctgagccggctggacaaggtggaggcagaggtgcagatcgaccggctgatcaccggccggctccagagcctccaga cctatgtgacacagcagctgatcagggccgccgagatcagggccagcgccaatctggcagcaaccaagatgtccga gtgcgtgctgggccagtctaagagagtggacttttgtggcaagggctatcacctgatgtccttccctcagtctgcc ccacacggcgtggtgtttctgcacgtgacctacgtgcccgcccaggagaagaacttcaccacagcccctgccatct gccacgatggcaaggcccactttccaagggagggcgtgttcgtgtccaacggcacccactggtttgtgacacagcg caatttctacgagccccagatcatcaccacagacaacaccttcgtgagcggcaactgtgacgtggtcatcggcatcgtgaacaataccgtgtatgatccactccagcccgagctggacagctttaaggaggagctggataagtatttcaaga atcacacctcccctgacgtggatctgggcgacatcagcggcatcaatgcctccgtggtgaacatccagaaggagat cgaccgcctgaacgaggtggctaagaatctgaacgagagcctgatcgacctccaggagctgggcaagtatgagcag tacatcaagtggccctggtacatctggctgggcttcatcgccggcctgatcgccatcgtgatggtgaccatcatgc tgtgctgtatgacatcctgctgttcttgcctgaagggctgctgtagctgtggctcctgctgtaagttattgaccat tgtcgttgctaatcgaaatagaatggagaattttgtttatcataaatgaAGTCGACTCATGGAATGCATACCAAAC ATTATTGACACTAATGACACACAAAATTGGTTTTAAGAAAAACCAAGAGAACAATAGGCCAGAATGGCTGGGTCTC GGGAGATATTACTCCCTGAAGTCCATCTCAATTCACCAATTGTAAAGCATAAGCTATACTATTACATTCTACTTGG AAACCTCCCAAATGAGATCGACCTTGACGATTTAGGTCCATTACATAATCAAAATTGGAATCAGATAGCACATGAA GAGTCTAACTTAGCTCAACGCTTGGTAAATGTAAGAAATTTTCTAATTACCCACATCCCTGATCTTAGAAAGGGCC ATTGGCAAGAGTATGTCAATGTAATACTGTGGCCGCGAATTCTTCCCTTGATCCCGGATTTTAAAATCAATGACCA ATTGCCTCTGCTCAAAAATTGGGACAAGTTAGTTAAAGAATCATGTTCAGTAATCAATGCAGGTACTTCCCAGTGC ATTCAGAATCTCAGCTATGGACTGACAGGTCGTGGGAACCTCTTTACACGATCACGTGAACTCTCTGGTGACCGCAGGGATATTGATCTTAAGACAGTTGTGGCAGCATGGCATGACTCAGACTGGAAAAGAATAAGTGATTTTTGGATTAT GATCAAATTCCAGATGAGACAATTAATTGTTAGGCAAACAGATCATAATGATTCTGATTTAATCACGTATATCGAA AATAGAGAAGGCATAATCATCATAACCCCTGAACTGGTAGCATTATTTAACACTGAGAATCATACACTAACATACA TGACCTTTGAAATTGTACTGATGGTTTCAGATATGTACGAAGGTCGTCACAACATTTTATCACTATGCACAGTTAG CACTTACCTGAATCCTCTGAAGAAAAGAATAACATATTTATTGAGCCTTGTAGATAACTTAGCTTTTCAGATAGGT DESCRIPTION Page 41 / 157 44 CN 121263205 A GATGCTGTATATAACATAATTGCTTTGCTAGAATCCTTTGTATATGCACAGTTGCAAATGTCAGATCCCATCCCAG AACTCAGAGGACAATTCCATGCATTCGTATGTTCTGAGATTCTTGATGCACTAAGAGGAACTAATAGTTTCACCCA GGATGAATTAAGAACTGTGACAACTAATTTGATATCCCCATTCCAAGATCTGACCCCAGATCTTACGGCTGAATTG CTCTGTATAATGAGGCTTTGGGGACACCCCATGCTCACTGCCAGTCAAGCTGCAGGAAAGGTACGCGAGTCTATGT GTGCTGGAAAAGTATTAGACTTTCCCACCATTATGAAAACACTAGCCTTTTTCCATACTATTCTGATCAATGGATA CAGGAGGAAGCATCATGGAGTATGGCCACCCTTAAACTTACCGGGTAATGCTTCAAAGGGTCTCACGGAACTTATG AATGACAATACTGAAATAAGCTATGAATTCACACTTAAGCATTGGAAGGAAGTCTCTCTTATAAAATTCAAGAAATGTTTTGATGCAGACGCAGGTGAGGAACTCAGTATATTTATGAAAGATAAGGCAATTAGTGCCCCAAAACAAGACTG GATGAGTGTGTTTAGAAGAAGCCTAATCAAACAGCGCCATCAGCATCATCAGGTCCCCCTACCAAATCCATTCAAT CGACGGCTGTTGCTAAACTTTCTCGGAGATGACAAATTCGACCCGAATGTGGAGCTACAGTATGTAACATCAGGTG AGTATCTACATGATGACACGTTTTGTGCATCATATTCACTAAAAGAGAAGGAAATTAAACCTGATGGTCGAATTTT TGCAAAGTTGACTAAGAGAATGAGATCATGTCAAGTTATAGCAGAATCTCTTTTAGCGAACCATGCTGGGAAGTTA ATGAAAGAGAATGGTGTTGTGATGAATCAGCTATCATTAACAAAATCACTATTAACAATGAGTCAGATTGGAATAA TATCCGAGAAAGCTAGAAAGTCAACTCGAGATAACATAAATCAACCTGGTTTCCAGAATATCCAGAGAAATAAATC ACATCACTCCAAGCAAGTCAATCAGCGAGATCCAAGTGATGACTTTGAATTGGCAGCATCTTTTTTAACTACTGAT CTCAAAAAATATTGTTTACAATGGAGGTACCAGACAATTATCCCATTTGCTCAATCATTAAACAGAATGTATGGTT ATCCTCATCTCTTTGAGTGGATTCACTTACGGCTAATGCGTAGTACACTTTACGTGGGGGATCCCTTCAACCCACC AGCAGATACCAGTCAATTTGATCTAGATAAAGTAATTAATGGAGATATCTTCATTGTATCACCCAGAGGTGGAATT GAAGGGCTGTGTCAAAAGGCTTGGACAATGATATCTATCGCTGTGATAATTCTATCTGCCACAGAGTCTGGCACAC GAGTAATGAGTATGGTGCAGGGAGATAATCAAGCAATTGCTGTCACCACACGAGTACCAAGGAGCCTGCCGACTCTTGAGAAAAAGACTATTGCTTTTAGATCTTGTAATCTATTCTTTGAGAGGTTAAAATGTAATAATTTTGGATTAGGT CACCATTTGAAAGAACAAGAGACTATCATTAGTTCTCACTTCTTTGTTTATAGCAAGAGAATATTCTATCAGGGGA GGATTCTAACGCAAGCCTTAAAAAATGCTAGTAAGCTCTGCTTGACAGCTGATGTCCTAGGAGAATGCACCCAATC ATCATGTTCTAATCTTGCAACTACTGTCATGAGGTTAACTGAGAATGGTGTTGAAAAAGATATCTGTTTCTACTTG AATATCTATATGACCATCAAACAGCTCTCCTATGATATCATCTTCCCTCAAGTGTCAATTCCTGGAGATCAGATCA CATTAGAATACATAAATAATCCACACCTGGTATCACGATTGGCTCTTTTGCCATCCCAGTTAGGAGGTCTAAACTA CCTGTCATGCAGTAGGCTGTTCAATCGAAACATAGGCGACCCGGTGGTTTCCGCAGTTGCAGATCTTAAGAGATTA ATTAAATCAGGATGTATGGATTACTGGATCCTTTATAACTTATTAGGGAGAAAACCGGGAAACGGCTCATGGGCTA CTTTAGCAGCTGACCCGTACTCAATCAATATAGAGTATCAATACCCTCCAACTACAGCTCTTAAGAGGCACACCCA ACAAGCTCTGATGGAACTCAGTACGAATCCAATGTTACGTGGCATATTCTCTGACAATGCACAGGCAGAAGAAAAT AACCTTGCTAGGTTTCTCCTGGATAGGGAGGTGATCTTTCCGCGTGTAGCTCACATCATCATTGAGCAAACCAGTG TCGGGAGGAGAAAACAGATTCAAGGATATTTGGATTCAACTAGATCGATAATGAGGAAATCACTAGAAATTAAGCC CTTATCCAATAGGAAGCTTAATGAAATACTGGATTACAACATCAATTACCTAGCTTACAATTTGGCATTACTCAAGAATGCTATTGAACCTCCGACTTATTTGAAGGCAATGACACTTGAAACATGTAGCATCGACATTGCAAGGAACCTCC GGAAGCTCTCCTGGGCCCCACTCTTGGGTGGGAGAAATCTTGAAGGATTAGAGACGCCAGATCCCATTGAAATTAC TGCAGGAGCATTAATTGTTGGATCGGGCTACTGTGAACAGTGTGCTGCAGGAGACAATCGATTCACATGGTTTTTC TTGCCATCTGGTATCGAGATAGGAGGGGATCCCCGTGATAATCCTCCTATCCGTGTACCGTACATTGGCTCCAGGA CTGATGAGAGGAGGGTAGCCTCAATGGCATACATCAGGGGTGCCTCGAGTAGCTTAAAAGCAGTTCTTAGACTGGC GGGAGTGTACATCTGGGCATTCGGAGATACTCTGGAGAATTGGATAGATGCACTGGATTTGTCTCACACTAGAGTT DESCRIPTION Page 42 of 157 45 CN 121263205 A AACATCACACTTGAACAGCTGCAATCCCTCACCCCACTTCCAACCTCTGCCAATCTAACCCATCGGTTGGATGATG GCACAACTACCCTAAAGTTTACTCCTGCGAGCTCTTACACCTTTTCAAGTTTCACTCATATATCAAATGATGAGCA ATACCTGACAATTAATGACAAAACTGCAGATTCAAATATAATCTACCAACAGTTAATGATCACTGGACTCGGAATC TTAGAAACATGGAATAATCCCCCAATCAATAGAACATTCGAAGAATCTACCCTACATTTGCACACTGGTGCATCAT GTTGTGTCCGACCTGTGGACTCCTGCATTCTCTCAGAAGCATTAACAGTCAAGCCACATATTACAGTACCGTACAG CAATAAATTTGTATTTGATGAGGACCCGCTATCTGAATATGAAACTGCAAAACTGGAATCGTTATCATTCCAAGCCCAATTAGGCAACATTGATGCTGTAGATATGACAGGTAAATTAACATTATTGTCCCAATTCACTGCAAGGCAGATTA TCAATGCAATCACTGGACTCGATGAGTCTGTCTCTCTTACTAATGATGCCATTGTTGCATCAGACTATGTCTCCAA TTGGATTAGTGAATGCATGTATACCAAATTAGATGAATTATTTATGTATTGTGGGTGGGAACTACTATTGGAACTA TCCTATCAAATGTATTATCTGAGGGTAGTTGGGTGGAGTAATATAGTGGATTATTCTTACATGATCTTGAGAAGAA TCCCGGGTGCAGCATTAAACAATCTGGCATCTACATTAAGTCATCCAAAACTTTTCCGACGAGCTATCAACCTAGA TATAGTTGCCCCCTTAAATGCTCCTCATTTTGCATCTCTGGACTACATCAAGATGAGTGTGGATGCAATACTCTGG GGCTGTAAAAGAGTCATCAATGTGCTCTCCAATGGAGGGGACTTAGAATTAGTTGTGACATCTGAAGATAGCCTTA TTCTCAGTGACCGATCCATGAATCTCATTGCAAGGAAATTAACTTTATTATCACTGATTCACCATAATGGTTTGGA ACTACCAAAGATTAAGGGGTTCTCTCCTGATGAGAAGTGTTTCGCTTTGACAGAATTTTTGAGGAAAGTGGTGAAC TCAGGGTTGAGTTCAATAGAGAACCTATCAAATTTTATGTACAATGTGGAGAACCCACGGCTTGCAGCATTCGCCA GCAACAATTACTACCTGACCAGAAAATTATTGAATTCAATACGAGATACTGAGTCGGGTCAAGTAGCAGTCACCTC ATATTATGAATCATTAGAATATATTGATAGTCTTAAGCTAACCCCACATGTGCCTGGCACCTCATGCATTGAGGAT GATAGTCTATGTACAAATGATTACATAATCTGGATCATAGAGTCTAATGCAAACTTGGAGAAGTATCCAATTCCAAATAGCCCTGAGGATGATTCCAATTTCCATAACTTTAAGTTGAATGCTCCATCGCACCATACCTTACGCCCATTAGG GTTGTCATCAACTGCTTGGTATAAGGGTATAAGCTGCTGCAGGTACCTTGAGCGATTAAAGCTACCACAAGGTGAT CATTTATATATTGCAGAAGGTAGTGGTGCCAGTATGACAATCATAGAATACCTATTCCCAGGAAGAAAGATATATT ACAATTCTTTATTTAGTAGTGGTGACAATCCCCCACAAAGAAATTATGCACCAATGCCTACTCAGTTCATTGAGAG TGTCCCATACAAGCTCTGGCAAGCACACACAGATCAATATCCCGAGATTTTTGAGGACTTCATCCCTCTATGGAAC GGAAACGCCGCCATGACTGACATAGGAATGACAGCTTGTGTAGAATTCATCATCAATCGAGTCGGCCCAAGGACTT GCAGTTTAGTACATGTAGATTTGGAATCAAGTGCAAGCTTAAATCAACAATGCCTGTCAAAGCCGATAATTAATGC TATCATCACTGCTACAACTGTTTTGTGCCCTCATGGGGTGCTTATTCTGAAATATAGTTGGTTGCCATTTACTAGA TTTAGTACTTTGATCACTTTCTTATGGTGCTACTTTGAGAGAATCACTGTTCTTAGGAGCACATATTCTGATCCAG CTAATCATGAGGTTTATTTAATTTGTATCCTTGCCAACAACTTTGCATTCCAGACTGTCTCGCAGGCAACAGGAAT GGCGATGACTTTAACTGATCAAGGGTTTACTTTGATATCACCTGAAAGAATAAATCAGTATTGGGATGGTCACTTG AAGCAAGAACGTATCGTAGCAGAAGCAATTGATAAGGTGGTTCTAGGAGAAAATGCTCTATTTAATTCGAGTGATA ATGAATTAATTCTCAAATGTGGAGGGACACCAAATGCACGGAATCTCATCGATATCGAGCCAGTCGCAACTTTCATAGAATTTGAACAATTGATCTGCACAATGTTGACAACCCACTTGAAGGAAATAATTGATATAACAAGGTCTGGAACC CAGGATTATGAAAGTTTATTACTCACTCCTTACAATTTAGGTCTTCTTGGTAAAATCAGTACGATAGTGAGATTAT TAACAGAAAGGATTCTAAATCATACTATCAGGAATTGGTTGATCCTCCCACCTTCGCTCCGGATGATCGTGAAGCA GGACTTGGAATTCGGCATATTCAGGATTACTTCCATCCTCAATTCTGATCGGTTCCTGAAGCTTTCTCCAAATAGG AAATACTTGATTGCACAATTAACTGCAGGCTACATTAGGAAATTGATTGAGGGGGATTGCAATATCGATCTAACCA GACCTATCCAAAAGCAAATCTGGAAAGCATTAGGTTGTGTAGTCTATTGTCACGATCCAATGGATCAAAGGGAGTC AACAGAGTTTATTGATATAAATATTAATGAAGAAATAGACCGCGGGATCGATGGCGAGGAAATCTAAACATATCAA Description Page 43 / 157 46 CN 121263205 A GAATCAGAATTAGTTTAAGAAAAAAGAAGAGGATTAATCTTGGTTTTCCCCTTGGTGGGTCGGCATGGCATCTCCA CCTCCTCGCGGTCCGACCTGGGCATCCGAAGGAGGACGCACGTCCACTCGGATGGCTAAGGGAGCGGCCGGGGATC CGGCTGCTAACAAAGCCCGAAAGGAAGCTGAGTTGGCTGCTGCCACCGCTGAGCAATAACTAGCATAACCCCTTGG GGCCTCTAAACGGGTCTTGAGGGGTTTTTTGCTGAAAGGAGGAACTATATCCGGATCATGTGAGCAAAAGGCCAGC AAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCC CTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGC TTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACC CCCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCG CCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGT GGCCTAACTACGGCTACACTAGAAGAACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAG AGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACG CGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGAACGAAAACTCAC GTTAAGGGATTTTGGTCATGAGATTATCAAAAAGGATCTTCACCTAGATCCTTTTAAATTAAAAATGAAGTTTTAA ATCAATCTAAAGTATATATGAGTAAACTTGGTCTGACAGTTACCAATGCTTAATCAGTGAGGCACCTATCTCAGCG ATCTGTCTATTTCGTTCATCCATAGTTGCCTGACTCCCCGTCGTGTAGATAACTACGATACGGGAGGGCTTACCAT CTGGCCCCAGTGCTGCAATGATACCGCGAGACCCACGCTCACCGGCTCCAGATTTATCAGCAATAAACCAGCCAGC CGGAAGGGCCGAGCGCAGAAGTGGTCCTGCAACTTTATCCGCCTCCATCCAGTCTATTAATTGTTGCCGGGAAGCTAGAGTAAGTAGTTCGCCAGTTAATAGTTTGCGCAACGTTGTTGCCATTGCTACAGGCATCGTGGTGTCACGCTCGT CGTTTGGTATGGCTTCATTCAGCTCCGGTTCCCAACGATCAAGGCGAGTTACATGATCCCCCATGTTGTGCAAAAA AGCGGTTAGCTCCTTCGGTCCTCCGATCGTTGTCAGAAGTAAGTTGGCCGCAGTGTTATCACTCATGGTTATGGCA GCACTGCATAATTCTCTTACTGTCATGCCATCCGTAAGATGCTTTTCTGTGACTGGTGAGTACTCAACCAAGTCAT TCTGAGAATAGTGTATGCGGCGACCGAGTTGCTCTTGCCCGGCGTCAATACGGGATAATACCGCGCCACATAGCAG AACTTTAAAAGTGCTCATCATTGGAAAACGTTCTTCGGGGCGAAAACTCTCAAGGATCTTACCGCTGTTGAGATCC AGTTCGATGTAACCCACTCGTGCACCCAACTGATCTTCAGCATCTTTTACTTTCACCAGCGTTTCTGGGTGAGCAA AAACAGGAAGGCAAAATGCCGCAAAAAAGGGAATAAGGGCGACACGGAAATGTTGAATACTCATACTCTTCCTTTT TCAATATTATTGAAGCATTTATCAGGGTTATTGTCTCATGAGCGGATACATATTTGAATGTATTTAGAAAAATAAA CAAATAGGGGTTCCGCGCACATTTCCCCGAAAAGT (SEQ ID NO: 4).
[0194] iii. CVL85
[0195] The nucleic acid sequence of CVL85 is:
[0196] GCCACCTGACGTCTAAGAAACCATTATTATCATGACATTAACCTATAAAAATAGGCGTATCACGAGGC CCTTTCGTCTCGCGCGTTTCGGTGATGACGGTGAAAACCTCTGACACATGCAGCTCCCGGAGACGGTCACAGCTTGTCTGTAAGCGGATGCCGGGAGCAGACAAGCCCGTCAGGGCGCGTCAGCGGGTGTTGGCGGGTGTCGGGGCTGGCTT AACTATGCGGCATCAGAGCAGATTGTACTGAGAGTGCACCATATATGCGGTGTGAAATACCGCACAGATGCGTAAG GAGAAAATACCGCATCAGGCTAATACGACTCACTATAGGGACCAAGGGGAAAATGAAGTGGTGACTCAAATCATCG AAGACCCTCGAGATTACATAGGTCCGGAACCTATGGCCTTCGTGACCGACCTCGAGTCAGAGTAGTTCAATAAGGA CCTATCAAGTTTGGGCAATTTTTCGTCCCCGACACAAAAATGTCATCCGTGCTTAAAGCATATGAGCGATTCACGC TCACTCAAGAACTGCAAGATCAGAGTGAGGAAGGTACAATCCCACCTACAACACTAAAACCGGTAATCAGGGTATT TATACTAACCTCTAATAACCCAGAGCTAAGATCCCGGCTTCTTCTATTCTGCCTACGGATTGTTCTCAGTAATGGT DESCRIPTION Page 44 / 157 47 CN 121263205 A GCAAGGGATTCCCATCGCTTTGGAGCATTACTCACAATGTTTTCGCTACCATCAGCCACAATGCTCAATCATGTCA AATTAGCTGACCAGTCACCAGAAGCTGATATCGAAAGGGTAGAGATCGATGGCTTTGAGGAGGGATCATTCCGCTT AATCCCCAATGCTCGTTCAGGTATGAGCCGTGGAGAGATCAATGCCTATGCTGCACTTGCAGAAGATCTACCTGAC ACACTAAACCATGCAACACCTTTCGTTGATTCCGAAGTCGAGGGAACTGCATGGGATGAGATTGAGACTTTCTTAG ATGTGTTACAGTGTCCTAATGCAGGCATGGATAGTGACTTGCAAGTGCATGACTGCGCCAGACCAACCTGCTGCTTCTATTGAGAAACGCCTGCAAAAATATCGTCAGCAAGGCAGGATCAACCCGAGATATCTCCTGCAACCGGAGGCT CGACGAATAATCCAGAATGTAATCCGGAAGGGAATGGTGGTCAGACATTTCCTCACCTTTGAACTGCAGCTTGCCC GAGCACAAAGCCTTGTATCAAATAGGTATTATGCTATGGTAGGGGATGTTGGAAAGTATATAGAGAATTGTGGAAT GGGAGGCTTCTTTTTGACACTAAAATATGCATTAGGAACTAGATGGCCCACACTTGCTTTAGCTGCATTTTCAGGA GAGCTAACAAAGCTAAAGTCCCTCATGGCATTATACCAGACCCTTGGTGAGCAGGCCCGATATTTGGCCCTATTGG AGTCACCACATTTGATGGATTTTGCTGCAGCAAACTACCCACTGCTATATAGCTATGCTATGGGAATAGGCTATGT GTTAGATGTCAACATGAGGAACTACGCTTTCTCCAGATCATACATGAACAAGACATATTTCCAATTGGGAATGGAA ACTGCAAGAAAACAACAGGGTGCAGTTGACATGAGGATGGCAGAAGATCTCGGTCTAACTCAAGCCGAACGCACCG AGATGGCAAATACACTTGCCAAATTGACCACAGCAAATCGAGGGGCAGACACCAGGGGAGGAGTCAACCCGTTCTC ATCTGTCACTGGGACAACTCAGGTGCCCGCTGCAGCAACAGGTGACACACTCGAGAGTTACATGGCAGCGGATCGA CTGAGGCAGAGATATGCTGATGCAGGCACCCATGATGATGAGATGCCACCATTGGAAGAGGAGGAAGAGGACGACA CATCTGCAGGTCCACGCACTGGACCAACTCTTGAACAAGTGGCCTTGGACATCCAGAACGCAGCAGTTGGAGCTCC CATCCATACAGATGACCTGAATGCCGCACTGGGTGATCTTGACATCTAGACAATTCAGATCCCAATCTAAAATTGACATACCTAATTGATTAGTTAGATGGAACTACAGTGGATTCCATAAGGTTCCTGCCTACCATCGGCTTTAAAGAAAA AAATAGGCCCGGACGGGTTAGCAACAAGCGACTGCCGGTGCCAACAGCGCAATCCACAATCTACAATGGATCCCAC TGATCTGAGCTTCTCCCCAGATGAGATCAATAAGCTCATAGAGACAGGCCTGAATACTGTAGAGTATTTTACTTCC CAACAAGTCACAGGAACATCCTCTCTTGGAAAGAATACAATACCACCAGGGGTCACAGGACTACTAACCAATGCTG CAGAGGCAAAGATCCAAGAGTCAACTAACCATCAGAAGGGCTCAGTTGGTGGGGGTGCAAAACCAAAGAAACCGCG ACCAAAAATTGCCATTGTGCCAGCAGATGACAAAACAGTGCCCGGAAAGCCGATCCCAAACCCTCTATTAGGTCTG GACTCCACCCCGAGCACCCAAACTGTGCTTGATCTAAGTGGGAAAACATTACCATCAGGATCCTATAAGGGGGTTA AGCTTGCGAAATTTGGAAAAGAAAATCTGATGACACGGTTCATCGAGGAACCCAGAGAGAATCCTATCGCAACCAG TTtCCCCATCGATTTTAAGAGGGGCAGGGATACCGGCGGGTTCCATAGAAGGGAGTACTCAATCGGATGGGTGGGA GATGAAGTCAAGGTCACTGAGTGGTGCAATCCATCCTGTTCTCCAATCACCGCTGCAGCAAGGCGATTTGAATGCA CTTGTCACCAGTGTCCAGTCACTTGCTCTGAATGTGAACGAGATACTTAATACAGTGAGAAATTTGGACTCTCGGA TGAATCAACTGGAGACAAAAGTAGATCGCATTCTCTCATCTCAGTCTCTAATCCAGACCATCAAGAATGACATAGT TGGACTTAAAGCAGGGATGGCTACTTTAGAAGGAATGATTACAACTGTGAAAATCATGGACCCGGGAGTTCCCAGTAATGTTACTGTGGAAGATGTACGCAAGACACTAAGTAACCATGCTGTTGTTGTGCCAGAATCATTCAATGATAGTT TCTTGACTCAATCTGAAGATGTAATTTCACTTGATGAGTTGGCTCGACCAACTGCAACAAGTGTTAAGAAGATTGT CAGGAAGGTTCCTCCTCAGAAGGATCTGACTGGATTGAAGATTACACTAGAGCAATTGGCAAAGGATTGCATCAGC AAACCGAAGATGAGGGAAGAGTATCTCCTCAAAATCAACCAGGCTTCCAGTGAGGCTCAGCTAATTGACCTCAAGA AAGCAATCATCCGCAGTGCAATTTGATCAAGAAACACCCAATTACACTACACTGGTATGACACTGTACTAACCCTG AGGGTTTTAGAAAAAACGATTAACGATAAATAAGCCCGAACACTACACACTACCTGAGGCAGCCATGCCATCCATC AGCATTCCCGCAGACCCCACCAATCCACGTCAATCAATAAAAGCGTTCCCAATTGTGATCAACAGTGATGGGGGTG AGAAAGGCCGCTTGGTTAAACAACTACGCACAACCTACTTGAATGACCTAGATACTCATGAGCCACTGGTGACATT Description Page 45 / 157 Page 48 CN 121263205 A CATAAATACCTATGGATTCATCTACGAACAGGATCGGGGGAATACCATTGTCGGAGAGGATCAACTTGGGAAGAAA AGAGAGGCTGTGACCGCTGCAATGGTTACCCTTGGATGTGGGCCTAATCTACCATCATTAGGGAATGTCCTGGGAC AACTGAGGGAATTCCAGGTCACTGTTAGGAAGACATCCAGCAAAGCGGAAGAGATGGTCTTTGAAATTGTTAAGTA TCCGAGAATATTTCGGGGTCATACATTAATCCAGAAAGGACTAGTCTGTGTCTCCGCAGAAAAATTTGTTAAGTCACCAGGGAAAAATACAATCTGGAATGGACTATCTCTTCATTCCGACATTTCTGTCAGTGACTTACTGTCCAGCTGCAA TCAAATTTCAGGTACTGGCCCCATGTTTGAAAATGAGATCAAGATACACTCAGAGCTTACAACTTGAACTAATGAT AAGAATCCTGTGTAAGCCCGATTCGCCACTTATGAAGGTCCATACCCCTGACAAGGAGGAAGGAAGGAGTGTCTTGTA TCAGTATGGCTGCATGTATGCAACATCTTCAAATCAGGAACAAGAAGGGCAGTGAGTGGCAGGAATACTGGGACCAACTATCATAGCCAAGGTGCTAAGTTGTTTTTTGGAAAGGTGGATGGACTGCCATCCACTTCACGAAGTTGTTCCA AGTGTCACTAAACACTATGGTCCGTGGGCTGTGAGATTACAAAGGCGAAGGCAATAATAACAAGAGAGTAGCATCT CTCTTCTCGTGGAGACTACTGACATCATAAGTCCAAAAGTCAAAATTTCATCTAAGCATCGCGCGCTTTGGGAAATC AAATTGGGGTCTGTTCAAGAAAACTAATCACTGCCTAACCTGACGGAGCTGGAATGACTGACCTCTAATCGAGAC TACACCGCCGCAAACTATAGGTGGGTGGTACCTCAGTGATTAATCTTGTAAGCACTGATCGTAGGCTACAACACAC TAATATTATCCAGATTAGAGAGCTTAATTAGCTCTGTATTAATAATAACACTACTATTCCAATAACTGGAATCACC AGCTTGATTTATCTCCAAAATGATTCAAAGAAAACAAATCATATTAAGACTATCCTAAGCACGAACCCATATCGTC CTTCAAATCATGGGTACTATAATTCAATTTCTGGTGGTCTCCTGTCTATTGGCAGGAGCAGGCAGCCTTGATCCAGCAGCCCTCATGCAAATCGGTGTCATTCCAACAAATGTCCGGCAACTTATGTATTATACTGAAGCTTCATCAGCATT CATTGTTGTGAAGTTAATGCCTACAATTGACTCGCCGATTAGTGGATGTAATATAACATCAATTTCAAGCTATAAT GCAACAGTGACAAAACTCCTACAGCCGATCGGTGAGAATTTGGAGACGATTAGGAACCAGTTGATTCCAACTCGGA GGAGACGCCGGTTTGCAGGGGTGGTGATTGGATTAGCTGCATTAGGAGTAGCTACTGCCGCACAGGTCACTGCCGC AGTGGCACTAGTAAAGGCAAATGAAAATGCTGCGGCTATACTCAATCTCAAAAATGCAATCCAAAAAACAAATGCA GCAGTTGCAGATGTGGTCCAGGCCACACAATCACTAGGAACGGCAGTTCAAGCAGTTCAAGATCACATAAACAGTG TGGTAAGTCCAGCAATTACAGCAGCCAATTGTAAGGCCCAAGATGCTATCATTGGCTCAATCCTCAATCTCTATTT GACCGAGTTGACAACCATCTTCCACAATCAAATTACAAACCCTGCATTGAGTCCCATTACAATTCAAGCTTTAAGG ATCCTACTGGGGAGTACCTTGCCGACTGTGGTCGAAAAATCTTTCAATACCCAGATAAGTGCAGCTGAGCTTCTCT CATCAGGGTTATTGACAGGCCAGATTGTGGGATTAGATTTGACCTATATGCAGATGGTCATAAAAATTGAGCTGCC AACTTTAACTGTACAACCTGCAACCCAGATCATAGATCTGGCCACCATTTCTGCATTCATTAACAATCAAGAAGTC ATGGCCCAATTACCAACACGTGTTATGGTGACTGGCAGCTTGATCCAAGCCTATCCCGCATCGCAATGCACCATTA CACCCAACACTGTGTACTGTAGGTATAATGATGCCCAAGTACTCTCAGATGATACTATGGCTTGCCTCCAAGGTAACTTGACAAGATGCACCTTCTCTCCAGTGGTTGGGAGCTTTCTCACTCGATTCGTGCTGTTCGATGGAATAGTTTAT GCAAATTGCAGGTCGATGTTGTGCAAGTGCATGCAACCTGCTGCTGTGATCCTACAGCCGAGTTCATCCCCTGTAA CTGTCATTGACATGTACAAATGTGTGAGTCTGCAGCTTGACAATCTCAGATTCACCATCACTCAATTGGCCAATGT AACCTACAATAGCACCATCAAGCTTGAATCATCCCAGATCTTGTCTATTGATCCGTTGGATATATCCCAGAATCTA GCTGCGGTGAATAAGAGTCTAAGTGATGCACTACAACACTTAGCACAAAGTGACACATATCTTTCTGCAATCACAT CAGCTACGACTACAAGTGTATTATCCATAATAGCAATCTGTCTTGGATCGTTAGGTTTAATATTAATAATCTTGCT CAGTGTAGTTGTGTGGAAGTTATTGACCATTGTCGTTGCTAATCGAAATAGAATGGAGAATTTTGTTTATCATAAA TAAGCATTCCACCACTCACGATCTGATCTCAGTGAGAAAAATCAACCTGCAACTCTTGGAACAAGATAAGACAGTC ATCCATTAGTAATTTTTAAGAAAAAAACGATAGGACCGAACCTAGTATTGAAAGAACCGTCTCGGTCAATCTAGGT Description Page 46 / 157 49 CN 121263205 A AATCGAGCTGATACCGTCTCGGAAAGCTCAAATCGCGCGCCACCatgtcagataacggaccacagaaccagaggaa cgcacccaggattactttcggaggaccaagcgatagcaccgggagcaaccagaatggagagcggagcggagcaaga tccaagcagagacggccccagggcctgccaaacaataccgcatcctggttcaccgccctgacacagcacggcaaggaggacctgaagtttccaaggggacagggagtgcctatcaacaccaatagctcccctgacgatcagatcggctacta taggagggcaacaaggagaatcaggggaggcgacggcaagatgaaggatctgagcccacgctggtacttctactat ctgggaaccggacctgaggcaggcctgccatatggcgccaacaaggacggaatcatctgggtggcaaccgagggcg ccctgaacacaccaaaggatcacatcggcacaagaaatcccgccaacaatgcagcaatcgtgctgcagctgccaca gggaaccacactgcccaagggcttttacgcagagggctctcggggaggcagccaggcatctagcagatcctctagc cggagcagaaactcctctaggaattccaccccaggaagctccaggggcacatcccctgcccgcatggcaggaaacg gaggcgacgccgccctggccctgctgctgctggatcgcctgaatcagctggagtccaagatgtctggcaagggaca gcagcagcagggacagaccgtgacaaagaagtccgccgccgaggcctctaagaagccaaggcagaagcgcaccgcc acaaaggcctacaacgtgacccaggccttcggcaggcgcggaccagagcagacacagggcaattttggcgaccagg agctgatcaggcagggaaccgattataagcactggcctcagatcgcccagttcgccccatctgccagcgccttctt tggcatgtctagaatcggcatggaggtgacccccagcggcacatggctgacctacacaggcgccatcaagctggac gataaggaccctaacttcaaggatcaggtcatcctgctgaacaagcacatcgacgcctataagacctttcccccta cagagcccaagaaggacaagaagaagaaggccgatgagacacaggccctgcctcagaggcagaagaagcagcagaccgtgacactgctgccagccgccgatctggacgatttctccaaacagctgcagcagagcatgtccagtgccgactcc acccaggcttgaCGTACGACCTGCTATAGGCTATCCACTGCATCATCTCTCCTGCCATACTTCCTACTCACATCAT ATCTATTTTAAAGAAAAAATAGGCCCGAACACTAATCGTGCCGGCAGTGCCACTGCACACACAACACTACACATAC AATACACTACAATGGTTGCAGAAGATGCCCCTGTTAGGGCCACTTGCCGAGTATTATTTCGAACAACAACTTTAAT CTTTCTATGCACACTACTAGCATTAAGCATCTCTATCCTTTATGAGAGTTTAATAACCCAAAAGCAAATCATGAGC CAAGCAGGCTCAACTGGATCTAATTCTGGATTAGGAAGTATCACTGATCTTCTTAATAATATTCTCTCTGTCGCAA ATCAGATTATATATAACTCTGCAGTCGCTCTACCTCTACAATTGGACACTCTTGAATCAACACTCCTTACAGCCAT TAAGTCTCTTCAAACCAGTGACAAGCTAGAACAGAACTGCTCGTGGAGTGCTGCACTGATTAATGATAATAGATAC ATTAATGGCATCAATCAGTTCTATTTTTCAATTGCTGAGGGTCGCAATCTGACACTTGGCCCACTTCTTAATATGC CTAGTTTCATTCCAACTGCCACGACACCAGAGGGCTGCACCAGGATCCCATCATTCTCGCTCACTAAGACACACTG GTGTTATACACACAATGTTATCCTGAATGGATGCCAGGATCATGTATCCTCAAATCAATTTGTTTCTATGGGAATC ATTGAACCCACTTCTGCCGGGTTTCCATTCTTTCGAACCCTAAAGACTCTATATCTCAGCGATGGGGTCAATCGTA AGAGCTGCTCTATCAGTACAGTTCCGGGGGGTTGTATGATGTACTGTTTTGTTTCTACTCAACCAGAGAGGGATGACTACTTTTCTGCCGCTCCTCCAGAACAACGAATTATTATAATGTACTATAATGATACAATCGTGGAGCGCATAATT AATCCACCCGGGGTACTAGATGTATGGGCAACATTGAACCCAGGAACAGGAAGCGGGGTATATTATTTAGGTTGGG TGCTCTTTCCAATATATGGCGGCGTGATTAAAGGTACGAGTTTATGGAATAATCAAGCAAATAAATACTTTATCCC CCAGATGGTTGCTGCTCTCTGCTCACAAAACCAGGCAACTCAAGTCCAAAATGCTAAGTCATCATACTATAGCAGC TGGTTTGGCAATCGAATGATTCAGTCTGGGATCCTGGCATGTCCTCTTCGACAGGATCTAACCAATGAGTGTTTAG TTCTGCCCTTTTCTAATGATCAGGTGCTTATGGGTGCTGAAGGGAGATTATACATGTATGGTGACTCGGTGTATTA CTATCAAAGAAGCAATAGTTGGTGGCCTATGACCATGCTGTATAAGGTAACCATAACATTCACTAATGGTCAGCCA TCTGCTATATCAGCTCAGAATGTGCCCACACAGCAGGTCCCTAGACCTGGGACAGGAGACTGCTCTGCAACCAATA GATGTCCCGGTTTTTGCTTGACAGGAGTGTATGCCGATGCCTGGTTACTGACCAACCCTTCGTCTACCAGTACATT TGGATCAGAAGCAACCTTCACTGGTTCTTATCTCAACACAGCAACTCAGCGTATCAATCCGACGATGTATATCGCG DESCRIPTION Page 47 / 157 50 CN 121263205 A AACAACACACAGATCATAAGCTCACAGCAATTTGGATCAAGCGGTCAAGAAGCAGCATATGGCCACACAACTTGTT TTAGGGACACAGGCTCTGTTATGGTATACTGTATCTATATTATTGAATTGTCCTCATCTCTCTTAGGACAATTTCAGATTGTCCCATTTATCCGTCAGGTGACACTATCCTAAAGGCAGAAGCCTTCAGGTCTGACCCAGCCAATCAAAGCA TTATACCAGACCATGGCCTACCATCGGCTTTAAAGAAAAAAATAGGCCCGGACGGGTTAGCAACAAGCGGCGGCCG CCatgttcgtcttcctggtcctgctgcctctggtctcctcacagtgcgtcaatctgacaactcggactcagctgcc acctgcttatactaatagcttcaccagaggcgtgtactatcctgacaaggtgtttagaagctccgtgctgcactct acacaggatctgtttctgccattctttagcaacgtgacctggttccacgccatccacgtgagcggcaccaatggca caaagcggttcgacaatcccgtgctgccttttaacgatggcgtgtacttcgcctctaccgagaagagcaacatcat cagaggctggatctttggcaccacactggactccaagacacagtctctgctgatcgtgaacaatgccaccaacgtg gtcatcaaggtgtgcgagttccagttttgtaatgatcccttcctgggcgtgtactatcacaagaacaataagagct ggatggagtccgagtttagagtgtattctagcgccaacaactgcacatttgagtacgtgagccagcctttcctgat ggacctggagggcaagcagggcaatttcaagaacctgagggagttcgtgtttaagaatatcgacggctacttcaaa atctactctaagcacacccccatcaacctggtgcgcgacctgcctcagggcttcagcgccctggagcccctggtgg atctgcctatcggcatcaacatcacccggtttcagacactgctggccctgcacagaagctacctgacacccggcga ctcctctagcggatggaccgccggcgctgccgcctactatgtgggctacctccagccccggaccttcctgctgaagtacaacgagaatggcaccatcacagacgcagtggattgcgccctggaccccctgagcgagacaaagtgtacactga agtcctttaccgtggagaagggcatctatcagacatccaatttcagggtgcagccaaccgagtctatcgtgcgctt tcctaatatcacaaacctgtgcccatttggcgaggtgttcaacgcaacccgcttcgccagcgtgtacgcctggaat aggaagcggatcagcaactgcgtggccgactatagcgtgctgtacaactccgcctctttcagcacctttaagtgct atggcgtgtcccccacaaagctgaatgacctgtgctttaccaacgtctacgccgattctttcgtgatcaggggcga cgaggtgcgccagatcgcccccggccagacaggcaagatcgcagactacaattataagctgccagacgatttcacc ggctgcgtgatcgcctggaacagcaacaatctggattccaaagtgggcggcaactacaattatctgtaccggctgt ttagaaagagcaatctgaagcccttcgagagggacatctctacagaaatctaccaggccggcagcaccccttgcaa tggcgtggagggctttaactgttatttcccactccagtcctacggcttccagcccacaaacggcgtgggctatcag ccttaccgcgtggtggtgctgagctttgagctgctgcacgccccagcaacagtgtgcggccccaagaagtccacca atctggtgaagaacaagtgcgtgaacttcaacttcaacggcctgaccggcacaggcgtgctgaccgagtccaacaa gaagttcctgccatttcagcagttcggcagggacatcgcagataccacagacgccgtgcgcgacccacagaccctg gagatcctggacatcacaccctgctctttcggcggcgtgagcgtgatcacacccggcaccaatacaagcaaccaggtggccgtgctgtatcaggacgtgaattgtaccgaggtgcccgtggctatccacgccgatcagctgaccccaacatg gcgggtgtacagcaccggctccaacgtcttccagacaagagccggatgcctgatcggagcagagcacgtgaacaat tcctatgagtgcgacatcccaatcggcgccggcatctgtgcctcttaccagacccagacaaactctcccagaagag cccggagcgtggcctcccagtctatcatcgcctataccatgtccctgggcgccgagaacagcgtggcctactctaa caatagcatcgccatcccaaccaacttcacaatctctgtgaccacagagatcctgcccgtgtccatgaccaagaca tctgtggactgcacaatgtatatctgtggcgattctaccgagtgcagcaacctgctgctccagtacggcagctttt gtacccagctgaatagagccctgacaggcatcgccgtggagcaggataagaacacacaggaggtgttcgcccaggt gaagcaaatctacaagaccccccctatcaaggactttggcggcttcaatttttcccagatcctgcctgatccatcc aagccttctaagcggagctttatcgaggacctgctgttcaacaaggtgaccctggccgatgccggcttcatcaagc agtatggcgattgcctgggcgacatcgcagccagggacctgatctgcgcccagaagtttaatggcctgaccgtgct gccacccctgctgacagatgagatgatcgcacagtacacaagcgccctgctggccggcaccatcacatccggatgg DESCRIPTION Page 48 / 157 51 CN 121263205 A accttcggcgcaggagccgccctccagatcccctttgccatgcagatggcctataggttcaacggcatcggcgtgacccagaatgtgctgtacgagaaccagaagctgatcgccaatcagtttaactcgccatcggcaagatccaggacag cctgtcctctacagccagcgccctgggcaagctccaggatgtggtgaatcagaacgcccaggccctgaataccctg gtgaagcagctgagcagcaacttcggcgccatctctagcgtgctgaatgacatcctgagccggctggcaaggtgg aggcagaggtgcagatcgaccggctgatcaccggccggctccagagcctccagacctatgtgacacagcagctgat cagggccgccgagatcagggccagcgccaatctggcagcaaccaagatgtccgagtgcgtgctgggccagtctaag agagtggacttttgtggcaagggctatcacctgatgtccttccctcagtctgccccacacggcgtggtgtttctgc acgtgacctacgtgcccgcccaggagaagaacttcaccacagcccctgccatctgccacgatggcaaggcccactt tccaagggagggcgtgttcgtgtccaacggcaccactggtttgtgacacagcgcaatttctacgagccccagatc atcaccacagacaacaccttcgtgagcggcaactgtgacgtggtcatcggcatcgtgaacaataccgtgtatgatc cactccagcccgagctggacagctttaaggaggactggataagtatttcaagaatcacacctcccctgacgtgga tctgggcgacatcagcggcatcaatgcctccgtggtgaacatccagaaggagatcgaccgcctgaacgaggtggct aagaatctgaacgagagcctgatcgacctccaggagctgggcaagtatgagcagtacatcaagtggccctggtaca tctggctggggcttcatcgccggcctgatcgccatcgtgatggtgaccatcatgctgctgcttgacatcctgctgctgttcttgcctgaagggctgctgtagctgtggctcctgctgtaagttattgaccattgtcgttgctaatcgaaataga atggagaattttgtttatcataaatgaAGTCGACTCATGGAATGCATACCAAACATTATTGACACTAATGACACAC AAAATTGGTTTTAAGAAAAACCAAGAGAACAATAGGCCAGAATGGCTGGGTCTCGGGAGATATTACTCCCTGAAGT CCATCTCAATTCACCAATTGTAAAGCATAAGCTATACTATTACATTCTACTTGGAAACCTCCCAAATGAGATCGAC CTTGACGATTTAGGTCCATTACATAATCAAAATTGGAATCAGATAGCACATGAAGAGTCTAACTTAGCTCAACGCT TGGTAAATGTAAGAAATTTTCTAATTACCCACATCCCTGATCTTAGAAAGGGCCATTGGCAAGAGTATGTCAATGT AATACTGTGGCCGCGAATTCTTCCCTTGATCCCGGATTTTAAAATCAATGACCAATTGCCTCTGCTCAAAAATTGG GACAAGTTAGTTAAAGAATCATGTTCAGTAATCAATGCAGGTACTTCCCAGTGCATTCAGAATCTCAGCTATGGAC TGACAGGTCGTGGGAACCTCTTTACACGATCACGTGAACTCTCTGGTGACCGCAGGGATATTGATCTTAAGACAGT TGTGGCAGCATGGCATGACTCAGACTGGAAAAGAATAAGTGATTTTTGGATTATGATCAAAATTCCAGATGAGACAA TTAATTGTTAGGCAAACAGATCATAATGATTCTGATTTAATCACGTATATCGAAAATAGAGAAGGCATAATCATCA TAACCCCTGAACTGGTAGCATTATTTAACACTGAGAATCATACACTAACATACATGACCTTTGAAAATTGTACTGAT GGTTTCAGATATGTACGAAGGTCGTCACAACATTTTATCACTATGCACAGTTAGCACTTACCTGAATCCTCTGAAGAAAAGAATAACATATTTATTGAGCCTTGTAGATAACTTAGCTTTTCAGATAGGTGATGCTGTATATAACATAATTG CTTTGCTAGAATCCTTTGTATATGCACAGTTGCAAATGTCAGATCCCATCCCAGAACTCAGAGGACAATTCCATGC ATTCGTATGTTCTGAGATTCTTGATGCACTAAGAGGAACTAATAGTTTCACCCAGGATGAATTAAGAACTGTGACA ACTAATTTGATATCCCCATTCCAAGATCTGACCCCAGATCTTACGGCTGAATTGCTCTGTATAATGAGGCTTTGGG GACACCCCATGCTCACTGCCAGTCAAGCTGCAGGAAAGGTACGCGAGTCTATGTGTGCTGGAAAAGTATTAGACTT TCCCACCATTATGAAAACACTAGCCTTTTTCCATACTATTCTGATCAATGGATACAGGAGGAAGCATCATGGAGTA TGGCCACCCTTAAACTTACCGGGTAATGCTTCAAAGGGTCTCACGGAACTTATGAATGACAATACTGAAATAAGCT ATGAATTCACACTTAAGCATTGGAAGGAAGTCTCTCTTATAAAATTCAAGAAATGTTTTGATGCAGACGCAGGTGA GGAACTCAGTATATTTATGAAAGATAAGGCAATTAGTGCCCCAAAACAAGACTGGATGAGTGTGTTTAGAAGAAGC CTAATCAAACAGCGCCATCAGCATCATCAGGTCCCCCTACCAAATCCATTCAATCGACGGCTGTTGCTAAACTTTC TCGGAGATGACAAATTCGACCCGAATGTGGAGCTACAGTATGTAACATCAGGTGAGTATCTACATGATGACACGTT TTGTGCATCATATTCACTAAAAGAGAAGGAAATTAAACCTGATGGTCGAATTTTTGCAAAGTTGACTAAGAGAATG DESCRIPTION Page 49 / 157 52 CN 121263205 AAGATCATGTCAAGTTATAGCAGAATCTCTTTTAGCGAACCATGCTGGGAAGTTAATGAAAGAGAATGGTGTTGTGTGA TGAATCAGCTATCATTAACAAAATCACTATTAACAATGAGTCAGATTGGAATAATATCCGAGAAAGCTAGAAAGTC AACTCGAGATAACATAAATCAACCTGGTTTCCAGAATATCCAGAGAAATAAATCACATCACTCCAAGCAAGTCAAT CAGCGAGATCCAAGTGATGACTTTGAATTGGCAGCATCTTTTTTAACTACTGATCTCAAAAAATATTGTTTACAAT GGAGGTACCAGACAATTATCCCATTTGCTCAATCATTAAACAGAATGTATGGTTATCCTCATCTCTTTGAGTGGAT TCACTTACGGCTAATGCGTAGTACACTTTACGTGGGGGATCCCTTCAACCCACCAGCAGATACCAGTCAATTTGAT CTAGATAAAGTAATTAATGGAGATATCTTCATTGTATCACCCAGAGGTGGAATTGAAGGGCTGTGTCAAAAGGCTT GGACAATGATATCTATCGCTGTGATAATTCTATCTGCCACAGAGTCTGGCACACGAGTAATGAGTATGGTGCAGGG AGATAATCAAGCAATTGCTGTCACCACACGAGTACCAAGGAGCCTGCCGACTCTTGAGAAAAAGACTATTGCTTTT AGATCTTGTAATCTATTCTTTGAGAGGTTAAAATGTAATAATTTTGGATTAGGTCACCATTTGAAAGAACAAGAGA CTATCATTAGTTCTCACTTCTTTGTTTATAGCAAGAGAATATTCTATCAGGGGAGGATTCTAACGCAAGCCTTAAA AAATGCTAGTAAGCTCTGCTTGACAGCTGATGTCCTAGGAGAATGCACCCAATCATCATGTTCTAATCTTGCAACT ACTGTCATGAGGTTAACTGAGAATGGTGTTGAAAAAGATATCTGTTTCTACTTGAATATCTATATGACCATCAAACAGCTCTCCTATGATATCATCTTCCCTCAAGTGTCAATTCCTGGAGATCAGATCACATTAGAATACATAAATAATCC ACACCTGGTATCACGATTGGCTTTTGCCATCCCAGTTAGGAGGTCTAAACTACCTGTCATGCAGTAGGCTTTTC AATCGAAACATAGGCGACCCGGTGGTTTCCGCAGTTGCAGATCTTAAGAGATTAATTAAATCAGGATGTATGGATT ACTGGATCCTTTATAACTTATTAGGGAGAAACCCGGGAAACGGCTCATGGGCTAACTTTAGCAGCTGACCCGTACT AATCAATATAGAGGTATCACATGTACGTGGCATATTCTCTGACAATGCACAGGCAGAAAAATAACCTTGCTAGGTTTCTCCTGG ATAGGGAGGTGATCTTTCCGCGTGTAGCTCACATCATCATCATCATCATTAGGACAAACCAGTGTTCGGGAGAAAACAGATTCA AGGATATTTGGATTCAACTAGATCGATAATGAAGGAAAATCACTAGAAATTAAGCCCTTATCCAATAGAGGAAGCTTAAT GAAATACTGGATTACAACATCAAATTACCTAGCTTACAATTTGGCATTACTCAAGAATGCTATTGAACCTCCGACTT ATTTGAAGGCAATGACACTTGAAACATGTAGCATCGACATTGCAAGGAACCTCCGGAAGCTCTCCTGGCCCCACT CTTGGGTGGGAGAAATCTTGAAGGATTAGAGACGCCAGATCCCATTGAAATTACTGCAGGAGCATTAATTGTTGGA TCGGGCTACTGTGAACAGTGTGCTGCAGGAGACAATCGATTCACATGGTTTTTCTTGCCATCTGGTATCGATAG GAGGGGATCCCCGTGATAATCCTCCTATCCGTGTACCGTACATTGGCTCCAGGACTGATGAGAGGAGGGTAGCCTCAATGGCATACATCAGGGGTGCCTCGAGTAGCTTAAAAGCAGTTCTTAGACTGGCGGGAGTGTACATCTGGGCATTC GGAGATACTCTGGAGAATTGGATAGATGCACTGGATTTGTCTCACACTAGAGTTAACATCACACTTGAACAGCTGC AATCCCTCACCCCACTTCCAACCTCTGCCAATCTAACCCATCGGTTGGATGATGGCACAACTACCCTAAAGTTTAC TCCTGCGAGCTCTTACACCTTTTCAAGTTTCACTCATATATCAAATGATGAGCAATACCTGACAATTAATGACAAA ACTGCAGATTCAAATATAATCTACCAACAGTTAATGATCACTGGACTCGGAATCTTAGAAACATGGAATAATCCCC CAATCAATAGAACATTCGAAGAATCTACCCTACATTTGCACACTGGTGCATCATGTTGTGTCCGACCTGTGGACTC CTGCATTCTCTCAGAAGCATTAACAGTCAAGCCACATATTACAGTACCGTACAGCAATAAATTTGTATTTGATGAG GACCCGCTATCTGAATATGAAACTGCAAAACTGGAATCGTTATCATTCCAAGCCCAATTAGGCAACATTGATGCTG TAGATATGACAGGTAAATTAACATTATTGTCCCAATTCACTGCAAGGCAGATTATCAATGCAATCACTGGACTCGA TGAGTCTGTCTCTCTTACTAATGATGCCATTGTTGCATCAGACTATGTCTCCAATTGGATTAGTGAATGCATGTAT ACCAAATTAGATGAATTATTTATGTATTGTGGGTGGGAACTACTATTGGAACTATCCTATCAAATGTATTATCTGA GGGTAGTTGGGTGGAGTAATATAGTGGATTATTCTTACATGATCTTGAGAAGAATCCCGGGTGCAGCATTAAACAA TCTGGCATCTACATTAAGTCATCCAAAACTTTTCCGACGAGCTATCAACCTAGATATAGTTGCCCCCTTAAATGCTDescription Page 50 / 157 53 CN 121263205 A CCTCATTTTGCATCTCTGGACTACATCAAGATGAGTGTGGATGCAATACTCTGGGGCTGTAAAAGAGTCATCAATG TGCTCTCCAATGGAGGGGACTTAGAATTAGTTGTGACATCTGAAGATAGCCTTATTCTCAGTGACCGATCCATGAA TCTCATTGCAAGGAAATTAACTTTATTATCACTGATTCACCATAATGGTTTGGAACTACCAAAGATTAAGGGGTTC TCTCCTGATGAGAAGTGTTTCGCTTTGACAGAATTTTTGAGGAAAGTGGTGAACTCAGGGTTGAGTTCAATAGAGA ACCTATCAAATTTTATGTACAATGTGGAGAACCCACGGCTTGCAGCATTCGCCAGCAACAATTACTACCTGACCAG AAAATTATTGAATTCAATACGAGATACTGAGTCGGGTCAAGTAGCAGTCACCTCATATTATGAATCATTAGAATAT ATTGATAGTCTTAAGCTAACCCCACATGTGCCTGGCACCTCATGCATTGAGGATGATAGTCTATGTACAAATGATT ACATAATCTGGATCATAGAGTCTAATGCAAACTTGGAGAAGTATCCAATTCCAAATAGCCCTGAGGATGATTCCAA TTTCCATAACTTTAAGTTGAATGCTCCATCGCACCATACCTTACGCCCATTAGGGTTGTCATCAACTGCTTGGTAT AAGGGTATAAGCTGCTGCAGGTACCTTGAGCGATTAAAGCTACCACAAGGTGATCATTTATATATTGCAGAAGGTA GTGGTGCCAGTATGACAATCATAGAATACCTATTCCCAGGAAGAAAGATATATTACAATTCTTTATTTAGTAGTGG TGACAATCCCCCACAAAGAAATTATGCACCAATGCCTACTCAGTTCATTGAGAGTGTCCCATACAAGCTCTGGCAAGCACACACAGATCAATATCCCGAGATTTTTGAGGACTTCATCCCTCTATGGAACGGAAACGCCGCCATGACTGACA TAGGAATGACAGCTTGTGTAGAATTCATCATCGAGTCGGCCCAAGGACTTGCAGTTTAGTACATGTAGATTTTT GGAATCAAGTGCAAGCTTAAATCAACAATGCCTGTCAAAGCCGATAATTAATGCTATCATCACTGCTACAACTGTT TTGTGCCCTCATGGGGTGCTTATTCTGAAATATAGTTGGTTGCCATTTACTAGATTTAGTACTTTGATCCACTTTCT TATGGTGCTACTTTGAGAGAATCACTGTTCTTAGGAGCACATATTCTGATCCAGCTAATCATGAGGTTTATTTAAT TTGTATCCTTGCCAACAACTTTGCATTCCAGACTGTCTCGCAGGCAACAGGAATGGCGATGACTTTAACTGATCAA GGGTTTACTTTGATATCACCTGAAAGAATAAATCAGTATTGGGATGGTCACTTGAAGCAAGAACGTATCGTAGCAG AAGCAATTGATAAGGTGGTTCTAGGAGAAAATGCTCTATTTAATTCGAGTGATAATGAATTAATTCTCAAATGGG AGGGACACCAAATGCACGGAATCTCATCGATATCGAGCCAGTCGCAACTTTCATAGAATTTGAACAATTGATCTGC ACAATGTTGACAACCCACTTGAAGGAAATATTGATATAACAAGGTCTGGAACCCAGGATTGAAAGTTTATTAC TCACTCCTTACAATTTAGGTCTTCTTGGTAAAATCAGTACGATAGTGAGATTTAACAGAAAGGATTCTAAATCA TACTATCAGGAATTGGTTGATCCTCCCACCTTCGCTCCGGATGATCGTGAAGCAGGACTGGAATTCGGCATATTC AGGATTACTTCCATCCTCAATTCTGATCGGTTCCTGAAGCTTTCTCCAAATAGGAAATACTTGATTGCACAATTAACTGCAGGCTACATTAGGAAATTGATTGAGGGGGATTGCAATATCGATCTAACCAGACCTATCCAAAAGCAAATCTG GAAAGCATTAGGTTGTGTAGTCTATTGTCACGATCCAATGGATCAAAGGGAGTCAACAGAGTTTATTGATATAAAT ATTAATGAAGAAATAGACCGCGGGATCGATGGCGAGGAAATCTAAACATATCAAGAATCAGAATTAGTTTAAGAAA AAAGAAGAGGATTAATCTTGGTTTTCCCCTTGGTGGGTCGGCATGGCATCTCCACCTCCTCGCGGTCCGACCTGGG CATCCGAAGGAGGACGCACGTCCACTCGGATGGCTAAGGGAGCGGCCGGGGATCCGGCTGCTAACAAAGCCCGAAA GGAAGCTGAGTTGGCTGCTGCCACCGCTGAGCAATAACTAGCATAACCCCTTGGGGCCTCTAAACGGGTCTTGAGG GGTTTTTTGCTGAAAGGAGGAACTATATCCGGATCATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAA GGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGG TGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGA CCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCATAGCTCACGCTGTAG GTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACCGCTGC GCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTA ACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGAACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGC SPECIFICATION Page 51 / 157 54 CN 121263205 A AAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAG AAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGAACGAAAACTCACGTTAAGGGATTTTGGTCATGAG ATTATCAAAAAGGATCTTCACCTAGATCCTTTTAAATTAAAAATGAAGTTTTAAATCAATCTAAAGTATATATGAG TAAACTTGGTCTGACAGTTACCAATGCTTAATCAGTGAGGCACCTATCTCAGCGATCTGTCTATTTCGTTCATCCA TAGTTGCCTGACTCCCCGTCGTGTAGATAACTACGATACGGGAGGGCTTACCATCTGGCCCCAGTGCTGCAATGAT ACCGCGAGACCCACGCTCACCGGCTCCAGATTTATCAGCAATAAACCAGCCAGCCGGAAGGGCCGAGCGCAGAAGT GGTCCTGCAACTTTATCCGCCTCCATCCAGTCTATTAATTGTTGCCGGGAAGCTAGAGTAAGTAGTTCGCCAGTTA ATAGTTTGCGCAACGTTGTTGCCATTGCTACAGGCATCGTGGTGTCACGCTCGTCGTTTGGTATGGCTTCATTCAG CTCCGGTTCCCAACGATCAAGGCGAGTTACATGATCCCCCATGTTGTGCAAAAAAGCGGTTAGCTCCTTCGGTCCT CCGATCGTTGTCAGAAGTAAGTTGGCCGCAGTGTTATCACTCATGGTTATGGCAGCACTGCATAATTCTCTTACTG TCATGCCATCCGTAAGATGCTTTTCTGTGACTGGTGAGTACTCAACCAAGTCATTCTGAGAATAGTGTATGCGGCGACCGAGTTGCTCTTGCCCGGCGTCAATACGGGATAATACCGCGCCACATAGCAGAACTTTAAAAGTGCTCATCATT GGAAAACGTTCTTCGGGGCGAAAACTCTCAAGGATCTTACCGCTGTTGAGATCCAGTTCGATGTAACCCACTCGTG CACCCAACTGATCTTCAGCATCTTTTACTTTCACCAGCGTTTCTGGGTGAGCAAAAACAGGAAGGCAAAATGCCGC AAAAAAGGGAATAAGGGCGACACGGAAATGTTGAATACTCATACTCTTCCTTTTTCAATATTATTGAAGCATTTAT CAGGGTTATTGTCTCATGAGCGGATACATATTTGAATGTATTTAGAAAAATAAACAAATAGGGGTTCCGCGCACAT TTCCCCGAAAAGT(SEQ ID NO:5).
[0197] iv. CVL83
[0198] The nucleic acid sequence of CVL83 is:
[0199] GCCACCTGACGTCTAAGAAACCATTATTATCATGACATTAACCTATAAAAATAGGCGTATCACGAGGC CCTTTCGTCTCGCGCGTTTCGGTGATGACGGTGAAAACCTCTGACACATGCAGCTCCCGGAGACGGTCACAGCTTG TCTGTAAGCGGATGCCGGGAGCAGACAAGCCCGTCAGGGCGCGTCAGCGGGTGTTGGCGGGTGTCGGGGCTGGCTT AACTATGCGGCATCAGAGCAGATTGTACTGAGAGTGCACCATATATGCGGTGTGAAATACCGCACAGATGCGTAAG GAGAAAATACCGCATCAGGCTAATACGACTCACTATAGGGACCAAGGGGAAAATGAAGTGGTGACTCAAATCATCG AAGACCCTCGAGATTACATAGGTCCGGAACCTATGGCCTTCGTGACCGACCTCGAGTCAGAGTAGTTCAATAAGGA CCTATCAAGTTTGGGCAATTTTTCGTCCCCGACACAAAAATGTCATCCGTGCTTAAAGCATATGAGCGATTCACGCTCACTCAAGAACTGCAAGATCAGAGTGAGGAAGGTACAATCCCACCTACAACACTAAAACCGGTAATCAGGGTATT TATACTAACCTCTAATAACCCAGAGCTAAGATCCCGGCTTCTTCTATTCTGCCTACGGATTGTTCTCAGTAATGGT GCAAGGGATTCCCATCGCTTTGGAGCATTACTCACAATGTTTTCGCTACCATCAGCCACAATGCTCAATCATGTCA AATTAGCTGACCAGTCACCAGAAGCTGATATCGAAAGGGTAGAGATCGATGGCTTTGAGGAGGGATCATTCCGCTT AATCCCCAATGCTCGTTCAGGTATGAGCCGTGGAGAGATCAATGCCTATGCTGCACTTGCAGAAGATCTACCTGAC ACACTAAACCATGCAACACCTTTCGTTGATTCCGAAGTCGAGGGAACTGCATGGGATGAGATTGAGACTTTCTTAG ATATGTGTTACAGTGTCCTAATGCAGGCATGGATAGTGACTTGCAAGTGCATGACTGCGCCAGACCAACCTGCTGC TTCTATTGAGAAACGCCTGCAAAAATATCGTCAGCAAGGCAGGATCAACCCGAGATATCTCCTGCAACCGGAGGCT CGACGAATAATCCAGAATGTAATCCGGAAGGGAATGGTGGTCAGACATTTCCTCACCTTTGAACTGCAGCTTGCCC GAGCACAAAGCCTTGTATCAAATAGGTATTATGCTATGGTAGGGGATGTTGGAAAGTATATAGAGAATTGTGGAAT GGGAGGCTTCTTTTTGACACTAAAATATGCATTAGGAACTAGATGGCCCACACTTGCTTTAGCTGCATTTTCAGGA GAGCTAACAAAGCTAAAGTCCCTCATGGCATTATACCAGACCCTTGGTGAGCAGGCCCGATATTTGGCCCTATTGG AGTCACCACATTTGATGGATTTTGCTGCAGCAAACTACCCACTGCTATATAGCTATGCTATGGGAATAGGCTATGTDescription Page 52 / 157 55 CN 121263205 A GTTAGATGTCAACATGAGGAACTACGCTTTCTCCAGATCATACATGAACAAGACATATTTCCAATTGGGAATGGAA ACTGCAAGAAAACAACAGGGTGCAGTTGACATGAGGATGGCAGAAGATCTCGGTCTAACTCAAGCCGAACGCACCG AGATGGCAAATACACTTGCCAAATTGACCACAGCAAATCGAGGGGCAGACACCAGGGGAGGAGTCAACCCGTTCTC ATCTGTCACTGGGACAACTCAGGTGCCCGCTGCAGCAACAGGTGACACACTCGAGAGTTACATGGCAGCGGATCGA CTGAGGCAGAGATATGCTGATGCAGGCACCCATGATGATGAGATGCCACCATTGGAAGAGGAGGAAGAGGACGACA CATCTGCAGGTCCACGCACTGGACCAACTCTTGAACAAGTGGCCTTGGACATCCAGAACGCAGCAGTTGGAGCTCC CATCCATACAGATGACCTGAATGCCGCACTGGGTGATCTTGACATCTAGACAATTCAGATCCCAATCTAAAATTGA CATACCTAATTGATTAGTTAGATGGAACTACAGTGGATTCCATAAGGTTCCTGCCTACCATCGGCTTTAAAGAAAA AAATAGGCCCGGACGGGTTAGCAACAAGCGACTGCCGGTGCCAACAGCGCAATCCACAATCTACAATGGATCCCAC TGATCTGAGCTTCTCCCCAGATGAGATCAATAAGCTCATAGAGACAGGCCTGAATACTGTAGAGTATTTTACTTCC CAACAAGTCACAGGAACATCCTCTCTTGGAAAGAATACAATACCACCAGGGGTCACAGGACTACTAACCAATGCTG CAGAGGCAAAGATCCAAGAGTCAACTAACCATCAGAAGGGCTCAGTTGGTGGGGGTGCAAAACCAAAGAAACCGCGACCAAAAATTGCCATTGTGCCAGCAGATGACAAAACAGTGCCCGGAAAGCCGATCCCAAACCCTCTATTAGGTCTG GACTCCACCCCGAGCACCCAAACTGTGCTTGATCTAAGTGGGAAAACATTACCATCAGGATCCTATAAGGGGGTTA AGCTTGCGAAATTTGGAAAAGAAAATCTGATGACACGGTTCATCGAGGAACCCAGAGAGAATCCTATCGCAACCAG TTtCCCCATCGATTTTAAGAGGGGCAGGGATACCGGCGGGTTCCATAGAAGGGAGTACTCAATCGGATGGGTGGGA GATGAAGTCAAGGTCACTGAGTGGTGCAATCCATCCTGTTCTCCAATCACCGCTGCAGCAAGGCGATTTGAATGCA CTTGTCACCAGTGTCCAGTCACTTGCTCTGAATGTGAACGAGATACTTAATACAGTGAGAAATTTGGACTCTCGGA TGAATCAACTGGAGACAAAAGTAGATCGCATTCTCTCATCTCAGTCTCTAATCCAGACCATCAAGAATGACATAGT TGGACTTAAAGCAGGGATGGCTACTTTAGAAGGAATGATTACAACTGTGAAAATCATGGACCCGGGAGTTCCCAGT AATGTTACTGTGGAAGATGTACGCAAGACACTAAGTAACCATGCTGTTGTTGTGCCAGAATCATTCAATGATAGTT TCTTGACTCAATCTGAAGATGTAATTTCACTTGATGAGTTGGCTCGACCAACTGCAACAAGTGTTAAGAAGATTGT CAGGAAGGTTCCTCCTCAGAAGGATCTGACTGGATTGAAGATTACACTAGAGCAATTGGCAAAGGATTGCATCAGC AAACCGAAGATGAGGGAAGAGTATCTCCTCAAAATCAACCAGGCTTCCAGTGAGGCTCAGCTAATTGACCTCAAGA AAGCAATCATCCGCAGTGCAATTTGATCAAGAAACACCCAATTACACTACACTGGTATGACACTGTACTAACCCTGAGGGTTTTAGAAAAACGATTAACGATAAATAAGCCCGAACACTACACACTACCTGAGGCAGCCATGCCATCCATC AGCATTCCCCGCAGACCCCACCAATCCACGTCAATCAAAAAGCGTTCCCAATTGTGATCAACAGTGATGGGGGTG AGAAAGGCGCCTTGGTTAAACAACTACGCACAACCTACTTGAATGACCTAGATACTCATGAGCCACTGGTGACATT CATAAATACCTATGGATTCATCTACGAACAGGATCGGGGGAATACCATTGTCGGAGAGGATCAACTTGGGAAAA AGAGAGGCTGTGACCGCTGCAATGGTTACCCTTGGAATTGGGCCTAATCTACCATTAGGGGAATGTCCTGGGAC AACTGAGGGAATTCCAGGTCACTGTTAGGAAGACATCCAGCAAAGCGGAAGAGATGGTCTTTGAAATTGTTAAGTA TCCGAGAATATTTCGGGGTCATACATTAATCCAGAAAGGACTAGTCTGTGTCTCCGCAGAAAAAATTGTTAAGTCCACCAGGAAAATACAATCTGGAATGGACTATCTCTTCATTCCGACATTTCTCTAGTGACTTTACTGTCCAGCTGCAA TCAAATTTCAGGTACCTGGCCCCATGTTGAAAATGAGATCAAGATACACTCAGAGCTTACAACTTGAACTAATGAT AAGAATCCTGTGTAAGCCCGATTCGCCACTTATGAAGGTCCATACCCCTGACAAGGAGGAAGGAGTGTCTTGTA TCAGTATGGCTGCATGTATGCAACATCTTCAAATCAGGAACAAGAAGGGCAGTGAGTGGCAGGAATACTGGATGA GAAAGTGTGCTAACAGTGCAACTTGAAGTGTGCATTGCAGATATGTGGGACCAACTATCATAATTCATGCCAGAGG TCACATTCCCAAAAGTGCTAAGTTGTTTTTGGAAAGGGTGGATGGAGTGCCATCCACTTCACGAAGTTGTTCCAAGTGTCACTAAAACACTATGGTCCGTGGGCTGTGAGATTACAAAGGCGAAGGCAATAATACAAGAGAGTAGCATCT DESCRIPTION Page 53 / 157 56 CN 121263205 A CTCTTCTCGTGGAGACTACTGACATCATAAGTCCAAAAGTCAAAATTTCATCTAAGCATCGCCGCTTTGGGAAATC AAATTGGGGTCTGTTCAAGAAAACTAAATCACTGCCTAACCTGACGGAGCTGGAATGACTGACCTCTAATCGAGAC TACACCGCCGCAAACTATAGGTGGGTGGTACCTCAGTGATTAATCTTGTAAGCACTGATCGTAGGCTACAACACAC TAATATTATCCAGATTAGAGAGCTTAATTAGCTCTGTATTAATAATAACACTACTATTCCAATAACTGGAATCACC AGCTTGATTTATCTCCAAAATGATTCAAAGAAAACAAATCATATTAAGACTATCCTAAGCACGAACCCATATCGTC CTTCAAATCATGGGTACTATAATTCAATTTCTGGTGGTCTCCTGTCTATTGGCAGGAGCAGGCAGCCTTGATCCAG CAGCCCTCATGCAAATCGGTGTCATTCCAACAAATGTCCGGCAACTTATGTATTATACTGAAGCTTCATCAGCATT CATTGTTGTGAAGTTAATGCCTACAATTGACTCGCCGATTAGTGGATGTAATATAACATCAATTTCAAGCTATAAT GCAACAGTGACAAAACTCCTACAGCCGATCGGTGAGAATTTGGAGACGATTAGGAACCAGTTGATTCCAACTCGGA GGAGACGCCGGTTTGCAGGGGTGGTGATTGGATTAGCTGCATTAGGAGTAGCTACTGCCGCACAGGTCACTGCCGC AGTGGCACTAGTAAAGGCAAATGAAAATGCTGCGGCTATACTCAATCTCAAAAATGCAATCCAAAAAACAAATGCAGCAGTTGCAGATGTGGTCCAGGCCACACAATCACTAGGAACGGCAGTTCAAGCAGTTCAAGATCACATAAACAGTG TGGTAAGTCCAGCAATTACAGCAGCCAATTGTAAGGCCCAAGATGCTATCATTGGCTCAATCCTCAATCTCTATTT GACCGAGTTGACAACCATCTTCCACAATCAAATTACAAACCCTGCATTGAGTCCCATTACAATTCAAGCTTTAAGG ATCCTACTGGGGAGTACCTTGCCGACTGTGGTCGAAAAATCTTTCAATACCCAGATAAGTGCAGCTGAGCTTCTCT CATCAGGGTTATTGACAGGCCAGATTGTGGGATTAGATTTGACCTATATGCAGATGGTCATAAAAATTGAGCTGCC AACTTTAACTGTACAACCTGCAACCCAGATCATAGATCTGGCCACCATTTCTGCATTCATTAACAATCAAGAAGTC ATGGCCCAATTACCAACACGTGTTATGGTGACTGGCAGCTTGATCCAAGCCTATCCCGCATCGCAATGCACCATTA CACCCAACACTGTGTACTGTAGGTATAATGATGCCCAAGTACTCTCAGATGATACTATGGCTTGCCTCCAAGGTAA CTTGACAAGATGCACCTTCTCTCCAGTGGTTGGGAGCTTTCTCACTCGATTCGTGCTGTTCGATGGAATAGTTTAT GCAAATTGCAGGTCGATGTTGTGCAAGTGCATGCAACCTGCTGCTGTGATCCTACAGCCGAGTTCATCCCCTGTAA CTGTCATTGACATGTACAAATGTGTGAGTCTGCAGCTTGACAATCTCAGATTCACCATCACTCAATTGGCCAATGT AACCTACAATAGCACCATCAAGCTTGAATCATCCCAGATCTTGTCTATTGATCCGTTGGATATATCCCAGAATCTA GCTGCGGTGAATAAGAGTCTAAGTGATGCACTACAACACTTAGCACAAAGTGACACATATCTTTCTGCAATCACATCAGCTACGACTACAAGTGTATTATCCATAATAGCAATCTGTCTTGGATCGTTAGGTTTAATATTAATAATCTTGCT CAGTGTAGTTGTGTGGAAGTTATTGACCATTGTCGTTGCTAATCGAAATAGAATGGAGAATTTTGTTTATCATAAA TAAGCATTCCACCACTCACGATCTGATCTCAGTGAGAAAAATCAACCTGCAACTCTTGGAACAAGATAAGACAGTC ATCCATTAGTAATTTTTAAGAAAAAAACGATAGGACCGAACCTAGTATTGAAAGAACCGTCTCGGTCAATCTAGGT AATCGAGCTGATACCGTCTCGGAAAGCTCAAATCGCGCGCCACCatgtcagataacggaccacagaaccagaggaa cgcacccaggattactttcggaggaccaagcgatagcaccgggagcaaccagaatggagagcggagcggagcaaga tccaagcagagacggccccagggcctgccaaacaataccgcatcctggttcaccgccctgacacagcacggcaagg aggacctgaagtttccaaggggacagggagtgcctatcaacaccaatagctcccctgacgatcagatcggctacta taggagggcaacaaggagaatcaggggaggcgacggcaagatgaaggatctgagcccacgctggtacttctactat ctgggaaccggacctgaggcaggcctgccatatggcgccaacaaggacggaatcatctgggtggcaaccgagggcg ccctgaacacaccaaaggatcacatcggcacaagaaatcccgccaacaatgcagcaatcgtgctgcagctgccaca gggaaccacactgcccaagggcttttacgcagagggctctcggggaggcagccaggcatctagcagatcctctagc cggagcagaaactcctctaggaattccaccccaggaagctccaggggcacatcccctgcccgcatggcaggaaacggaggcgacgccgccctggccctgctgctgctggatcgcctgaatcagctggagtccaagatgtctggcaagggaca gcagcagcagcagggacagaccgtgacaaagaagtccgccgccgaggcctctaagaagccaaggcagaagcgcaccgcc Description Page 54 / 157 57 CN 121263205 A acaaaggcctacaacgtgacccaggccttcggcaggcgcggaccagagcagacacagggcaattttggcgaccagg agctgatcaggcagggaaccgattataagcactggcctcagatcgcccagttcgccccatctgccagcgccttctt tggcatgtctagaatcggcatggaggtgacccccagcggcacatggctgacctacacaggcgccatcaagctggac gataaggaccctaacttcaaggatcaggtcatcctgctgaacaagcacatcgacgcctataagacctttcccccta cagagcccaagaaggacaagaagaagaaggccgatgagacacaggccctgcctcagaggcagaagaagcagcagac cgtgacactgctgccagccgccgatctggacgatttctccaaacagctgcagcagagcatgtccagtgccgactcc acccaggcttgaCGTACGACCTGCTATAGGCTATCCACTGCATCATCTCTCCTGCCATACTTCCTACTCACATCAT ATCTATTTTAAAGAAAAAATAGGCCCGAACACTAATCGTGCCGGCAGTGCCACTGCACACACAACACTACACATAC AATACACTACAATGGTTGCAGAAGATGCCCCTGTTAGGGCCACTTGCCGAGTATTATTTCGAACAACAACTTTAAT CTTTCTATGCACACTACTAGCATTAAGCATCTCTATCCTTTATGAGAGTTTAATAACCCAAAAGCAAATCATGAGCCAAGCAGGCTCAACTGGATCTAATTCTGGATTAGGAAGTATCACTGATCTTCTTAATAATATTCTCTCTGTCGCAA ATCAGATTATATATAACTCTGCAGTCGCTCTACCTCTACAATTGGACACTCTTGAATCAACACTCCTTACAGCCAT TAAGTCTCTTCAAACCAGTGACAAGCTAGAACAGAACTGCTCGTGGAGTGCTGCACTGATTAATGATAATAGATAC ATTAATGGCATCAATCAGTTCTATTTTTCAATTGCTGAGGGTCGCAATCTGACACTTGGCCCACTTCTTAATATGC CTAGTTTCATTCCAACTGCCACGACACCAGAGGGCTGCACCAGGATCCCATCATTCTCGCTCACTAAGACACACTG GTGTTATACACACAATGTTATCCTGAATGGATGCCAGGATCATGTATCCTCAAATCAATTTGTTTCTATGGGAATC ATTGAACCCACTTCTGCCGGGTTTCCATTCTTTCGAACCCTAAAGACTCTATATCTCAGCGATGGGGTCAATCGTA AGAGCTGCTCTATCAGTACAGTTCCGGGGGGTTGTATGATGTACTGTTTTGTTTCTACTCAACCAGAGAGGGATGA CTACTTTTCTGCCGCTCCTCCAGAACAACGAATTATTATAATGTACTATAATGATACAATCGTGGAGCGCATAATT AATCCACCCGGGGTACTAGATGTATGGGCAACATTGAACCCAGGAACAGGAAGCGGGGTATATTATTTAGGTTGGG TGCTCTTTCCAATATATGGCGGCGTGATTAAAGGTACGAGTTTATGGAATAATCAAGCAAATAAATACTTTATCCC CCAGATGGTTGCTGCTCTCTGCTCACAAAACCAGGCAACTCAAGTCCAAAATGCTAAGTCATCATACTATAGCAGC TGGTTTGGCAATCGAATGATTCAGTCTGGGATCCTGGCATGTCCTCTTCGACAGGATCTAACCAATGAGTGTTTAGTTCTGCCCTTTTCTAATGATCAGGTGCTTATGGGTGCTGAAGGGAGATTATACATGTATGGTGACTCGGTGTATTA CTATCAAAGAAGCAATAGTTGGTGGCCTATGACCATGCTGTATAAGGTAACCATAACATTCACTAATGGTCAGCCA TCTGCTATATCAGCTCAGAATGTGCCCACACAGCAGGTCCCTAGACCTGGGACAGGAGACTGCTCTGCAACCAATA GATGTCCCGGTTTTTGCTTGACAGGAGTGTATGCCGATGCCTGGTTACTGACCAACCCTTCGTCTACCAGTACATT TGGATCAGAAGCAACCTTCACTGGTTCTTATCTCAACACAGCAACTCAGCGTATCAATCCGACGATGTATATCGCG AACAACACACAGATCATAAGCTCACAGCAATTTGGATCAAGCGGTCAAGAAGCAGCATATGGCCACACAACTTGTT TTAGGGACACAGGCTCTGTTATGGTATACTGTATCTATATTATTGAATTGTCCTCATCTCTCTTAGGACAATTTCA GATTGTCCCATTTATCCGTCAGGTGACACTATCCTAAAGGCAGAAGCCTTCAGGTCTGACCCAGCCAATCAAAGCA TTATACCAGACCATGGCCTACCATCGGCTTTAAAGAAAAAAATAGGCCCGGACGGGTTAGCAACAAGCGGCGGCCG CCACCatgttcgtcttcctggtcctgctgcctctggtctcctcacagtgcgtcaatctgacaactcggactcagct gccacctgcttatactaatagcttcaccagaggcgtgtactatcctgacaaggtgtttagaagctccgtgctgcac tctacacaggatctgtttctgccattctttagcaacgtgacctggttccacGTGatcagcggcaccaatggcacaa agcggttcgacaatcccgtgctgccttttaacgatggcgtgtacttcgcctctATCgagaagagcaacatcatcagaggctggatctttggcaccacactggactccaagacacagtctctgctgatcgtgaacaatgccaccaacgtggtc atcaaggtgtgcgagttccagttttgtaatgatcccttcctgGATcacaagaacaataagagctggatggagtccg agtttagagtgtattctagcgccaacaactgcacatttgagtacgtgagccagcctttcctgatggacctggaggg DESCRIPTION Page 55 / 157 58 CN 121263205 A caagcagggcaatttcaagaacctgagggagttcgtgtttaagaatatcgacggctacttcaaaatctactctaag cacacccccATCATCgtgcgcGAGCCTGAGgacctgcctcagggcttcagcgccctggagcccctggtggatctgc ctatcggcatcaacatcacccggtttcagacactgctggccctgcacagaagctacctgacacccggcgactcctc tagcggatggaccgccggcgctgccgcctactatgtgggctacctccagccccggaccttcctgctgaagtacaac gagaatggcaccatcacagacgcagtggattgcgccctggaccccctgagcgagacaaagtgtacactgaagtcct ttaccgtggagaagggcatctatcagacatccaatttcagggtgcagccaaccgagtctatcgtgcgctttcctaa tatcacaaacctgtgcccatttGACgaggtgttcaacgcaacccgcttcgccagcgtgtacgcctggaataggaag cggatcagcaactgcgtggccgactatagcgtgctgtacaacCTGgccCCCttcTTCacctttaagtgctatggcg tgtcccccacaaagctgaatgacctgtgctttaccaacgtctacgccgattctttcgtgatcaggggcgacgaggtgcgccagatcgcccccggccagacaggcAATatcgcagactacaattataagctgccagacgatttcaccggctgc gtgatcgcctggaacagcaacAAGctggattccaaagtgTCCggcaactacaattatctgtaccggctgtttagaa agagcaatctgaagcccttcgagagggacatctctacagaaatctaccaggccggcAATAAGccttgcaatggcgt gGCCggctttaactgttatttcccactcAAGtcctacTCCttcCGCcccacaTATggcgtgggcCACcagccttac cgcgtggtggtgctgagctttgagctgctgcacgccccagcaacagtgtgcggccccaagaagtccaccaatctgg tgaagaacaagtgcgtgaacttcaacttcaacggcctgAAGggcacaggcgtgctgaccgagtccaacaagaagtt cctgccatttcagcagttcggcagggacatcgcagataccacagacgccgtgcgcgacccacagaccctggagatc ctggacatcacaccctgctctttcggcggcgtgagcgtgatcacacccggcaccaatacaagcaaccaggtggccg tgctgtatcagGGCgtgaattgtaccgaggtgcccgtggctatccacgccgatcagctgaccccaacatggcgggt gtacagcaccggctccaacgtcttccagacaagagccggatgcctgatcggagcagagTACgtgaacaattcctat gagtgcgacatcccaatcggcgccggcatctgtgcctcttaccagacccagacaAAGtctCACagaagagcccgga gcgtggcctcccagtctatcatcgcctataccatgtccctgggcgccgagaacagcgtggcctactctaacaatag catcgccatcccaaccaacttcacaatctctgtgaccacagagatcctgcccgtgtccatgaccaagacatctgtggactgcacaatgtatatctgtggcgattctaccgagtgcagcaacctgctgctccagtacggcagcttttgtaccc agctgAAGagagccctgacaggcatcgccgtggagcaggataagaacacacaggaggtgttcgcccaggtgaagca aatctacaagaccccccctatcaagTACtttggcggcttcaatttttcccagatcctgcctgatccatccaagcct tctaagcggagctttatcgaggacctgctgttcaacaaggtgaccctggccgatgccggcttcatcaagcagtatg gcgattgcctgggcgacatcgcagccagggacctgatctgcgcccagaagtttAAGggcctgaccgtgctgccacc cctgctgacagatgagatgatcgcacagtacacaagcgccctgctggccggcaccatcacatccggatggaccttc ggcgcaggagccgccctccagatcccctttgccatgcagatggcctataggttcaacggcatcggcgtgacccaga atgtgctgtacgagaaccagaagctgatcgccaatcagtttaactccgccatcggcaagatccaggacagcctgtc ctctacagccagcgccctgggcaagctccaggatgtggtgaatCACaacgcccaggccctgaataccctggtgaag cagctgagcagcAAGttcggcgccatctctagcgtgctgaatgacatcTTTagccggctggacaaggtggaggcag aggtgcagatcgaccggctgatcaccggccggctccagagcctccagacctatgtgacacagcagctgatcagggc cgccgagatcagggccagcgccaatctggcagcaaccaagatgtccgagtgcgtgctgggccagtctaagagagtg gacttttgtggcaagggctatcacctgatgtccttccctcagtctgccccacacggcgtggtgtttctgcacgtgacctacgtgcccgcccaggagaagaacttcaccacagcccctgccatctgccacgatggcaaggcccactttccaag ggagggcgtgttcgtgtccaacggcacccactggtttgtgacacagcgcaatttctacgagccccagatcatcacc acagacaacaccttcgtgagcggcaactgtgacgtggtcatcggcatcgtgaacaataccgtgtatgatccactcc agcccgagctggacagctttaaggaggagctggataagtatttcaagaatcacacctcccctgacgtggatctggg Description Page 56 / 157 59 CN 121263205 A cgacatcagcggcatcaatgcctccgtggtgaacatccagaaggagatcgaccgcctgaacgaggtggctaagaat ctgaacgagagcctgatcgacctccaggagctgggcaagtatgagcagtacatcaagtggccctggtacatctggc tgggcttcatcgccggcctgatcgccatcgtgatggtgaccatcatgctgtgctgtatgacatcctgctgttcttg cctgaagggctgctgtagctgtggctcctgctgtaagttattgaccattgtcgttgctaatcgaaatagaatggag aattttgtttatcataaatgaAGTCGACTCATGGAATGCATACCAAACATTATTGACACTAATGACACACAAAATT GGTTTTAAGAAAAACCAAGAGAACAATAGGCCAGAATGGCTGGGTCTCGGGAGATATTACTCCCTGAAGTCCATCT CAATTCACCAATTGTAAAGCATAAGCTATACTATTACATTCTACTTGGAAACCTCCCAAATGAGATCGACCTTGAC GATTTAGGTCCATTACATAATCAAAATTGGAATCAGATAGCACATGAAGAGTCTAACTTAGCTCAACGCTTGGTAAATGTAAGAAATTTTCTAATTACCCACATCCCTGATCTTAGAAAGGGCCATTGGCAAGAGTATGTCAATGTAATACT GTGGCCGCGAATTCTTCCCTTGATCCCGGATTTTAAAATCAATGACCAATTGCCTCTGCTCAAAAATTGGGACAAG TTAGTTAAAGAATCATGTTCAGTAATCAATGCAGGTACTTCCCAGTGCATTCAGAATCTCAGCTATGGACTGACAG GTCGTGGGAACCTCTTTACACGATCACGTGAACTCTCTGGTGACCGCAGGGATATTGATCTTAAGACAGTTGTGGC AGCATGGCATGACTCAGACTGGAAAAGAATAAGTGATTTTTGGATTATGATCAAATTCCAGATGAGACAATTAATT GTTAGGCAAACAGATCATAATGATTCTGATTTAATCACGTATATCGAAAATAGAGAAGGCATAATCATCATAACCC CTGAACTGGTAGCATTATTTAACACTGAGAATCATACACTAACATACATGACCTTTGAAATTGTACTGATGGTTTC AGATATGTACGAAGGTCGTCACAACATTTTATCACTATGCACAGTTAGCACTTACCTGAATCCTCTGAAGAAAAGA ATAACATATTTATTGAGCCTTGTAGATAACTTAGCTTTTCAGATAGGTGATGCTGTATATAACATAATTGCTTTGC TAGAATCCTTTGTATATGCACAGTTGCAAATGTCAGATCCCATCCCAGAACTCAGAGGACAATTCCATGCATTCGT ATGTTCTGAGATTCTTGATGCACTAAGAGGAACTAATAGTTTCACCCAGGATGAATTAAGAACTGTGACAACTAAT TTGATATCCCCATTCCAAGATCTGACCCCAGATCTTACGGCTGAATTGCTCTGTATAATGAGGCTTTGGGGACACC CCATGCTCACTGCCAGTCAAGCTGCAGGAAAGGTACGCGAGTCTATGTGTGCTGGAAAAGTATTAGACTTTCCCACCATTATGAAAACACTAGCCTTTTTCCATACTATTCTGATCAATGGATACAGGAGGAAGCATCATGGAGTATGGCCA CCCTTAAACTTACCGGGTAATGCTTCAAAGGGTCTCACGGAACTTATGAATGACAATACTGAAATAAGCTATGAAT TCACACTTAAGCATTGGAAGGAAGTCTCTCTTATAAAATTCAAGAAATGTTTTGATGCAGACGCAGGTGAGGAACT CAGTATATTTATGAAAGATAAGGCAATTAGTGCCCCAAAACAAGACTGGATGAGTGTGTTTAGAAGAAGCCTAATC AAACAGCGCCATCAGCATCATCAGGTCCCTACCAAATCCATTCAATCGACGGCTGTTGCTAAACTTTCTCGGAG ATGACAAATTCGACCCGAATGTGGAGCTACAGTATGTAACATCAGGTGAGTATCTACATGATGACACGTTTTGTGC ATCATATTCACTAAAAGAGAAGGAAATTAAACCTGATGGTCGAATTTTTGCAAAGTTGACTAAGAGAATGAGATCA TGTCAAGTTATAGCAGAATCTCTTTTAGCGAACCATGCTGGGAAGTTAATGAAAGAGAATGGTGTTGTGATGAATC AGCTATCATTAACAAAATCACTATTAACAATGAGTCAGATTGGAATAATATCCGAGAAAGCTAGAAAGTCAACTCG AGATAACATAAATCAACCTGGTTTCCAGAATATCCAGAGAAATAATCACATCACTCCAAGCAAGTCAATCAGCGA GATCCAAGTGATGACTTTGAATTGGCAGCATCTTTTTTAACTACTGATCTCAAAAAATATTGTTTACAATGGAGGT ACCAGACAATTATCCCATTTGCTCAATCATTAAACAGAATGTATGGTTATCCTCATCTCTTTGAGTGGATTCACTT ACGGCTAATGCGTAGTACACTTTACGTGGGGGATCCCTTCAACCCACCAGCAGATACCAGTCAATTTGATCTAGATAAAGTAATTAATGGAGATATCTTCATTGTATCACCCAGAGGTGGAATTGAAGGGCTGTGTCAAAAGGCTTGGACAA TGATATCTATCGCTGTGATAATTCTATCTGCCACAGAGTCTGGCACACGAGTAATGAGTATGGTGCAGGGAGATAA TCAAGCAATTGCTGTCACCACACGAGTACCAAGGAGCCTGCCGACTCTTGAGAAAAAGACTATTGCTTTTAGATCT TGTAATCTATTCTTTGAGAGGTTAAAATGTAATAATTTTGGATTAGGTCACCATTTGAAAGAACAAGAGACTATCA TTAGTTCTCACTTCTTTGTTTATAGCAAGAGAATATTCTATCAGGGGAGGATTCTAACGCAAGCCTTAAAAAATGC DESCRIPTION Page 57 / 157 60 CN 121263205 A TAGTAAGCTCTGCTTGACAGCTGATGTCCTAGGAGAATGCACCCAATCATCATGTTCTAATCTTGCAACTACTGTC ATGAGGTTAACTGAGAATGGTGTTGAAAAAGATATCTGTTTCTACTTGAATATCTATATGACCATCAAACAGCTCT CCTATGATATCATCTTCCCTCAAGTGTCAATTCCTGGAGATCAGATCACATTAGAATACATAAATAATCCACACCT GGTATCACGATTGGCTCTTTTGCCATCCCAGTTAGGAGGTCTAAACTACCTGTCATGCAGTAGGCTGTTCAATCGA AACATAGGCGACCCGGTGGTTTCCGCAGTTGCAGATCTTAAGAGATTAATTAAATCAGGATGTATGGATTACTGGA TCCTTTATAACTTATTAGGGAGAAAACCGGGAAACGGCTCATGGGCTACTTTAGCAGCTGACCCGTACTCAATCAA TATAGAGTATCAATACCCTCCAACTACAGCTCTTAAGAGGCACACCCAACAAGCTCTGATGGAACTCAGTACGAATCCAATGTTACGTGGCATATTCTCTGACAATGCACAGGCAGAAGAAAATAACCTTGCTAGGTTTCTCCTGGATAGGG AGGTGATCTTTCCGCGTGTAGCTCACATCATCATTGAGCAAACCAGTGTCGGGAGGAGAAAACAGATTCAAGGATA TTTGGATTCAACTAGATCGATAATGAGGAAATCACTAGAAATTAAGCCCTTATCCAATAGGAAGCTTAATGAAATA CTGGATTACAACATCAATTACCTAGCTTACAATTTGGCATTACTCAAGAATGCTATTGAACCTCCGACTTATTTGA AGGCAATGACACTTGAAACATGTAGCATCGACATTGCAAGGAACCTCCGGAAGCTCTCCTGGGCCCCACTCTTGGG TGGGAGAAATCTTGAAGGATTAGAGACGCCAGATCCCATTGAAATTACTGCAGGAGCATTAATTGTTGGATCGGGC TACTGTGAACAGTGTGCTGCAGGAGACAATCGATTCACATGGTTTTTCTTGCCATCTGGTATCGAGATAGGAGGGG ATCCCCGTGATAATCCTCCTATCCGTGTACCGTACATTGGCTCCAGGACTGATGAGAGGAGGGTAGCCTCAATGGC ATACATCAGGGGTGCCTCGAGTAGCTTAAAAGCAGTTCTTAGACTGGCGGGAGTGTACATCTGGGCATTCGGAGAT ACTCTGGAGAATTGGATAGATGCACTGGATTTGTCTCACACTAGAGTTAACATCACACTTGAACAGCTGCAATCCC TCACCCCACTTCCAACCTCTGCCAATCTAACCCATCGGTTGGATGATGGCACAACTACCCTAAAGTTTACTCCTGC GAGCTCTTACACCTTTTCAAGTTTCACTCATATATCAAATGATGAGCAATACCTGACAATTAATGACAAAACTGCA GATTCAAATATAATCTACCAACAGTTAATGATCACTGGACTCGGAATCTTAGAAACATGGAATAATCCCCCAATCAATAGAACATTCGAAGAATCTACCCTACATTTGCACACTGGTGCATCATGTTGTGTCCGACCTGTGGACTCCTGCAT TCTCTCAGAAGCATTAACAGTCAAGCCACATATTACAGTACCGTACAGCAATAAATTTGTATTTGATGAGGACCCG CTATCTGAATATGAAACTGCAAAACTGGAATCGTTATCATTCCAAGCCCAATTAGGCAACATTGATGCTGTAGATA TGACAGGTAAATTAACATTATTGTCCCAATTCACTGCAAGGCAGATTATCAATGCAATCACTGGACTCGATGAGTC TGTCTCTCTTACTAATGATGCCATTGTTGCATCAGACTATGTCTCCAATTGGATTAGTGAATGCATGTATACCAAA TTAGATGAATTATTTATGTATTGTGGGTGGGAACTACTATTGGAACTATCCTATCAAATGTATTATCTGAGGGTAG TTGGGTGGAGTAATATAGTGGATTATTCTTACATGATCTTGAGAAGAATCCCGGGTGCAGCATTAAACAATCTGGC ATCTACATTAAGTCATCCAAAACTTTTCCGACGAGCTATCAACCTAGATATAGTTGCCCCCTTAAATGCTCCTCAT TTTGCATCTCTGGACTACATCAAGATGAGTGTGGATGCAATACTCTGGGGCTGTAAAAGAGTCATCAATGTGCTCT CCAATGGAGGGGACTTAGAATTAGTTGTGACATCTGAAGATAGCCTTATTCTCAGTGACCGATCCATGAATCTCAT TGCAAGGAAATTAACTTTATTATCACTGATTCACCATAATGGTTTGGAACTACCAAAGATTAAGGGGTTCTCTCCT GATGAGAAGTGTTTCGCTTTGACAGAATTTTTGAGGAAAGTGGTGAACTCAGGGTTGAGTTCAATAGAGAACCTAT CAAATTTTATGTACAATGTGGAGAACCCACGGCTTGCAGCATTCGCCAGCAACAATTACTACCTGACCAGAAAATTATTGAATTCAATACGAGATACTGAGTCGGGTCAAGTAGCAGTCACCTCATATTATGAATCATTAGAATATATTGAT AGTCTTAAGCTAACCCCACATGTGCCTGGCACCTCATGCATTGAGGATGATAGTCTATGTACAAATGATTACATAA TCTGGATCATAGAGTCTAATGCAAACTTGGAGAAGTATCCAATTCCAAATAGCCCTGAGGATGATTCCAATTTCCA TAACTTTAAGTTGAATGCTCCATCGCACCATACCTTACGCCCATTAGGGTTGTCATCAACTGCTTGGTATAAGGGT ATAAGCTGCTGCAGGTACCTTGAGCGATTAAAGCTACCACAAGGTGATCATTTATATATTGCAGAGAAGGTAGTGGTG CCAGTATGACAATCATAGAATACCTATTCCCAGGAAGAAAGATATATTACAATTCTTTATTTAGTAGTGGTGACAA Description Page 58 / 157 61 CN 121263205 A TCCCCCACAAAGAAATTATGCACCAATGCCTACTCAGTTCATTGAGAGTGTCCCATACAAGCTCTGGCAAGCACAC ACAGATCAATATCCCGAGATTTTTGAGGACTTCATCCCTCTATGGAACGGAAACGCCGCCATGACTGACATAGGAA TGACAGCTTGTGTAGAATTCATCATCAATCGAGTCGGCCCAAGGACTTGCAGTTTAGTACATGTAGATTTGGAATC AAGTGCAAGCTTAAATCAACAATGCCTGTCAAAGCCGATAATTAATGCTATCATCACTGCTACAACTGTTTTGTGC CCTCATGGGGTGCTTATTCTGAAATATAGTTGGTTGCCATTTACTAGATTTAGTACTTTGATCACTTTCTTATGGT GCTACTTTGAGAGAATCACTGTTCTTAGGAGCACATATTCTGATCCAGCTAATCATGAGGTTTATTTAATTTGTATCCTTGCCAACAACTTTGCATTCCAGACTGTCTCGCAGGCAACAGGAATGGCGATGACTTTAACTGATCAAGGGTTT ACTTTGATATCACCTGAAAGAATAAATCAGTATTGGGATGGTCACTTGAAGCAAGAACGTATCGTAGCAGAAGCAA TTGATAAGGTGGTTCTAGGAGAAAATGCTCTATTTAATTCGAGTGATAATGAATTAATTCTCAAATGTGGAGGGAC ACCAAATGCACGGAATCTCATCGATATCGAGCCAGTCGCAACTTTCATAGAATTTGAACAATTGATCTGCACAATG TTGACAACCCACTTGAAGGAAATAATTGATATAACAAGGTCTGGAACCCAGGATTATGAAAGTTTATTACTCACTC CTTACAATTTAGGTCTTCTTGGTAAAATCAGTACGATAGTGAGATTATTAACAGAAAGGATTCTAAATCATACTAT CAGGAATTGGTTGATCCTCCCACCTTCGCTCCGGATGATCGTGAAGCAGGACTTGGAATTCGGCATATTCAGGATT ACTTCCATCCTCAATTCTGATCGGTTCCTGAAGCTTTCCAAATAGGAAATACTTGATTGCACAAATTAACTGCAG GCTACATTAGGAAATTGATTGAGGGGGATTGCAATATCGATCTAACCAGACCTATCCAAAAGCAAATCTGGAAAGC ATTAGGTTGTGTAGTCTATTGTCACGATCCAATGGATCAAAGGGAGTCAACAGAGTTTATTGATATAAATATTAAT GAAGAAATAGACCGCGGGATCGATGGCGAAGAAATCTAACATATCAAGAATCAGAATTAGTTTAAGAAAAAGAA GAGGATTAATCTTGGTTCCCCTTGGTGGGTCGGCATGGCATCTCCACCTCCTCGCGGTCGACCTGGGCATCCG AAGGAGGACGCAGTCCACTCGGATGGCTAAGGGGACGCCGGGATCCGGCTGCTAACAAAGCCCGAAGGAAGCTGAGTTGGCTGCTGCCACCGCTGAGCAATAACTAGCATAACCCCTTGGGGCCTCTAAACGGGTCTTGAGGGGTTTT TTGCTGAAAGGAGGAACTATATCCGGATCATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGC GTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGA AACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGC CGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCATAGCTCACGCTGTAGGTATCT CAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCCTTA TCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGA TTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGAAC AGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAA ACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATC CTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGAACGAAAACTCACGTTAAGGGATTTTGGTCATGAGATTATC AAAAAGGATCTTCACCTAGATCCTTTTAAATTAAAAATGAAGTTTTAAATCAATCTAAAGTATATATGAGTAAACT TGGTCTGACAGTTACCAATGCTTAATCAGTGAGGCACCTATCTCAGCGATCTGTCTATTTCGTTCATCCATAGTTGCCTGACTCCCCGTCGTGTAGATAACTACGATACGGGAGGGCTTACCATCTGGCCCCAGTGCTGCAATGATACCGCG AGACCCACGCTCACCGGCTCCAGATTTATCAGCAATAAACCAGCCAGCCGGAAGGGCCGAGCGCAGAAGTGGTCCT GCAACTTTATCCGCCTCCATCCAGTCTATTAATTGTTGCCGGGAAGCTAGAGTAAGTAGTTCGCCAGTTAATAGTT TGCGCAACGTTGTTGCCATTGCTACAGGCATCGTGGTGTCACGCTCGTCGTTTGGTATGGCTTCATTCAGCTCCGG TTCCCAACGATCAAGGCGAGTTACATGATCCCCCATGTTGTGCAAAAAAGCGGTTAGCTCCTTCGGTCCTCCGATC GTTGTCAGAAGTAAGTTGGCCGCAGTGTTATCACTCATGGTTATGGCAGCACTGCATAATTCTCTTACTGTCATGC CATCCGTAAGATGCTTTTCTGTGACTGGTGAGTACTCAACCAAGTCATTCTGAGAATAGTGTATGCGGCGACCGAG DESCRIPTION Page 59 / 157 62 CN 121263205 A TTGCTCTTGCCCGGCGTCAATACGGGATAATACCGCGCCACATAGCAGAACTTTAAAAGTGCTCATCATTGGAAAA CGTTCTTCGGGGCGAAAACTCTCAAGGATCTTACCGCTGTTGAGATCCAGTTCGATGTAACCCACTCGTGCACCCA ACTGATCTTCAGCATCTTTTACTTTCACCAGCGTTTCTGGGTGAGCAAAAACAGGAAGGCAAAATGCCGCAAAAAA GGGAATAAGGGCGACACGGAAATGTTGAATACTCATACTCTTCCTTTTTCAATATTATTGAAGCATTTATCAGGGT TATTGTCTCATGAGCGGATACATATTTGAATGTATTTAGAAAAATAAACAAATAGGGGTTCCGCGCACATTTCCCC GAAAAGT(SEQ ID NO:6).
[0200] v.CVL109
[0201] The nucleic acid sequence of CVL109 is:
[0202] GCCACCTGACGTCTAAGAAACCATTATTATCATGACATTAACCTATAAAAATAGGCGTATCACGAGGC CCTTTCGTCTCGCGCGTTTCGGTGATGACGGTGAAAACCTCTGACACATGCAGCTCCCGGAGACGGTCACAGCTTG TCTGTAAGCGGATGCCGGGAGCAGACAAGCCCGTCAGGGCGCGTCAGCGGGTGTTGGCGGGTGTCGGGGCTGGCTT AACTATGCGGCATCAGAGCAGATTGTACTGAGAGTGCACCATATATGCGGTGTGAAATACCGCACAGATGCGTAAG GAGAAAATACCGCATCAGGCTAATACGACTCACTATAGGGACCAAGGGGAAAATGAAGTGGTGACTCAAATCATCG AAGACCCTCGAGATTACATAGGTCCGGAACCTATGGCCTTCGTGACCGACCTCGAGTCAGAGTAGTTCAATAAGGA CCTATCAAGTTTGGGCAATTTTTCGTCCCCGACACAAAAATGTCATCCGTGCTTAAAGCATATGAGCGATTCACGC TCACTCAAGAACTGCAAGATCAGAGTGAGGAAGGTACAATCCCACCTACAACACTAAAACCGGTAATCAGGGTATT TATACTAACCTCTAATAACCCAGAGCTAAGATCCCGGCTTCTTCTATTCTGCCTACGGATTGTTCTCAGTAATGGT GCAAGGGATTCCCATCGCTTTGGAGCATTACTCACAATGTTTTCGCTACCATCAGCCACAATGCTCAATCATGTCA AATTAGCTGACCAGTCACCAGAAGCTGATATCGAAAGGGTAGAGATCGATGGCTTTGAGGAGGGATCATTCCGCTT AATCCCCAATGCTCGTTCAGGTATGAGCCGTGGAGAGATCAATGCCTATGCTGCACTTGCAGAAGATCTACCTGACACACTAAACCATGCAACACCTTTCGTTGATTCCGAAGTCGAGGGAACTGCATGGGATGAGATTGAGACTTTCTTAG ATATGTGTTACAGTGTCCTAATGCAGGCATGGATAGTGACTTGCAAGTGCATGACTGCGCCAGACCAACCTGCTGC TTCTATTGAGAAACGCCTGCAAAAATATCGTCAGCAAGGCAGGATCAACCCGAGATATCTCCTGCAACCGGAGGCT CGACGAATAATCCAGAATGTAATCCGGAAGGGAATGGTGGTCAGACATTTCCTCACCTTTGAACTGCAGCTTGCCC GAGCACAAAGCCTTGTATCAAATAGGTATTATGCTATGGTAGGGGATGTTGGAAAGTATATAGAGAATTGTGGAAT GGGAGGCTTCTTTTTGACACTAAAATATGCATTAGGAACTAGATGGCCCACACTTGCTTTAGCTGCATTTTCAGGA GAGCTAACAAAGCTAAAGTCCCTCATGGCATTATACCAGACCCTTGGTGAGCAGGCCCGATATTTGGCCCTATTGG AGTCACCACATTTGATGGATTTTGCTGCAGCAAACTACCCACTGCTATATAGCTATGCTATGGGAATAGGCTATGT GTTAGATGTCAACATGAGGAACTACGCTTTCTCCAGATCATACATGAACAAGACATATTTCCAATTGGGAATGGAA ACTGCAAGAAAACAACAGGGTGCAGTTGACATGAGGATGGCAGAAGATCTCGGTCTAACTCAAGCCGAACGCACCG AGATGGCAAATACACTTGCCAAATTGACCACAGCAAATCGAGGGGCAGACACCAGGGGAGGAGTCAACCCGTTCTC ATCTGTCACTGGGACAACTCAGGTGCCCGCTGCAGCAACAGGTGACACACTCGAGAGTTACATGGCAGCGGATCGA CTGAGGCAGAGATATGCTGATGCAGGCACCCATGATGATGAGATGCCACCATTGGAAGAGGAGGAAGAGGACGACACATCTGCAGGTCCACGCACTGGACCAACTCTTGAACAAGTGGCCTTGGACATCCAGAACGCAGCAGTTGGAGCTCC CATCCATACAGATGACCTGAATGCCGCACTGGGTGATCTTGACATCTAGACAATTCAGATCCCAATCTAAAATTGA CATACCTAATTGATTAGTTAGATGGAACTACAGTGGATTCCATAAGGTTCCTGCCTACCATCGGCTTTAAAGAAAA AAATAGGCCCGGACGGGTTAGCAACAAGCGACTGCCGGTGCCAACAGCGCAATCCACAATCTACAATGGATCCCAC TGATCTGAGCTTCTCCCCAGATGAGATCAATAAGCTCATAGAGACAGGCCTGAATACTGTAGAGTATTTTACTTCC CAACAAGTCACAGGAACATCCTCTCTTGGAAAGAATACAATACCACCAGGGGTCACAGGACTACTAACCAATGCTG DESCRIPTION Page 60 of 157 63 CN 121263205 A CAGAGGCAAAGATCCAAGAGTCAACTAACCATCAGAAGGGCTCAGTTGGTGGGGGTGCAAAACCAAAGAAACCGCG ACCAAAAATTGCCATTGTGCCAGCAGATGACAAAACAGTGCCCGGAAAGCCGATCCCAAACCCTCTATTAGGTCTG GACTCCACCCCGAGCACCCAAACTGTGCTTGATCTAAGTGGGAAAACATTACCATCAGGATCCTATAAGGGGGTTA AGCTTGCGAAATTTGGAAAAGAAAATCTGATGACACGGTTCATCGAGGAACCCAGAGAGAATCCTATCGCAACCAG TTtCCCCATCGATTTTAAGAGGGGCAGGGATACCGGCGGGTTCCATAGAAGGGAGTACTCAATCGGATGGGTGGGA GATGAAGTCAAGGTCACTGAGTGGTGCAATCCATCCTGTTCTCCAATCACCGCTGCAGCAAGGCGATTTGAATGCACTTGTCACCAGTGTCCAGTCACTTGCTCTGAATGTGAACGAGATACTTAATACAGTGAGAAATTTGGACTCTCGGA TGAATCAACTGGAGACAAAAGTAGATCGCATTCTCTCATCTCAGTCTCTAATCCAGACCATCAAGAATGACATAGT TGGACTTAAAGCAGGGATGGCTACTTTAGAAGGAATGATTACAACTGTGAAAATCATGGACCCGGGAGTTCCCAGT AATGTTACTGTGGAAGATGTACGCAAGACACTAAGTAACCATGCTGTTGTTGTGCCAGAATCATTCAATGATAGTT TCTTGACTCAATCTGAAGATGTAATTTCACTTGATGAGTTGGCTCGACCAACTGCAACAAGTGTTAAGAAGATTGT CAGGAAGGTTCCTCCTCAGAAGGATCTGACTGGATTGAAGATTACACTAGAGCAATTGGCAAAGGATTGCATCAGC AAACCGAAGATGAGGGAAGAGTATCTCCTCAAAATCAACCAGGCTTCCAGTGAGGCTCAGCTAATTGACCTCAAGA AAGCAATCATCCGCAGTGCAATTTGATCAAGAAACACCCAATTACACTACACTGGTATGACACTGTACTAACCCTG AGGGTTTTAGAAAAAACGATTAACGATAAATAAGCCCGAACACTACACACTACCTGAGGCAGCCATGCCATCCATC AGCATTCCCGCAGACCCCACCAATCCACGTCAATCAATAAAAGCGTTCCCAATTGTGATCAACAGTGATGGGGGTG AGAAAGGCCGCTTGGTTAAACAACTACGCACAACCTACTTGAATGACCTAGATACTCATGAGCCACTGGTGACATT CATAAATACCTATGGATTCATCTACGAACAGGATCGGGGGAATACCATTGTCGGAGAGGATCAACTTGGGAAGAAA AGAGAGGCTGTGACCGCTGCAATGGTTACCCTTGGATGTGGGCCTAATCTACCATCATTAGGGAATGTCCTGGGACAACTGAGGGAATTCCAGGCACTGTTAGGAAGACATCCAGCAAAGCGGAAGAGATGGTCTTTGAAATTTGTAAGTA TCCGAGAATATTTCGGGTCATATTAATCCCAGAAAAGACTAGTCTGTGTCTCCGCAGAAAATTTGTTAAGTCA CCAGGGAAAATACAATCTGGAATGGACTATCTCTTCATTCCGACATTTCTGCAGTGTGACTTACTGTTCCAGCTGCAA TCAAATTTCAGGTTACCTGGCCCCATGTTTGAAAATGAGATCAAGATACACTCAGAGGAAGGAAGGAGTGTCTTGTA TCAGTATGGCTGCATGTATGCAACATCTTCAAATCAGGAAACAAGAAGGGCAGTGATGTCTGGCAGGAATACTGGATGAGAATACTGGATGA GAAAAGTGTGCTAACATGCAACTTGAAGTGTCGATTGCAGATATGGGACCAACTATCATATCCATGCCAAGGG TCACATTCCCAAAAAGTGCTAAGTGTTTTTGGAAAGGGTGGATGCTGCCATCCACTTCACGAAGGTGTTCCA AGTGTCACTAAACACTATGGTCCGTGGGCTGTGAGATTACAAAGGCGAAGGCAATAATACAAGAGAGTAGCATCT CTCTTCTCGTGGAGACTACTGACATCATAAGTCCAAAAGTCAAAATTTCATCTAAGCATCGCCGCTTTGGAAAATC AAATTGGGGTCTGTTCAAGAAAACTAAATCACTGCCTAACCTGACGGAGCTGGAATGACTGACCTCTAATCGAGAC TACACCGCCGCAAACTATAGGTGGGTGGTACCTCAAGTGATTGAATCTTGTAAGCACTGATCGTAGGCTAACACAC TAATATTATCCAGATTAGAGAGCTTAATTAGCTCTGTATTAATAATAACACTACTATTCCAATAACTGGAATCACCAGCTTGATTTATCTCCAAAATGATTCAAAGAAAACAAATCATATTAAGACTATCCTAAGCACGAACCCATATCGTC CTTCAAATCATGGGTACTATAATTCAATTTCTGGTGGTCTCCTGTCTATTGGCAGGAGCAGGCAGCCTTGATCCAG CAGCCCTCATGCAAATCGGTGTCATTCCAACAAATGTCCGGCAACTTATGTATTATACTGAAGCTTCATCAGCATT CATTGTTGTGAAGTTAATGCCTACAATTGACTCGCCGATTAGTGGATGTAATATAACATCAATTTCAAGCTATAAT GCAACAGTGACAAAACTCCTACAGCCGATCGGTGAGAATTTGGAGACGATTAGGAACCAGTTGATTCCAACTCGGA GGAGACGCCGGTTTGCAGGGGTGGTGATTGGATTAGCTGCATTAGGAGTAGCTACTGCCGCACAGGTCACTGCCGC AGTGGCACTAGTAAAGGCAAATGAAAATGCTGCGGCTATACTCAATCTCAAAAATGCAATCCAAAAAACAAATGCA DESCRIPTION Page 61 / 157 64 CN 121263205 A GCAGTTGCAGATGTGGTCCAGGCCACACAATCACTAGGAACGGCAGTTCAAGCAGTTCAAGATCACATAAACAGTG TGGTAAGTCCAGCAATTACAGCAGCCAATTGTAAGGCCCAAGATGCTATCATTGGCTCAATCCTCAATCTCTATTT GACCGAGTTGACAACCATCTTCCACAATCAAATTACAAACCCTGCATTGAGTCCCATTACAATTCAAGCTTTAAGG ATCCTACTGGGGAGTACCTTGCCGACTGTGGTCGAAAAATCTTTCAATACCCAGATAAGTGCAGCTGAGCTTCTCT CATCAGGGTTATTGACAGGCCAGATTGTGGGATTAGATTTGACCTATATGCAGATGGTCATAAAAATTGAGCTGCCAACTTTAACTGTACAACCTGCAACCCAGATCATAGATCTGGCCACCATTTCTGCATTCATTAACAATCAAGAAGTC ATGGCCCAATTACCAACACGTGTTATGGTGACTGGCAGCTTGATCCAAGCCTATCCCGCATCGCAATGCACCATTA CACCCAACACTGTGTACTGTAGGTATAATGATGCCCAAGTACTCTCAGATGATACTATGGCTTGCCTCCAAGGTAA CTTGACAAGATGCACCTTCTCTCCAGTGGTTGGGAGCTTTCTCACTCGATTCGTGCTGTTCGATGGAATAGTTTAT GCAAATTGCAGGTCGATGTTGTGCAAGTGCATGCAACCTGCTGCTGTGATCCTACAGCCGAGTTCATCCCCTGTAA CTGTCATTGACATGTACAAATGTGTGAGTCTGCAGCTTGACAATTCTCAGATTCACCATCACTCAATTGGCCAATGT AACCTACAATAGCACCATCAAGCTTGAATCATCCCAGATCTTGTCTATTGATCCGTTGGATATATCCCAGAATCTA GCTGCGGTGAATAAGAGTCTAAGTGATGCACTACAACACTTAGCACAAAGTGACACATATCTTTCTGCAATCACAT CAGCTACGACTACAAGTGTATTATCCATAATAGCAATCTGTCTTGGATCGTTAGGTTTAATATTAATAATCTTGCT CAGTGTAGTTGTGTGGAAGTTATTGACCATTGTCGTTGCTAATCGAAATAGAATGGAGAATTTTGTTTATCATAAA TAAGCATTCCACCACTCACGATCTGATCTCAGTGAGAAAAATCAACCTGCAACTCTTGGAACAAGATAAGACAGTC ATCCATTAGTAATTTTTAAGAAAAAAACGATAGGACCGAACCTAGTATTGAAAGAACCGTCTCGGTCAATCTAGGT AATCGAGCTGATACCGTCTCGGAAAGCTCAAATCGGCGCGCCACCatgtcagataacggaccacagaaccagaggaacgcacccaggattactttcggaggaccaagcgatagcaccgggagcaaccagaatggagagcggagcggagcaaga tccaagcagagacggccccagggcctgccaaacaataccgcatcctggttcaccgccctgacacagcacggcaagg aggacctgaagtttccaaggggacagggagtgcctatcaacaccaatagctcccctgacgatcagatcggctacta taggagggcaacaaggagaatcaggggaggcgacggcaagatgaaggatctgagcccacgctggtacttctactat ctgggaaccggacctgaggcaggcctgccatatggcgccaacaaggacggaatcatctgggtggcaaccgagggcg ccctgaacacaccaaaggatcacatcggcacaagaaatcccgccaacaatgcagcaatcgtgctgcagctgccaca gggaaccacactgcccaagggcttttacgcagagggctctcggggaggcagccaggcatctagcagatcctctagc cggagcagaaactcctctaggaattccaccccaggaagctccaggggcacatcccctgcccgcatggcaggaaacg gaggcgacgccgccctggccctgctgctgctggatcgcctgaatcagctggagtccaagatgtctggcaagggaca gcagcagcagggacagaccgtgacaaagaagtccgccgccgaggcctctaagaagccaaggcagaagcgcaccgcc acaaaggcctacaacgtgacccaggccttcggcaggcgcggaccagagcagacacagggcaattttggcgaccagg agctgatcaggcagggaaccgattataagcactggcctcagatcgcccagttcgccccatctgccagcgccttctt tggcatgtctagaatcggcatggaggtgacccccagcggcacatggctgacctacacaggcgccatcaagctggacgataaggaccctaacttcaaggatcaggtcatcctgctgaacaagcacatcgacgcctataagacctttcccccta cagagcccaagaaggacaagaagaagaaggccgatgagacacaggccctgcctcagaggcagaagaagcagcagac cgtgacactgctgccagccgccgatctggacgatttctccaaacagctgcagcagagcatgtccagtgccgactcc acccaggcttgaCGTACGACCTGCTATAGGCTATCCACTGCATCATCTCTCCTGCCATACTTCCTACTCACATCAT ATCTATTTTAAAGAAAAAATAGGCCCGAACACTAATCGTGCCGGCAGTGCCACTGCACACACAACACTACACATAC AATACACTACAATGGTTGCAGAAGATGCCCCTGTTAGGGCCACTTGCCGAGTATTATTTCGAACAACAACTTTAAT CTTTCTATGCACACTACTAGCATTAAGCATCTCTATCCTTTATGAGAGTTTAATAACCCAAAAGCAAATCATGAGC CAAGCAGGCTCAACTGGATCTAATTCTGGATTAGGAAGTATCACTGATCTTCTTAATAATATTCTCTCTGTCGCAA DESCRIPTION Page 62 / 157 65 CN 121263205 A ATCAGATTATATATAACTCTGCAGTCGCTCTACCTCTACAATTGGACACTCTTGAATCAACACTCCTTACAGCCAT TAAGTCTCTTCAAACCAGTGACAAGCTAGAACAGAACTGCTCGTGGAGTGCTGCACTGATTAATGATAATAGATAC ATTAATGGCATCAATCAGTTCTATTTTTCAATTGCTGAGGGTCGCAATCTGACACTTGGCCCACTTCTTAATATGC CTAGTTTCATTCCAACTGCCACGACACCAGAGGGCTGCACCAGGATCCCATCATTCTCGCTCACTAAGACACACTGGTGTTATACACACAATGTTATCCTGAATGGATGCCAGGATCATGTATCCTCAAATCAATTTGTTTCTATGGGAATC ATTGAACCCACTTCTGCCGGGTTTCCATTCTTTCGAACCCTAAAGACTCTATATCTCAGCGATGGGGTCAATCGTA AGAGCTGCTCTATCAGTACAGTTCCGGGGGGTTGTATGATGTACTGTTTTGTTTCTACTCAACCAGAGAGGGATGA CTACTTTTCTGCCGCTCCTCCAGAACAACGAATTATTATAATGTACTATAATGATACAATCGTGGAGCGCATAATT AATCCACCCGGGGTACTAGATGTATGGGCAACATTGAACCCAGGAACAGGAAGCGGGGTATATTATTTAGGTTGGG TGCTCTTTCCAATATATGGCGGCGTGATTAAAGGTACGAGTTTATGGAATAATCAAGCAAATAAATACTTTATCCC CCAGATGGTTGCTGCTCTCTGCTCACAAAACCAGGCAACTCAAGTCCAAAATGCTAAGTCATCATACTATAGCAGC TGGTTTGGCAATCGAATGATTCAGTCTGGGATCCTGGCATGTCCTCTTCGACAGGATCTAACCAATGAGTGTTTAG TTCTGCCCTTTTCTAATGATCAGGTGCTTATGGGTGCTGAAGGGAGATTATACATGTATGGTGACTCGGTGTATTA CTATCAAAGAAGCAATAGTTGGTGGCCTATGACCATGCTGTATAAGGTAACCATAACATTCACTAATGGTCAGCCA TCTGCTATATCAGCTCAGAATGTGCCCACACAGCAGGTCCCTAGACCTGGGACAGGAGACTGCTCTGCAACCAATA GATGTCCCGGTTTTTGCTTGACAGGAGTGTATGCCGATGCCTGGTTACTGACCAACCCTTCGTCTACCAGTACATT TGGATCAGAAGCAACCTTCACTGGTTCTTATCTCAACACAGCAACTCAGCGTATCAATCCGACGATGTATATCGCGAACAACACACAGATCATAAGCTCACAGCAATTTGGATCAAGCGGTCAAGAAGCAGCATATGGCCACACAACTTGTT TTAGGGACACAGGCTCTGTTATGGTATACTGTATCTATATTATTGAATTGTCCTCATCTCTCTTAGGACAATTTCA GATTGTCCCATTTATCCGTCAGGTGACACTATCCTAAAGGCAGAAGCCTTCAGGTCTGACCCAGCCAATCAAAGCA TTATACCAGACCATGGCCTACCATCGGCTTTAAAGAAAAAAATAGGCCCGGACGGGTTAGCAACAAGCGGCGGCCG CCACCatgttcgtcttcctggtcctgctgcctctggtctcctcacagtgcgtcaatctgatcactcggactcagtc ctatactaatagcttcaccagaggcgtgtactatcctgacaaggtgtttagaagctccgtgctgcactctacacag gatctgtttctgccattctttagcaacgtgacctggttccacgccatcagcggcaccaatggcacaaagcggttcg acaatcccgtgctgccttttaacgatggcgtgtacttcgcctctaccgagaagagcaacatcatcagaggctggat ctttggcaccacactggactccaagacacagtctctgctgatcgtgaacaatgccaccaacgtggtcatcaaggtg tgcgagttccagttttgtaatgatcccttcctggacgtgtactatcacaagaacaataagagctggatggagtccg agtttagagtgtattctagcgccaacaactgcacatttgagtacgtgagccagcctttcctgatggacctggaggg caagcagggcaatttcaagaacctgagggagttcgtgtttaagaatatcgacggctacttcaaaatctactctaag cacacccccatcaacctgggccgcgacctgcctcagggcttcagcgccctggagcccctggtggatctgcctatcggcatcaacatcacccggtttcagacactgctggccctgcacagaagctacctgacacccggcgactcctctagcgg atggaccgccggcgctgccgcctactatgtgggctacctccagccccggaccttcctgctgaagtacaacgagaat ggcaccatcacagacgcagtggattgcgccctggaccccctgagcgagacaaagtgtacactgaagtcctttaccg tggagaagggcatctatcagacatccaatttcagggtgcagccaaccgagtctatcgtgcgctttcctaatatcac aaacctgtgcccatttgacgaggtgttcaacgcaacccgcttcgccagcgtgtacgcctggaataggaagcggatc agcaactgcgtggccgactatagcgtgctgtacaacctggcccccttcttcgcctttaagtgctatggcgtgtccc ccacaaagctgaatgacctgtgctttaccaacgtctacgccgattctttcgtgatcaggggcaacgaggtgtccca gatcgcccccggccagacaggcaatatcgcagactacaattataagctgccagacgatttcaccggctgcgtgatc gcctggaacagcaacaagctggattccaaagtgggcggcaactacaattatagataccggctgtttagaaagagca DESCRIPTION Page 63 of 157 Page 66 CN 121263205 A atctgaagcccttcgagagggacatctctacagaaatctaccaggccggcaataagccttgcaatggcgtggccgg cgtgaactgttatttcccactccagtcctacggcttccgccccacatatggcgtgggccaccagccttaccgcgtg gtggtgctgagctttgagctgctgcacgccccagcaacagtgtgcggccccaagaagtccaccaatctggtgaagaacaagtgcgtgaacttcaacttcaacggcctgaccggcacaggcgtgctgaccgagtccaacaagaagttcctgcc atttcagcagttcggcagggacatcgcagataccacagacgccgtgcgcgacccacagaccctggagatcctggac atcacaccctgctctttcggcggcgtgagcgtgatcacacccggcaccaatacaagcaaccaggtggccgtgctgt atcagggcgtgaattgtaccgaggtgcccgtggctatccacgccgatcagctgaccccaacatggcgggtgtacag caccggctccaacgtcttccagacaagagccggatgcctgatcggagcagagtacgtgaacaattcctatgagtgc gacatcccaatcggcgccggcatctgtgcctcttaccagacccagacaaagtctcacagaagagcccggagcgtgg cctcccagtctatcatcgcctataccatgtccctgggcgccgagaacagcgtggcctactctaacaatagcatcgc catcccaaccaacttcacaatctctgtgaccacagagatcctgcccgtgtccatgaccaagacatctgtggactgc acaatgtatatctgtggcgattctaccgagtgcagcaacctgctgctccagtacggcagcttttgtacccagctga agagagccctgacaggcatcgccgtggagcaggataagaacacacaggaggtgttcgcccaggtgaagcaaatcta caagaccccccctatcaagtactttggcggcttcaatttttcccagatcctgcctgatccatccaagccttctaag cggagctttatcgaggacctgctgttcaacaaggtgaccctggccgatgccggcttcatcaagcagtatggcgatt gcctgggcgacatcgcagccagggacctgatctgcgcccagaagtttaatggcctgaccgtgctgccacccctgctgacagatgagatgatcgcacagtacacaagcgccctgctggccggcaccatcacatccggatggaccttcggcgca ggagccgccctccagatcccctttgccatgcagatggcctataggttcaacggcatcggcgtgacccagaatgtgc tgtacgagaaccagaagctgatcgccaatcagtttaactccgccatcggcaagatccaggacagcctgtcctctac agccagcgccctgggcaagctccaggatgtggtgaatcacaacgcccaggccctgaataccctggtgaagcagctg agcagcaagttcggcgccatctctagcgtgctgaatgacatcctgagccggctggacaaggtggaggcagaggtgc agatcgaccggctgatcaccggccggctccagagcctccagacctatgtgacacagcagctgatcagggccgccga gatcagggccagcgccaatctggcagcaaccaagatgtccgagtgcgtgctgggccagtctaagagagtggacttt tgtggcaagggctatcacctgatgtccttccctcagtctgccccacacggcgtggtgtttctgcacgtgacctacg tgcccgcccaggagaagaacttcaccacagcccctgccatctgccacgatggcaaggcccactttccaagggaggg cgtgttcgtgtccaacggcacccactggtttgtgacacagcgcaatttctacgagccccagatcatcaccacagac aacaccttcgtgagcggcaactgtgacgtggtcatcggcatcgtgaacaataccgtgtatgatccactccagcccg agctggacagctttaaggaggagctggataagtatttcaagaatcacacctcccctgacgtggatctgggcgacat cagcggcatcaatgcctccgtggtgaacatccagaaggagatcgaccgcctgaacgaggtggctaagaatctgaacgagagcctgatcgacctccaggagctgggcaagtatgagcagtacatcaagtggccctggtacatctggctgggct tcatcgccggcctgatcgccatcgtgatggtgaccatcatgctgtgctgtatgacatcctgctgttcttgcctgaa gggctgctgtagctgtggctcctgctgtaagttattgaccattgtcgttgctaatcgaaatagaatggagaatttt gtttatcataaatgaAGTCGACTCATGGAATGCATACCAAACATTATTGACACTAATGACACACAAAATTGGTTTT AAGAAAAACCAAGAGAACAATAGGCCAGAATGGCTGGGTCTCGGGAGATATTACTCCCTGAAGTCCATCTCAATTC ACCAATTGTAAAGCATAAGCTATACTATTACATTCTACTTGGAAACCTCCCAAATGAGATCGACCTTGACGATTTA GGTCCATTACATAATCAAAATTGGAATCAGATAGCACATGAAGAGTCTAACTTAGCTCAACGCTTGGTAAATGTAA GAAATTTTCTAATTACCCACATCCCTGATCTTAGAAAGGGCCATTGGCAAGAGTATGTCAATGTAATACTGTGGCC GCGAATTCTTCCCTTGATCCCGGATTTTAAAATCAATGACCAATTGCCTCTGCTCAAAAATTGGGACAAGTTAGTT AAAGAATCATGTTCAGTAATCAATGCAGGTACTTCCCAGTGCATTCAGAATCTCAGCTATGGACTGACAGGTCGTG Description Page 64 / 157 67 CN 121263205 A GGAACCTCTTTACACGATCACGTGAACTCTCTGGTGACCGCAGGGATATTGATCTTAAGACAGTTGTGGCAGCATG GCATGACTCAGACTGGAAAAGAATAAGTGATTTTTGGATTATGATCAAATTCCAGATGAGACAATTAATTGTTAGGCAAACAGATCATAATGATTCTGATTTAATCACGTATATCGAAAATAGAGAAGGCATAATCATCATAACCCCTGAAC TGGTAGCATTATTTAACACTGAGAATCATACACTAACATACATGACCTTTGAAATTGTACTGATGGTTTCAGATAT GTACGAAGGTCGTCACAACATTTTATCACTATGCACAGTTAGCACTTACCTGAATCCTCTGAAGAAAAGAATAACA TATTTATTGAGCCTTGTAGATAACTTAGCTTTTCAGATAGGTGATGCTGTATATAACATAATTGCTTTGCTAGAAT CCTTTGTATATGCACAGTTGCAAATGTCAGATCCCATCCCAGAACTCAGAGGACAATTCCATGCATTCGTATGTTC TGAGATTCTTGATGCACTAAGAGGAACTAATAGTTTCACCCAGGATGAATTAAGAACTGTGACAACTAATTTGATA TCCCCATTCCAAGATCTGACCCCAGATCTTACGGCTGAATTGCTCTGTATAATGAGGCTTTGGGGACACCCCATGC TCACTGCCAGTCAAGCTGCAGGAAAGGTACGCGAGTCTATGTGTGCTGGAAAAGTATTAGACTTTCCCACCATTAT GAAAACACTAGCCTTTTTCCATACTATTCTGATCAATGGATACAGGAGGAAGCATCATGGAGTATGGCCACCCTTA AACTTACCGGGTAATGCTTCAAAGGGTCTCACGGAACTTATGAATGACAATACTGAAATAAGCTATGAATTCACAC TTAAGCATTGGAAGGAAGTCTCTCTTATAAAATTCAAGAAATGTTTTGATGCAGACGCAGGTGAGGAACTCAGTAT ATTTATGAAAGATAAGGCAATTAGTGCCCCAAAACAAGACTGGATGAGTGTGTTTAGAAGAAGCCTAATCAAACAG CGCCATCAGCATCATCAGGTCCCCCTACCAAATCCATTCAATCGACGGCTGTTGCTAAACTTTCTCGGAGATGACAAATTCGACCCGAATGTGGAGCTACAGTATGTAACATCAGGTGAGTATCTACATGATGACACGTTTTGTGCATCATA TTCACTAAAAGAGAAGGAAATTAAACCTGATGGTCGAATTTTTGCAAAGTTGACTAAGAGAATGAGATCATGTCAA GTTATAGCAGAATCTCTTTTAGCGAACCATGCTGGGAAGTTAATGAAAGAGAATGGTGTTGTGATGAATCAGCTAT CATTAACAAAATCACTATTAACAATGAGTCAGATTGGAATAATATCCGAGAAAGCTAGAAAGTCAACTCGAGATAA CATAAATCAACCTGGTTTCCAGAATATCCAGAGAAATAATCACATCACTCCAAGCAAGTCAATCAGCGATCCA AGTGATGACTTTGAATTGGCAGCATCTTTTTTAACTACTGATCTCAAAAAATATTGTTTACAATGGAGGTACCAGA CAATTATCCCATTTGCTCAATCATTAAACAGAATGTATGGTTATCCTCATCTCTTTGAGTGGATTCACTTACGGCT AATGCGTAGTACACTTTACGTGGGGGATCCCTTCAACCCACCAGCAGATACCAGTCAATTTGATCTAGATAAAGTA ATTAATGGAGATATCTTCATTGTATCACCCAGAGGTGGAATTGAAGGGCTGTGTCAAAAGGCTTGGACAATGATAT CTATCGCTGTGATAATTCTATCTGCCACAGAGTCTGGCACACGAGTAATGAGTATGGTGCAGGGAGATAATCAAGC AATTGCTGTCACCACACGAGTACCAAGGAGCCTGCCGACTCTTGAGAAAAAGACTATTGCTTTTAGATCTTGTAAT CTATTCTTTGAGAGGTTAAAATGTAATAATTTTGGATTAGGTCACCATTTGAAAGAACAAGAGACTATCATTAGTT CTCACTTCTTGTTTATAGCAAGAGAATATTCTATTCAGGGGAGGATTCTAACGCAAGCCTTAAAAAATGCTAGTAAGCTCTGCTTGACAGCTGATGTCCTAGGAGAATGCACCCAATCATCATGTTCTAATCTTGCAACTACTGTCATGAGG TTAACTGAGAATGGTGTTGAAAAAGATATCTGTTTCTACTTGAATATCTATATGACCATCAAACAGCTCTCCTATG ATATCATCTTCCCTCAAGTGTCAATTCCTGGAGATCAGATCACATTAGAATACATAAATAATCCACACCTGGTATC ACGATTGGCTCTTTTGCCATCCCAGTTAGGAGGTCTAAACTACCTGTCATGCAGTAGGCTGTTCAATCGAAACATA GGCGACCCGGTGGTTTCCGCAGTTGCAGATCTTAAGAGATTAATTAAATCAGGATGTATGGATTACTGGATCCTTT ATAACTTATTAGGGAGAAAACCGGGAAACGGCTCATGGGCTACTTTAGCAGCTGACCCGTACTCAATCAATATAGA GTATCAATACCCTCCAACTACAGCTCTTAAGAGGCACACCCAACAAGCTCTGATGGAACTCAGTACGAATCCAATG TTACGTGGCATATTCTCTGACAATGCACAGGCAGAAGAAAATAACCTTGCTAGGTTTCTCCTGGATAGGGAGGTGA TCTTTCCGCGTGTAGCTCACATCATCATTGAGCAAACCAGTGTCGGGAGGAGAAAACAGATTCAAGGATATTTGGA TTCAACTAGATCGATAATGAGGAAATCACTAGAAATTAAGCCCTTATCCAATAGGAAGCTTAATGAAATACTGGAT TACAACATCAATTACCTAGCTTACAATTTGGCATTACTCAAGAATGCTATTGAACCTCCGACTTATTTGAAGGCAA DESCRIPTION Page 65 / 157 68 CN 121263205 A TGACACTTGAAACATGTAGCATCGACATTGCAAGGAACCTCCGGAAGCTCTCCTGGGCCCCACTCTTGGGTGGGAGAAATCTTGAAGGATTAGAGACGCCAGATCCCATTGAAATTACTGCAGGAGCATTAATTGTTGGATCGGGCTACTGT GAACAGTGTGCTGCAGGAGACAATCGATTCACATGGTTTTTCTTGCCATCTGGTATCGAGATAGGAGGGGATCCCC GTGATAATCCTCCTATCCGTGTACCGTACATTGGCTCCAGGACTGATGAGAGGAGGGTAGCCTCAATGGCATACAT CAGGGGTGCCTCGAGTAGCTTAAAAGCAGTTCTTAGACTGGCGGGAGTGTACATCTGGGCATTCGGAGATACTCTG GAGAATTGGATAGATGCACTGGATTTGTCTCACACTAGAGTTAACATCACACTTGAACAGCTGCAATCCCTCACCC CACTTCCAACCTCTGCCAATCTAACCCATCGGTTGGATGATGGCACAACTACCCTAAAGTTTACTCCTGCGAGCTC TTACACCTTTTCAAGTTTCACTCATATATCAAATGATGAGCAATACCTGACAATTAATGACAAAACTGCAGATTCA AATATAATCTACCAACAGTTAATGATCACTGGACTCGGAATCTTAGAAACATGGAATAATCCCCCAATCAATAGAA CATTCGAAGAATCTACCCTACATTTGCACACTGGTGCATCATGTTGTGTCCGACCTGTGGACTCCTGCATTCTCTC AGAAGCATTAACAGTCAAGCCACATATTACAGTACCGTACAGCAATAAATTTGTATTTGATGAGGACCCGCTATCT GAATATGAAACTGCAAAACTGGAATCGTTATCATTCCAAGCCCAATTAGGCAACATTGATGCTGTAGATATGACAG GTAAATTAACATTATTGTCCCAATTCACTGCAAGGCAGATTATCAATGCAATCACTGGACTCGATGAGTCTGTCTC TCTTACTAATGATGCCATTGTTGCATCAGACTATGTCTCCAATTGGATTAGTGAATGCATGTATACCAAATTAGATGAATTATTTATGTATTGTGGGTGGGAACTACTATTGGAACTATCCTATCAAATGTATTATCTGAGGGTAGTTGGGT GGAGTAATATAGTGGATTATTCTTACATGATCTTGAGAAGAATCCCGGGTGCAGCATTAAACAATCTGGCATCTAC ATTAAGTCATCCAAAACTTTTCCGACGAGCTATCAACCTAGATATAGTTGCCCCCTTAAATGCTCCTCATTTTGCA TCTCTGGACTACATCAAGATGAGTGTGGATGCAATACTCTGGGGCTGTAAAAGAGTCATCAATGTGCTCTCCAATG GAGGGGACTTAGAATTAGTTGTGACATCTGAAGATAGCCTTATTCTCAGTGACCGATCCATGAATCTCATTGCAAG GAAATTAACTTTATTATCACTGATTCACCATAATGGTTTGGAACTACCAAAGATTAAGGGGTTCTCTCCTGATGAG AAGTGTTTCGCTTTGACAGAATTTTTGAGGAAAGTGGTGAACTCAGGGTTGAGTTCAATAGAGAACCTATCAAATT TTATGTACAATGTGGAGAACCCACGGCTTGCAGCATTCGCCAGCAACAATTACTACCTGACCAGAAAATTATTGAA TTCAATACGAGATACTGAGTCGGGTCAAGTAGCAGTCACCTCATATTATGAATCATTAGAATATATTGATAGTCTT AAGCTAACCCCACATGTGCCTGGCACCTCATGCATTGAGGATGATAGTCTATGTACAAATGATTACATAATCTGGA TCATAGAGTCTAATGCAAACTTGGAGAAGTATCCAATTCCAAATAGCCCTGAGGATGATTCCAATTTCCATAACTT TAAGTTGAATGCTCCATCGCACCATACCTTACGCCCATTAGGGTTGTCATCAACTGCTTGGTATAAGGGTATAAGC TGCTGCAGGTACCTTGAGCGATTAAAGCTACCACAAGGTGATCATTTATATATTGCAGAAGGTAGTGGTGCCAGTATGACAATCATAGAATACCTATTCCCAGGAAGAAAGATATATTACAATTCTTTATTTAGTAGTGGTGACAATCCCCC ACAAAGAAATTATGCACCAATGCCTACTCAGTTCATTGAGAGTGTCCCATACAAGCTCTGGCAAGCACACACAGAT CAATATCCCGAGATTTTTGAGGACTTCATCCCTCTATGGAACGGAAACGCCGCCATGACTGACATAGGAATGACAG CTTGTGTAGAATTCATCATCAATCGAGTCGGCCCAAGGACTTGCAGTTTAGTACATGTAGATTTGGAATCAAGTGC AAGCTTAAATCAACAATGCCTGTCAAAGCCGATAATTAATGCTATCATCACTGCTACAACTGTTTTGTGCCCTCAT GGGGTGCTTATTCTGAAATATAGTTGGTTGCCATTTACTAGATTTAGTACTTTGATCACTTTCTTATGGTGCTACT TTGAGAGAATCACTGTTCTTAGGAGCACATATTCTGATCCAGCTAATCATGAGGTTTATTTAATTTGTATCCTTGC CAACAACTTTGCATTCCAGACTGTCTCGCAGGCAACAGGAATGGCGATGACTTTAACTGATCAAGGGTTTACTTTG ATATCACCTGAAAGAATAAATCAGTATTGGGATGGTCACTTGAAGCAAGAACGTATCGTAGCAGAAGCAATTGATA AGGTGGTTCTAGGAGAAAATGCTCTATTTAATTCGAGTGATAATGAATTAATTCTCAAATGTGGAGGGACACCAAA TGCACGGAATCTCATCGATATCGAGCCAGTCGCAACTTTCATAGAATTTGAACAATTGATCTGCACAATGTTGACA ACCCACTTGAAGGAAATAATTGATATAACAAGGTCTGGAACCCAGGATTATGAAAGTTTATTACTCACTCCTTACA DESCRIPTION Page 66 / 157 69 CN 121263205 AATTTAGGTCTTCTTGGTAAAATCAGTACGATAGTGAGATTATTAACAGAAAGGATTCTAAATCATACTATCAGGAA TTGGTTGATCCTCCCACCTTCGCTCCGGATGATCGTGAAGCAGGACTTGGAATTCGGCATATTCAGGATTACTTCC ATCCTCAATTCTGATCGGTTCCTGAAGCTTTCTCCAAATAGGAAATACTTGATTGCACAATTAACTGCAGGCTACA TTAGGAAATTGATTGAGGGGGATTGCAATATCGATCTAACCAGACCTATCCAAAAGCAAATCTGGAAAGCATTAGG TTGTGTAGTCTATTGTCACGATCCAATGGATCAAAGGGAGTCAACAGAGTTTATTGATATAAATATTAATGAAGAA ATAGACCGCGGGATCGATGGCGAGGAAATCTAAACATATCAAGAATCAGAATTAGTTTAAGAAAAAAGAAGAGGAT TAATCTTGGTTTTCCCCTTGGTGGGTCGGCATGGCATCTCCACCTCCTCGCGGTCCGACCTGGGCATCCGAAGGAG GACGCACGTCCACTCGGATGGCTAAGGGAGCGGCCGGGGATCCGGCTGCTAACAAAGCCCGAAAGGAAGCTGAGTT GGCTGCTGCCACCGCTGAGCAATAACTAGCATAACCCCTTGGGGCCTCTAAACGGGTCTTGAGGGGTTTTTTGCTG AAAGGAGGAACTATATCCGGATCATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCT GGCGTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCG ACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTA CCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCCGGT AACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCA GAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGAACAGTATT TGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACC GCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGA TCTTTTCTACGGGGTCTGACGCTCAGTGGAACGAAAACTCACGTTAAGGGATTTTGGTCATGAGATTATCAAAAAG GATCTTCACCTAGATCCTTTTAAATTAAAAATGAAGTTTTAAATCAATCTAAAGTATATATGAGTAAACTTGGTCT GACAGTTACCAATGCTTAATCAGTGAGGCACCTATCTCAGCGATCTGTCTATTTCGTTCATCCATAGTTGCCTGAC TCCCCGTCGTGTAGATAACTACGATACGGGAGGGCTTACCATCTGGCCCCAGTGCTGCAATGATACCGCGAGACCC ACGCTCACCGGCTCCAGATTTATCAGCAATAAACCAGCCAGCCGGAAGGGCCGAGCGCAGAAGTGGTCCTGCAACT TTATCCGCCTCCATCCAGTCTATTAATTGTTGCCGGGAAGCTAGAGTAAGTAGTTCGCCAGTTAATAGTTTGCGCA ACGTTGTTGCCATTGCTACAGGCATCGTGGTGTCACGCTCGTCGTTTGGTATGGCTTCATTCAGCTCCGGTTCCCA ACGATCAAGGCGAGTTACATGATCCCCCATGTTGTGCAAAAAAGCGGTTAGCTCCTTCGGTCCTCCGATCGTTGTCAGAAGTAAGTTGGCCGCAGTGTTATCACTCATGGTTATGGCAGCACTGCATAATTCTCTTACTGTCATGCCATCCG TAAGATGCTTTTCTGTGACTGGTGAGTACTCAACCAAGTCATTCTGAGAATAGTGTATGCGGCGACCGAGTTGCTC TTGCCCGGCGTCAATACGGGATAATACCGCGCCACATAGCAGAACTTTAAAAGTGCTCATCATTGGAAAACGTTCT TCGGGGCGAAAACTCTCAAGGATCTTACCGCTGTTGAGATCCAGTTCGATGTAACCCACTCGTGCACCCAACTGAT CTTCAGCATCTTTTACTTTCACCAGCGTTTCTGGGTGAGCAAAAACAGGAAGGCAAAATGCCGCAAAAAAGGGAAT AAGGGCGACACGGAAATGTTGAATACTCATACTCTTCCTTTTTCAATATTATTGAAGCATTTATCAGGGTTATTGT CTCATGAGCGGATACATATTTGAATGTATTTAGAAAAATAAACAAATAGGGGTTCCGCGCACATTTCCCCGAAAAGT (SEQ ID NO:7).
[0203] vi. CVL110
[0204] The nucleic acid sequence of CVL110 is:
[0205] GCCACCTGACGTCTAAGAAACCATTATTATCATGACATTAACCTATAAAAATAGGCGTATCACGAGGC CCTTTCGTCTCGCGCGTTTCGGTGATGACGGTGAAAACCTCTGACACATGCAGCTCCCGGAGACGGTCACAGCTTG TCTGTAAGCGGATGCCGGGAGCAGACAAGCCCGTCAGGGCGCGTCAGCGGGTGTTGGCGGGTGTCGGGGCTGGCTT DESCRIPTION Page 67 / 157 70 CN 121263205 A AACTATGCGGCATCAGAGCAGATTGTACTGAGAGTGCACCATATATGCGGTGTGAAATACCGCACAGATGCGTAAGGAGAAAATACCGCATCAGGCTAATACGACTCACTATAGGGACCAAGGGGAAAATGAAGTGGTGACTCAAATCATCG AAGACCCTCGAGATTACATAGGTCCGGAACCTATGGCCTTCGTGACCGACCTCGAGTCAGAGTAGTTCAATAAGGA CCTATCAAGTTTGGGCAATTTTTCGTCCCCGACACAAAAATGTCATCCGTGCTTAAAGCATATGAGCGATTCACGC TCACTCAAGAACTGCAAGATCAGAGTGAGGAAGGTACAATCCCACCTACAACACTAAAACCGGTAATCAGGGTATT TATACTAACCTCTAATAACCCAGAGCTAAGATCCCGGCTTCTTCTATTCTGCCTACGGATTGTTCTCAGTAATGGT GCAAGGGATTCCCATCGCTTTGGAGCATTACTCACAATGTTTTCGCTACCATCAGCCACAATGCTCAATCATGTCA AATTAGCTGACCAGTCACCAGAAGCTGATATCGAAAGGGTAGAGATCGATGGCTTTGAGGAGGGATCATTCCGCTT AATCCCCAATGCACGTTCAGGTATGAGCCGTGGAGAGATCAATGCCTATGCTGCACTTGCAGAAGATCTACCTGAC ACACTAAACCATGCAACACCTTTCGTTGATTCCGAAGTCGAGGGAACTGCATGGGATGAGATTGAGACTTTCTTAG ATATGTGTTACAGTGTCCTAATGCAGGCATGGATAGTGACTTGCAAGTGCATGACTGCGCCAGACCAACCTGCTGC TTCTATTGAGAAACGCCTGCAAAAATATCGTCAGCAAGGCAGGATCAACCCGAGATATCTCCTGCAACCGGAGGCT CGACGAATAATCCAGAATGTAATCCGGAAGGGAATGGTGGTCAGACATTTCCTCACCTTTGAACTGCAGCTTGCCC GAGCACAAAGCCTTGTATCAAATAGGTATTATGCTATGGTAGGGGATGTTGGAAAGTATATAGAGAATTGTGGAATGGGAGGCTTCTTTTTGACACTAAAATATGCATTAGGAACTAGATGGCCCACACTTGCTTTAGCTGCATTTTCAGGA GAGCTAACAAAGCTAAAGTCCCTCATGGCATTATACCAGACCCTTGGTGAGCAGGCCCGATATTTGGCCCTATTGG AGTCACCACATTTGATGGATTTTGCTGCAGCAAACTACCCACTGCTATATAGCTATGCTATGGGAATAGGCTATGT GTTAGATGTCAACATGAGGAACTACGCTTTCTCCAGATCATACATGAACAAGACATATTTCCAATTGGGAATGGAA ACTGCAAGAAAACAACAGGGTGCAGTTGACATGAGGATGGCAGAAGATCTCGGTCTAACTCAAGCCGAACGCACCG AGATGGCAAATACACTTGCCAAATTGACCACAGCAAATCGAGGGGCAGACACCAGGGGAGGAGTCAACCCGTTCTC ATCTGTCACTGGGACAACTCAGGTGCCCGCTGCAGCAACAGGTGACACACTCGAGAGTTACATGGCAGCGGATCGA CTGAGGCAGAGATATGCTGATGCAGGCACCCATGATGATGAGATGCCACCATTGGAAGAGGAGGAAGAGGACGACA CATCTGCAGGTCCACGCACTGGACCAACTCTTGAACAAGTGGCCTTGGACATCCAGAACGCAGCAGTTGGAGCTCC CATCCATACAGATGACCTGAATGCCGCACTGGGTGATCTTGACATCTAGACAATTCAGATCCCAATCTAAAATTGA CATACCTAATTGATTAGTTAGATGGAACTACAGTGGATTCCATAAGGTTCCTGCCTACCATCGGCTTTAAAGAAAA AAATAGGCCCGGACGGGTTAGCAACAAGCGACTGCCGGTGCCAACAGCGCAATCCACAATCTACAATGGATCCCAC TGATCTGAGCTTCTCCCCAGATGAGATCAATAAGCTCATAGAGACAGGCCTGAATACTGTAGAGTATTTTACTTCCCAACAAGTCACAGGAACATCCTCTCTTGGAAAGAATACAATACCACCAGGGGTCACAGGACTACTAACCAATGCTG CAGAGGCAAAGATCCAAGAGTCAACTAACCATCAGAAGGGCTCAGTTGGTGGGGGTGCAAAACCAAAGAAACCGCG ACCAAAAATTGCCATTGTGCCAGCAGATGACAAAACAGTGCCCGGAAAGCCGATCCCAAACCCTCTATTAGGTCTG GACTCCACCCCGAGCACCCAAACTGTGCTTGATCTAAGTGGGAAAACATTACCATCAGGATCCTATAAGGGGGTTA AGCTTGCGAAATTTGGAAAAGAAAATCTGATGACACGGTTCATCGAGGAACCCAGAGAGAATCCTATCGCAACCAG TTtCCCCATCGATTTTAAGAGGGGCAGGGATACCGGCGGGTTCCATAGAAGGGAGTACTCAATCGGATGGGTGGGA GATGAAGTCAAGGTCACTGAGTGGTGCAATCCATCCTGTTCTCCAATCACCGCTGCAGCAAGGCGATTTGAATGCA CTTGTCACCAGTGTCCAGTCACTTGCTCTGAATGTGAACGAGATACTTAATACAGTGAGAAATTTGGACTCTCGGA TGAATCAACTGGAGACAAAAGTAGATCGCATTCTCTCATCTCAGTCTCTAATCCAGACCATCAAGAATGACATAGT TGGACTTAAAGCAGGGATGGCTACTTTAGAAGGAATGATTACAACTGTGAAAATCATGGACCCGGGAGTTCCCAGT AATGTTACTGTGGAAGATGTACGCAAGACACTAAGTAACCATGCTGTTGTTGTGCCAGAATCATTCAATGATAGTT TCTTGACTCAATCTGAAGATGTAATTTCACTTGATGAGTTGGCTCGACCAACTGCAACAAGTGTTAAGAAGATTGT DESCRIPTION Page 68 / 157 71 CN 121263205 ACAGGAAGGTTCCTCCTCAGAAGGATCTGACTGGATTGAAGATTACACTAGAGCAATTGGCAAAGGATTGCATCAGC AAACCGAAGATGAGGGAAGAGTATCTCCTCAAAATCAACCAGGCTTCCAGTGAGGCTCAGCTAATTGACCTCAAGA AAGCAATCATCCGCAGTGCAATTTGATCAAGAAACACCCAATTACACTACACTGGTATGACACTGTACTAACCCTG AGGGTTTTAGAAAAACGATTAACGATAAATAAGCCCGAACACTACACACTACCTGAGGCAGCCATGCCATCCAT AGCATTCCCGCAGACCCCACCAATCCACGTCAATCAATAAAAGCGTTCCCAATTGTGATCAACAGTGATGGGGGTG AGAAAGGCGCCTTGGTTAAACAACTACGCACAACCTACTTGAATGACCTAGATACTCATGAGCCACTGGTGACATT CATAAATACCTATGGATTCATCTACGAACCAGGATCGGGGGAATACCATTGTCGGAGAGGAATCAACTTGGGAAGAAA AGAGAGGCTTGGACCGCTGCAATGGTTACCCTTGGATGTGGGCCTAATCTACCATCATTAGGAATGTCCTGGGAC AACTGAGGGAATTCCAGGCACTGTTAGGAAGACATCCAGCAAAGCGGAAGAGATGGTCTTTGAAATTGTTAAGTA TCCGAGAATATTTCGGGTCATAATCCAGAAAAGACTAGTCTGTGTCTCCGCAGAAAATTTGTTAAGTCA CCAGGGAAAATACAATCTGGAATGGACTATCTCTTCATTCCGACATTTCTGTCAGTGACTTACTGTTCCAGCTGCAA TCAAATTTCAGGTACCTGGCCCCATGTTGAAAATGAGATCAAGATACACTCAGAGCTTACAACTTGAACTAATGAT AAGAATCCTGTGTAAGCCGATTCGCCACTTATGAAGGTCCATACCCCTGACAAGGAGGGAAGGAGGATGTCTTGTATCAGTATGGCTGCATGTATGCAACATCTTCAAATCAGGAAACAAGAATGGCAGTGAGTGGCAGGAATACTGGATGA GAAAGTGTGCTAACATGCAACTTGAAGTGTCGATTGCAGATATGTGGGGACCAACTATCATAATTCATGCCAGAGG TCACATTCCCAAAAGTGCTAAGTTGTTTTTTGGAAAGGGTGGATGGAGCTGCCATCCACTTCACGAAGTTGTTCCA AGTGTCACTAAAACACTATGGTCCGTGGGCTGTGAGATTACAAAGGCGAAGGCAATAATACAAGAGAGTAGCATCT CTCTTCTCGTGGAGACTACTGACATCATAAGTCCAAAAGTCAAAATTTCATCTAAGCATCGCCGCTTTGTGAAATC AAATTGGGGTCTGTTCAAGAAAACTAAATCACTGCCTAACCTGACGGAGCTGGAATGACTGACCTCTAATCGAGAC TACACCGCCGCAAACTATAGGTGGGTGGTACCTCAGTGATTAATCTTGTAAGCACTGACCGTAGGCTACAACACAC TAATATTATCCAGATTAGAGAGCTTAATTAGCTCTGTATTAATAATAACACTACTATTCCAATAACTGGAATCACC AGCTTGATTTATCTCCAAAATGATTCAAAGAAAACAAATCATATTAAGACTATCCTAAGCACGAACCCATATCGTC CTTCAAATCATGGGTACTATAATTCAATTTCTGGTGGTCTCCTGTCTATTGGCAGGAGCAGGCAGCCTTGATCCAG CAGCCCTCATGCAAATCGGTGTCATTCCAACAAATGTCCGGCAACTTATGTATTATACTGAAGCCTCATCAGCATT CATTGTTGTGAAGTTAATGCCTACAATTGACTCGCCGATTAGTGGATGTAATATAACATCAATTTCAAGCTATAAT GCAACAGTGACAAAACTCCTACAGCCGATCGGTGAGAATTTGGAGACGATTAGGAACCAGTTGATTCCAACTCGGAGGAGACGCCGGTTTGCAGGGGTGGTGATTGGATTAGCTGCATTAGGAGTAGCTACTGCCGCACAGGTCACTGCCGC AGTGGCACTAGTAAAGGCAAATGAAAATGCTGCGGCTATACTCAATCTCAAAAATGCAATCCAAAAAACAAATGCA GCAGTTGCAGATGTGGTCCAGGCCACACAATCACTAGGAACGGCAGTTCAAGCAGTTCAAGATCACATAAACAGTG TGGTAAGTCCAGCAATTACAGCAGCCAATTGTAAGGCCCAAGATGCTATCATTGGCTCAATCCTCAATCTCTATTT GACCGAGTTGACAACCATCTTCCACAATCAAATTACAAACCCTGCATTGAGTCCCATTACAATTCAAGCTTTAAGG ATCCTACTGGGGAGTACCTTGCCGACTGTGGTCGAAAAATCTTTCAATACCCAGATAAGTGCAGCTGAGCTTCTCT CATCAGGGTTATTGACAGGCCAGATTGTGGGATTAGATTTGACCTATATGCAGATGGTCATAAAAATTGAGCTGCC AACTTTAACTGTACAACCTGCAACCCAGATCATAGATCTGGCCACCATTTCTGCATTCATTAACAATCAAGAAGTC ATGGCCCAATTACCAACACGTGTTATGGTGACTGGCAGCTTGATCCAAGCCTATCCCGCATCGCAATGCACCATTA CACCCAACACTGTGTACTGTAGGTATAATGATGCCCAAGTACTCTCAGATGATACTATGGCTTGCCTCCAAGGTAA CTTGACAAGATGCACCTTCTCTCCAGTGGTTGGGAGCTTTCTCACTCGATTCGTGCTGTTCGATGGAATAGTTTAT GCAAATTGCAGGTCGATGTTGTGCAAGTGCATGCAACCTGCTGCTGTGATCCTACAGCCGAGTTCATCCCCTGTAA CTGTCATTGACATGTACAAATGTGTGAGTCTGCAGCTTGACAATCTCAGATTCACCATCACTCAATTGGCCAATGTDescription Page 69 / 157 72 CN 121263205 A AACCTACAATAGCACCATCAAGCTTGAATCATCCCAGATCTTGTCTATTGATCCGTTGGATATATCCCAAAATCTA GCTGCGGTGAATAAGAGTCTAAGTGATGCACTACAACACTTAGCACAAAGTGACACATATCTTTCTGCAATCACAT CAGCTACGACTACAAGTGTATTATCCATAATAGCAATCTGTCTTGGATCGTTAGGTTTAATATTAATAATCTTGCT CAGTGTAGTTGTGTGGAAGTTATTGACCATTGTCGTTGCTAATCGAAATAGAATGGAGAATTTTGTTTATCATAAA TAAGCATTCCACCACTCACGATCTGATCTCAGTGAGAAAAATCAACCTGCAACTCTTGGAACAAGATAAGACAGTC ATCCATTAGTAATTTTTAAGAAAAAAACGATAGGACCGAACCTAGTATTGAAAGAACCGTCTCGGTCAATCTAGGT AATCGAGCTGATACCGTCTCGGAAAGCTCAAATCAGCTAGCCGGCAGTGCCACTGCACACACAACACTACACATAC AATACACTACAATGGTTGCAGAAGATGCCCCTGTTAGGGCCACTTGCCGAGTATTATTTCGAACAACAACTTTAAT CTTTCTATGCACACTACTAGCATTAAGCATCTCTATCCTTTATGAGAGTTTAATAACCCAAAAGCAAATCATGAGC CAAGCAGGCTCAACTGGATCTAATTCTGGATTAGGAAGTATCACTGATCTTCTTAATAATATTCTCTCTGTCGCAA ATCAGATTATATATAACTCTGCAGTCGCTCTACCTCTACAATTGGACACTCTTGAATCAACACTCCTTACAGCCAT TAAGTCTCTTCAAACCAGTGACAAGCTAGAACAGAACTGCTCGTGGAGTGCTGCACTGATTAATGATAATAGATACATTAATGGCATCAATCAGTTCTATTTTTCAATTGCTGAGGGTCGCAATCTGACACTTGGCCCACTTCTTAATATGC CTAGTTTCATTCCAACTGCCACGACACCAGAGGGCTGCACCAGGATCCCATCATTCTCGCTCACTAAGACACACTG GTGTTATACACACAATGTTATCCTGAATGGATGCCAGGATCATGTATCCTCAAATCAATTTGTTTCTATGGGAATC ATTGAACCCACTTCTGCCGGGTTTCCATTCTTTCGAACCCTAAAGACTCTATATCTCAGCGATGGGGTCAATCGTA AGAGCTGCTCTATCAGTACAGTTCCGGGGGGTTGTATGATGTACTGTTTTGTTTCTACTCAACCAGAGAGGGATGA CTACTTTTCTGCCGCTCCTCCAGAACAACGAATTATTATAATGTACTATAATGATACAATCGTGGAGCGCATAATT AATCCACCCGGGGTACTAGATGTATGGGCAACATTGAACCCAGGAACAGGAAGCGGGGTATATTATTTAGGTTGGG TGCTCTTTCCAATATATGGCGGCGTGATTAAAGGTACGAGTTTATGGAATAATCAAGCAAATAAATACTTTATCCC CCAGATGGTTGCTGCTCTCTGCTCACAAAACCAGGCAACTCAAGTCCAAAATGCTAAGTCATCATACTATAGCAGC TGGTTTGGCAATCGAATGATTCAGTCTGGGATCCTGGCATGTCCTCTTCGACAGGATCTAACCAATGAGTGTTTAG TTCTGCCCTTTTCTAATGATCAGGTGCTTATGGGTGCTGAAGGGAGATTATACATGTATGGTGACTCGGTGTATTA CTATCAAAGAAGCAATAGTTGGTGGCCTATGACCATGCTGTATAAGGTAACCATAACATTCACTAATGGTCAGCCA TCTGCTATATCAGCTCAGAATGTGCCCACACAGCAGGTCCCTAGACCTGGGACAGGAGACTGCTCTGCAACCAATAGATGTCCCGGTTTTTGCTTGACAGGAGTGTATGCCGATGCCTGGTTACTGACCAACCCTTCGTCTACCAGTACATT TGGATCAGAAGCAACCTTCACTGGTTCTTATCTCAACACAGCAACTCAGCGTATCAATCCGACGATGTATATCGCG AACAACACACAGATCATAAGCTCACAGCAATTTGGATCAAGCGGTCAAGAAGCAGCATATGGCCACACAACtTGTT TTAGGGACACAGGCTCTGTTATGGTATACTGTATCTATATTATTGAATTGTCCTCATCTCTCTTAGGACAATTTCA GATTGTCCCATTTATCCGTCAGGTGACACTATCCTAAAGGCAGAAGCCTTCAGGTCTGACCCAGCCAATCAAAGCA TTATACCAGACCATGGCCTACCATCGGCTTTAAAGAAAAAAATAGGCCCGGACGGGTTAGCAACAAGCGcGCGGCC GCCACCatgttcgtcttcctggtcctgctgcctctggtctcctcacagtgcgtcaatctgatcactcggactcagt cctatactaatagcttcaccagaggcgtgtactatcctgacaaggtgtttagaagctccgtgctgcactctacaca ggatctgtttctgccattctttagcaacgtgacctggttccacgccatcagcggcaccaatggcacaaagcggttc gacaatcccgtgctgccttttaacgatggcgtgtacttcgcctctaccgagaagagcaacatcatcagaggctgga tctttggcaccacactggactccaagacacagtctctgctgatcgtgaacaatgccaccaacgtggtcatcaaggt gtgcgagttccagttttgtaatgatcccttcctggacgtgtactatcacaagaacaataagagctggatggagtcc gagtttagagtgtattctagcgccaacaactgcacatttgagtacgtgagccagcctttcctgatggacctggagggcaagcagggcaatttcaagaacctgagggagttcgtgtttaagaatatcgacggctacttcaaaatctactctaa DESCRIPTION Page 70 / 157 73 CN 121263205 A gcacacccccatcaacctgggccgcgacctgcctcagggcttcagcgccctggagcccctggtggatctgcctatc ggcatcaacatcacccggtttcagacactgctggccctgcacagaagctacctgacacccggcgactcctctagcg gatggaccgccggcgctgccgcctactatgtgggctacctccagccccggaccttcctgctgaagtacaacgagaa tggcaccatcacagacgcagtggattgcgccctggaccccctgagcgagacaaagtgtacactgaagtcctttacc gtggagaagggcatctatcagacatccaatttcagggtgcagccaaccgagtctatcgtgcgctttcctaatatca caaacctgtgcccatttgacgaggtgttcaacgcaacccgcttcgccagcgtgtacgcctggaataggaagcggat cagcaactgcgtggccgactatagcgtgctgtacaacctggcccccttcttcgcctttaagtgctatggcgtgtcc cccacaaagctgaatgacctgtgctttaccaacgtctacgccgattctttcgtgatcaggggcaacgaggtgtccc agatcgcccccggccagacaggcaatatcgcagactacaattataagctgccagacgatttcaccggctgcgtgat cgcctggaacagcaacaagctggattccaaagtgggcggcaactacaattatagataccggctgtttagaaagagc aatctgaagcccttcgagagggacatctctacagaaatctaccaggccggcaataagccttgcaatggcgtggccggcgtgaactgttatttcccactccagtcctacggcttccgccccacatatggcgtgggccaccagccttaccgcgt ggtggtgctgagctttgagctgctgcacgccccagcaacagtgtgcggccccaagaagtccaccaatctggtgaag aacaagtgcgtgaacttcaacttcaacggcctgaccggcacaggcgtgctgaccgagtccaacaagaagttcctgc catttcagcagttcggcagggacatcgcagataccacagacgccgtgcgcgacccacagaccctggagatcctgga catcacaccctgctctttcggcggcgtgagcgtgatcacacccggcaccaatacaagcaaccaggtggccgtgctg tatcagggcgtgaattgtaccgaggtgcccgtggctatccacgccgatcagctgaccccaacatggcgggtgtaca gcaccggctccaacgtcttccagacaagagccggatgcctgatcggagcagagtacgtgaacaattcctatgagtg cgacatcccaatcggcgccggcatctgtgcctcttaccagacccagacaaagtctcacagaagagcccggagcgtg gcctcccagtctatcatcgcctataccatgtccctgggcgccgagaacagcgtggcctactctaacaatagcatcg ccatcccaaccaacttcacaatctctgtgaccacagagatcctgcccgtgtccatgaccaagacatctgtggactg cacaatgtatatctgtggcgattctaccgagtgcagcaacctgctgctccagtacggcagcttttgtacccagctg aagagagccctgacaggcatcgccgtggagcaggataagaacacacaggaggtgttcgcccaggtgaagcaaatct acaagaccccccctatcaagtactttggcggcttcaatttttcccagatcctgcctgatccatccaagccttctaagcggagctttatcgaggacctgctgttcaacaaggtgaccctggccgatgccggcttcatcaagcagtatggcgat tgcctgggcgacatcgcagccagggacctgatctgcgcccagaagtttaatggcctgaccgtgctgccacccctgc tgacagatgagatgatcgcacagtacacaagcgccctgctggccggcaccatcacatccggatggaccttcggcgc aggagccgccctccagatcccctttgccatgcagatggcctataggttcaacggcatcggcgtgacccagaatgtg ctgtacgagaaccagaagctgatcgccaatcagtttaactccgccatcggcaagatccaggacagcctgtcctcta cagccagcgccctgggcaagctccaggatgtggtgaatcacaacgcccaggccctgaataccctggtgaagcagct gagcagcaagttcggcgccatctctagcgtgctgaatgacatcctgagccggctggacaaggtggaggcagaggtg cagatcgaccggctgatcaccggccggctccagagcctccagacctatgtgacacagcagctgatcagggccgccg agatcagggccagcgccaatctggcagcaaccaagatgtccgagtgcgtgctgggccagtctaagagagtggactt ttgtggcaagggctatcacctgatgtccttccctcagtctgccccacacggcgtggtgtttctgcacgtgacctac gtgcccgcccaggagaagaacttcaccacagcccctgccatctgccacgatggcaaggcccactttccaagggagg gcgtgttcgtgtccaacggcacccactggtttgtgacacagcgcaatttctacgagccccagatcatcaccacaga caacaccttcgtgagcggcaactgtgacgtggtcatcggcatcgtgaacaataccgtgtatgatccactccagcccgagctggacagctttaaggaggagctggataagtatttcaagaatcacacctcccctgacgtggatctgggcgaca tcagcggcatcaatgcctccgtggtgaacatccagaaggagatcgaccgcctgaacgaggtggctaagaatctgaa DESCRIPTION Page 71 of 157 74 CN 121263205 A cgagagcctgatcgacctccaggagctgggcaagtatgagcagtacatcaagtggccctggtacatctggctgggc ttcatcgccggcctgatcgccatcgtgatggtgaccatcatgctgtgctgtatgacatcctgctgttcttgcctga agggctgctgtagctgtggctcctgctgtaagttattgaccattgtcgttgctaatcgaaatagaatggagaattt tgtttatcataaatgaACGCGTGTCGACTCATGGAATGCATACCAAACATTATTGACACTAATGACACACAAAATT GGTTTTAAGAAAAACCAAGAGAACAATAGGCCAGAATGGCTGGGTCTCGGGAGATATTACTCCCTGAAGTCCATCT CAATTCACCAATTGTAAAGCATAAGCTATACTATTACATTCTACTTGGAAACCTCCCAAATGAGATCGACCTTGAC GATTTAGGTCCATTACATAATCAAAATTGGAATCAGATAGCACATGAAGAGTCTAACTTAGCTCAACGCTTGGTAA ATGTAAGAAATTTTCTAATTACCCACATCCCTGATCTTAGAAAGGGCCATTGGCAAGAGTATGTCAATGTAATACT GTGGCCGCGAATTCTTCCCTTGATCCCGGATTTTAAAATCAATGACCAATTGCCTCTGCTCAAAAATTGGGACAAG TTAGTTAAAGAATCATGTTCAGTAATCAATGCAGGTACTTCCCAGTGCATTCAGAATCTCAGCTATGGACTGACAGGTCGTGGGAACCTCTTTACACGATCACGTGAACTCTCTGGTGACCGCAGGGATATTGATCTTAAGACAGTTGTGGC AGCATGGCATGACTCAGACTGGAAAAGAATAAGTGATTTTTGGATTATGATCAAATTCCAGATGAGACAATTAATT GTTAGGCAAACAGATCATAATGATTCTGATTTAATCACGTATATCGAAAATAGAGAAGGCATAATCATCATAACCC CTGAACTGGTAGCATTATTTAACACTGAGAATCATACACTAACATACATGACCTTTGAAATTGTACTGATGGTTTC AGATATGTACGAAGGTCGTCACAACATTTTATCACTATGCACAGTTAGCACTTACCTGAATCCTCTGAAGAAAAGA ATAACATATTTATTGAGCCTTGTAGATAACTTAGCTTTTCAGATAGGTGATGCTGTATATAACATAATTGCTTTGC TAGAATCCTTTGTATATGCACAGTTGCAAATGTCAGATCCCATCCCAGAACTCAGAGGACAATTCCATGCATTCGT ATGTTCTGAGATTCTTGATGCACTAAGAGGAACTAATAGTTTCACCCAGGATGAATTAAGAACTGTGACAACTAAT TTGATATCCCCATTCCAAGATCTGACCCCAGATCTTACGGCTGAATTGCTCTGTATAATGAGGCTTTGGGGACACC CCATGCTCACTGCCAGTCAAGCTGCAGGAAAGGTACGCGAGTCTATGTGTGCTGGAAAAGTATTAGACTTTCCCAC CATTATGAAAACACTAGCCTTTTTCCATACTATTCTGATCAATGGATACAGGAGGAAGCATCATGGAGTATGGCCA CCCTTAAACTTACCGGGTAATGCTTCAAAGGGTCTCACGGAACTTATGAATGACAATACTGAAATAAGCTATGAAT TCACACTTAAGCATTGGAAGGAAGTCTCTCTTATAAAATTCAAGAAATGTTTTGATGCAGACGCAGGTGAGGAACTCAGTATATTTATGAAAGATAAGGCAATTAGTGCCCCAAAACAAGACTGGATGAGTGTGTTTAGAAGAAGCCTAATC AAACAGCGCCATCAGCATCATCAGGTCCCCCTACCAAATCCATTCAATCGACGGCTGTTGCTAAACTTTCTCGGAG ATGACAAATTCGACCCGAATGTGGAGCTACAGTATGTAACATCAGGTGAGTATCTACATGATGACACGTTTTGTGC ATCATATTCACTAAAAGAGAAGGAAATTAAACCTGATGGTCGAATTTTTGCAAAGTTGACTAAGAGAATGAGATCA TGTCAAGTTATAGCAGAATCTCTTTTAGCGAACCATGCTGGGAAGTTAATGAAAGAGAATGGTGTTGTGATGAATC AGCTATCATTAACAAAATCACTATTAACAATGAGTCAGATTGGAATAATATCCGAGAAAGCTAGAAAGTCAACTCG AGATAACATAAATCAACCTGGTTTCCAGAATATCCAGAGAAATAAATCACATCACTCCAAGCAAGTCAATCAGCGA GATCCAAGTGATGACTTTGAATTGGCAGCATCTTTTTTAACTACTGATCTCAAAAAATATTGTTTACAATGGAGGT ACCAGACAATTATCCCATTTGCTCAATCATTAAACAGAATGTATGGTTATTCCTCATCTCTTTGAGTGGATTCACTT ACGGCTAATGCGTAGTACACTTTACGTGGGGGATCCCTTCAACCCACCAGCAGATACCAGTCAATTTGATCTAGAT AAAGTAATTAATGGAGATATCTTCATTGTATCACCCAGAGGTGGAATTGAAGGGCTGTGTCAAAAGGCTTGGACAA TGATATCTATCGCTGTGATAATTCTATCTGCCACAGAGTCTGGCACACGAGTAATGAGTATGGTGCAGGGAGATAA TCAAGCAATTGCTGTCACCACACGAGTACCAAGGAGCCTGCCGACTCTTGAGAAAAGACTATTGCTTTTAGATCTTGTAATCTATTCTTTGAGAGGTTAAAATGTAATAATTTTGGATTAGGTCACCATTTGAAAGAACAAGAGACTATCA TTAGTTCTCACTTCTTTGTTTATAGCAAGAGAATATTCTATCAGGGGAGGATTCTAACGCAAGCCTTAAAAAATGC TAGTAAGCTCTGCTTGACAGCTGATGTCCTAGGAGAATGCACCCAATCATCATGTTCTAATCTTGCAACTACTGTC DESCRIPTION Page 72 / 157 75 CN 121263205 A ATGAGGTTAACTGAGAATGGTGTTGAAAAAGATATCTGTTTCTACTTGAATATCTATATGACCATCAAACAGCTCT CCTATGATATCATCTTCCCTCAAGTGTCAATTCCTGGAGATCAGATCACATTAGAATACATAAATAATCCACACCT GGTATCACGATTGGCTCTTTTGCCATCCCAGTTAGGAGGTCTAAACTACCTGTCATGCAGTAGGCTGTTCAATCGA AACATAGGCGACCCGGTGGTTTCCGCAGTTGCAGATCTTAAGAGATTAATTAAATCAGGATGTATGGATTACTGGA TCCTTTATAACTTATTAGGGAGAAAACCGGGAAACGGCTCATGGGCTACTTTAGCAGCTGACCCGTACTCAATCAA TATAGAGTATCAATACCCTCCAACTACAGCTCTTAAGAGGCACACCCAACAAGCTCTGATGGAACTCAGTACGAAT CCAATGTTACGTGGCATATTCTCTGACAATGCACAGGCAGAAGAAAATAACCTTGCTAGGTTTCTCCTGGATAGGG AGGTGATCTTTCCGCGTGTAGCTCACATCATCATTGAGCAAACCAGTGTCGGGAGGAGAAAACAGATTCAAGGATA TTTGGATTCAACTAGATCGATAATGAGGAAATCACTAGAAATTAAGCCCTTATCCAATAGGAAGCTTAATGAAATACTGGATTACAACATCAATTACCTAGCTTACAATTTGGCATTACTCAAGAATGCTATTGAACCTCCGACTTATTTGA AGGCAATGACACTTGAAACATGTAGCATCGACATTGCAAGGAACCTCCGGAAGCTCTCCTGGGCCCCACTCTTGGG TGGGAGAAATCTTGAAGGATTAGAGACGCCAGATCCCATTGAAATTACTGCAGGAGCATTAATTGTTGGATCGGGC TACTGTGAACAGTGTGCTGCAGGAGACAATCGATTCACATGGTTTTTCTTGCCATCTGGTATCGAGATAGGAGGGG ATCCCCGTGATAATCCTCCTATCCGTGTACCGTACATTGGCTCCAGGACTGATGAGAGGAGGGTAGCCTCAATGGC ATACATCAGGGGTGCCTCGAGTAGCTTAAAAGCAGTTCTTAGACTGGCGGGAGTGTACATCTGGGCATTCGGAGAT ACTCTGGAGAATTGGATAGATGCACTGGATTTGTCTCACACTAGAGTTAACATCACACTTGAACAGCTGCAATCCC TCACCCCACTTCCAACCTCTGCCAATCTAACCCATCGGTTGGATGATGGCACAACTACCCTAAAGTTTACTCCTGC GAGCTCTTACACCTTTTCAAGTTTCACTCATATATCAAATGATGAGCAATACCTGACAATTAATGACAAAACTGCA GATTCAAATATAATCTACCAACAGTTAATGATCACTGGACTCGGAATCTTAGAAACATGGAATAATCCCCCAATCA ATAGAACATTCGAAGAATCTACCCTACATTTGCACACTGGTGCATCATGTTGTGTCCGACCTGTGGACTCCTGCAT TCTCTCAGAAGCATTAACAGTCAAGCCACATATTACAGTACCGTACAGCAATAAATTTGTATTTGATGAGGACCCG CTATCTGAATATGAAACTGCAAAACTGGAATCGTTATCATTCCAAGCCCAATTAGGCAACATTGATGCTGTAGATATGACAGGTAAATTAACATTATTGTCCCAATTCACTGCAAGGCAGATTATCAATGCAATCACTGGACTCGATGAGTC TGTCTCTCTTACTAATGATGCCATTGTTGCATCAGACTATGTCTCCAATTGGATTAGTGAATGCATGTATACCAAA TTAGATGAATTATTTATGTATTGTGGGTGGGAACTACTATTGGAACTATCCTATCAAATGTATTATCTGAGGGTAG TTGGGTGGAGTAATATAGTGGATTATTCTTACATGATCTTGAGAAGAATCCCGGGTGCAGCATTAAACAATCTGGC ATCTACATTAAGTCATCCAAAACTTTTCCCGACGAGCTATCAACCTAGATATAGTTGCCCCCTTAAATGCTCCTCAT TTTGCATCTCTGGACTACATCAAGATGAGTGTGGATGCAATACTCTGGGGCTGTAAAAGAGTCATCAATGTGCTCCT CCAATGGAGGGGACTTAGAATTAGTTGTGACATCTGAAGATAGCCTTATTCTCAGTGACCGATCCATGAATCTCAT TGCAAGGAAATTAACTTTATTATCACTGATTCACCATAATGGTTTGGAACTACCAAAGATTAAGGGGTTCTCTCCT GATGAGAAGTGTTTCGCTTTGACAGAATTTTTGAGGAAAGTGGTGAACTCAGGGTTGAGTTCAATAGAGAACCTAT CAAAATTTTATGTACAATGTGGAGAACCCACGGCTTGCAGCATTCGCCAGCAACAATTACTACCTGACCAGAAAATT ATTGAATTCAATACGAGATACTGAGTCGGGTCAAGTAGCAGTCACCTCATATTATGAATCATTAGAATATATTGAT AGTCTTAAGCTAACCCCACATGTGCCTGGCACCTCATGCATTGAGGATGATAGTCTATGTACAAATGATTACATAA TCTGGATCATAGAGTCTAATGCAAACTTGGAGAAGTATCCAATTCCAAATAGCCCTGAGGATGATTCCAATTTCCATAACTTTAAGTTGAATGCTCCATCGCACCATACCTTACGCCCATTAGGGTTGTCATCAACTGCTTGGTATAAGGGT ATAAGCTGCTGCAGGTACCTTGAGCGATTAAAGCTACCACAAGGTGATCATTTATATATTGCAGAAGGTAGTGGTG CCAGTATGACAATCATAGAATACCTATTCCCAGGAAGAAAGATATATTACAATTCTTTATTTAGTAGTGGTGACAA TCCCCCACAAAGAAATTATGCACCAATGCCTACTCAGTTCATTGAGAGTGTCCCATACAAGCTCTGGCAAGCACAC DESCRIPTION Page 73 / 157 76 CN 121263205 A ACAGATCAATATCCCGAGATTTTTGAGGACTTCATCCCTCTATGGAACGGAAACGCCGCCATGACTGACATAGGAA TGACAGCTTGTGTAGAATTCATCATCAATCGAGTCGGCCCAAGGACTTGCAGTTTAGTACATGTAGATTTGGAATC AAGTGCAAGCTTAAATCAACAATGCCTGTCAAAGCCGATAATTAATGCTATCATCACTGCTACAACTGTTTTGTGC CCTCATGGGGTGCTTATTCTGAAATATAGTTGGTTGCCATTTACTAGATTTAGTACTTTGATCACTTTCTTATGGT GCTACTTTGAGAGAATCACTGTTCTTAGGAGCACATATTCTGATCCAGCTAATCATGAGGTTTATTTAATTTGTAT CCTTGCCAACAACTTTGCATTCCAGACTGTCTCGCAGGCAACAGGAATGGCGATGACTTTAACTGATCAAGGGTTT ACTTTGATATCACCTGAAAGAATAAATCAGTATTGGGATGGTCACTTGAAGCAAGAACGTATCGTAGCAGAAGCAA TTGATAAGGTGGTTCTAGGAGAAAATGCTCTATTTAATTCGAGTGATAATGAATTAATTCTCAAATGTGGAGGGACACCAAATGCACGGAATCTCATCGATATCGAGCCAGTCGCAACTTTCATAGAATTTGAACAATTGATCTGCACAATG TTGACAACCCACTTGAAGGAAATAATTGATAACAAGGTCTGGAACCCCAGGATTATGAAAGTTTATTACTCACTC CTTACAATTTAGGTCTTCTTGGTAAAATCAGTAGATTATTAACAGAAAGGATTCTAAATCATACTAT CAGGAATTGGTTGATCCCACCTTCGCTCCGGATGATGAATCGTGTAAGCAGGACTTGGAATTCGGCATATTCAGGATT ACTTCCATCCTCAATTCGGGTTCCTGAAGCTTTCTCCAAATAGGAAAATACTTGATTGCACAATTAACTGCAG GCTACATTAGGAAATTGATTGAGGGGGATTGCAATATCGATCTAACCAGACCATATCCAAAAGCAAATCTGGGAAAGC ATTAGGTTGTGTAGTCTATTGTCACGATCCAATGGATCAAAGGAGTCAACAGAGTTTATTGATATAAATATTAAT GAAGAAATAGACCGCGGGATCGATGCGGAAGAAATCTAAACATATCAAGAATCAGAATTAGTTTAAGAAAAAAGA GAGGATTAATCTTGGTTTCCCCTTGGTGGTGGGTCGGCATGGCATCTCCACCTCCTCGCGGTCGACCTGGGCATCCG AAGGAGGACGCACGTCCACTCGGATGGCTAAGGGGAGCGGCCGGGGATCCGGCTGAACAAAGCCCGAAAGGAAGC TGAGTTGGCTGCTGCCACCGCTGAGCAATAACTAGCATAACCCTTGGGGCCTCTAAAACGGGTCTGAGGGGTTTT TTGCTGAAAGGAGGAACTATATCCGGATCATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAAGCCGC GTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGC CGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCATAGCTCACGCTGTAGGTATCT CAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCCTTA TCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGA TTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGGAC AGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAA ACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATC CTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGAACGAAAACTCACGTTAAGGGATTTTGGTCATGAGATTATC AAAAAGGATCTTCACCTAGATCCTTTTAAATTAAAAATGAAGTTTTAAATCAATCTAAAGTATATATGAGTAAACT TGGTCTGACAGTTACCAATGCTTAATCAGTGAGGCACCTATCTCAGCGATCTGTCTATTTCGTTCATCCATAGTTG CCTGACTCCCCGTCGTGTAGATAACTACGATACGGGAGGGCTTACCATCTGGCCCCAGTGCTGCAATGATACCGCG AGACCCACGCTCACCGGCTCCAGATTTATCAGCAATAAACCAGCCAGCCGGAAGGGCCGAGCGCAGAAGTGGTCCT GCAACTTTATCCGCCTCCATCCAGTCTATTAATTGTTGCCGGGAAGCTAGAGTAAGTAGTTCGCCAGTTAATAGTTTGCGCAACGTTGTTGCCATTGCTACAGGCATCGTGGTGTCACGCTCGTCGTTTGGTATGGCTTCATTCAGCTCCGG TTCCCAACGATCAAGGCGAGTTACATGATCCCCCATGTTGTGCAAAAAAGCGGTTAGCTCCTTCGGTCCTCCGATC GTTGTCAGAAGTAAGTTGGCCGCAGTGTTATCACTCATGGTTATGGCAGCACTGCATAATTCTCTTACTGTCATGC CATCCGTAAGATGCTTTTCTGTGACTGGTGAGTACTCAACCAAGTCATTCTGAGAATAGTGTATGCGGCGACCGAG TTGCTCTTGCCCGGCGTCAATACGGGATAATACCGCGCCACATAGCAGAACTTTAAAAGTGCTCATCATTGGAAAA DESCRIPTION Page 74 / 157 77 CN 121263205 A CGTTCTTCGGGGCGAAAACTCTCAAGGATCTTACCGCTGTTGAGATCCAGTTCGATGTAACCCACTCGTGCACCCA ACTGATCTTCAGCATCTTTTACTTTCACCAGCGTTTCTGGGTGAGCAAAAACAGGAAGGCAAAATGCCGCAAAAAA GGGAATAAGGGCGACACGGAAATGTTGAATACTCATACTCTTCCTTTTTCAATATTATTGAAGCATTTATCAGGGT TATTGTCTCATGAGCGGATACATATTTGAATGTATTTAGAAAAATAAACAAATAGGGGTTCCGCGCACATTTCCCC GAAAAGT(SEQ ID NO: 8).
[0206] vii. CVL112
[0207] The nucleic acid sequence of CVL112 is:
[0208] GCCACCTGACGTCTAAGAAACCATTATTATCATGACATTAACCTATAAAAATAGGCGTATCACGAGGC CCTTTCGTCTCGCGCGTTTCGGTGATGACGGTGAAAACCTCTGACACATGCAGCTCCCGGAGACGGTCACAGCTTGTCTGTAAGCGGATGCCGGGAGCAGACAAGCCCGTCAGGGCGCGTCAGCGGGTGTTGGCGGGTGTCGGGGCTGGCTT AACTATGCGGCATCAGAGCAGATTGTACTGAGAGTGCACCATATATGCGGTGTGAAATACCGCACAGATGCGTAAG GAGAAAATACCGCATCAGGCTAATACGACTCACTATAGGGACCAAGGGGAAAATGAAGTGGTGACTCAAATCATCG AAGACCCTCGAGATTACATAGGTCCGGAACCTATGGCCTTCGTGACCGACCTCGAGTCAGAGTAGTTCAATAAGGA CCTATCAAGTTTGGGCAATTTTTCGTCCCCGACACAAAAATGTCATCCGTGCTTAAAGCATATGAGCGATTCACGC TCACTCAAGAACTGCAAGATCAGAGTGAGGAAGGTACAATCCCACCTACAACACTAAAACCGGTAATCAGGGTATT TATACTAACCTCTAATAACCCAGAGCTAAGATCCCGGCTTCTTCTATTCTGCCTACGGATTGTTCTCAGTAATGGT GCAAGGGATTCCCATCGCTTTGGAGCATTACTCACAATGTTTTCGCTACCATCAGCCACAATGCTCAATCATGTCA AATTAGCTGACCAGTCACCAGAAGCTGATATCGAAAGGGTAGAGATCGATGGCTTTGAGGAGGGATCATTCCGCTT AATCCCCAATGCTCGTTCAGGTATGAGCCGTGGAGAGATCAATGCCTATGCTGCACTTGCAGAAGATCTACCTGAC ACACTAAACCATGCAACACCTTTCGTTGATTCCGAAGTCGAGGGAACTGCATGGGATGAGATTGAGACTTTCTTAG ATATGTGTTACAGTGTCCTAATGCAGGCATGGATAGTGACTTGCAAGTGCATGACTGCGCCAGACCAACCTGCTGC TTCTATTGAGAAACGCCTGCAAAAATATCGTCAGCAAGGCAGGATCAACCCGAGATATCTCCTGCAACCGGAGGCTCGACGAATAATCCAGAATGTAATCCGGAAGGGAATGGTGGTCAGACATTTCCTCACCTTTGAACTGCAGCTTGCCC GAGCACAAAGCCTTGTATCAAATAGGTATTATGCTATGGTAGGGGATGTTGGAAAGTATATAGAGAATTGTGGAAT GGGAGGCTTCTTTTTGACACTAAAATATGCATTAGGAACTAGATGGCCCACACTTGCTTTAGCTGCATTTTCAGGA GAGCTAACAAAGCTAAAGTCCCTCATGGCATTATACCAGACCCTTGGTGAGCAGGCCCGATATTTGGCCCTATTGG AGTCACCACATTTGATGGATTTTGCTGCAGCAAACTACCCACTGCTATATAGCTATGCTATGGGAATAGGCTATGT GTTAGATGTCAACATGAGGAACTACGCTTTCTCCAGATCATACATGAACAAGACATATTTCCAATTGGGAATGGAA ACTGCAAGAAAACAACAGGGTGCAGTTGACATGAGGATGGCAGAAGATCTCGGTCTAACTCAAGCCGAACGCACCG AGATGGCAAATACACTTGCCAAATTGACCACAGCAAATCGAGGGGCAGACACCAGGGGAGGAGTCAACCCGTTCTC ATCTGTCACTGGGACAACTCAGGTGCCCGCTGCAGCAACAGGTGACACACTCGAGAGTTACATGGCAGCGGATCGA CTGAGGCAGAGATATGCTGATGCAGGCACCCATGATGATGAGATGCCACCATTGGAAGAGGAGGAAGAGGACGACA CATCTGCAGGTCCACGCACTGGACCAACTCTTGAACAAGTGGCCTTGGACATCCAGAACGCAGCAGTTGGAGCTCC CATCCATACAGATGACCTGAATGCCGCACTGGGTGATCTTGACATCTAGACAATTCAGATCCCAATCTAAAATTGA CATACCTAATTGATTAGTTAGATGGAACTACAGTGGATTCCATAAGGTTCCTGCCTACCATCGGCTTTAAAGAAAAAAATAGGCCCGGACGGGTTAGCAACAAGCGACTGCCGGTGCCAACAGCGCAATCCACAATCTACAATGGATCCCAC TGATCTGAGCTTCTCCCCAGATGAGATCAATAAGCTCATAGAGACAGGCCTGAATACTGTAGAGTATTTTACTTCC CAACAAGTCACAGGAACATCCTCTCTTGGAAAGAATACAATACCACCAGGGGTCACAGGACTACTAACCAATGCTG CAGAGGCAAAGATCCAAGAGTCAACTAACCATCAGAAGGGCTCAGTTGGTGGGGGTGCAAAACCAAAGAAACCGCG Description Page 75 / 157 Page 78 CN 121263205 A ACCAAAAATTGCCATTGTGCCAGCAGATGACAAAACAGTGCCCGGAAAGCCGATCCCAAACCCTCTATTAGGTCTG GACTCCACCCCGAGCACCCAAACTGTGCTTGATCTAAGTGGGAAAACATTACCATCAGGATCCTATAAGGGGGTTA AGCTTGCGAAATTTGGAAAAGAAAATCTGATGACACGGTTCATCGAGGAACCCAGAGAGAATCCTATCGCAACCAG TTtCCCCATCGATTTTAAGAGGGGCAGGGATACCGGCGGGTTCCATAGAAGGGAGTACTCAATCGGATGGGTGGGA GATGAAGTCAAGGTCACTGAGTGGTGCAATCCATCCTGTTCTCCAATCACCGCTGCAGCAAGGCGATTTGAATGCA CTTGTCACCAGTGTCCAGTCACTTGCTCTGAATGTGAACGAGATACTTAATACAGTGAGAAATTTGGACTCTCGGA TGAATCAACTGGAGACAAAAGTAGATCGCATTCTCTCATCTCAGTCTCTAATCCAGACCATCAAGAATGACATAGT TGGACTTAAAGCAGGGATGGCTACTTTAGAAGGAATGATTACAACTGTGAAAATCATGGACCCGGGAGTTCCCAGTAATGTTACTGTGGAAGATGTACGCAAGACACTAAGTAACCATGCTGTTGTTGTGCCAGAATCATTCAATGATAGTT TCTTGACTCAATCTGAAGATGTAATTTCACTTGATGAGTTGGCTCGACCAACTGCAACAAGTGTTAAGAAGATTGT CAGGAAGGTTCCTCCTCAGAAGGATCTGACTGGATTGAAGATTACACTAGAGCAATTGGCAAAGGATTGCATCAGC AAACCGAAGATGAGGGAAGAGTATCTCCTCAAAATCAACCAGGCTTCCAGTGAGGCTCAGCTAATTGACCTCAAGA AAGCAATCATCCGCAGTGCAATTTGATCAAGAAACACCCAATTACACTACACTGGTATGACACTGTACTAACCCTG AGGGTTTTAGAAAAAACGATTAACGATAAATAAGCCCGAACACTACACACTACCTGAGGCAGCCATGCCATCCATC AGCATTCCCGCAGACCCCACCAATCCACGTCAATCAATAAAAGCGTTCCCAATTGTGATCAACAGTGATGGGGGTG AGAAAGGCCGCTTGGTTAAACAACTACGCACAACCTACTTGAATGACCTAGATACTCATGAGCCACTGGTGACATT CATAAATACCTATGGATTCATCTACGAACAGGATCGGGGGAATACCATTGTCGGAGAGGATCAACTTGGGAAGAAA AGAGAGGCTGTGACCGCTGCAATGGTTACCCTTGGATGTGGGCCTAATCTACCATCATTAGGGAATGTCCTGGGAC AACTGAGGGAATTCCAGGTCACTGTTAGGAAGACATCCAGCAAAGCGGAAGAGATGGTCTTTGAAATTGTTAAGTA TCCGAGAATATTTCGGGGTCATACATTAATCCAGAAAGGACTAGTCTGTGTCTCCGCAGAAAAATTTGTTAAGTCA CCAGGGAAAATACAATCTGGAATGGACTATCTCTTCATTCCGACATTTCTGTCAGTGACTTACTGTCCAGCTGCAATCAAATTTCAGGTACTGGCCCCATGTTGAAAATGAGATCAAGATACACTCAGAGCTTACAACTTGAACTAATGAT AAGAATCCTGTGTAAGCCCGATTCGCCACTTATGAAGGTCCATACCCCTGACAAGGAGGAAGGAGGATGTCTTGTA TCAGTATGGCTGCATGTATGCAACATCTTCAAATCAGGAACAAGAATGGCAGTGAGTGGCAGGAATACTGGATGA GAAAGTGTGCTAACATGCAACTTGAAGTGTCGATTGCAGATATGGGGACCAACTATCATAGCCAAAAGTGCTAAGTTGTTTTTTGGAAAGGTGGATGGCCATCCACTTCACGAAGTTGTTCCA AGTGTCACTAAACACTATGGTCCGTGGGCTGTGAGATTACAAAGGCGAAGGCAATAATAACAAGAGAGAGAGTAGCATCT CTCTTCTCGTGGAGACTACTGACATCATAAGTCCAAAAGTCAAAATTTCATCTAAGCATCGCGCGCTTGGGAAATC AAATTGGGTCTGTTTCAAGAAAACTAAATCACTGCCTAACCTGACGGAGCTGGAAgctagcGGCAGAAGACCCTT CAGGTCTGACCCAGCCAATCAAAGCATTATACCAGACCATGGCCTACCATCGGCTTTAAAGAAAAAAATAGGCCCG GACGGGTTAGCAACAAGCGGCGGCGCCatgttcgtcttcctggtcctgctgcctctggtctcctcacagtgcgtc aatctgacaactcggactcagctgccacctgcttatactaatagcttcaccagaggcgtgtactatccgacaagg tgtttagaagctccgtgctgcactctacacaggatctgtttctgccattctttagcaacgtgacctggttccacgc catccacgtgagcggcaccaatggcacaaagcggttcgacaatcccgtgctgccttttaacgatggcgtgtacttcgcctctaccgagaagagcaacatcatcagaggctggatctttggcaccacactggactccaagacacagtctctgc tgatcgtgaacaatgccaccaacgtggtcatcaaggtgtgcgagttccagttttgtaatgatcccttcctgggcgt gtactatcacaagaacaataagagctggatggagtccgagtttagagtgtattctagcgccaacaactgcacattt gagtacgtgagccagcctttcctgatggacctggagggcaagcagggcaatttcaagaacctgagggagttcgtgt ttaagaatatcgacggctacttcaaaatctactctaagcacacccccatcaacctggtgcgcgacctgcctcaggg Description Page 76 / 157 79 CN 121263205 A cttcagcgccctggagcccctggtggatctgcctatcggcatcaacatcacccggtttcagacactgctggccctg cacagaagctacctgacacccggcgactcctctagcggatggaccgccggcgctgccgcctactatgtgggctacc tccagccccggaccttcctgctgaagtacaacgagaatggcaccatcacagacgcagtggattgcgccctggaccc cctgagcgagacaaagtgtacactgaagtcctttaccgtggagaagggcatctatcagacatccaatttcagggtg cagccaaccgagtctatcgtgcgctttcctaatatcacaaacctgtgcccatttggcgaggtgttcaacgcaaccc gcttcgccagcgtgtacgcctggaataggaagcggatcagcaactgcgtggccgactatagcgtgctgtacaactc cgcctctttcagcacctttaagtgctatggcgtgtcccccacaaagctgaatgacctgtgctttaccaacgtctacgccgattctttcgtgatcaggggcgacgaggtgcgccagatcgcccccggccagacaggcaagatcgcagactaca attataagctgccagacgatttcaccggctgcgtgatcgcctggaacagcaacaatctggattccaaagtgggcgg caactacaattatctgtaccggctgtttagaaagagcaatctgaagcccttcgagagggacatctctacagaaatc taccaggccggcagcaccccttgcaatggcgtggagggctttaactgttatttcccactccagtcctacggcttcc agcccacaaacggcgtgggctatcagccttaccgcgtggtggtgctgagctttgagctgctgcacgccccagcaac agtgtgcggccccaagaagtccaccaatctggtgaagaacaagtgcgtgaacttcaacttcaacggcctgaccggc acaggcgtgctgaccgagtccaacaagaagttcctgccatttcagcagttcggcagggacatcgcagataccacag acgccgtgcgcgacccacagaccctggagatcctggacatcacaccctgctctttcggcggcgtgagcgtgatcac acccggcaccaatacaagcaaccaggtggccgtgctgtatcaggacgtgaattgtaccgaggtgcccgtggctatc cacgccgatcagctgaccccaacatggcgggtgtacagcaccggctccaacgtcttccagacaagagccggatgcc tgatcggagcagagcacgtgaacaattcctatgagtgcgacatcccaatcggcgccggcatctgtgcctcttacca gacccagacaaactctcccagaagagcccggagcgtggcctcccagtctatcatcgcctataccatgtccctgggc gccgagaacagcgtggcctactctaacaatagcatcgccatcccaaccaacttcacaatctctgtgaccacagagatcctgcccgtgtccatgaccaagacatctgtggactgcacaatgtatatctgtggcgattctaccgagtgcagcaa cctgctgctccagtacggcagcttttgtacccagctgaatagagccctgacaggcatcgccgtggagcaggataag aacacacaggaggtgttcgcccaggtgaagcaaatctacaagaccccccctatcaaggactttggcggcttcaatt tttcccagatcctgcctgatccatccaagccttctaagcggagctttatcgaggacctgctgttcaacaaggtgac cctggccgatgccggcttcatcaagcagtatggcgattgcctgggcgacatcgcagccagggacctgatctgcgcc cagaagtttaatggcctgaccgtgctgccacccctgctgacagatgagatgatcgcacagtacacaagcgccctgc tggccggcaccatcacatccggatggaccttcggcgcaggagccgccctccagatcccctttgccatgcagatggc ctataggttcaacggcatcggcgtgacccagaatgtgctgtacgagaaccagaagctgatcgccaatcagtttaac tccgccatcggcaagatccaggacagcctgtcctctacagccagcgccctgggcaagctccaggatgtggtgaatc agaacgcccaggccctgaataccctggtgaagcagctgagcagcaacttcggcgccatctctagcgtgctgaatga catcctgagccggctggacaaggtggaggcagaggtgcagatcgaccggctgatcaccggccggctccagagcctc cagacctatgtgacacagcagctgatcagggccgccgagatcagggccagcgccaatctggcagcaaccaagatgt ccgagtgcgtgctgggccagtctaagagagtggacttttgtggcaagggctatcacctgatgtccttccctcagtctgccccacacggcgtggtgtttctgcacgtgacctacgtgcccgcccaggagaagaacttcaccacagcccctgcc atctgccacgatggcaaggcccactttccaagggagggcgtgttcgtgtccaacggcacccactggtttgtgacac agcgcaatttctacgagccccagatcatcaccacagacaacaccttcgtgagcggcaactgtgacgtggtcatcgg catcgtgaacaataccgtgtatgatccactccagcccgagctggacagctttaaggaggagctggataagtatttc aagaatcacacctcccctgacgtggatctgggcgacatcagcggcatcaatgcctccgtggtgaacatccagaagg agatcgaccgcctgaacgaggtggctaagaatctgaacgagagcctgatcgacctccaggagctgggcaagtatga Description Page 77 / 157 Page 80 CN 121263205 A gcagtacatcaagtggccctggtacatctggctgggcttcatcgccggcctgatcgccatcgtgatggtgaccatc atgctgtgctgtatgacatcctgctgttcttgcctgaagggctgctgtagctgtggctcctgctgtaagttattga ccattgtcgttgctaatcgaaatagaatggagaattttgtttatcataaatgaAGTCGACTCATGGAATGCATACC AAACATTATTGACACTAATGACACACAAAATTGGTTTTAAGAAAAACCAAGAGAACAATAGGCCAGAATGGCTGGG TCTCGGGAGATATTACTCCCTGAAGTCCATCTCAATTCACCAATTGTAAAGCATAAGCTATACTATTACATTCTAC TTGGAAACCTCCCAAATGAGATCGACCTTGACGATTTAGGTCCATTACATAATCAAAATTGGAATCAGATAGCACATGAAGAGTCTAACTTAGCTCAACGCTTGGTAAATGTAAGAAATTTTCTAATTACCCACATCCCTGATCTTAGAAAG GGCCATTGGCAAGAGTATGTCAATGTAATACTGTGGCCGCGAATTCTTCCCTTGATCCCGGATTTTAAAATCAATG ACCAATTGCCTCTGCTCAAAAATTGGGACAAGTTAGTTAAAGAATCATGTTCAGTAATCAATGCAGGTACTTCCCA GTGCATTCAGAATCTCAGCTATGGACTGACAGGTCGTGGGAACCTCTTTACACGATCACGTGAACTCTCTGGTGAC CGCAGGGATATTGATCTTAAGACAGTTGTGGCAGCATGGCATGACTCAGACTGGAAAAGAATAAGTGATTTTTGGA TTATGATCAAAATTCCAGATGAGACAATTAATTGTTAGGCAAACAGATCATAATGATTCTGATTTAATCACGTATAT CGAAAATAGAGAAGGCATAATCATCATAACCCCTGAACTGGTAGCATTATTTAACACTGAGAATCATACACTAACA TACATGACCTTTGAAATTGTACTGATGGTTTCAGATATGTACGAAGGTCGTCACAACATTTTATCACTATGCACAG TTAGCACTTACCTGAATCCTCTGAAGAAAAGAATAACATATTTATTGAGCCTTGTAGATAACTTAGCTTTTCAGAT AGGTGATGCTGTATATAACATAATTGCTTTGCTAGAATCCTTTGTATATGCACAGTTGCAAATGTCAGATCCCATC CCAGAACTCAGAGGACAATTCCATGCATTCGTATGTTCTGAGATTCTTGATGCACTAAGAGGAACTAATAGTTTCA CCCAGGATGAATTAAGAACTGTGACAACTAATTTGATATCCCCATTCCAAGATCTGACCCCAGATTCTTACGGCTGA ATTGCTCTGTATAATGAGGCTTTGGGGACACCCCATGCTCACTGCCAGTCAAGCTGCAGGAAAGGTACGCGAGTCTATGTGTGCTGGAAAAGTATTAGACTTTCCCACCATTATGAAAACACTAGCCTTTTTCCATACTATTCTGATCAATG GATACAGGAGGAAGCATCATGGAGTATGGCCACCCTTAAACTTACCGGGTAATGCTTCAAAGGGTCTCACGGAACT TATGAATGACAATACTGAAATAAGCTATGAATTCACACTTAAGCATTGGAAGGAAGTCTCTCTTATAAAATTCAAG AAATGTTTTGATGCAGACGCAGGTGAGGAACTCAGTATATTTATGAAAGATAAGGCAATTAGTGCCCCAAAACAAG ACTGGATGAGTGTGTTTAGAAGAAGCCTAATCAAACAGCGCCATCAGCATCATCAGGTCCCCCTACCAAATCCATT CAATCGACGGCTGTTGCTAAACTTTCTCGGAGATGACAAATTCGACCCGAATGTGGAGCTACAGTATGTAACATCA GGTGAGTATCTACATGATGACACGTTTTGTGCATCATATTCACTAAAAGAGAAGGAAATTAAACCTGATGGTCGAA TTTTTGCAAAGTTGACTAAGAGAATGAGATCATGTCAAGTTATAGCAGAATCTCTTTTAGCGAACCATGCTGGGAA GTTAATGAAAGAGAATGGTGTTGTGATGAATCAGCTATCATTAACAAAATCACTATTAACAATGAGTCAGATTGGA ATAATATCCGAGAAAGCTAGAAAGTCAACTCGAGATAACATAAATCAACCTGGTTTCCAGAATATCCAGAGAAATA AATCACATCACTCCAAGCAAGTCAATCAGCGAGATCCAAGTGATGACTTTGAATTGGCAGCATCTTTTTTAACTAC TGATCTCAAAAAATATTGTTTACAATGGAGGTACCAGACAATTATCCCATTTGCTCAATCATTAAACAGAATGTAT GGTTATCCTCATCTCTTTGAGTGGATTCACTTACGGCTAATGCGTAGTACACTTTACGTGGGGGATCCCTTCAACCCACCAGCAGATACCAGTCAATTTGATCTAGATAAAGTAATTAATGGAGATATCTTCATTGTATCACCCAGAGGTGG AATTGAAGGGCTGTGTCAAAAGGCTTGGACAATGATATCTATCGCTGTGATAATTCTATCTGCCACAGAGTCTGGC ACACGAGTAATGAGTATGGTGCAGGGAGATAATCAAGCAATTGCTGTCACCACACGAGTACCAAGGAGCCTGCCGA CTCTTGAGAAAAAGACTATTGCTTTTAGATCTTGTAATCTATTCTTTGAGAGGTTAAAATGTAATAATTTTGGATT AGGTCACCATTTGAAAGAACAAGAGACTATCATTAGTTCTCACTTCTTTGTTTATAGCAAGAGAATATTCTATCAG GGGAGGATTCTAACGCAAGCCTTAAAAAATGCTAGTAAGCTCTGCTTGACAGCTGATGTCCTAGGAGAATGCACCC AATCATCATGTTCTAATCTTGCAACTACTGTCATGAGGTTAACTGAGAATGGTGTTGAAAAAGATATCTGTTTCTA DESCRIPTION Page 78 / 157 Page 81 CN 121263205 A CTTGAATATCTATATGACCATCAAACAGCTCTCCTATGATATCATCTTCCCTCAAGTGTCAATTCCTGGAGATCAG ATCACATTAGAATACATAAATAATCCACACCTGGTATCACGATTGGCTCTTTTGCCATCCCAGTTAGGAGGTCTAA ACTACCTGTCATGCAGTAGGCTGTTCAATCGAAACATAGGCGACCCGGTGGTTTCCGCAGTTGCAGATCTTAAGAG ATTAATTAAATCAGGATGTATGGATTACTGGATCCTTTATAACTTATTAGGGAGAAAACCGGGAAACGGCTCATGG GCTACTTTAGCAGCTGACCCGTACTCAATCAATATAGAGTATCAATACCCTCCAACTACAGCTCTTAAGAGGCACACCCAACAAGCTCTGATGGAACTCAGTACGAATCCAATGTTACGTGGCATATTCTCTGACAATGCACAGGCAGAAGA AAATAACCTTGCTAGGTTTCTCCTGGATAGGGAGGTGATCTTTCCGCGTGTAGCTCACATCATCATTGAGCAAACC AGTGTCGGGAGGAGAAAACAGATTCAAGGATATTTGGATTCAACTAGATCGATAATGAGGAAATCACTAGAAATTA AGCCCTTATCCAATAGGAAGCTTAATGAAATACTGGATTACAACATCAATTACCTAGCTTACAATTTGGCATTACT CAAGAATGCTATTGAACCTCCGACTTATTTGAAGGCAATGACACTTGAAACATGTAGCATCGACATTGCAAGGAAC CTCCGGAAGCTCTCCTGGGCCCCACTCTTGGGTGGGAGAAATCTTGAAGGATTAGAGACGCCAGATCCCATTGAAA TTACTGCAGGAGCATTAATTGTTGGATCGGGCTACTGTGAACAGTGTGCTGCAGGAGACAATCGATTCACATGGTT TTTCTTGCCATCTGGTATCGAGATAGGAGGGGATCCCCGTGATAATCCTCCTATCCGTGTACCGTACATTGGCTCC AGGACTGATGAGAGGAGGGTAGCCTCAATGGCATACATCAGGGGTGCCTCGAGTAGCTTAAAAGCAGTTCTTAGAC TGGCGGGAGTGTACATCTGGGCATTCGGAGATACTCTGGAGAATTGGATAGATGCACTGGATTTGTCTCACACTAG AGTTAACATCACACTTGAACAGCTGCAATCCCTCACCCCACTTCCAACCTCTGCCAATCTAACCCATCGGTTGGAT GATGGCACAACTACCCTAAAGTTTACTCCTGCGAGCTCTTACACCTTTTCAAGTTTCACTCATATATCAAATGATG AGCAATACCTGACAATTAATGACAAAACTGCAGATTCAAATATAATCTACCAACAGTTAATGATCACTGGACTCGGAATCTTAGAAACATGGAATAATCCCCCAATCAATAGAACATTCGAAGAATCTACCCTACATTTGCACACTGGTGCA TCATGTTGTGTCCGACCTGTGGACTCCTGCATTCTCTCAGAAGCATTAACAGTCAAGCCACATATTACAGTACCGT ACAGCAATAAATTTGTATTTGATGAGGACCCGCTATCTGAATATGAAACTGCAAAACTGGAATCGTTATCATTCCA AGCCCAATTAGGCAACATTGATGCTGTAGATATGACAGGTAAATTAACATTATTGTCCCAATTCACTGCAAGGCAG ATTATCAATGCAATCACTGGACTCGATGAGTCTGTCTCTCTTACTAATGATGCCATTGTTGCATCAGACTATGTCT CCAATTGGATTAGTGAATGCATGTATACCAAATTAGATGAATTATTTATGTATTGTGGGTGGGAACTACTATTGGA ACTATCCTATCAAATGTATTATCTGAGGGTAGTTGGGTGGAGTAATATAGTGGATTATTCTTACATGATCTTGAGA AGAATCCCGGGTGCAGCATTAAACAATCTGGCATCTACATTAAGTCATCCAAAACTTTTCCGACGAGCTATCAACC TAGATATAGTTGCCCCCTTAAATGCTCCTCATTTTGCATCTCTGGACTACATCAAGATGAGTGTGGATGCAATACT CTGGGGCTGTAAAAGAGTCATCAATGTGCTCTCCAATGGAGGGGACTTAGAATTAGTTGTGACATCTGAAGATAGC CTTATTCTCAGTGACCGATCCATGAATCTCATTGCAAGGAAATTAACTTTATTATCACTGATTCACCATAATGGTT TGGAACTACCAAAGATTAAGGGGTTCTCTCCTGATGAGAAGTGTTTCGCTTTGACAGAATTTTTGAGGAAAGTGGT GAACTCAGGGTTGAGTTCAATAGAGAACCTATCAAATTTTATGTACAATGTGGAGAACCCACGGCTTGCAGCATTCGCCAGCAACAATTACTACCTGACCAGAAAATTATTGAATTCAATACGAGATACTGAGTCGGGTCAAGTAGCAGTCA CCTCATATTATGAATCATTAGAATATATTGATAGTCTTAAGCTAACCCCACATGTGCCTGGCACCTCATGCATTGA GGATGATAGTCTATGTACAAATGATTACATAATCTGGATCATAGAGTCTAATGCAAACTTGGAGAAGTATCCAATT CCAAATAGCCCTGAGGATGATTCCAATTTCCATAACTTTAAGTTGAATGCTCCATCGCACCATACCTTACGCCCAT TAGGGTTGTCATCAACTGCTTGGTATAAGGGTATAAGCTGCTGCAGGTACCTTGAGCGATTAAAGCTACCACAAGG TGATCATTTATATATTGCAGAAGGTAGTGGTGCCAGTATGACAATCATAGAATACCTATTCCCAGGAAGAAAGATA TATTACAATTCTTTATTTAGTAGTGGTGACAATCCCCCACAAAGAAATTATGCACCAATGCCTACTCAGTTCATTG AGAGTGTCCCATACAAGCTCTGGCAAGCACACACAGATCAATATCCCGAGATTTTTGAGGACTTCATCCCTCTATG DESCRIPTION Page 79 / 157 Page 82 CN 121263205 A GAACGGAAACGCCGCCATGACTGACATAGGAATGACAGCTTGTGTAGAATTCATCATCAATCGAGTCGGCCCAAGG ACTTGCAGTTTAGTACATGTAGATTTGGAATCAAGTGCAAGCTTAAATCAACAATGCCTGTCAAAGCCGATAATTA ATGCTATCATCACTGCTACAACTGTTTTGTGCCCTCATGGGGTGCTTATTCTGAAATATAGTTGGTTGCCATTTAC TAGATTTAGTACTTTGATCACTTTCTTATGGTGCTACTTTGAGAGAATCACTGTTCTTAGGAGCACATATTCTGATCCAGCTAATCATGAGGTTTATTTAATTTGTATCCTTGCCAACAACTTTGCATTCCAGACTGTCTCGCAGGCAACAG GAATGGCGATGACTTTAACTGATCAAGGGTTTACTTTGATATCACCTGAAAGAATAAATCAGTATTGGGATGGTCA CTTGAAGCAAGAACGTATCGTAGCAGAAGCAATTGATAAGGTGGTTCTAGGAGAAAATGCTCTATTTAATTCGAGT GATAATGAATTAATTCTCAAATGTGGAGGAACCAAATGCACGGAATCTCATCGATATCGAGCCAGTCGCAACT. TCATAGAATTTGAACAAATTGATCTGCACAATGTTGACAACCCACTTGAAGGAAATAATTGATATAACAAGGTCTGG AACCCAGGATTATGAAAGTTTATTACTCACTCCTTACAATTTAGGTCTTCTTGGTAAAATCAGTACGATAGTGAGA TTATTAACAGAAAGGATTCTAAATCATACTATCAGGAATTGGTTGATCCTCCCACCTTCGCTCCGGATGATCGTGA AGCAGGACTTGGAATTCGGCATATTCAGGATTACTTCCATCCTCAATTCTGATCGGTTCCTGAAGCTTTCCAAA TAGGAAATACTTGATTGCACAATTAACTGCAGGCTACATTAGGAAATTGATTGAGGGGGATTGCAATATCGATCTA ACCAGACCTATCCAAAAGCAAATCTGGAAAGCATTAGGTTGTGTAGTCTATTGTCACGATCCAATGGATCAAAGGG AGTCAACACAGAGTTTATTGATATAAATATTAATGAAGAAATAGACCGCGGGATCGATGGCGAAGAAATCTAAACATA TCAAGAATCAGAATGTTTTAAGAAAAAAGAAGAGATTAATCTTGGTTTCCCCTTGGTGGTCGGCATGGCATC TCCACCTCCCGGTCCGACCTGGGCATCCGAAGGAGGACGCACGTCCACTCGGATGGCTAAGGGGACGCCGGGGATCCGGCTGCTAACAAAGCCCGAAAGGAAGCTGAGTTGGCTGCTGCCACCGCTGAGCAATAACTAGCATAACCCC TTGGGGCCTCTAAACGGGTCTTGAGGGGTTTTTTGCTGAAAGGAGGAACTATATCCGGATCATGTGAGCAAAAGGC CAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATC ACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAG CTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTG GCGCTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACG AACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTT ATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAG TGGTGGCCTAACTACGGCTACACTAGAAGAACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAA AAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGAT TACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGAACGAAAAC TCACGTTAAGGGATTTTGGTCATGAGATTATCAAAAAGGATCTTCACCTAGATCCTTTTAAATTAAAAATGAAGTT TTAAATCAATCTAAAGTATATATGAGTAAACTTGGTCTGACAGTTACCAATGCTTAATCAGTGAGGCACCTATCTCAGCGATCTGTCTATTTCGTTCATCCATAGTTGCCTGACTCCCCGTCGTGTAGATAACTACGATACGGGAGGGCTTA CCATCTGGCCCCAGTGCTGCAATGATACCGCGAGACCCACGCTCACCGGCTCCAGATTTATCAGCAATAAACCAGC CAGCCGGAAGGGCCGAGCGCAGAAGTGGTCCTGCAACTTTATCCGCCTCCATCCAGTCTATTAATTGTTGCCGGGA AGCTAGAGTAAGTAGTTCGCCAGTTAATAGTTTGCGCAACGTTGTTGCCATTGCTACAGGCATCGTGGTGTCACGC TCGTCGTTTGGTATGGCTTCATTCAGCTCCGGTTCCCAACGATCAAGGCGAGTTACATGATCCCCCATGTTGTGCA AAAAAGCGGTTAGCTCCTTCGGTCCTCCGATCGTTGTCAGAAGTAAGTTGGCCGCAGTGTTATCACTCATGGTTAT GGCAGCACTGCATAATTCTCTTACTGTCATGCCATCCGTAAGATGCTTTTCTGTGACTGGTGAGTACTCAACCAAG TCATTCTGAGAATAGTGTATGCGGCGACCGAGTTGCTCTTGCCCGGCGTCAATACGGGATAATACCGCGCCACATA GCAGAACTTTAAAAGTGCTCATCATTGGAAAACGTTCTTCGGGGCGAAAACTCTCAAGGATCTTACCGCTGTTGAG Description Page 80 / 157 83 CN 121263205 A ATCCAGTTCGATGTAACCCACTCGTGCACCCAACTGATCTTCAGCATCTTTTACTTTCACCAGCGTTTCTGGGTGA GCAAAAACAGGAAGGCAAAATGCCGCAAAAAAGGGAATAAGGGCGACACGGAAATGTTGAATACTCATACTCTTCC TTTTTCAATATTATTGAAGCATTTATCAGGGTTATTGTCTCATGAGCGGATACATATTTGAATGTATTTAGAAAAA TAAACAAATAGGGGTTCCGCGCACATTTCCCCGAAAAGT(SEQID NO: 9).
[0209] viii. CVL119
[0210] The nucleic acid sequence of CVL119 is:
[0211] GCCACCTGACGTCTAAGAAACCATTATTATCATGACATTAACCTATAAAAATAGGCGTATCACGAGGC CCTTTCGTCTCGCGCGTTTCGGTGATGACGGTGAAAACCTCTGACACATGCAGCTCCCGGAGACGGTCACAGCTTG TCTGTAAGCGGATGCCGGGAGCAGACAAGCCCGTCAGGGCGCGTCAGCGGGTGTTGGCGGGTGTCGGGGCTGGCTT AACTATGCGGCATCAGAGCAGATTGTACTGAGAGTGCACCATATATGCGGTGTGAAATACCGCACAGATGCGTAAG GAGAAAATACCGCATCAGGCTAATACGACTCACTATAGGGACCAAGGGGAAAATGAAGTGGTGACTCAAATCATCG AAGACCCTCGAGATTACATAGGTCCGGAACCTATGGCCTTCGTGACCGACCTCGAGTCAGAGTAGTTCAATAAGGA CCTATCAAGTTTGGGCAATTTTTCGTCCCCGACACAAAAATGTCATCCGTGCTTAAAGCATATGAGCGATTCACGC TCACTCAAGAACTGCAAGATCAGAGTGAGGAAGGTACAATCCCACCTACAACACTAAAACCGGTAATCAGGGTATT TATACTAACCTCTAATAACCCAGAGCTAAGATCCCGGCTTCTTCTATTCTGCCTACGGATTGTTCTCAGTAATGGT GCAAGGGATTCCCATCGCTTTGGAGCATTACTCACAATGTTTTCGCTACCATCAGCCACAATGCTCAATCATGTCA AATTAGCTGACCAGTCACCAGAAGCTGATATCGAAAGGGTAGAGATCGATGGCTTTGAGGAGGGATCATTCCGCTT AATCCCCAATGCTCGTTCAGGTATGAGCCGTGGAGAGATCAATGCCTATGCTGCACTTGCAGAAGATCTACCTGACACACTAAACCATGCAACACCTTTCGTTGATTCCGAAGTCGAGGGAACTGCATGGGATGAGATTGAGACTTTCTTAG ATATGTGTTACAGTGTCCTAATGCAGGCATGGATAGTGACTTGCAAGTGCATGACTGCGCCAGACCAACCTGCTGC TTCTATTGAGAAACGCCTGCAAAAATATCGTCAGCAAGGCAGGATCAACCCGAGATATCTCCTGCAACCGGAGGCT CGACGAATAATCCAGAATGTAATCCGGAAGGGAATGGTGGTCAGACATTTCCTCACCTTTGAACTGCAGCTTGCCC GAGCACAAAGCCTTGTATCAAATAGGTATTATGCTATGGTAGGGGATGTTGGAAAGTATATAGAGAATTGTGGAAT GGGAGGCTTCTTTTTGACACTAAAATATGCATTAGGAACTAGATGGCCCACACTTGCTTTAGCTGCATTTTCAGGA GAGCTAACAAAGCTAAAGTCCCTCATGGCATTATACCAGACCCTTGGTGAGCAGGCCCGATATTTGGCCCTATTGG AGTCACCACATTTGATGGATTTTGCTGCAGCAAACTACCCACTGCTATATAGCTATGCTATGGGAATAGGCTATGT GTTAGATGTCAACATGAGGAACTACGCTTTCTCCAGATCATACATGAACAAGACATATTTCCAATTGGGAATGGAA ACTGCAAGAAAACAACAGGGTGCAGTTGACATGAGGATGGCAGAAGATCTCGGTCTAACTCAAGCCGAACGCACCG AGATGGCAAATACACTTGCCAAATTGACCACAGCAAATCGAGGGGCAGACACCAGGGGAGGAGTCAACCCGTTCTC ATCTGTCACTGGGACAACTCAGGTGCCCGCTGCAGCAACAGGTGACACACTCGAGAGTTACATGGCAGCGGATCGA CTGAGGCAGAGATATGCTGATGCAGGCACCCATGATGATGAGATGCCACCATTGGAAGAGGAGGAAGAGGACGACACATCTGCAGGTCCACGCACTGGACCAACTCTTGAACAAGTGGCCTTGGACATCCAGAACGCAGCAGTTGGAGCTCC CATCCATACAGATGACCTGAATGCCGCACTGGGTGATCTTGACATCTAGACAATTCAGATCCCAATCTAAAATTGA CATACCTAATTGATTAGTTAGATGGAACTACAGTGGATTCCATAAGGTTCCTGCCTACCATCGGCTTTAAAGAAAA AAATAGGCCCGGACGGGTTAGCAACAAGCGACTGCCGGTGCCAACAGCGCAATCCACAATCTACAATGGATCCCAC TGATCTGAGCTTCTCCCCAGATGAGATCAATAAGCTCATAGAGACAGGCCTGAATACTGTAGAGTATTTTACTTCC CAACAAGTCACAGGAACATCCTCTCTTGGAAAGAATACAATACCACCAGGGGTCACAGGACTACTAACCAATGCTG CAGAGGCAAAGATCCAAGAGTCAACTAACCATCAGAAGGGCTCAGTTGGTGGGGGTGCAAAACCAAAGAAACCGCG ACCAAAAATTGCCATTGTGCCAGCAGATGACAAAACAGTGCCCGGAAAGCCGATCCCAAACCCTCTATTAGGTCTG Description Page 81 / 157 84 CN 121263205 A GACTCCACCCCGAGCACCCAAACTGTGCTTGATCTAAGTGGGAAAACATTACCATCAGGATCCTATAAGGGGGTTA AGCTTGCGAAATTTGGAAAAGAAAATCTGATGACACGGTTCATCGAGGAACCCAGAGAGAATCCTATCGCAACCAG TTtCCCCATCGATTTTAAGAGGGGCAGGGATACCGGCGGGTTCCATAGAAGGGAGTACTCAATCGGATGGGTGGGA GATGAAGTCAAGGTCACTGAGTGGTGCAATCCATCCTGTTCTCCAATCACCGCTGCAGCAAGGCGATTTGAATGCACTTGTCACCAGTGTCCAGTCACTTGCTCTGAATGTGAACGAGATACTTAATACAGTGAGAAATTTGGACTCTCGGA TGAATCAACTGGAGACAAAAGTAGATCGCATTCTCTCATCTCAGTCTCTAATCCAGACCATCAAGAATGACATAGT TGGACTTAAAGCAGGGATGGCTACTTTAGAAGGAATGATTACAACTGTGAAAATCATGGACCCGGGAGTTCCCAGT AATGTTACTGTGGAAGATGTACGCAAGACACTAAGTAACCATGCTGTTGTTGTGCCAGAATCATTCAATGATAGTT TCTTGACTCAATCTGAAGATGTAATTTCACTTGATGAGTTGGCTCGACCAACTGCAACAAGTGTTAAGAAGATTGT CAGGAAGGTTCCTCCTCAGAAGGATCTGACTGGATTGAAGATTACACTAGAGCAATTGGCAAAGGATTGCATCAGC AAACCGAAGATGAGGGAAGAGTATCTCCTCAAAATCAACCAGGCTTCCAGTGAGGCTCAGCTAATTGACCTCAAGA AAGCAATCATCCGCAGTGCAATTTGATCAAGAAACACCCAATTACACTACACTGGTATGACACTGTACTAACCCTG AGGGTTTTAGAAAAAACGATTAACGATAAATAAGCCCGAACACTACACACTACCTGAGGCAGCCATGCCATCCATC AGCATTCCCGCAGACCCCACCAATCCACGTCAATCAATAAAAGCGTTCCCAATTGTGATCAACAGTGATGGGGGTG AGAAAGGCCGCTTGGTTAAACAACTACGCACAACCTACTTGAATGACCTAGATACTCATGAGCCACTGGTGACATT CATAAATACCTATGGATTCATCTACGAACAGGATCGGGGGAATACCATTGTCGGAGAGGATCAACTTGGGAAGAAA AGAGAGGCTGTGACCGCTGCAATGGTTACCCTTGGATGTGGGCCTAATCTACCATCATTAGGGAATGTCCTGGGACAACTGAGGGAATTCCAGGCACTGTTAGGAAGACATCCAGCAAAGCGGAAGAGATGGTCTTTGAAATTTGTAAGTA TCCGAGAATATTTCGGGTCATATTAATCCCAGAAAAGACTAGTCTGTGTCTCCGCAGAAAATTTGTTAAGTCA CCAGGGAAAATACAATCTGGAATGGACTATCTCTTCATTCCGACATTTCTGCAGTGTGACTTACTGTTCCAGCTGCAA TCAAATTTCAGGTTACCTGGCCCCATGTTTGAAAATGAGATCAAGATACACTCAGAGGAAGGAAGGAGTGTCTTGTA TCAGTATGGCTGCATGTATGCAACATCTTCAAATCAGGAAACAAGAAGGCAGTGAGTGGCAGGAATACTGGATGAGAATACTGGATGA GAAAGTGTGCTAACATGCAACTTGAAGTGTCGATTGCAGATATGGGGACCAACTATCATATCCATGCCAAGGG TCACATTCCCAAAAAGTGCTAAGTGTTTTTGGAAAGGGTGGATGGCCATCCACTTCACGAAGTGTTTCCA AGTGTCACTAAACACTATGGTCCGTGGGCTGTGAGATTACAAAGGCGAAGGCAATAATACAAGAGAGTAGCATCT CTCTTCTCGTGGAGACTACTGACATCATAAGTCCAAAAGTCAAAATTTCATCTAAGCATCGCCGCTTTGGGAAATC AAATTGGGGTCTGTTCAAGAAAACTAAATCACTGCCTAACCTGACGGAGCTGGAATGACTGACCTCTAATCGAGAC TACACCGCCGCAAACTATAGGTGGGTGGTACCTCAAGTGATTGAATCTTGTAAGCACTGATCGTAGGCTAACACAC. TAATATTATCCAGATTAGAGAGCTTAATTAGCTCTGTATTAATAATAACACTACTATTCCAATAACTGGAATCACCAGCTTGATTTATCTCCAAAATGATTCAAAGAAAACAAATCATATTAAGACTATCCTAAGCACGAACCCATATCGTC CTTCAAATCATGGGTACTATAATTCAATTTCTGGTGGTCTCCTGTCTATTGGCAGGAGCAGGCAGCCTTGATCCAG CAGCCCTCATGCAAATCGGTGTCATTCCAACAAATGTCCGGCAACTTATGTATTATACTGAAGCTTCATCAGCATT CATTGTTGTGAAGTTAATGCCTACAATTGACTCGCCGATTAGTGGATGTAATATAACATCAATTTCAAGCTATAAT GCAACAGTGACAAAACTCCTACAGCCGATCGGTGAGAATTTGGAGACGATTAGGAACCAGTTGATTCCAACTCGGA GGAGACGCCGGTTTGCAGGGGTGGTGATTGGATTAGCTGCATTAGGAGTAGCTACTGCCGCACAGGTCACTGCCGC AGTGGCACTAGTAAAGGCAAATGAAAATGCTGCGGCTATACTCAATCTCAAAAATGCAATCCAAAAAACAAATGCA GCAGTTGCAGATGTGGTCCAGGCCACACAATCACTAGGAACGGCAGTTCAAGCAGTTCAAGATCACATAAACAGTG TGGTAAGTCCAGCAATTACAGCAGCCAATTGTAAGGCCCAAGATGCTATCATTGGCTCAATCCTCAATCTCTATTT DESCRIPTION Page 82 / 157 85 CN 121263205 A GACCGAGTTGACAACCATCTTCCACAATCAAATTACAAACCCTGCATTGAGTCCCATTACAATTCAAGCTTTAAGG ATCCTACTGGGGAGTACCTTGCCGACTGTGGTCGAAAAATCTTTCAATACCCAGATAAGTGCAGCTGAGCTTCTCT CATCAGGGTTATTGACAGGCCAGATTGTGGGATTAGATTTGACCTATATGCAGATGGTCATAAAAATTGAGCTGCCAACTTTAACTGTACAACCTGCAACCCAGATCATAGATCTGGCCACCATTTCTGCATTCATTAACAATCAAGAAGTC ATGGCCCAATTACCAACACGTGTTATGGTGACTGGCAGCTTGATCCAAGCCTATCCCGCATCGCAATGCACCATTA CACCCAACACTGTGTACTGTAGGTATAATGATGCCCAAGTACTCTCAGATGATACTATGGCTTGCCTCCAAGGTAA CTTGACAAGATGCACCTTCTCTCCAGTGGTTGGGAGCTTTCTCACTCGATTCGTGCTGTTCGATGGAATAGTTTAT GCAAATTGCAGGTCGATGTTGTGCAAGTGCATGCAACCTGCTGCTGTGATCCTACAGCCGAGTTCATCCCCTGTAA CTGTCATTGACATGTACAAATGTGTGAGTCTGCAGCTTGACAATTCTCAGATTCACCATCACTCAATTGGCCAATGT AACCTACAATAGCACCATCAAGCTTGAATCATCCCAGATCTTGTCTATTGATCCGTTGGATATATCCCAGAATCTA GCTGCGGTGAATAAGAGTCTAAGTGATGCACTACAACACTTAGCACAAAGTGACACATATCTTTCTGCAATCACAT CAGCTACGACTACAAGTGTATTATCCATAATAGCAATCTGTCTTGGATCGTTAGGTTTAATATTAATAATCTTGCT CAGTGTAGTTGTGTGGAAGTTATTGACCATTGTCGTTGCTAATCGAAATAGAATGGAGAATTTTGTTTATCATAAA TAAGCATTCCACCACTCACGATCTGATCTCAGTGAGAAAAATCAACCTGCAACTCTTGGAACAAGATAAGACAGTC ATCCATTAGTAATTTTTAAGAAAAAAACGATAGGACCGAACCTAGTATTGAAAGAACCGTCTCGGTCAATCTAGGT AATCGAGCTGATACCGTCTCGGAAAGCTCAAATCGGCGCGCCACCatgtcagataacggaccacagaaccagaggaacgcacccaggattactttcggaggaccaagcgatagcaccgggagcaaccagaatggagagcggagcggagcaaga tccaagcagagacggccccagggcctgccaaacaataccgcatcctggttcaccgccctgacacagcacggcaagg aggacctgaagtttccaaggggacagggagtgcctatcaacaccaatagctcccctgacgatcagatcggctacta taggagggcaacaaggagaatcaggggaggcgacggcaagatgaaggatctgagcccacgctggtacttctactat ctgggaaccggacctgaggcaggcctgccatatggcgccaacaaggacggaatcatctgggtggcaaccgagggcg ccctgaacacaccaaaggatcacatcggcacaagaaatcccgccaacaatgcagcaatcgtgctgcagctgccaca gggaaccacactgcccaagggcttttacgcagagggctctcggggaggcagccaggcatctagcagatcctctagc cggagcagaaactcctctaggaattccaccccaggaagctccaggggcacatcccctgcccgcatggcaggaaacg gaggcgacgccgccctggccctgctgctgctggatcgcctgaatcagctggagtccaagatgtctggcaagggaca gcagcagcagggacagaccgtgacaaagaagtccgccgccgaggcctctaagaagccaaggcagaagcgcaccgcc acaaaggcctacaacgtgacccaggccttcggcaggcgcggaccagagcagacacagggcaattttggcgaccagg agctgatcaggcagggaaccgattataagcactggcctcagatcgcccagttcgccccatctgccagcgccttctt tggcatgtctagaatcggcatggaggtgacccccagcggcacatggctgacctacacaggcgccatcaagctggacgataaggaccctaacttcaaggatcaggtcatcctgctgaacaagcacatcgacgcctataagacctttcccccta cagagcccaagaaggacaagaagaagaaggccgatgagacacaggccctgcctcagaggcagaagaagcagcagac cgtgacactgctgccagccgccgatctggacgatttctccaaacagctgcagcagagcatgtccagtgccgactcc acccaggcttgaCGTACGACCTGCTATAGGCTATCCACTGCATCATCTCTCCTGCCATACTTCCTACTCACATCAT ATCTATTTTAAAGAAAAAATAGGCCCGAACACTAATCGTGCCGGCAGTGCCACTGCACACACAACACTACACATAC AATACACTACAATGGTTGCAGAAGATGCCCCTGTTAGGGCCACTTGCCGAGTATTATTTCGAACAACAACTTTAAT CTTTCTATGCACACTACTAGCATTAAGCATCTCTATCCTTTATGAGAGTTTAATAACCCAAAAGCAAATCATGAGC CAAGCAGGCTCAACTGGATCTAATTCTGGATTAGGAAGTATCACTGATCTTCTTAATAATATTCTCTCTGTCGCAA ATCAGATTATATATAACTCTGCAGTCGCTCTACCTCTACAATTGGACACTCTTGAATCAACACTCCTTACAGCCAT TAAGTCTCTTCAAACCAGTGACAAGCTAGAACAGAACTGCTCGTGGAGTGCTGCACTGATTAATGATAATAGATAC DESCRIPTION Page 83 / 157 86 CN 121263205 A ATTAATGGCATCAATCAGTTCTATTTTTCAATTGCTGAGGGTCGCAATCTGACACTTGGCCCACTTCTTAATATGC CTAGTTTCATTCCAACTGCCACGACACCAGAGGGCTGCACCAGGATCCCATCATTCTCGCTCACTAAGACACACTGGTGTTATACACACAATGTTATCCTGAATGGATGCCAGGATCATGTATCCTCAAATCAATTTGTTTCTATGGGAATC ATTGAACCCACTTCTGCCGGGTTTCCATTCTTTCGAACCCTAAAGACTCTATATCTCAGCGATGGGGTCAATCGTA AGAGCTGCTCTATCAGTACAGTTCCGGGGGGTTGTATGATGTACTGTTTTGTTTCTACTCAACCAGAGAGGGATGA CTACTTTTCTGCCGCTCCTCCAGAACAACGAATTATTATAATGTACTATAATGATACAATCGTGGAGCGCATAATT AATCCACCCGGGGTACTAGATGTATGGGCAACATTGAACCCAGGAACAGGAAGCGGGGTATATTATTTAGGTTGGG TGCTCTTTCCAATATATGGCGGCGTGATTAAAGGTACGAGTTTATGGAATAATCAAGCAAATAAATACTTTATCCC CCAGATGGTTGCTGCTCTCTGCTCACAAAACCAGGCAACTCAAGTCCAAAATGCTAAGTCATCATACTATAGCAGC TGGTTTGGCAATCGAATGATTCAGTCTGGGATCCTGGCATGTCCTCTTCGACAGGATCTAACCAATGAGTGTTTAG TTCTGCCCTTTTCTAATGATCAGGTGCTTATGGGTGCTGAAGGGAGATTATACATGTATGGTGACTCGGTGTATTA CTATCAAAGAAGCAATAGTTGGTGGCCTATGACCATGCTGTATAAGGTAACCATAACATTCACTAATGGTCAGCCA TCTGCTATATCAGCTCAGAATGTGCCCACACAGCAGGTCCCTAGACCTGGGACAGGAGACTGCTCTGCAACCAATA GATGTCCCGGTTTTTGCTTGACAGGAGTGTATGCCGATGCCTGGTTACTGACCAACCCTTCGTCTACCAGTACATT TGGATCAGAAGCAACCTTCACTGGTTCTTATCTCAACACAGCAACTCAGCGTATCAATCCGACGATGTATATCGCGAACAACACACAGATCATAAGCTCACAGCAATTTGGATCAAGCGGTCAAGAAGCAGCATATGGCCACACAACTTGTT TTAGGGACACAGGCTCTGTTATGGTATACTGTATCTATATTATTGAATTGTCCTCATCTCTCTTAGGACAATTTCA GATTGTCCCATTTATCCGTCAGGTGACACTATCCTAAAGGCAGAAGCCTTCAGGTCTGACCCAGCCAATCAAAGCA TTATACCAGACCATGGCCTACCATCGGCTTTAAAGAAAAAAATAGGCCCGGACGGGTTAGCAACAAGCGGCGGCCG CCGCCACCatgttcgtcttcctggtcctgctgcctctggtctcctcacagtgcgtcaatctgacaactcggactca gctgccacctgcttatactaatagcttcaccagaggcgtgtactatcctgacaaggtgtttagaagctccgtgctg cactctacacaggatctgtttctgccattctttagcaacgtgacctggttccacgccatccacgtgagcggcacca atggcacaaagcggttcgacaatcccgtgctgccttttaacgatggcgtgtacttcgcctctaccgagaagagcaa catcatcagaggctggatctttggcaccacactggactccaagacacagtctctgctgatcgtgaacaatgccacc aacgtggtcatcaaggtgtgcgagttccagttttgtaatgatcccttcctgggcgtgtactatcacaagaacaata agagctggatggagtccgagtttagagtgtattctagcgccaacaactgcacatttgagtacgtgagccagccttt cctgatggacctggagggcaagcagggcaatttcaagaacctgagggagttcgtgtttaagaatatcgacggctac ttcaaaatctactctaagcacacccccatcaacctggtgcgcgacctgcctcagggcttcagcgccctggagcccctggtggatctgcctatcggcatcaacatcacccggtttcagacactgctggccctgcacagaagctacctgacacc cggcgactcctctagcggatggaccgccggcgctgccgcctactatgtgggctacctccagccccggaccttcctg ctgaagtacaacgagaatggcaccatcacagacgcagtggattgcgccctggaccccctgagcgagacaaagtgta cactgaagtcctttaccgtggagaagggcatctatcagacatccaatttcagggtgcagccaaccgagtctatcgt gcgctttcctaatatcacaaacctgtgcccatttggcgaggtgttcaacgcaacccgcttcgccagcgtgtacgcc tggaataggaagcggatcagcaactgcgtggccgactatagcgtgctgtacaactccgcctctttcagcaccttta agtgctatggcgtgtcccccacaaagctgaatgacctgtgctttaccaacgtctacgccgattctttcgtgatcag gggcgacgaggtgcgccagatcgcccccggccagacaggcaagatcgcagactacaattataagctgccagacgat ttcaccggctgcgtgatcgcctggaacagcaacaatctggattccaaagtgggcggcaactacaattatctgtacc ggctgtttagaaagagcaatctgaagcccttcgagagggacatctctacagaaatctaccaggccggcagcacccc ttgcaatggcgtggagggctttaactgttatttcccactccagtcctacggcttccagcccacaaacggcgtgggc DESCRIPTION Page 84 / 157 87 CN 121263205 A tatcagccttaccgcgtggtggtgctgagctttgagctgctgcacgccccagcaacagtgtgcggccccaagaagtccaccaatctggtgaagaacaagtgcgtgaacttcaacttcaacggcctgaccggcacaggcgtgctgaccgagtc caacaagaagttcctgccatttcagcagttcggcagggacatcgcagataccacagacgccgtgcgcgacccacag accctggagatcctggacatcacaccctgctctttcggcggcgtgagcgtgatcacacccggcaccaatacaagca accaggtggccgtgctgtatcaggacgtgaattgtaccgaggtgcccgtggctatccacgccgatcagctgacccc aacatggcgggtgtacagcaccggctccaacgtcttccagacaagagccggatgcctgatcggagcagagcacgtg aacaattcctatgagtgcgacatcccaatcggcgccggcatctgtgcctcttaccagacccagacaaactctccca gaagagcccggagcgtggcctcccagtctatcatcgcctataccatgtccctgggcgccgagaacagcgtggccta ctctaacaatagcatcgccatcccaaccaacttcacaatctctgtgaccacagagatcctgcccgtgtccatgacc aagacatctgtggactgcacaatgtatatctgtggcgattctaccgagtgcagcaacctgctgctccagtacggca gcttttgtacccagctgaatagagccctgacaggcatcgccgtggagcaggataagaacacacaggaggtgttcgc ccaggtgaagcaaatctacaagaccccccctatcaaggactttggcggcttcaatttttcccagatcctgcctgat ccatccaagccttctaagcggagctttatcgaggacctgctgttcaacaaggtgaccctggccgatgccggcttca tcaagcagtatggcgattgcctgggcgacatcgcagccagggacctgatctgcgcccagaagtttaatggcctgaccgtgctgccacccctgctgacagatgagatgatcgcacagtacacaagcgccctgctggccggcaccatcacatcc ggatggaccttcggcgcaggagccgccctccagatcccctttgccatgcagatggcctataggttcaacggcatcg gcgtgacccagaatgtgctgtacgagaaccagaagctgatcgccaatcagtttaactccgccatcggcaagatcca ggacagcctgtcctctacagccagcgccctgggcaagctccaggatgtggtgaatcagaacgcccaggccctgaat accctggtgaagcagctgagcagcaacttcggcgccatctctagcgtgctgaatgacatcctgagccggctggaca aggtggaggcagaggtgcagatcgaccggctgatcaccggccggctccagagcctccagacctatgtgacacagca gctgatcagggccgccgagatcagggccagcgccaatctggcagcaaccaagatgtccgagtgcgtgctgggccag tctaagagagtggacttttgtggcaagggctatcacctgatgtccttccctcagtctgccccacacggcgtggtgt ttctgcacgtgacctacgtgcccgcccaggagaagaacttcaccacagcccctgccatctgccacgatggcaaggc ccactttccaagggagggcgtgttcgtgtccaacggcacccactggtttgtgacacagcgcaatttctacgagccc cagatcatcaccacagacaacaccttcgtgagcggcaactgtgacgtggtcatcggcatcgtgaacaataccgtgt atgatccactccagcccgagctggacagctttaaggaggagctggataagtatttcaagaatcacacctcccctga cgtggatctgggcgacatcagcggcatcaatgcctccgtggtgaacatccagaaggagatcgaccgcctgaacgaggtggctaagaatctgaacgagagcctgatcgacctccaggagctgggcaagtatgagcagtacatcaagtggccct ggtacatctggctgggcttcatcgccggcctgatcgccatcgtgatggtgaccatcatgctgtgctgtatgacatc ctgctgttcttgcctgaagggctgctgtagctgtggctcctgctgtaagtttgacgaggatgactctgaacctgtg ctgaagggcgtgaagctgcattacacctaaTAAGGTCGACTCATGGAATGCATACCAAACATTATTGACACTAATG ACACACAAAATTGGTTTTAAGAAAAACCAAGAGAACAATAGGCCAGAATGGCTGGGTCTCGGGAGATATTACTCCC TGAAGTCCATCTCAATTCACCAATTGTAAAGCATAAGCTATACTATTACATTCTACTTGGAAACCTCCCAAATGAG ATCGACCTTGACGATTTAGGTCCATTACATAATCAAAATTGGAATCAGATAGCACATGAAGAGTCTAACTTAGCTC AACGCTTGGTAAATGTAAGAAATTTTCTAATTACCCACATCCCTGATCTTAGAAAGGGCCATTGGCAAGAGTATGT CAATGTAATACTGTGGCCGCGAATTCTTCCCTTGATCCCGGATTTTAAAATCAATGACCAATTGCCTCTGCTCAAA AATTGGGACAAGTTAGTTAAAGAATCATGTTCAGTAATCAATGCAGGTACTTCCCAGTGCATTCAGAATCTCAGCT ATGGACTGACAGGTCGTGGGAACCTCTTTACACGATCACGTGAACTCTCTGGTGACCGCAGGGATATTGATCTTAA GACAGTTGTGGCAGCATGGCATGACTCAGACTGGAAAAGAATAAGTGATTTTTGGATTATGATCAAATTCCAGATG DESCRIPTION Page 85 / 157 88 CN 121263205 AAGACAATTAATTGTTAGGCAAACAGATCATAATGATTCTGATTTAATCACGTATATCGAAAATAGAGAAGGCATAA TCATCATAACCCCTGAACTGGTAGCATTATTTAACACTGAGAATCATACACTAACATACATGACCTTTGAAATTGT ACTGATGGTTTCAGATATGTACGAAGGTCGTCACAACATTTTATCACTATGCACAGTTAGCACTTACCTGAATCCT CTGAAGAAAAGAATAACATATTTATTGAGCCTTGTAGATAACTTAGCTTTTCAGATAGGTGATGCTGTATATAACA TAATTGCTTTGCTAGAATCCTTTGTATATGCACAGTTGCAAATGTCAGATCCCATCCCAGAACTCAGAGGACAATT CCATGCATTCGTATGTTCTGAGATTCTTGATGCACTAAGAGGAACTAATAGTTTCACCCAGGATGAATTAAGAACT GTGACAACTAATTTGATATCCCCATTCCAAGATCTGACCCCAGATCTTACGGCTGAATTGCTCTGTATAATGAGGC TTTGGGGACACCCCATGCTCACTGCCAGTCAAGCTGCAGGAAAGGTACGCGAGTCTATGTGTGCTGGAAAAGTATT AGACTTTCCCACCATTATGAAAACACTAGCCTTTTTCCATACTATTCTGATCAATGGATACAGGAGGAAGCATCAT GGAGTATGGCCACCCTTAAACTTACCGGGTAATGCTTCAAAGGGTCTCACGGAACTTATGAATGACAATACTGAAA TAAGCTATGAATTCACACTTAAGCATTGGAAGGAAGTCTCTCTTATAAAATTCAAGAAATGTTTTGATGCAGACGC AGGTGAGGAACTCAGTATATTTATGAAAGATAAGGCAATTAGTGCCCCAAAACAAGACTGGATGAGTGTGTTTAGA AGAAGCCTAATCAAACAGCGCCATCAGCATCATCAGGTCCCCCTACCAAATCCATTCAATCGACGGCTGTTGCTAAACTTTCTCGGAGATGACAAATTCGACCCGAATGTGGAGCTACAGTATGTAACATCAGGTGAGTATCTACATGATGA CACGTTTTGTGCATCATATTCACTAAAAGAGAAGGAAATTAAACCTGATGGTCGAATTTTTGCAAAGTTGACTAAG AGAATGAGATCATGTCAAGTTATAGCAGAATCTCTTTTAGCGAACCATGCTGGGAAGTTAATGAAAGAGAATGGTG TTGTGATGAATCAGCTATCATTAACAAAATCACTATTAACAATGAGTCAGATTGGAATAATATCCGAGAAAGCTAG AAAGTCAACTCGAGATAACATAAATCAACCTGGTTTCCAGAATATCCAGAGAAATAAATCACATCACTCCAAGCAA GTCAATCAGCGAGATCCAAGTGATGACTTTGAATTGGCAGCATCTTTTTTAACTACTGATCTCAAAAAATATTGTT TACAATGGAGGTACCAGACAATTATCCCATTTGCTCAATCATTAAACAGAATGTATGGTTATCCTCATCTCTTTGA GTGGATTCACTTACGGCTAATGCGTAGTACACTTTACGTGGGGGATCCCTTCAACCCACCAGCAGATACCAGTCAA TTTGATCTAGATAAAGTAATTAATGGAGATATCTTCATTGTATCACCCAGAGGTGGAATTGAAGGGCTGTGTCAAA AGGCTTGGACAATGATATCTATCGCTGTGATAATTCTATCTGCCACAGAGTCTGGCACACGAGTAATGAGTATGGT GCAGGGAGATAATCAAGCAATTGCTGTCACCACACGAGTACCAAGGAGCCTGCCGACTCTTGAGAAAAAGACTATT GCTTTTAGATCTTGTAATCTATTCTTTGAGAGGTTAAAATGTAATAATTTTGGATTAGGTCACCATTTGAAAGAAC AAGAGACTATCATTAGTTCTCACTTCTTTGTTTATAGCAAGAGAATATTCTATCAGGGGAGGATTCTAACGCAAGCCTTAAAAAATGCTAGTAAGCTCTGCTTGACAGCTGATGTCCTAGGAGAATGCACCCAATCATCATGTTCTAATCTT GCAACTACTGTCATGAGGTTAACTGAGAATGGTGTTGAAAAAGATATCTGTTTCTACTTGAATATCTATATGACCA TCAAACAGCTCTCCTATGATATCATCTTCCCTCAAGTGTCAATTCCTGGAGATCAGATCACATTAGAATACATAAA TAATCCACACCTGGTATCACGATTGGCTCTTTTGCCATCCCAGTTAGGAGGTCTAAACTACCTGTCATGCAGTAGG CTGTTCAATCGAAACATAGGCGACCCGGTGGTTTCCGCAGTTGCAGATCTTAAGAGATTAATTAAATCAGGATGTA TGGATTACTGGATCCTTTATAACTTATTAGGGAGAAAACCGGGAAACGGCTCATGGGCTACTTTAGCAGCTGACCC GTACTCAATCAATATAGAGTATCAATACCCTCCAACTACAGCTCTTAAGAGGCACACCCAACAAGCTCTGATGGAA CTCAGTACGAATCCAATGTTACGTGGCATATTCTCTGACAATGCACAGGCAGAAGAAAATAACCTTGCTAGGTTTC TCCTGGATAGGGAGGTGATCTTTCCGCGTGTAGCTCACATCATCATTGAGCAAACCAGTGTCGGGAGGAGAAAACA GATTCAAGGATATTTGGATTCAACTAGATCGATAATGAGGAAATCACTAGAAATTAAGCCCTTATCCAATAGGAAG CTTAATGAAATACTGGATTACAACATCAATTACCTAGCTTACAATTTGGCATTACTCAAGAATGCTATTGAACCTC CGACTTATTTGAAGGCAATGACACTTGAAACATGTAGCATCGACATTGCAAGGAACCTCCGGAAGCTCTCCTGGGC CCCACTCTTGGGTGGGAGAAATCTTGAAGGATTAGAGACGCCAGATCCCATTGAAATTACTGCAGGAGCATTAATTDescription Page 86 / 157 89 CN 121263205 A GTTGGATCGGGCTACTGTGAACAGTGTGCTGCAGGAGACAATCGATTCACATGGTTTTTCTTGCCATCTGGTATCG AGATAGGAGGGGATCCCCGTGATAATCCTCCTATCCGTGTACCGTACATTGGCTCCAGGACTGATGAGAGGAGGGT AGCCTCAATGGCATACATCAGGGGTGCCTCGAGTAGCTTAAAAGCAGTTCTTAGACTGGCGGGAGTGTACATCTGG GCATTCGGAGATACTCTGGAGAATTGGATAGATGCACTGGATTTGTCTCACACTAGAGTTAACATCACACTTGAAC AGCTGCAATCCCTCACCCCACTTCCAACCTCTGCCAATCTAACCCATCGGTTGGATGATGGCACAACTACCCTAAA GTTTACTCCTGCGAGCTCTTACACCTTTTCAAGTTTCACTCATATATCAAATGATGAGCAATACCTGACAATTAAT GACAAAACTGCAGATTCAAATATAATCTACCAACAGTTAATGATCACTGGACTCGGAATCTTAGAAACATGGAATA ATCCCCCAATCAATAGAACATTCGAAGAATCTACCCTACATTTGCACACTGGTGCATCATGTTGTGTCCGACCTGT GGACTCCTGCATTCTCTCAGAAGCATTAACAGTCAAGCCACATATTACAGTACCGTACAGCAATAAATTTGTATTT GATGAGGACCCGCTATCTGAATATGAAACTGCAAAACTGGAATCGTTATCATTCCAAGCCCAATTAGGCAACATTG ATGCTGTAGATATGACAGGTAAATTAACATTATTGTCCCAATTCACTGCAAGGCAGATTATCAATGCAATCACTGG ACTCGATGAGTCTGTCTCTCTTACTAATGATGCCATTGTTGCATCAGACTATGTCTCCAATTGGATTAGTGAATGCATGTATACCAAATTAGATGAATTATTTATGTATTGTGGGTGGGAACTACTATTGGAACTATCCTATCAAATGTATT ATCTGAGGGTAGTTGGTGGAGTAATATAGTGGATTATTCTTACATGATCTTGAGAAGAATCCCGGTGCAGCATT AAAACAATCTGGCATCTACATTAAGTCATCCAAAACTTTCCGACGAGCTATCAACCTAGATATAGTTGCCCCCTTA AATGCTCCTCATTTTGCATCTCTGGACTACATCAAGATGAGTGTGGATGCAATACTCTGGGGCTGTTAAAAGAGTCATCAATGTGCTCTCCAATGGAGGGGACTTAGAATTAGTTGTGACATCTGAAGATAGCCTTATTCTCAGTGACCGATC CATGAATCTCATTGCAAGGAAATTAACTTTATTACACTGATTCACCATAATGGTTTGGAACTACCAAAGATTAAG GGGTTCTCTCCTGATGGAAGTGTTTCGCTTTGACAGAATTTTTGAGGAAAAGTGGTGAACTCAGGGTTGAGTTCAA TAGAGAACCTATCAAATTTTATGTACAAATGTGACAATGGCACGGCTTGCAGCATTCGCCAGCAACAATTACTACTACCTAC GACCAGAAAATTATTGAATTCAATACGAGATACTGAGTCGGGTCAAGTAGCAGTCACCTCATATTATGAATCATTA GAATATATTGATAGTCTTAAGCTAACCCCACATGTGCCTGGCACCTCATGCATTGAGGATGATAGTCTATGTACAA ATGATTACATAATCTGGATCATAGAGTCTAATGCAAACTTGGAGAAGTATCCAATTCCAAATAGCCCTGAGGATGA TTCCAATTTCCATAACTTTAAGTTGAATGCTCCATCGCACCATACCTTACGCCCATTAGGGTTGTCATCAACTGCT TGGTATAAGGGTATAAGCTGCTGCAGGTACCTTGAGCGATTAAAGCTACCACAAGGTGATCATTTATATATTGCAGAAGGTAGTGGTGCCAGTATGACAATCATAGAATACCTATTCCCAGGAAGAAAGATATATTACAATTCTTTATTTAG TAGTGGTGACAATCCCCCACAAAGAAATTATGCACCAATGCCTACTCAGTTCATTGAGAGTGTCCCATACAAGCTC TGGCAAGCACACACAGATCAATATCCCGAGATTTTTGAGGACTTCATCCCTCTATGGAACGGAAACGCCGCCATGA CTGACATAGGAATGACAGCTTGTGTAGAATTCATCATCAATCGAGTCGGCCCAAGGACTTGCAGTTTAGTACATGT AGATTTGGAATCAAGTGCAAGCTTAAATCAACAATGCCTGTCAAAGCCGATAATTAATGCTATCATCACTGCTACA ACTGTTTTGTGCCCTCATGGGGGTGCTTATTCTGAAATATAGTTGGTTGCCATTTACTAGATTTAGTACTTTGATCA CTTTCTTATGGTGCTACTTTGAGAGAATCACTGTTCTTAGGAGCACATATTCTGATCCAGCTAATCATGAGGTTTA TTTAATTTGTATCCTTGCCAACAACTTTGCATTCCAGACTGTCTCGCAGGCAACAGGAATGGCGATGACTTTAACT GATCAAGGGTTTACTTTGATATCACCTGAAAGAATAAATCAGTATTGGGATGGTCACTTGAAGCAAGAACGTATCG TAGCAGAAGCAATTGATAAGGTGGTTCTAGGAGAAAATGCTCTATTTAATTCGAGTGATAATGAATAATTCTCAA ATGTGGAGGGACACCAAATGCACGGAATCTCATCGATATCGAGCCAGTCGCAACTTTCATAGAATTTGAACAATTG ATCTGCACAATGTTGACAACCCACTTGAAGGAAATAATTGATATAACAAGGTCTGGAACCCAGGATTATGAAAGTT TATTACTCACTCCTTACAATTTAGGTCTTCTTGGTAAAATCAGTACGATAGTGAGATTATTAACAGAAAGGATTCTAAATCATACTATCAGGAATTGGTTGATCCTCCCACCTTCGCTCCGGATGATCGTGAAGCAGGACTTGGAATTCGGC Description Page 87 / 157 Page 90 CN 121263205 A ATATTCAGGATTACTTCCATCCTCAATTCTGATCGGTTCCTGAAGCTTTCTCCAAATAGGAAATACTTGATTGCAC AATTAACTGCAGGCTACATTAGGAAATTGATTGAGGGGGATTGCAATATCGATCTAACCAGACCTATCCAAAAGCA AATCTGGAAAGCATTAGGTTGTGTAGTCTATTGTCACGATCCAATGGATCAAAGGGAGTCAACAGAGTTTATTGAT ATAAATATTAATGAAGAAATAGACCGCGGGATCGATGGCGAGGAAATCTAAACATATCAAGAATCAGAATTAGTTT AAGAAAAAAGAAGAGGATTAATCTTGGTTTTCCCCTTGGTGGGTCGGCATGGCATCTCCACCTCCTCGCGGTCCGA CCTGGGCATCCGAAGGAGGACGCACGTCCACTCGGATGGCTAAGGGAGCGGCCGGGGATCCGGCTGCTAACAAAGC CCGAAAGGAAGCTGAGTTGGCTGCTGCCACCGCTGAGCAATAACTAGCATAACCCCTTGGGGCCTCTAAACGGGTC TTGAGGGGTTTTTTGCTGAAAGGAGGAACTATATCCGGATCATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCG TAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGT CAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTG TTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGAC CGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCA CTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTA CACTAGAAGAACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGA TCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGAT CTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGAACGAAAACTCACGTTAAGGGATTTTGGT CATGAGATTATCAAAAAGGATCTTCACCTAGATCCTTTTAAATTAAAAATGAAGTTTTAAATCAATCTAAAGTATA TATGAGTAAACTTGGTCTGACAGTTACCAATGCTTAATCAGTGAGGCACCTATCTCAGCGATCTGTCTATTTCGTT CATCCATAGTTGCCTGACTCCCCGTCGTGTAGATAACTACGATACGGGAGGGCTTACCATCTGGCCCCAGTGCTGC AATGATACCGCGAGACCCACGCTCACCGGCTCCAGATTTATCAGCAATAAACCAGCCAGCCGGAAGGGCCGAGCGC AGAAGTGGTCCTGCAACTTTATCCGCCTCCATCCAGTCTATTAATTGTTGCCGGGAAGCTAGAGTAAGTAGTTCGC CAGTTAATAGTTTGCGCAACGTTGTTGCCATTGCTACAGGCATCGTGGTGTCACGCTCGTCGTTTGGTATGGCTTC ATTCAGCTCCGGTTCCCAACGATCAAGGCGAGTTACATGATCCCCCATGTTGTGCAAAAAAGCGGTTAGCTCCTTCGGTCCTCCGATCGTTGTCAGAAGTAAGTTGGCCGCAGTGTTATCACTCATGGTTATGGCAGCACTGCATAATTCTC TTACTGTCATGCCATCCGTAAGATGCTTTTCTGTGACTGGTGAGTACTCAACCAAGTCATTCTGAGAATAGTGTAT GCGGCGACCGAGTTGCTCTTGCCCGGCGTCAATACGGGATAATACCGCGCCACATAGCAGAACTTTAAAAGTGCTC ATCATTGGAAAACGTTCTTCGGGGCGAAAACTCTCAAGGATCTTACCGCTGTTGAGATCCAGTTCGATGTAACCCA CTCGTGCACCCAACTGATCTTCAGCATCTTTACTACTTTCACCAGCGTTTCTGGGTGAGCAAAAACAGGAAGGCAAAA TGCCGCAAAAAAGGGAATAAGGGCGACACGGAAATGTTGAATACTCATACTCTTCCTTTTTCAATATTGAAGC ATTTATCAGGGTTATTGTCTCATGAGCGGATACATATTTGAATGTATTTAGAAAAATAAACAAATAGGGGTTCCGCGCACATTTCCCCGAAAAGT (SEQ ID NO: 10).
[0212] ix. CVL120
[0213] The nucleic acid sequence of CVL120 is
[0214] Specification 88 / 157 page 91 CN 121263205 A
[0215] Specification 89 / 157 page 92 CN 121263205 A
[0216] Specification 90 / 157 page 93 CN 121263205 A
[0217] Specification 91 / 157 page 94 CN 121263205 A
[0218] Specification 92 / 157 page 95 CN 121263205 A
[0219] Specification 93 / 157 page 96 CN 121263205 A
[0220] Specification 94 / 157 page 97 CN 121263205 A
[0221] Specification page 95 / 157, page 98, CN 121263205 A
[0222] Specification page 96 / 157, page 99, CN 121263205 A
[0223] Specification page 97 / 157, page 100, CN121263205 A
[0224] Specification 98 / 157 pages 101 CN 121263205 A
[0225] Specification 99 / 157 pages 102 CN 121263205 A
[0226] Specification 100 / 157 pages 103 CN 121263205 A
[0227] Specification 101 / 157 pages 104 CN 121263205 A
[0228] Specification 102 / 157 pages 105 CN 121263205 A
[0229] Specification 103 / 157 pages 106 CN 121263205 A
[0230]
[0231] x.CVL121
[0232] The nucleic acid sequence of CVL121 is:
[0233] Specification 104 / 157 Page 107 CN 121263205 A
[0234] Specification 105 / 157 Page 108 CN 121263205 A
[0235] Specification 106 / 157 Page 109 CN 121263205 A
[0236] Specification 107 / 157 Page 110 CN 121263205 A
[0237] Specification 108 / 157 Page 111 CN 121263205 A
[0238] Specification 109 / 157 Page 112 CN 121263205 A
[0239] Specification 110 / 157 Page 113 CN 121263205 A
[0240] Specification 111 / 157 Page 114 CN 121263205 A
[0241] Specification page 112 / 157, 115 CN 121263205 A
[0242] Specification page 113 / 157, 116 CN 121263205 A
[0243] Specification page 114 / 157, 117 CN 121263205 A
[0244] Specification page 115 / 157, 118 CN 121263205 A
[0245] Specification page 116 / 157, 119 CN 121263205 A
[0246] Specification page 117 / 157, 120 CN 121263205 A
[0247] Specification page 118 / 157, 121 CN 121263205 A
[0248] Specification page 119 / 157, 122 CN 121263205 A
[0249]
[0250] xi.CVL128
[0251] The nucleic acid sequence of CVL128 is:
[0252] Specification 120 / 157 page 123 CN 121263205 A
[0253] Specification 121 / 157 page 124 CN 121263205 A
[0254] Specification 122 / 157 page 125 CN 121263205 A
[0255] Specification 123 / 157 page 126 CN 121263205 A
[0256] Specification 124 / 157 page 127 CN 121263205 A
[0257] Specification 125 / 157 page 128 CN 121263205 A
[0258] Specification 126 / 157 page 129 CN 121263205 A
[0259] Specification page 127 / 157, 130 CN 121263205 A
[0260] Specification page 128 / 157, 131 CN 121263205 A
[0261] Specification page 129 / 157, 132 CN 121263205 A
[0262] Specification page 130 / 157, 133 CN 121263205 A
[0263] Specification page 131 / 157, 134 CN 121263205 A
[0264] Specification page 132 / 157, 135 CN 121263205 A
[0265] Specification page 133 / 157, 136 CN 121263205 A
[0266] Specification page 134 / 157, 137 CN 121263205 A
[0267] Specification 135 / 157 pages 138 CN 121263205 A
[0268]
[0269] V. Manufacturing Method
[0270] The present invention also includes methods for manufacturing and using CVB viral expression vectors, including but not limited to any of the methods described herein.
[0271] For example, the present invention includes a method for expressing coronavirus S protein (including but not limited to the S protein of SARS-CoV-2) in cells by infecting cells with CVB viral expression vectors, viral particles or compositions as described herein.
[0272] The present invention includes a method for inducing an immune response in a subject to coronavirus S protein (including but not limited to the S protein of SARS-CoV-2) by administering to a subject a viral expression vector, viral particle or composition as described herein. The immune response may include humoral immune response and / or cellular immune response. The immune response may enhance innate and / or adaptive specifications.Pages 136 / 157, 139 CN 121263205 A Immune Response.
[0273] The present invention includes a method for expressing heterologous coronavirus S proteins (including, but not limited to, the S protein of SARS-CoV-2) in a subject by administering to a subject a viral expression vector, viral particle, or composition as described herein.
[0274] The present invention includes a method for expressing heterologous coronavirus S proteins (including, but not limited to, the S proteins of SARS-CoV-2 α, γ, δ, and O strains) in a subject by administering to a subject a viral expression vector, viral particle, or composition as described herein.
[0275] VI. Treatment Methods
[0276] This disclosure can be used for gene therapy and / or treatment methods involving the increase or decrease of nucleotide sequences of interest in host cells for the treatment of diseases. In these embodiments, the expressible heterologous nucleotide sequences may be derived from mammalian genomes. In some embodiments, having expressible heterologous nucleotide sequences derived from human genomes may be particularly useful, wherein the expression of wild-type RNA and / or proteins may produce therapeutic effects in patients. For example, the expressible heteronucleotide sequence may encode CFTR, NeuroD1, Cas9, and guide RNA, or any other such sequence. In other embodiments, the heteronucleotide sequence encodes a secretory protein.
[0277] In other embodiments, the expressible heteronucleotide sequence responds to a positive selection stimulus. In other embodiments, the expressible heteronucleotide sequence also responds to a negative selection stimulus. In other embodiments, the polynucleotide sequence may further include a reporter gene, which may be useful. For example, the reporter gene may be a luciferase or green fluorescent protein.
[0278] In some embodiments, the CVB expresses one or more nucleotide sequences (e.g., siRNA) that modify the translation and / or transcription of a host cell nucleotide sequence of interest within the host cell. In some embodiments, the transcription and / or translation of the expressible heteronucleotide sequence is modified such that its nucleotide sequence is codon-degenerate relative to an endogenous gene in the cell. Additionally, the expressible heteronucleotide sequence may be modified such that it co-expresses a suppressor or silencing sequence capable of suppressing or silencing a host cell nucleotide sequence of interest within the host cell.
[0279] In some embodiments of this disclosure, the CVB composition can be used to prepare an antigenic preparation for use as a vaccine. Any suitable antigen can be prepared according to this disclosure, including antigens obtained from prions, viruses, mycobacteria, protozoa (e.g., Plasmodium falciparum (malaria)), trypanosomes, bacteria (e.g., Streptococcus, Neisseria, etc.).
[0280] Host cells can be transfected with a single CVB particle containing one or more heteropolynucleotide sequences, or with multiple CVB particles, each containing the same or different heteropolynucleotide sequences. For example, multi-subunit antigens (including intracellular and cell surface multi-subunit components) can be prepared by expressing a single subunit on a separate vector but infecting the same host cell with all vectors, such that assembly occurs within the host cell.
[0281] Vaccines typically contain multiple antigenic components, such as those derived from different proteins and / or from different epitope regions of the same protein. For example, a vaccine against a viral disease may contain one or more polypeptide sequences derived from a virus that, when administered to a host, can elicit an immunogenic or protecti...
Claims
1. A composition comprising a modified PIV5 CVB virus expression vector having at least 98% sequence identity with SEQ ID NO:1, wherein the CVB virus expression vector comprises a mutation at amino acid residue S157 or S156 of the P / V gene of the PIV5 viral genome, causing removal of phosphorylation sites and higher transcriptional activity, thereby increasing viral titer in cell culture, and wherein the CVB virus expression vector is highly immunogenic and can be used as an effective vaccine platform.
2. The composition of claim 1, wherein the mutation at amino acid residue S157 or S156 comprises a serine (S) replaced by an amino acid residue selected from the group consisting of: alanine (A), cysteine (C), aspartic acid (D), glutamic acid (E), phenylalanine (F), glycine (G), histidine (H), isoleucine (I), lysine (K), leucine (L), methionine (M), asparagine (N), proline (P), glutamine (Q), arginine (R), selenocysteine (U), valine (V), tryptophan (W), and tyrosine (Y).
3. The composition of claim 1, wherein the mutation at amino acid residue S157 or S156 comprises replacing serine (S) at amino acid residue S157 with phenylalanine (F) or replacing serine (S) at amino acid residue S156 with asparagine (N).
4. The composition of claim 1, wherein the CVB viral expression vector expresses a heterologous polypeptide comprising a viral antigen selected from the group consisting of SARS-CoV-2, RSV, or viral or bacterial antigens.
5. The composition of claim 1, wherein the PIV5 genome has a heterologous nucleic acid sequence having at least 98% sequence identity with SEQ ID NO:2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or 13 and wherein the viral expression vector expresses a heterologous polypeptide comprising coronavirus spike (S) and / or nucleocapsid (N) protein or RSV-F protein.
6. The composition of claim 5, wherein the coronavirus spike (S) and / or nucleocapsid (N) protein is the S or N protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a SARS-CoV-2 strain, or a variant of SARS-CoV-2, wherein the SARS-CoV-2 variant is a SARS-CoV-2β variant, a SARS-CoV-2γ variant, a SARS-CoV-2δ variant, a SARS-CoV-2O variant, a SARS-CoV-2OBA.1, a SARS-CoV-2OBA.5, BQ1, or XBB1, or any future variant.
7. The composition of claim 5, wherein the coronavirus S gene comprises the coronavirus S gene of SARS-CoV-2 and wherein the cytoplasmic tail of the coronavirus S gene has been replaced by the cytoplasmic tail of the fusion (F) gene of the CVB or CPI vector.
8. The composition of claim 5, wherein the PIV5 genome (CVB) having S157F or S156N in the P / V gene of the PIV5 viral genome further comprises an open reading frame deletion mutation of the SH gene, and wherein the N gene of the SARS-CoV-2 strain is inserted to replace the SH gene of the PIV5 and the S gene of the SARS-CoV-2 strain or other variant strain is inserted between the PIV5 hemagglutinin (HN) gene and the polymerase (L) gene of the CVB.
9. The composition of claim 5, wherein the entire SH gene transcription unit of the PIV5 viral genome is deleted and the S gene of the SARS-CoV-2 strain or other variant strain is placed between the HN gene and the L gene of the CVB.
10. The composition of claim 5, wherein the S gene of the SARS-CoV-2 variant is inserted to replace the S gene of the SARS-CoV-2 strain and the N gene of the SARS-CoV-2 strain is inserted to replace the SH gene of PIV5.
11. The composition of claim 5, wherein the S gene of the SARS-CoV-2 OBA.5 variant is inserted between the HN gene and the L gene of PIV5 to replace the S gene of the SARS-CoV-2 strain.
12. The composition of claim 5, wherein the S gene of the SARS-CoV-2 OBA.5 variant is inserted to replace the S gene of the SARS-CoV-2 strain and the N gene of the SARS-CoV-2 strain is inserted to replace the SH gene of CVB.
13. The composition of claim 5, wherein the PIV5 F and HN genes are deleted and wherein the S gene of the SARS-CoV-2 strain is located between the HN gene and the L gene of the CVB.
14. The composition of claim 5, wherein the N gene of the SARS-CoV-2 strain is inserted between F and HN, and the S gene of the SARS-CoV-2 strain is inserted between the HN gene and the L gene of the CVB.
15. The composition of claim 5, wherein the M gene from the SARS-CoV-2 strain is inserted between F and HN, and the S gene from the SARS-CoV-2 strain is inserted between HN and L of CVB.
16. The composition of claim 5, wherein the M gene from the SARS-CoV-2 strain is inserted after F of PIV5, the E gene from the SARS-CoV-2 strain is inserted between the M gene and HN of SARS-CoV-2, and the S gene from the SARS-CoV-2 strain is inserted between HN and L of CVB.
17. The composition of claim 5, wherein the M gene from the SARS-CoV-2 strain is inserted after F of PIV5, the N gene from the SARS-CoV-2 strain is inserted between the M gene and the E gene of SARS-CoV-2, the E gene from the SARS-CoV-2 strain is inserted between the N gene and HN of SARS-CoV-2, and the S gene from the SARS-CoV-2 strain is inserted between HN and L of CVB.
18. The composition of claim 5, wherein the RSV-F protein is inserted in place of the PIV5 SH gene (ΔSH) or inserted between PIV5 SH and NH (SH-NH) or between HN and L (HN-L).
19. A method for inducing an immune response in a subject who has or is at risk of SARS-CoV-2, RSV or other viral or bacterial infection, the method comprising administering the composition of claim 1 to the subject in the form of a primary or booster vaccine, wherein the immune response comprises humoral immune response and / or cellular immune response.
20. The method of claim 19, wherein the composition is administered intranasally, intramuscularly, topically, or orally.
